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Abstract 
This thesis is a critical literature review of trisomy 18 (Edwards syndrome), focused on 
maternal serum and ultrasound markers between 10 and 20 weeks’ gestation.  Based on 
comprehensive meta-analyses, existing findings are clarified, new knowledge has emerged, 
and novel statistical modeling demonstrates clinically useful algorithms to guide screening 
policies. 
 
Trisomy 18 is, after Down syndrome, the autosomal aneuploidy with the highest birth 
prevalence, about 2.4/10,000.  Only 1 in 5 live born survives to two weeks, with 1 in 20 
surviving one year.  Strategies for identifying trisomy 18 in early pregnancy rely on re-
interpretation of markers measured as part of Down syndrome screening.  Diagnosis 
requires collecting fetal or placental material obtained from an invasive procedure 
(amniocentesis or a chorionic villus sampling) and subsequent karyotyping or specific 
aneuploidy testing such as fluorescent in situ hybridization.   
 
The second trimester Triple Test (serum markers alpha-fetoprotein, unconjugated estriol 
and human chorionic gonadotropin [hCG]) has an 81% detection rate at a 0.4% false 
positive rate.  Adding pregnancy-associated plasma protein-A (PAPP-A) is effective; the 
detection rate improves to 88% while false positives are reduced to 0.1%.  In the first 
trimester Combined Test, the serum markers (free β hCG and PAPP) in combination with 
unbiased estimates of ultrasound marker nuchal translucency (NT) thickness, yields 
detection and false positive rates of 86% and 0.2%, respectively.  For these tests, hCG and 
free β hCG measurements are essentially interchangeable.  Combining existing markers 
from both trimesters into a Full Integrated Test (NT, PAPP-A, and the Triple Test), also 
yields high performance (91% detection rate at 0.2% false positive rate).  Ultrasound 
markers, apart from NT, are not suitable for routine practice, but some could be used in 
specialist centers.  In the future, testing of circulating cell free nucleic acids in maternal 
plasma may allow for a reduction in the use of invasive procedures.  
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Chapter 1: Historical Context and Original Description 1 
Chapter 1.  Historical context and original description  
 
In the late 1950s, it became possible to examine the number of chromosomes using 
cultured bone marrow cells.  By that time, it was also known that the normal human cell 
contained 22 pairs of autosomal chromosomes and two sex chromosomes.  Based on 
chromosome size and the location of the centromere, chromosomes were assigned to 
general categories A through G (Table 1.1-1).  At that time, it was difficult to distinguish 
between chromosomes within a given group.   
  
Table 1.1-1.  Classification of human chromosomes 
 
Group Size Centromere location Chromosomes 
    
A Large metacentric (middle) 1, 2 and 3 
B Large submetacentric (near the middle) 4 and 5 
C Medium submetacentric 6 through 12, and X 
D Medium acrocentric (near the end) 13, 14 and 15 
E Short submetacentric 16, 17 and 18 
F Short metacentric 19 and 20 
G Short acrocentric 21, 22 and Y 
 
Nearly 100 years earlier, John Langdon Down classified types of mental retardation 
based on the similarity of their looks to a ‘great division of the human race’, rather than 
‘the class from which they have sprung.(Down, 1866).  One of these groups was 
identified as Mongolian (or ‘mongols’), while other groups were termed Ethiopian or 
Malay.  The cause of ‘mongolism’ had still not been identified by the 1950s, but was 
thought to possibly be a single gene defect.  A French geneticist, Jerome Lejeune, 
observed that mongolism nearly always affected both identical twins, but rarely affected 
both fraternal twins (editorial, (Hulten, 1994).  This inheritance pattern was not consistent 
with a single gene defect, and Lejeune postulated that it might be an abnormality in the 
number of chromosomes.  Subsequently, Lejeune and his colleagues published a paper 
(Lejeune et al., 1959) documenting that, among three cases of mongolism, all had 47 
chromosomes, the excess chromosome being in the G group.  They were not able to 
determine whether it was an additional 21, 22 or Y chromosome.  Later that year, Jacobs 
and her colleagues confirmed these findings in an additional four cases (Jacobs et al., 
1959), each having an additional G chromosome.  They ruled out the Y chromosome, 
because the female cases they observed did not have clinical characteristics of 
Chapter 1: Historical Context and Original Description 2 
Klinefelter syndrome (already known to be caused by an extra Y chromosome in 
females).  Several years later, the extra chromosome was shown to be the 21st and that 
so called ‘mongolism’ was the result of trisomy 21.  By the 1960s, the term ‘mongoloid’ 
was changed to Down’s syndrome or to Down syndrome.   
 
Exactly one year after the article by Jacobs and colleagues on Down syndrome 
appeared (Jacobs et al., 1959), back-to-back articles on two other autosomal trisomies 
were published in the Lancet.  The first was by John Edwards and his colleagues in 
Oxford (Edwards et al., 1960).  They described a single female with:  
 
“an odd-shaped skull, low-set and malformed ears, a triangular mouth with receding chin, 
webbing of the neck, a shield-like chest, short stubby fingers and toes with short nails, 
webbing of toes, ventricular septal defect, mental retardation and neonatal hepatitis”. 
 
The main indication that this infant might have a chromosome abnormality was the 
webbed neck.  Neck webbing was a common finding in Turner syndrome that was 
already known to be caused by missing sex chromosome (45, X).  Edwards also cited 
three published descriptions of similar cases to establish the definition of a syndrome.  
They identified 47 chromosomes, the extra being in the E group.  The tentative 
assignment was an additional 17th chromosome, or trisomy 17. 
 
The second paper was by Klaus Patau and his colleagues describing another new 
chromosome abnormality (Patau et al., 1960).  A single female infant with multiple 
congenital abnormalities (cerebral defect, cleft palate, hare lip, simian creases, trigger 
thumbs, polydactyly, capillary haemangiomata and heart defect) whose karyotype also 
showed 47 chromosomes.  The additional chromosome was found to be in the D group 
and Patau did not speculate on which it might be (13, 14 or 15).  Later, it was shown to 
be the 13th chromosome, or trisomy 13. 
 
Also in 1960, David Smith (a co-author with Patau on the trisomy 13 article) reported “a 
new autosomal trisomy syndrome” (Smith, 1960).  Based on three patients, he provided 
an extensive description of the congenital defects and, upon analysis, found 47 
chromosomes.  The extra chromosome was in the E group and was identified as 
chromosome 18.  In an addendum, Smith reported four more unrelated infants with 
trisomy 18 and adds: 
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“Recently, Edwards and colleagues have described a trisomy syndrome that seems to be the 
same as the one presented above.  However, these authors identified the extra chromosome 
as No. 17”.   
 
The question of whether this abnormality was due to an extra chromosome 17 or 18 
persisted for some time.  In articles from the mid 1960s, the syndrome was referred to as 
trisomy 17-18 (Hecht et al., 1963; Weber, 1967).  Regardless, this syndrome is still 
referred to as Edwards syndrome, rather than Smith syndrome. 
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Chapter 2.  Natural history of trisomy 18 
2.1  The medical disorder: trisomy 18 and its variants 
In the late 1950s and 1960s, karyotyping was limited, due to its difficulty and expense.  It 
was likely that most perinatal deaths, for example, would not be routinely karyotyped.  
Thus, data from this earlier time period may underestimate the prevalence of the 
disorder, as well as the type and frequency of clinical manifestations (more severe cases 
that died early would often not be karyotyped or counted).  On the other hand, 
widespread prenatal screening for Down syndrome (and trisomy 18) may also bias the 
more recent data, as the more severely affected that might not survive to term may be 
prenatally diagnosed and terminated.  Table 2.1-1 provides summary information from 
four large representative studies regarding the natural history of trisomy 18, spanning the 
time period from 1964 through 2006.  Three types of information are presented: clinically 
apparent findings from a physical examination, characteristics at birth and after, and 
findings at autopsy (earlier studies) or high resolution ultrasound (later studies).  The last 
column contains the same data, but for mosaic trisomy 18 (to be discussed later). 
 
The most common clinical findings for trisomy 18 infants are malformed ears, a small jaw 
(micrognathia), clenched/overlapping fingers, prominent calcaneus (heel bone leading to 
the term ‘rocker bottom’ feet), and a prominent occiput (back of the head).  Other 
findings that are more variable or less common include ocular hypertelorism (wide set 
eyes), short sternum, limited hip abduction, extra skin at nape of neck (nuchal folds), 
hypertonia and a high palate.  Infants with trisomy 18 are small for gestational age, with 
an average birthweight of about 2000 grams.  They often fail to suckle and thus suffer 
from failure to thrive.  All are developmentally delayed.  The most common heart defects 
are ventricular septal defects (VSD), atrial septal defects (ASD), and persistent ductus 
arteriosus.  Also common are renal and diaphragmatic defects.  Companion papers 
(Ramirez-Castro and Bersu, 1978; Bersu and Ramirez-Castro, 1977) provide extensive 
autopsy data regarding the head and neck (Bersu and Ramirez-Castro, 1977) as well as 
the upper and lower limbs (Ramirez-Castro and Bersu, 1978).  
 
All of the originally reported cases of trisomy 18 (Edwards et al., 1960; Smith, 1960) 
were complete, or full, trisomy 18, as they involved 47 chromosomes.  By 1963, it was 
clear that several clinically defined cases of trisomy 18 had only 46 chromosomes, but 
with an additional translocated 18th chromosome (or part of an 18th chromosome) (Hecht 
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et al., 1963).  These are also called partial trisomy 18.  Among 36 cases collected by 
Hecht (Hecht et al., 1963), four (11%) were due to a translocation.  As might be 
expected, among those cases of trisomy 18 that were clinically identified, there was no 
apparent difference between those with, or without, a translocation.  However, further 
study suggested a variable phenotype, depending on how much, and which, material 
from the extra chromosome is duplicated (Carey, 2005).  Trisomy 18 can also be mosaic, 
where an individual has two (or more) cell lines; one normal, and the other trisomy 18.  In 
a 2005 summary of the literature (Carey, 2005), 165 of 176 affected newborns had a full 
trisomy 18 karyotype (94%, 95% CI 89% to 97%), eight were mosaic trisomy 18 (4.6%, 
95% CI 2.0% to 8.8%) and the remaining three had a translocation or partial trisomy 18 
(1.7%, 95% CI 0.4% to 4.9%).   
 
A mosaic trisomy 18 can have all the features of full trisomy 18, or have no dysmorphic 
features, including normal intelligence.  In one study summarizing 33 patients reported in 
the literature (Tucker et al., 2007), nine (27%) were karyotyped only because of infertility, 
recurrent miscarriages, birth of an affected child, or an attempt to donate bone marrow.  
It is possible that some proportion of mosaic trisomy 18 cases will not be identified, 
unless routine diagnostic testing is undertaken in a wider setting.  The proportion of 
trisomic cells varies by tissue tested, and it cannot be used to predict phenotype.   
 
The last column of Table 2.1-1 summarizes the phenotypes of mosaic trisomy 18 
reported in the literature as summarized by Tucker and colleagues (Tucker et al., 2007).  
On average, the mosaicism was higher for cytogenetic studies of blood (average 53% of 
cells, range 8% to 100%) than for study of skin cells (average 29%, range 0% to 100%).  
Individual case reports may, however, not be representative of the totality of mosaic 
trisomy 18 individuals, because a diagnosis is more likely to have been made (and be 
more publishable) if found at a more advanced age.  For example, one report in the 
literature refers to the loss of three individuals with mosaic trisomy 18 in early pregnancy, 
but there is no information about their phenotype (Carter et al., 1985). 
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Table 2.1-1.  Characteristics of infants with trisomy 18   
 
 Canada 
(Lewis, 
1964) 
England 
(Taylor, 
1968) 
Taiwan 
(Lin et al., 
2006) 
Indiana 
(Tucker et 
al., 2007) 
Year published 1964 1968 2006 2007 
Number of samples 48 27 39 / 31 33 mosaica 
     
Clinically apparent features (>50%)    
Heart defect     >90% 85%     >90% 77% 
Micrognathia (small jaw) 92% 92% 64% 22% 
Malformed ears 90% 88% 90% 26% 
Flexion of fingers 75% 89% - - 
Overlapping fingers 58% 89% 95%   4% 
Prominent calcaneus - 77% 90%    7% 
Prominent occiput 54% 93% 72% 22% 
Ocular hypertelorism - 81% 33%   5% 
Short sternum 63% 68% 23% 33% 
Limited hip abduction 48% 68% 59% - 
Extra skin at nape of neck - 56% - - 
Hypertonia - 50% - 27% 
High palate 54%  38% 71% 
    
Characteristics after birth (>50%)    
Feeding difficulty - 96% - 67% 
Failure to thrive - 96% - - 
Developmental delay - 96% - 59% 
Mental retardation (mod to severe) - 96% - 36% 
Birthweight (gm) - 2242 1977 - 
     
Features identified at autopsy/US (>25%)    
Ventricular Septal Defect (VSD) 93% 43% 94% 46% 
Atrial Septal Defect (ASD) 24% 31% 68%   8% 
Persistent ductus arteriosus 68% 53% 77%   7% 
Renal anomaly 71% 62% - 25% 
Diaphragmatic defects 34% 40% - - 
 
a many features not evaluated in all 33 cases 
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2.2  Birth prevalence of trisomy 18 
Cytogenetic typing of products of conception shows that nearly every autosome can be 
associated with trisomy (Byrne et al., 1985).  Among very early losses, trisomy 16 is 
most common, but usually not associated with an organized embryo.  Many of the other 
trisomies are nearly always associated with miscarriage of fetal tissue membranes.  
These include chromosomes 2, 5, 7, 8, 15, 20 and 22.  That study (Byrne et al., 1985) 
found that the widest phenotypic expression was among miscarriages affected with 
trisomies that can be associated with live birth (i.e., 13, 18 and 21).  Among the 17 
fetuses >30 mm in length that were karyotyped, there were seven trisomy 21, six trisomy 
18 and one trisomy 13 (the three remaining fetuses were trisomy 7, 15 and 20). 
 
As early as 1963 (Hecht et al., 1963), evidence was convincing that trisomy 18 occurred 
more often with advancing maternal age, similar to the relationship already reported for 
Down syndrome.  Table and Figure 2.2-1 summarize the 12 published datasets identified 
via a structured literature search, in which the birth prevalence of trisomy 18 (per 10,000 
births) can be directly computed or estimated.  None of these studies provided results 
stratified by maternal age, except for those above and below 35 years of age.  One 
additional study was identified after the initial searching took place (Savva et al., 2010).  
This large study from the UK is also included in the table.  The studies include over 6 
million births and 674 live-born trisomy 18 pregnancies.  Only the most recent study 
(Savva et al., 2010) was sufficiently large to report maternal age-specific birth 
prevalences.  In five of the earlier studies (Hecht et al., 1963; Smith, 1964; Taylor, 1967; 
Taylor, 1968; Root, 1994), the birth prevalence could be directly computed as prenatal 
diagnosis and selective termination were either not available or not widely available.  In 
the remaining studies (Parker et al., 2003; Forrester and Merz, 1999; Nielsen, 1991; 
Maeda et al., 1991; Forrester and Merz, 2002; Crider et al., 2008) prenatal diagnoses 
and terminations of trisomy 18 fetuses were separately recorded.  In some instances, 
there were more terminations than live births (Parker et al., 2003) where there were nine 
observed live births but 66 terminations.  Of course, not all of the terminations would 
have been live-born.  An estimated 65% would be spontaneously lost between the time 
of amniocentesis (15 to 20 weeks’ gestation) and term (Morris and Savva, 2008).  To 
account for this, the number of terminations was multiplied by 0.35, the proportion likely 
to survive.  For each rate, the 95% confidence interval is provided, using the binomial 
distribution.  The overall rate of 1.9 per 10,000 was derived using a random effects 
model (95% CI 1.5 to 2.4 per 10,000) that also showed significant and important 
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heterogeneity (Q=44, I2=77%, p=0.004).  Figure 2.2-1 presents these data in graphic 
form.  Much of the heterogeneity is likely due to the underlying maternal age distribution.  
One study (Savva et al., 2010) stratified their results into two time periods (1989-1996, 
and 1997-2004).  Using the age-associated model developed in their data, the observed 
rates for these two periods both showed 25% increases in birth prevalence for trisomy 18 
(e.g., 1.81 / 10,000 to 2.27 / 10,000).  The best estimate for England and Wales for 1997 
through 2004 is the modeled rate of 2.37 / 10,000 (Savva et al., 2010).  
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Table 2.2-1.  Estimated birth prevalence of trisomy 18 in population-based cohorts 
 
   Trisomy 18 Rate per  
Study Years Births Live / Terminationa Adjustedb 10,000 95% CI 
       
(Hecht et al., 1963) 1962-1963           999       2 /   0   2 +   0 =   2    20   2.0  -  72 
(Smith, 1964) 1960-1964      10,345       3 /   0   3 +   0 =   3      2.9 0.6  -    8.5 
(Taylor, 1967) 1962-1963        9,688       1 /   0   1 +   0 =   1      1.0 0.1  -    5.7 
(Taylor, 1968) NR      94,000     11 /   0 11 +   0 = 11      1.2 0.6  -    2.1 
(Nielsen, 1991) 1969-1988      34,910       7 /   3   7 +   1 =   8      2.3 1.0  -    4.5 
(Maeda et al., 1991) 1975-1986      14,835       6 /   0   6 +   0 =   6      4.0 1.4  -    8.8 
(Root, 1994) 1979-1988    388,563     64 /   0 64 +   0 = 64      1.6 1.3  -    2.1 
(Embleton et al., 1996) 1986-1992    282,583     34 / 23 34 +   8 = 42      1.5 1.1  -    2.0 
(Forrester and Merz, 2002) 1986-1999    282,900     38 / 64 35 + 22 = 57      2.0 1.6  -    2.6 
(Parker et al., 2003) 1997-2001    259,009       9 / 66   9 + 23 = 32      1.2  0.9  -    1.8 
(Crider et al., 2008) 1994-2003    457,000     53 / 89 53 + 31 = 84      1.8 1.5  -    2.3 
(Savva et al., 2010) 1980-2004 4,500,000   447 / 1,334c       2.3 2.1 -    2.5 
       
Allc  6,334,832   675/ 1,585       1.9 1.5  -   2.4 
 
a  Number of live-born trisomy 18/number of trisomy 18 fetuses selectively terminated within the cohort 
b  Adjusted for selective terminations by counting each as a 0.35 live birth (expressed as an integer). 
C  Also included in the study were 313 cases with known fetal losses and 160 cases with unknown time of diagnosis (adjustments for fetal 
loss performed by the author)
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Figure 2.2-1.  The birth prevalence of trisomy 18.  Table 2.2-1 provides the data 
for this graph.  In five of the earlier studies, no selective terminations of trisomy 18 
pregnancies were observed.  In the remaining six studies, the live births were 
estimated by adding the observed births to the number of selective terminations * 
0.35, to account for fetal loss between the time of diagnosis and delivery.  The overall 
rate was computed using a random effects model.  Important heterogeneity was 
observed (I2 = 77%), most likely due to differences in the underlying maternal age 
distributions. 
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2.3  Recurrence risk for trisomy 18 
Fewer data are available on the recurrence risk for trisomy 18 among women who have 
already delivered an affected infant.  It is generally thought that the risk of non-
disjunction is not chromosome-specific (i.e., equal recurrence risks for trisomies 13, 18 
and 21).  The recurrence risk (for any trisomy) among women diagnosed with a trisomy 
21 offspring has been reported to be about 1% higher than the age associated risk 
(Stene et al., 1984), and this rate is often used for counseling (Gardener, 1996).  Seven 
studies provide information about recurrence risks after an initial trisomy 18 birth, and 
these are summarized in Table 2.3-1.  A European collaborative study on prenatal 
diagnoses examined 171 karyotypes collected after an initial diagnosis of trisomy 18; two 
chromosomal abnormalities (both trisomy 18) were found (Stene et al., 1984).  A 
Yugoslavian group diagnosed 107 fetuses and newborns with trisomy 18 as part of 
clinical practice and found only one with an affected sibling (Ristic et al., 1991).  Another 
study reported recurrence risks among 98 women who had delivered a child with trisomy 
18 (Baty et al., 1994a).  No trisomies occurred among 168 subsequent sibs or among 98 
previously born sibs.  However, one woman subsequently had a fetal loss that was 
karyotyped as trisomy 13 (among 42 pregnancy losses; some of which were selective 
terminations).  Among a Japanese cohort of 170 women with a trisomy 18 birth (Uehara 
et al., 1999), none delivered another infant with a trisomy.  In another cohort of 107 
trisomy 18 fetuses, the authors found only one woman with a recurrence (Ristic et al., 
1991).  A report from Finland (Ryynanen et al., 1997) found one recurrence of trisomy 18 
in 28 pregnancies in 23 women with a trisomy 18 fetus.  The largest study of 495 women 
have five trisomy 18 pregnancies diagnosed (among 676 subsequent pregnancies) is 
based on Australian data (De Souza et al., 2009). 
 
Together, these studies are consistent with an estimated risk of recurrence of 0.8%.  
This can be compared with the corresponding risk for Down syndrome.  For example, the 
large study from Japan (Uehara et al., 1999) provided recurrence risks for Down 
syndrome as well, and found 10 recurrences among 842 women, for a rate of 1.1% (95% 
CI 0.6% to 2.2%).  One explanation for a higher than expected recurrence risk for 
autosomal trisomies is that the age-related risk is non-chromosome specific 
predisposition to non-disjunction (FitzPatrick and Boyd, 1989).  This was demonstrated 
in a case report involving a 40 year old woman who received a diagnosis of trisomy 21 
and chose to terminate the pregnancy at 16 weeks’ gestation.  In her next pregnancy, 
trisomy 13 was diagnosed at 16 weeks’ gestation and again termination was chosen.  No 
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family history of chromosomal abnormalities was reported.  At age 43, her third 
pregnancy was diagnosed with trisomy 18.  
 
 
Table 2.3-1.  Trisomy 18 recurrence risk for women diagnosed with a trisomy 18 
fetus 
 
 Number of   Recurrence 
Study women fetuses Recurrences rate (%) 
     
(Stene et al., 1984) NR 171 47,XX+18 
46,XY,inv(18) 
1.1 
(Ristic et al., 1991) NR 107 47,XX+18 0.9 
(Baty et al., 1994a)   98  308a Noneb 0.0 
(Ryynanen et al., 1997)   23   28 1 3.6 
(Uehara et al., 1999) 170 200 None              <0.1 
(Warburton et al., 2004) 235 391   1c 0.2 
(De Souza et al., 2009) 495 676   5 0.7 
     
All  1,205 10 0.8 
95% CI (0.4 to 1.5) 
 
a  includes previous children and spontaneous losses (the one affected fetus was from a 
previous therapeutic termination) 
b  reported a trisomy 13 in a subsequent pregnancy 
c  also reported two other viable trisomies that were not trisomy 18 
NR=not reported 
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2.4  Fetal loss during pregnancy 
A literature search identified seven studies that provided data on the proportion of 
trisomy 18 fetuses spontaneously aborted during pregnancy.  The most commonly 
reported loss rates are from the time of CVS (around 12 weeks’ gestation) and from the 
time of amniocentesis (around 18 weeks’ gestation), to term.  Table 2.4-1 summarizes 
the results by gestational age at the onset of monitoring, from earliest to latest.  By far 
the most comprehensive study to date is by Morris and Savva (Morris and Savva, 2008) 
who examined five congenital anomaly registers in England.  Rather than limiting the 
study to those women choosing to continue their pregnancy, they utilized all data via a 
survival analysis.  Thus, their report provides a week-by-week proportion surviving that 
can be compared with all previously published results.  Their data are provided as a 
reference for the other six studies in Table 2.4-1. 
 
 At the time of CVS (12 weeks’ gestation):  Snijders and her colleagues (Snijders et 
al., 1994) reported a fetal loss rate of 45% for trisomy in association with a first 
trimester Down syndrome screening program, but this was based on a limited 
number of observations.  Morris and Savva found the loss rate to be much higher, 
at 72% (95% CI 61% to 81%) (Morris and Savva, 2008).  One possible explanation 
for the discrepancy is the small number of observations in the Snijders study 
(Snijders et al., 1994).  Alternatively, that group is composed of skilled 
sonographers, who may have provided prognostic information that was used by 
some women in their decision-making process, resulting in a tendency for the less 
severely affected cases to be continued.  
 At the time of amniocentesis (18 weeks’ gestation):  The first three of these reports 
(Hook, 1978; Hook et al., 1989; Embleton et al., 1996) focused on women having a 
prenatal diagnosis of trisomy 18 via amniocentesis performed due to advanced 
maternal age.  The data from the two reports from Hook are combined in the latter 
publication (Embleton et al., 1996).  They are based on small numbers, as only 
women who chose not to terminate after prenatal diagnosis were eligible for study.  
Taken together, between 60% and 75% of the trisomy 18 fetuses viable at the time 
of amniocentesis were lost prior to delivery (Anandakumar et al., 1999).  A small 
study from England (Parker et al., 2003) found a lower rate, but again with a small 
sample set.  A larger study from California found a much lower loss rate of 32%, 
after second trimester serum screening (Won et al., 2005).  Morris and Savva 
found the loss rate to be consistent with the earlier studies, at 65% (95% CI 47% to 
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79%).  One possible explanation for the lower rate found in the California study is 
that all those women also received an ultrasound examination as part of the 
diagnostic process.  That prognostic information may have factored into the 
decision-making process, resulting in a tendency for the less severely affected 
cases to be continued.  
 One study looked at sonographically identified viable trisomy 18 pregnancies at 28 
weeks’ gestation and found a 45% loss rate to term (Yamanaka et al., 2006).  The 
corresponding rate from Morris and Savva is 52% (95% CI 41% to 65%).  These 
two rates agree reasonably well, even though the cases were identified via an 
abnormal ultrasound.  This may be due to the late time in gestation in which the 
cases have been identified, and the lack of access to termination. 
 
Overall, the studies provide a reasonably consistent picture of fetal loss for trisomy 18 
pregnancies from 12 weeks’ gestation to term.  Figure 2.4-1 is the survival curve (with 
95% confidence interval) from Morris and Savva (Morris and Savva, 2008).  Included on 
the figure are the seven additional estimates derived from the remaining studies (solid 
straight lines).  There is some indication that when ultrasound-based prognosis is 
available early in pregnancies (when termination is readily available), the fetal loss rate 
appears lower.  This may be due to a systematic use of the prognostic information in the 
women’s’ decision-making process. 
 
By comparing the rate of chromosome abnormalities at the time of CVS with that found 
at amniocentesis (some 6 weeks later), Kratzer and his colleagues (Kratzer et al., 1992) 
found evidence for a higher rate of loss as maternal age increases from age 34 to 50 for 
Down syndrome.  Fewer data were available to study this age-enhanced spontaneous 
miscarriage for trisomy 18.  The trend was in the same direction, but the results were not 
statistically significant.  A plausible basis for this might include a lessening in the ability of 
the maternal compartment to compensate for the imbalances in biochemistry brought on 
by the trisomic fetuses.  
 
Overall, the fetal loss during pregnancy for trisomy 18 fetuses is consistent.  In future 
analyses, the loss rates of 72% and 65% (Morris and Savva, 2008) will be used, as 
estimates from the late first trimester (11 to 13 weeks’ gestation) and the early second 
trimester (15 to 20 weeks’ gestation), respectively. 
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Table 2.4-1.  Spontaneous loss rates for trisomy 18 pregnancies, from specified 
gestational age to term 
 
  Number From  
Study Source Total Lost (wks)a Loss 
(%) 
      
(Snijders et al., 1999) After 1st trimester screening    7  12 86 
(Morris and Savva, 
2008) 
Congenital anomaly registries 475  12 72 
      
(Hook et al., 1989) Advanced maternal age   36 24 18 68 
(Embleton et al., 1996) Advanced maternal age    5   3 18 60 
(Snijders et al., 1999) After amniocentesis    7  18 70 
(Parker et al., 2003) After abnormal US    8  18 38 
(Won et al., 2005) After 2nd trimester serum 106  18 32 
(Morris and Savva, 
2008) 
Congenital anomaly registries 475  18 65 
      
(Yamanaka et al., 2006) After 2nd trimester ultrasound  63  28 45 
(Morris and Savva, 
2008) 
Congenital anomaly registries 475  28 52 
 
a  From the provided gestational week to term (amniocentesis set to 18 weeks, CVS set to 
12 weeks) 
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Figure 2.4-1.  Survival of trisomy 18 fetuses during pregnancies.  The horizontal axis provides the gestational age in completed weeks.  
The vertical axis shows the proportion of trisomy 18 fetuses surviving.  In the left graphic, the solid line indicates the Kaplan-Meier estimate 
for the survival of trisomy 18 fetuses from 12 weeks’ to term from the largest available study.(Morris and Savva, 2008).  The upper and 
lower dashed lines indicate the 95% confidence interval of that estimate.  In the right graphic, the solid line is removed, and seven loss 
rates from six other studies are superimposed on the 95% confidence intervals.  The seven estimates begin at 12 weeks’, 18 weeks’, or 28 
weeks’ gestation (data for the graphic can be found in Table 2.4-1). 
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2.5  Complications of a trisomy 18 pregnancy 
As shown earlier (Section 2.1), most fetuses with trisomy 18 will be small for gestational 
age.  Late in pregnancy, fetuses with trisomy 18 are also often associated with 
hydramnios and fetal distress.  If undiagnosed, these findings can lead to a cesarean 
section, with associated maternal morbidity.  A study from the US (Schneider et al., 
1981) found a higher cesarean section rate in trisomy 18 pregnancies.  Between 1969 
and mid-1975, the rate was 20% (4 of 20 cases) compared to 6% in the general 
population.  Between late 1974 and 1979, the rate was 56% (15 of 28 cases) compared 
to 10% in the general population.  A similar study from England reported 11 of 21 
affected pregnancies (all undiagnosed) required a cesarean section (Young et al., 1986).  
Four were planned, due to a small for gestational age fetus, while the other seven were 
emergency procedures due to fetal distress.  Avoidance of an emergency cesarean 
section is one important reason to identify trisomy 18 early in pregnancy. 
 
2.6  Survival after birth 
Trisomy 18 is often said to be a lethal condition, and this is generally true.  Survival is 
usually very short (measured in days and weeks).  Several studies have identified a 
cohort of newborns with trisomy 18 for a more exact documentation.  Table 2.6-1 
summarizes 13 studies reporting survival among newborns diagnosed with trisomy 18.  
One study (Weber, 1967) was a summary analysis of the existing literature prior to 1967.  
The studies varied in their methods for identifying affected newborns, and this is likely to 
have led to important biases that will be discussed later.  The studies also varied in the 
time points chosen to report the proportion of surviving individuals, making summary 
analysis difficult.  The 13 studies are arranged chronologically (by date of publication) 
from left to right, with the exception of two excluded studies that are listed first.  Rows 
are defined by selected time points used in the various studies, ranging from one day to 
six years.  All of the data refer to live-born infants; the one exception being the Australian 
study (Carter et al., 1985) that included three stillborn males.  These have been removed 
and the proportion alive at each interval adjusted.  In many of the studies, only a figure 
was present and the data had to be estimated.  In some instances, later authors 
obtained additional information from the original authors, and this has been used instead 
of the original data.  Eight of the studies reported fewer than 100 cases, while the 
remaining five included between 114 and 680 cases.  The last row of Table 2.6-1 
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provides the median survival in days.  In 11 of the studies, the median survival is 
between 2.5 and 14.5 days.  In another two, the median survival is 70 and 201 days.  In 
one study it was not possible to definitively determine the median survival, but fewer than 
50% survived to 14 days (Naguib et al., 1999).  The cause of this heterogeneity may be 
due to specific study design issues.  The following studies were removed from the 
summary analysis for the following reasons. 
   
 The earliest study providing a summary of existing literature (Weber, 1967) found a 
median survival of 70 days.  That study collected data published prior to 1967, a 
time when karyotyping was difficult and expensive.  It is likely that early losses (at 
one or two days) might not have been routinely karyotyped, even if key 
abnormalities had been present.  This was acknowledged by the author (Weber, 
1967).   
 One of the studies from Utah (Baty et al., 1994a) found a median survival of 201 
days.  To collect these data, the authors queried members of the Support 
Organization for Trisomy 18, 13 and Related Disorders (SOFT) for information 
about their affected child.  It is plausible that the longer an affected child lives, the 
more likely the parents are to find and to join a support organization and register 
their child’s information.  This would bias that dataset towards longer survival.   
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Table 2.6-1.  Summary of studies reporting survival of live-born trisomy 18 infants 
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Total 
Cases 
(All) 
Number 192a 98  76 36b 21 64 34 118 680 84 114 39 352 1,584 
                
Alive at NOT USED    Proportion of live-born trisomy 18 infants surviving (%) 
1 day  98a   60 65 67 86 71  83 88 86 95 68 78 
1 week 89 88  44  32 45 29  56 43 63 47 40 47 
2 weeks 81   32 39 27 41   47   50 27 31 37 
1 month 72 79  21  18 34 15 18 40 28 38 16 22 36 
2 months 52     13 22    6   30 11 17 17 
3 months 38 64     6 10 20   6    21   5 13 13 
4 months 30       5 14     19   5 12 11 
5 months 23     3    0   9     12   3   9   7 
6 months 13 56       9     11   3   9   7 
1 year   8 41    1     5   0   1 10   3   6   3   6   5 
2 years   5     1   0    5        3   4   4 
3 years   3        5        3   3   2 
4 years   2        5       5   3   2   2 
5 years   1 10       3        3   2   2 
6 years      0.3        3        3   1   2 
Median (days) 70 201    6   5 2.5   4   3 NRe ~14 6 14.5   6   4   6 
 
a  numbers as extrapolated in Root and Carey, 1994. 
b  three stillbirths removed from the original data 
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All of the remaining studies were in Caucasians or Asians, and relied on karyotype 
reports to confirm the diagnosis of trisomy 18.  The summary analysis is based on 10 
studies, after excluding two (Weber, 1967; Baty et al., 1994a). 
 
The last column of Table 2.6-1 shows the summary proportion of trisomy 18 newborns 
alive at each time interval, weighted by the number of observations in the seven included 
studies.  Based on these data, the median survival is about five days.  Another important 
finding, however, is that about 1 in 20 newborns with trisomy 18 are expected to be alive 
at one year.  Figure 2.6-1 provides a graphic representation of the data in Table 2.6-1.  
The horizontal logarithmic axis shows the survival time, from one day to 1,000 days 
(about 2.7 years).  The vertical axis shows the proportion of live-born trisomy 18 infants 
still alive for each of the 11 included studies (thin solid lines).  The summary estimate is 
shown by the thick solid line.  This type of comprehensive analysis of these data has not 
previously been reported. 
 
Long-term survival with trisomy 18 is defined as being greater than one year.  Assuming 
four million live births and a birth prevalence of 1.9 per 10,000 (Table 2.2-1), 
approximately 760 trisomy 18 infants may be born each year in the US (in the absence 
of prenatal detection and selective termination).  Of these 780 newborns, 38 (5%) might 
be expected to survive for more than one year.  A more reasonable estimate might be 
fewer than half that number, given current access to prenatal screening, diagnosis and 
selective termination.  An invited commentary (Carey, 2006) included an analysis of the 
SOFT (Support Organization For Trisomy 18 and 13, and related disorders) database.  It 
contains five times the number of children with full trisomy 18 (N=51) over the age of 10 
than are contained in the entire medical literature (Kelly et al., 2002; Petek et al., 2003; 
Shanske, 2006).  The database also contains 15 females over the age of 20.  These 
data clearly indicate that a small proportion of full trisomy 18 newborns, especially 
females, can survive for years. 
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Figure 2.6-1.  Survival of live-born infants with trisomy 18.  From 11 studies 
suitable for analysis (thin solid lines), along with the median of those estimates (solid 
thick line).  Corresponding data in Table 2.6-1. 
 
 
A difference in survival based on gender was reported as early as 1963 (Hecht et al., 
1963) (1 male:2.7 female).  The authors found this to be perplexing, as they did not find 
that girls survived longer.  Using a much larger series in 1967 (Weber, 1967), Weber 
found that males do have poorer survival after birth than females.  The ratio of males to 
females was 1:1.8 at 14 days, then 1:2.9 after three months or more.  Given the bias 
already described in this study, however, other sources were sought to confirm 
differences in survival by gender.  Of the seven acceptable studies used in Table 2.6.1, 
four provided results stratified by gender, and these are shown in Table 2.6-2.  In all of 
these, there is an important survival advantage for females, especially over the first few 
weeks.  None of the males were alive at one year, while about 5% of females survived.   
 
This higher rate of loss after live birth in males compared to females with trisomy 18 is 
the continuation of a pattern reported by others studying fetal loss.  Using a very large 
dataset (Morris and Savva, 2008), UK researchers found that the male:female ratio at 
the time of diagnosis (1:1.2) and at birth (1:1.6) both favor females.  An earlier large 
dataset from California (Huether et al., 1996) reported similar ratios at the time of 
prenatal diagnosis (1:1.1) and term (1:1.4).  These findings support the hypothesis that 
males are subject to preferential spontaneous loss as pregnancy nears term. 
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Table 2.6-2.  Survival of live-born trisomy 18 infants stratified by gender 
 
 
Australia 
(Carter et al., 1985)a 
 
Utah  
(Root, 1994) 
 
Taiwan 
(Lin et al., 2006) 
 
Switzerland  
(Niedrist et al., 2006) 
 Alla 
               
Gender Males Females  Malesb Femalesb  Males Females  Males Females  Males Females 
Number 13 23     17 22  26 37  82 120 
               
Alive at Percent of trisomy live-born infants  
1 day 46 76  79 87  88 100  46 100  65 92 
1 wk    22 46  23 68  26 48  23 52 
2 wk 38 40  12 41  6 50  15 40  16 43 
1 mo    12 35  6 32    7 32    9 33 
2 mo      8 22  0 22    7 23    6 23 
3 mo   0 10    8 20     9    5 18    4 15 
4 mo      4 14     9    5 16    2 13 
5 mo      4   9     5    2 13    2   9 
6 mo      4   9     5    2 13    2   9 
1 yr      0   5     5    0 10    0   7 
2 yr    0     5     5     6     4 
 
a  three male stillbirths removed from the original data 
b  Only total of 138 reported, but male:female ratio assumed to be the same as for the other three studies (56:82) 
NR = not reported 
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Figure 2.6-2.  Survival of live-born infants with trisomy 18, stratified by gender.  The left graphic shows the summary survival curve for 
the females (dashed line) and males (solid line).  The right graphic shows the survival curves for the four individual studies.  Corresponding 
data in Table 2.6-2. 
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Some of the survival studies already noted also stratified results by other factors.  Carter 
found only a small advantage (among live-born infants) for infants with no defects 
requiring surgery, with or without cardiac defects (Carter et al., 1985).  Root and Carey 
suggest that gestational age at delivery and clinical care are likely to play a major role in 
survival (Root, 1994).  Care of newborns/infants with trisomy 18 is addressed in Section 
2.8.  Rasmussen and colleagues had access to 115 trisomy 18 births, in a racially 
diverse population (Rasmussen et al., 2003).  Although there is some evidence that the 
data may be biased through the use of birth records, stratified analyses might still be 
instructive.  The median survival among Caucasian infants was 4 days (N=59), versus 24 
days (N=51) among African American newborns.  Both the one month and one year 
survival rates were significantly higher among African Americans (p=0.02, p=0.01, 
respectively).  If a heart defect was present, median survival was 14 days (N=67) 
compared to 20 days for those without a heart defect.  There was a clear temporal trend 
towards increasing median survival with 10, 14 and 19 days for the periods of 1968 to 
1979, 1980 to 1989, and 1990 to 1999, respectively.  A Swiss group (Niedrist et al., 
2006) showed that gestational age at delivery was a strong predictor.  The median 
survival was <1 day, 2 days, and 7 days for <32, 32-36 and 37 weeks’ gestation and 
later at delivery. 
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2.7  Diagnostic testing for trisomy 18 
In the 1950s and early 1960s, determining the karyotype required fresh cells, usually 
from the bone marrow.  Thus, it was not possible to karyotype an individual after death.  
As described earlier, it was also not possible to determine the specific chromosome, only 
the group (Table 1.1-1).  With chromosome banding and the ability to store sample 
specimens, karyotyping became more widely available, and it was possible to not only 
identify the chromosome, but parts of chromosome involved in balanced and unbalanced 
translocations.  With prenatal procedures such as amniocentesis and chorionic villus 
sampling (CVS), it became possible in the 1980s to karyotype the fetus and offer 
prenatal diagnosis and selective termination.  However, because of the procedure-
related risk and costs, diagnostic testing could not be made available to all pregnant 
women. 
 
Currently, prenatal diagnosis relies on the collection of fetal cells by either amniocentesis 
or CVS.  Amniocentesis is usually performed no earlier than 15 weeks’ gestation.  Earlier 
than 14 weeks can result in an excess risk of talipes (club foot) (Johnson et al., 1999).  In 
amniocentesis, an ultrasound-guided needle is inserted into the amniotic sac, and 10 to 
20 mL of amniotic fluid is removed.  Fetal (and maternal) cells are present in the fluid.  
Various methods are used to culture the fetal cells, while inhibiting the growth of 
maternal cells.  It is important to avoid maternal cell contamination, so that the final 
karyotype is fetal-specific.   
 
The CVS procedure collects placental tissue either trans-abdominally or trans-vaginally 
under ultrasound guidance.  The placenta and fetus are nearly always karyotypically 
identical (in some instances confined placental mosaicism exists and a subsequent 
amniocentesis must be performed).  CVS is performed at 10 or 11 weeks’ gestation or 
later, due to the risk of limb reduction abnormalities, if done earlier (Golden et al., 2003; 
Burton et al., 1992).  In the U.S, CVS is rarely performed after 13 weeks’ gestation while 
in Europe it may also be performed in the second trimester.  One advantage to CVS 
sampling is that a direct karyotype may be performed, reducing the time to diagnosis.  
However, culturing of cells is more reliable due to the possibility of the direct karyotype 
being performed on maternal cells (maternal cell contamination).  The main advantage of 
CVS is that it can be performed earlier than amniocentesis.  The main advantages for 
amniocentesis are that it is more widely available and is likely to be associated with a 
lower procedure-related fetal loss rate (www.cochrane.org/reviews/en/ab003252.html).   
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Less commonly performed is percutaneous umbilical blood sampling (PUBS), in which 
fetal blood is taken directly from the umbilical artery.  This has the advantage of rapid 
karyotyping, but is associated with a higher risk of fetal loss.  This procedure might be 
appropriate if an ultrasound identified clinical signs of trisomy 18 (e.g., heart defect and 
clenched fists) and the pregnancy is relatively late (e.g., 19 weeks’ gestation).  A rapid 
karyotype would allow more time for the couple’s decision-making process.  
 
Although a karyotype is still considered the gold standard for identifying chromosome 
abnormalities, it requires a specialized high-complexity laboratory, is expensive, and 
usually takes seven to 10 days (or more) for a final result.  Recent advances in genetic 
testing have provided alternatives to karyotyping, and they will be reviewed in a later 
Section. 
27 
Chapter 2: Natural History of Trisomy 18 
2.8  The child with trisomy 18  
Case histories of two infants (Van Dyke and Allen, 1990) are paraphrased in the next 
sections as an introduction to the range of experiences possible with a trisomy 18 child 
who survives for more than one year. 
 
Case 1:  An infant girl delivered at 2166 g with respiratory difficulties necessitating transfer to 
pediatric intensive care.  During the first four weeks, life was complicated by multiple 
infections, poor feeding, heart murmur and respiratory difficulties.  A genetic consult resulted 
in a peripheral blood karyotype of 47,XX +18.  By one year of age, the child weighed 3.3 kg.  
She continued to have severe hypotonia and severe developmental delay.  She was 
diagnosed with a ventricular septal defect.  Pulmonary hypertension and central cyanosis 
developed.  As congestive heart failure became more difficult to control, apneic episodes and 
upper respiratory-type infection developed, resulting in a gradual deterioration and death at 
19 months. 
 
Case 2:  An infant girl delivered at 1845 g and was karyotyped as 47 XX +18 using peripheral 
blood.  She was diagnosed with a ventricular septal defect and a patent ductus arteriosus that 
were surgically repaired at two years.  At five years of age she showed many of the 
phenotypic features of trisomy 18, including significant developmental delay.  She could not 
sit or stand until she was three.  At six years of age she was crawling on hands and knees 
and using a walker.  She attended a special school program for children with severe 
developmental disabilities.  Teachers reported that she stood with support, made vowel 
sounds, did not have speech, but was able to feed herself finger foods. 
 
A widely quoted study regarding the cause of death in live-born trisomy 18 is from 
Northern England (Embleton et al., 1996).  A cohort of 66 trisomy 18 pregnancies was 
followed, with 34 live births.  Twenty-one of these were delivered by caesarean section, 
with only one of these (a twin pregnancy) diagnosed prior to delivery.  Average 
gestational age at delivery was 37 weeks with a mean birthweight of 1.8 kg.  The median 
survival was three days, and only one lived longer than a week.  The most common 
cause of death was central apnea (32%), followed by “never stabilized” (29%) and 
“episodic cyanosis” (13%).  The remaining cases of death were sepsis (10%), 
“extubated” (10%) and unknown (6%).  There was no relationship between cardiac 
malformations and the mode of death, except for two newborns with double outlet right 
ventricle.  These died at ages two and three days without any signs of cardiac failure.  
Given this information, few thought that aggressive cardiac interventions would be 
warranted. 
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Until recently, there were no studies of systematic aggressive treatment protocols for 
infants born with trisomy 18.  A 2008 study from Japan (Kaneko et al., 2008) reported the 
impact of routine intensive cardiac management on a consecutive series of trisomy 18 
and trisomy 13 newborns between 2000 and 2005.  During the first time period, all 
cardiac treatment was withheld (10 trisomy 18 and three trisomy 13), during the second 
time period pharmacological interventions were allowed, but surgery was not (five 
trisomy 18, four trisomy 13), and during the third time period, aggressive treatment was 
allowed (seven, two) that was equivalent to that available for other neonates without an 
identified trisomy.  All patients in the first group died within 79 days (median survival 
seven days).  Patients in the second group all died by 367 days (median survival 23 
days).  Four of the nine patients in the last group were still surviving at 834 days (median 
survival 243 days).  The survival advantage was statistically significant for the third group 
compared to the other two groups, but there was no clear advantage between the first 
two groups.   
 
Data collected from the Support Organization for Trisomy 18, 13 and Related Disorders 
(SOFT), can be used to summarize psychomotor development as reported by parents of 
affected children (Baty et al., 1994b).  The developmental quotient (assessed 
developmental age divided by the chronological age) was always below 0.8, and in all 
but a few, below 0.3 by two years of age.  Rather than a loss in skill, the reduction is due 
to an increase in skills for the comparative group of normal children.  When skill areas 
are examined separately, trisomy 18 children are better at using language and daily 
living skills (mean developmental age of about 8 to 9 months) but are less adept at 
communication and motor skills (mean developmental age of 4 to 5 months).  This 
source of these data must be viewed carefully because of likely selection bias, but can 
provide insight into the capabilities of a subset of children with trisomy 18. 
 
Two reports provide specific guidance on caring for children with trisomy 18 and other 
life-limiting diagnoses.  A group from the Children’s Hospital of Philadelphia addresses 
palliative care for the family with a lethal condition (Munson and Leuthner, 2007).  They 
stress communications between the care givers and the family, as well as examining the 
role of spirituality and the roles that family members might wish to play in creating 
memories.  Many of their suggestions can be implemented, regardless of the family 
choice.  Based on the WHO definition of palliative care, they suggest seven tenets of 
palliative care (Munson and Leuthner, 2007) that are summarized below: 
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 Affirm life while accepting death 
 Intend to neither hasten nor postpone death 
 Offer a support system to help family cope 
 Aim interventions at comfort and quality of life 
 Consider values beyond the physical needs of a dying individual 
 Apply palliative care early in the course of illness in conjunction with other 
therapies 
 Begin pediatric palliative care at diagnosis and continue regardless when 
treatment is directed at the disease 
 
A formal method of classifying sick newborns/children in Japan was reviewed recently 
(Kosho, 2008).  Class A includes all possible treatments.  Class B restricts care by 
withholding aggressive treatments, such as surgeries and hemodialysis.  Class C 
continues only routine care, such as nutrition and temperature control.  Class D 
discontinues all treatment.  In Japan, trisomy 18 infants fall under the C classification.  
He also reported the results of an informal survey from 107 health care institutions in 
Japan reporting that the most common condition in which “withholding or withdrawal of 
treatment had been considered was trisomy 18”.  Sample palliative care plans are 
available (Leuthner, 2004). 
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2.9  Do we ‘screen’ for trisomy 18? 
 
Screening can be defined as (Wald, 2008): 
 
the systematic application of a test or inquiry, to identify individuals at sufficient risk of a 
specific disorder to benefit from further investigation or direct preventive action, among 
persons who have not sought medical attention on account of symptoms of that disorder 
 
Would the use of maternal age, ultrasound markers, serum markers or other markers of 
increased risk of trisomy 18 satisfy this definition of screening?  Certainly, trisomy 18 is 
an important disorder, prenatal identification is medically useful, and systematic methods 
of identifying those at high risk have been developed and will be examined in more detail 
in subsequent sections.  Applying the test in the general pregnancy population satisfies 
the last condition.  The key condition that may, or may not, be satisfied is whether the 
risk of trisomy 18 is sufficient to “benefit from”, further investigation.  To “benefit from” 
implies “Something that promotes or enhances well-being; an advantage”.  Both the 
justification and benefits from screening can be examined from the medical, 
social/ethical, and economic perspective, as there is the potential for harms to be 
associated with these actions, including unnecessary anxiety and options that include 
procedure-related fetal losses of unaffected pregnancies. 
 
From the medical perspective, one can ask whether testing will result in actions that will 
improve the health of the mother and fetus?  One could ask whether the benefits of 
identifying (and terminating) some proportion of trisomy 18 fetuses is considered an 
acceptable action by the local population in general as well as individual women and 
their partners?  Would there be an impact on the care of newborns with trisomy 18 
associated with a prenatal testing program?  Lastly, the question can be viewed from the 
economic perspective.  A formal cost effectiveness analysis would be difficult to conduct 
as it requires a monetary value to be placed on human life.  Rather, it would be important 
to consider the additional monetary costs associated with the prenatal testing process for 
trisomy 18 and balance this with the additional family and societal costs associated with 
the birth and care of a newborn with trisomy 18.  
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Chapter 3. Second trimester maternal serum markers for trisomy 18 
3.1  Introduction and background 
Introduction  The aim of this chapter is to review the literature to answer a series of 
questions relating to second trimester serum-based testing for trisomy 18. 
 Based on observational studies, what are the summary population parameters for 
maternal serum markers in second trimester trisomy 18 pregnancies, and do they 
agree with those in wide use today (Palomaki et al., 1995)?   
 Do trisomy 18 demonstration studies using AFP, uE3 and hCG confirm the screening 
performance of the risk-based model (Palomaki et al., 1995), as defined by the 
false positive rate and positive predictive value? 
 Are measurements of inhibin-A useful to add to the risk-based model?  If so, describe 
the algorithm and model the expected increase in performance.  
 Are there other serum markers that may be of use in a risk-based model?  If so, 
describe the algorithm and model the expected increase in performance. 
 
After a brief introduction to risk-based screening for Down syndrome (the model system 
upon which trisomy 18 testing is based), at least six separate markers will be examined 
in some detail (AFP, uE3, hCG, free β subunit of hCG, inhibin-A and PAPP-A).  
Additional markers will be included if relevant data are found to show that inclusion is 
warranted.  A final parameter set will be created, and combinations of useful markers for 
predicting patient-specific risks will be explored.  Results from demonstration studies of 
already implemented testing protocols will also be examined. 
 
Methods  When examining each of the six markers, a structured literature search 
(through 2009) was conducted and results restricted to studies of singleton unaffected 
pregnancies, and pregnancies affected by trisomy 18.  Specific inclusion criteria for each 
analyte will be provided.  A figure representing the publication date and number of 
trisomy 18 pregnancies will be presented to examine sizes of studies, types of studies 
and trends over time.  These figures also make explicit the number and size of each 
study that did not meet the exclusion criteria.  A summary estimate of the central value 
will be derived using a weighted random effects model on the median (or geometric 
mean) MoM value in the trisomy 18 pregnancies, after a logarithmic transformation.  
Studies may have provided only the median MoM, only the geometric mean (in the form 
of the mean MoM after a logarithmic transformation), or both.  Tables will provide both 
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estimates.  If one of them was not reported, it will be estimated using the other (e.g., a 
missing median value will be assigned the antilog of the logarithmic mean).  If feasible, 
analysis will be restricted to studies with at least a minimum number of affected 
pregnancies.  This requirement helps protect the summary from publication biases, and 
acknowledges that small datasets often do not report the summary information needed 
for the proposed analyses (e.g., logarithmic standard deviation). Often, the data for 
trisomy 18 is contained within a study focused on Down syndrome and because of this, it 
is possible that some reports that included relatively small number may be missed. 
 
The summary effect size estimates (usually the median marker measurement in trisomy 
18 pregnancies) from the larger studies will be examined for heterogeneity between 
studies using the Q-statistic (weighted sum of squared differences between the individual 
and overall effect size), the I2 value (representing the percentage of variability not 
explained by random chance) and a corresponding two-sided p-value.  Q tends to have 
low power with analyses having relatively few entries, while being too likely to show 
significant heterogeneity when analyzing a large number of studies.  Interpretation of I2 
does not depend on the number of studies.  In general, I2 < 25% indicate limited 
heterogeneity, 26% to 49% moderate, and >50% high heterogeneity.   When significant 
and/or high heterogeneity is identified, stratified analyses will be undertaken, when 
possible, to identify potential sources for that heterogeneity.  The analysis of AFP, the 
first marker associated with aneuploidy, is provided in detail, but less detail is provided 
for the remaining markers that utilize the same analytic methodology.  
 
Background.  Measurements of serum markers are expressed as multiples of the median 
level in unaffected pregnancies.  This concept was introduced as part of the First UK 
Collaborative Study (Wald et al., 1977), due to large differences in standardization 
between AFP assays in use at collaborating centers.  Median levels at 16 weeks’ 
gestation, for example, varied by more than a factor of two.  In addition, the median AFP 
levels increased with advancing gestational age, presenting another barrier to the use of 
a fixed mass unit cut-off level (e.g., >100 ng/mL).  Figure 3.1-1 provides an introduction 
into the computation of the multiple of the median (MoM) for an individual woman, using 
the median level found in the general population as the reference.  The relative 
distributions are plotted rather than the absolute distributions, in order to demonstrate 
how likelihood ratios can be computed.  Likelihood ratios are the relative increase, or 
decrease, in risk resulting from the woman having a specific marker measurement.  The 
median was chosen, rather than the average, because of the effect an occasional high 
outlying value might have on the estimate of the central measure.  Reporting results in 
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MoM is considered the ‘common currency’ that allows laboratories to compare values, 
regardless of their testing platform.  Factors other than gestational age (e.g., maternal 
weight, maternal race) can be accounted for by adjusting the MoM levels.  Test results 
reported in MoM are also the basic component used in creating patient-specific risks for 
Down syndrome and other fetal anomalies.  
 
 
 
 
Figure 3.1-1.  Sample calculations of an AFP multiple of the median (MoM).  The 
solid thick line shows the AFP median levels increasing by gestational age by about 
15% per week.  The open circles represent the AFP measurements in three different 
women.  The vertical lines indicate the gestational age, and the horizontal lines 
indicate the corresponding median AFP value.  The MoM level is computed by taking 
the woman’s value, divided by the corresponding median. 
 
 
In the 1970s, reports began emerging about the relationship between open neural tube 
defects (ONTD) and levels of alpha-fetoprotein (AFP) in the amniotic fluid, and maternal 
serum AFP (Brock et al., 1973; Field et al., 1976; Brock and Sutcliffe, 1972).  The 
methods for reporting analytic measurements in MoMs, computing detection and false 
positive rates, and computing patient specific risks were developed at this time (Wald et 
al., 1977; Wald, 1976).  Prenatal screening for ONTD became widespread in Europe and 
North America by the early 1980s (Ferguson-Smith et al., 1978; Wald et al., 1979; Burton 
et al., 1983; Haddow et al., 1983).  In 1983, as part of routine prenatal care, a woman in 
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New York received a very low risk for ONTD due to an undetectable AFP result.  She 
continued her pregnancy and delivered a trisomy 18 child.  Later, she consulted with her 
physician to determine whether the low levels might be indicative of her baby’s outcome.  
Her consistent probing prompted the original report by a New York group (Merkatz et al., 
1984) of reduced maternal serum AFP levels not only in trisomy 18 and 13 pregnancies, 
but also in 25 Down syndrome pregnancies.  
 
Within months, the finding was confirmed for Down syndrome (Cuckle et al., 1984), and 
existing prenatal screening programs for ONTD quickly introduced an additional 
interpretation of the maternal serum AFP test results for Down syndrome.  Down 
syndrome was the initial target of screening rather than trisomy 18 because it is more 
common, and because long-term survival after birth places ongoing burdens on the 
family.  Unlike ONTD screening, which relies on a fixed AFP MoM cut-off level (e.g., >2.5 
MoM), Down syndrome screening utilizes a patient-specific risk.  This risk can be 
computed using the woman’s age-specific risk for Down syndrome, multiplied by the AFP 
likelihood ratio (relative increase or decrease in risk).  Figure 3.1-2 shows the 
overlapping distributions of AFP measurements in unaffected and Down syndrome 
pregnancies.  The three vertical lines indicate the likelihood ratio corresponding to three 
different AFP test results.  This methodology was published in 1987 and is still widely 
used (Palomaki and Haddow, 1987; Cuckle et al., 1987).  This same approach can be 
applied to testing for trisomy 18. 
 
With Figure 3.1-2 as a guide, one can compute patient specific risks using the maternal 
age-related a-priori, or background risk as a starting point.  In Down syndrome, for 
example, the risk at term for 20, 30 and 40 year old women are about 1:1500, 1:690 and 
1:53, respectively (Morris et al., 2002).  If each of these women were to have an AFP 
value of 0.5 MoM, the corresponding likelihood ratio (LR) would be 4.1 for all three.  This 
indicates a 4.1-fold increase to their age-related background risk, so the right hand side 
of the odds are divided by this factor to produce the post-test odds of about 1:370, 1:170 
and 1:13, respectively.  The two Gaussian curves cross at 0.79 MoM, indicating an LR of 
1.0.  This means that their post test odds are the same as their background odds (i.e., 
1:1500, 1:690 and 1:53).  As a third example, consider the three women’s risk at 1.5 
MoM.  The corresponding LR is 0.38, indicating reduced risk of having a fetus affected 
with Down syndrome.  The three post-test odds would now be approximately 1:3900, 
1:1800 and 1:40, respectively.   
 
 
Chapter 3: Second Trimester Maternal Serum Markers for Trisomy 18 35 
As an aside, the risk at term is used to indicate the possibility of delivering a viable baby 
with Down syndrome.  When this risk is presented as a numeric value, it can be in the 
form of an odds, or as a probability.  A 10% probability is equivalent to an odds of 1:9.  
That is, one Down syndrome birth to nine unaffected births, or one out of the 10 births, or 
10%.  The “1 in 10” form may be confusing, as some could read it as an odds, while 
others as a probability.  Therefore, it would be best to avoid this format. 
 
 
Figure 3.1-2.  Overlapping maternal serum AFP measurements in unaffected 
and Down syndrome pregnancies.  The solid curve shows the logarithmic 
Gaussian distribution of second trimester maternal serum AFP measurements in 
unaffected pregnancies (centered at 1.0 MoM).  The dashed curve shows that the 
distribution in Down syndrome pregnancies is slightly lower (centered at 0.72 MoM) 
and somewhat broader (higher logarithmic standard deviation) than in unaffected 
pregnancies.  The thin vertical lines at three AFP MoM levels provide examples of 
likelihood ratios of 4.0, 1.0 and 0.38, respectively.   
 
 
One question to demonstrate understanding of the likelihood ratio is: “what happens to a 
woman’s risk if the results were ‘average’ or 1.00 MoM?  A common misconception is 
that the risk does not change.  However, it can be easily seen from Figure 3.1-2 that the 
risk is actually decreased at 1.00 MoM, with a likelihood ratio of about 0.75.  The more 
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useful a marker is, the higher the reduction in risk given the ‘average’ test result.  The 
range of likelihood ratios provides some estimate of the power of the individual markers.  
Maternal age can also be treated as a ‘screening test’ in the same way as AFP 
measurements were in the previous paragraphs.  The risk at term for a general 
population of women is about 1:600.  If overlapping distributions of maternal age in 
women with, and without, a Down syndrome fetus were plotted, likelihood ratios could be 
generated at the three maternal ages provided earlier (20, 30 and 40 years of age).  
Although the curves would not be Gaussian, the ratio of the heights of the relative curves 
would still allow an approximate computation of the likelihood ratio.  The expectation 
would be LRs of about 0.4, 0.9 and 11, respectively.  When combinations of markers are 
used, LR in the hundreds or even thousands (or the reciprocals of these numbers) can 
be generated. 
 
When combining multiple markers, each of which fits a logarithmic Gaussian distribution 
reasonably well, a multivariate Gaussian model can be used.  These models are widely 
applied, and there is general agreement that they fit the data well (Wald et al., 2003).  In 
addition to the logarithmic mean and standard deviation for each marker in both affected 
and unaffected pregnancies, one also needs to have pair-wise correlation coefficients in 
both populations.  Truncation limits need to be specified as well.  Truncation limits are 
relatively extreme values for each of the markers that are used to help ensure the 
robustness of likelihood ratios generated by the model.  A reasonable value for the lower 
truncation limit is the mean minus 2.5 standard deviations of the higher distribution (i.e., 
the unaffected distribution for AFP measurements), while the upper limit would be the 
mean plus 2.5 standard deviations of the lower distribution (i.e., Down syndrome 
pregnancies in this example).  Several other factors need to then be considered before 
choosing a final set of truncation limits, including an inspection of the probability plots, 
lower limit of detection for the assay, similarity of the two standard deviations and overall 
range of possible likelihood ratios.  Together, these means, standard deviations, 
correlation coefficients and truncation limits are called a set of population parameters.  A 
‘set’ of population parameters in a Gaussian model is used to calculate patient specific 
risks for Down syndrome, as well as several other outcomes (e.g., trisomy 18, neural 
tube defects) using from one to five, or more, markers. 
 
Table 3.1-1 provides a summary listing of the 14 studies supplying data for the analysis 
of AFP, uE3, hCG, the free β subunit of hCG, inhibin-A and PAPP-A in trisomy 18 
pregnancies.  As can be seen from the table, the majority of these studies report on 
more than one marker.  The next sections examines each marker more closely. 
 
Chapter 3: Second Trimester Maternal Serum Markers for Trisomy 18 37 
Table 3.1-1.  Studies of second trimester maternal serum markers and trisomy 18 
included in the analyses 
 
Included Publication N AFP uE3 hCG Free β Inhibin-A PAPP-A 
        
(Lindenbaum et al., 1987) 38 X      
(Zeitune et al., 1991) 19 X      
(Spencer et al., 1993) 52 X   X   
(Palomaki et al., 1995) 89 X X X    
(Aitken et al., 1996) 32 X  X X X  
(Leporrier et al., 1996) 33  X X    
(Wenstrom et al., 1998) 13     X  
(Lambert-Messerlian et al., 
1998) 
21 X X X  X  
(Sancken et al., 1999) 30 X X X    
(Spencer et al., 1999) 65 X   X  X 
(Bersinger et al., 1999) 20  X X   X 
(Kennedy et al., 2000) 46 X  X    
(Muller et al., 2002) 45 X   X  X 
        
Included studies  10 5 7 4 3 3 
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3.2  Second trimester AFP measurements  
As part of prenatal screening and/or diagnostic programs, an occasional trisomy 18 fetus 
is identified.  By the late 1970s, it was well known that open ventral wall or open neural 
tube defects occurred in about 10 to 15% of trisomy 18 fetuses, and a proportion of 
these pregnancies were already being identified by ONTD screening programs.  In the 
initial report of reduced AFP measurement and Down syndrome, the case that prompted 
further investigation was actually a trisomy 18 fetus (Merkatz et al., 1984) not a Down 
syndrome fetus.  By 1987, Lindenbaum and his colleagues in England and Finland 
reported that maternal serum AFP levels in 58 trisomy 18 pregnancies without open 
defects were reduced even more than that found for Down syndrome.  Most had been 
collected as part of ONTD screening (Lindenbaum et al., 1987).  After removing these 
results, (the 20 trisomy 18 pregnancies with an associated open defect), they reported 
that a high proportion of the remaining affected fetuses could be detected as part of 
existing Down syndrome screening, without additional false positives.  For example, 
using a fixed AFP MoM cut-off level of <0.5 MoM, 26% of Down syndrome and 34% of 
trisomy 18 fetuses (without ONTD) could be identified, along with about 8.4% of the 
unaffected pregnancies (Lindenbaum et al., 1987).  Since screening algorithms for Down 
syndrome screening at that time were based on only maternal age and serum AFP 
measurements, there was no reason to have a separate algorithm for trisomy 18, as 
these pregnancies would already be screen positive for Down syndrome. 
 
The English literature through 2009 was searched for primary references regarding 
second trimester maternal serum AFP measurements in cytogenetically confirmed 
trisomy 18 pregnancies that were not part of a demonstration study for trisomy 18.  A 
demonstration study is defined as a follow-up study of a testing protocol that includes a 
medical intervention to determine the effectiveness of the testing protocol in practice.  
This includes examining implementation issues such as uptake rates, and decision-
making, and usually includes some sort of outcome follow-up.  For example, a 
manuscript describing the reporting of trisomy 18 risks as part of a Down syndrome 
screening program (with pregnancy follow-up for those with a positive test result) would 
be considered a demonstration study.  A Medline search (key words: trisomy 18, AFP, 
second trimester) yielded 36 references, 30 of which were not relevant.  Based on the six 
relevant publications and a search of their reference lists, a total of 37 candidate 
publications were identified.  Inclusion criteria were: 1) the peer-reviewed study was 
observational and would not be classified as a demonstration project, 2) the median or 
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geometric mean for trisomy 18 pregnancies was reported or could be computed from a 
published figure or table, 3) the gestational age range was reported and all, or nearly all, 
were in the range of 15 to 20 completed weeks’ gestation, 4) information was available 
regarding how the pregnancy was identified for prenatal diagnosis (e.g., live birth with an 
anomaly, serum screen positive, abnormal ultrasound) and 5) a reasonable number of 
observations were available.  This latter inclusion criterion was added because of a large 
number of publications that focused on Down syndrome provided only sparse data for 
trisomy 18.  A reasonable minimum number is 15 to 20 cases.  All of the studies that 
focused on trisomy 18 are higher than this number, while most of the smaller studies that 
reported fragmented results are well below.  Also extracted from the larger studies, when 
possible, were the logarithmic standard deviations and pair-wise correlation coefficients 
with other second trimester serum markers in both affected and unaffected pregnancies.   
 
Three abstracts were identified and removed from further consideration (Subramanian, 
1988; Darnule, 1990; Arab, 1988) as these were not considered peer-reviewed 
publications.  One publication was in German (Dix et al., 1988) and was also removed.  
None of these four publications contained more than five trisomy 18 pregnancies.  An 
additional 22 publications had 14 or fewer observations and were not formally 
summarized (Staples et al., 1991; Greenberg et al., 1992; Canick et al., 1990; Macri et 
al., 1986; DiMaio et al., 1987; Ashwood et al., 1987; Doran et al., 1986; Wenstrom et al., 
1998; Norgaard-Pedersen et al., 1990; Palomaki et al., 1992; Nebiolo et al., 1990; 
Hershey et al., 1985; Suchy and Yeager, 1990; Heyl et al., 1990; Bogart et al., 1987; 
Merkatz et al., 1984; Huderer-Duric et al., 2000; Crossley et al., 1991; Cowchock, 1984).  
Several of these 22 publications might also have been excluded based on the majority of 
cases being identified as part of a demonstration study for trisomy 18.  These are, 
therefore, likely to provide a biased estimate of the true levels of any serum marker in 
affected pregnancies.  The 10 included studies were published between 1987 and 2002, 
and contained between 19 and 89 samples (Palomaki et al., 1995; Muller et al., 2002; 
Lindenbaum et al., 1987; Kennedy et al., 2000; Sancken et al., 1999; Zeitune et al., 
1991; Spencer et al., 1999; Aitken et al., 1996; Lambert-Messerlian et al., 1998; Spencer 
et al., 1993).  Of the 558 trisomy 18 pregnancies with maternal serum AFP 
measurements reported in the peer-reviewed literature, the 10 larger publications 
contained 436 observations (78% of the total) while the 22 smaller publications 
contained the remaining 122 observations (22% of the total).  Figure 3.2-1 provides a 
graphical summary of year of publication versus numbers of trisomy 18 observations 
reported, and notes those studies included in the formal summaries (above dashed line) 
as well as those not included (below dashed line).  
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Figure 3.2-1.  Maternal serum AFP measurements in trisomy 18 pregnancies.  
The horizontal dashed line is drawn at 19, a reasonable demarcation between small 
and large studies.  Overall, 22 publications would be considered small (14 or fewer 
pregnancies) and the focus is usually not trisomy 18.  A total of 10 studies included 
19 or more trisomy 18 pregnancies (between 19 and 89) and would be considered 
large.  In these larger studies, the focus was more often directed towards trisomy 18 
rather than Down syndrome.  These 10 studies form the basis of further analyses 
summarizing the second trimester serum AFP measurements in trisomy 18 
pregnancies. 
 
The AFP and trisomy 18 data are summarized in Table 3.2-1, ordered by the effect size 
(largest to smallest) as measured by the logarithmic mean.  Stratified analyses can be 
performed using the covariates listed in the last three columns of Table 3.2-1.  For 
example, do studies with earlier publication dates systematically differ from the later 
studies?  This might occur because of improvements in assays or the routine inclusion of 
maternal weight adjustments.  Also, do studies that included some proportion of samples 
identified via low maternal serum AFP measurements have a lower central estimate than 
those in which serum screening played no part in the identification of pregnancy 
outcomes?  
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Table 3.2-1.  Maternal serum AFP measurements in trisomy 18 and unaffected pregnancies 
 
  Trisomy 18 pregnancies  Unaffected pregnancies  Categories 
 
Reference 
 
GA 
 
N 
AFP Central 
Estimate 
(MoM)a 
AFP 
Log SD  
 
N 
AFP 
MoM 
(Median) 
AFP 
Log SD  
>20% 
Screened 
by AFP 
Pub 
After 
1995 
 
Log SD 
< 0.2113 
             
(Aitken et al., 1996) 8-18 32b -0.2757  (0.53) NR  438 1.00 NR  Yes Yes NR 
(Lambert-Messerlian et al., 1998) 15-20 21 -0.2757  (0.53) 0.2117  105 1.00 0.1990  Yes Yes  High 
(Sancken et al., 1999) 14-20 30 -0.2579  (0.73) 0.2215  29.081 1.00 0.1565  Yes Yes  High 
(Lindenbaum et al., 1987) early 2nd 38 -0.2170  (0.60) 0.3120  NR NR NR  No No High 
(Muller et al., 2002) early 2nd 45 -0.2147  (0.61) 0.1830  15,000 1.00 NR  No Yes  Low 
(Spencer et al., 1999) 14-19 65 -0.2050  (0.66) 0.2100  450 1.00 0.1750  Yes Yes  Low 
(Palomaki et al., 1995) 13-22 89 -0.1970  (0.65) 0.2239  NR NR NR  Yes No High 
(Zeitune et al., 1991) 16-19 19 -0.1675  (0.68) 0.2201  133,045 1.00 0.1740  Yes No High 
(Spencer et al., 1993) 14-21 52 -0.1668  (0.71) 0.2037  6,661 0.99 0.1889  No No High 
(Kennedy et al., 2000) 14-21 46 -0.1565  (0.70) 0.1651  48,150 1.02 0.1415  No Yes Low 
             
Summary  436 -0.1830d (0.66c) 0.1817d   1.00 0.1664     
           95% CI (0.56-0.69)         
 
NR=not reported, GA=gestational age, log SD=logarithmic standard deviation 
a geometric mean (median).  If only one was reported, the other was directly computed. 
b Only four of the 32 samples were collected under 15 weeks’ gestation. 
c After restriction to studies that did not include a high proportion of cases that had previous AFP testing (Figure 3.2-3). 
e After regression analysis accounted for a significant temporal trend of reduced variances in affected pregnancies. 
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All studies in Table 3.2-1 confirmed the finding of trisomy 18 via karyotype, supplied the 
number of observations, provided results in multiples of the median, and reported central 
estimates (e.g., median AFP MoM) after excluding trisomy 18 pregnancies that were also 
affected by an open defect (e.g., open neural tube or ventral wall).  None of the studies 
included twin pregnancies.   
 
The logarithmic standard deviations for AFP measurements in trisomy 18 pregnancies 
uncomplicated by an open defect.  The logarithmic standard deviation was reported for 
eight of the studies (Table 3.2-1).  Methods for estimating the standard deviation varied, 
but using the interval from the 10th to 90th centiles divided by 1.282*2 was common, as a 
way to account for outlying values.  In one study (Aitken et al., 1996), the focus was on 
Down syndrome and inhibin-A measurements, and no estimate for the standard 
deviation in trisomy 18 pregnancies was possible.  In another (Lambert-Messerlian et al., 
1998), the raw data were obtained from the authors, and the general formula for 
standard deviation was used (the study included 20 observations, and no outliers were 
present).   
 
The earliest paper (Lindenbaum et al., 1987) had the largest standard deviation, while a 
much later paper (Kennedy et al., 2000) had the smallest.  Figure 3.2-2 shows a plot of 
all nine reported estimates of the AFP variance in trisomy 18 pregnancies by year of 
publication.  There is a clear and statistically significant trend towards reduced variance 
in the more recent studies.  Although it was not possible to determine the exact cause, 
others have reported an important reduction in variance over time in AFP measurements 
in unaffected pregnancies (Wald et al., 2000), and have applied that reduction in 
variance to existing Down syndrome parameters as a way to account for these changes.  
The most likely reason for this reduction is an improvement in AFP assays, but other 
possibilities include improvements in assigning gestational age and inclusion of routine 
adjustments for maternal weight. 
 
A linear regression analysis (weighted by the square root of the number of observations) 
was applied to the log of the variance versus the year of publication using all 10 
observations.  The result was highly significant (p<0.01), but the slope was highly 
influenced by one quite high early observation (Lindenbaum et al., 1987).  The analysis 
was then rerun with this observation removed.  The resulting regression line was not 
significant (p=0.07), but fitted the data well (r=0.674), is plausible, and confirms an earlier 
finding (Wald et al., 2000).  Given that no data were available after 2002, the regressed 
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variance at that time (0.3301) was taken to be a reasonable estimate for the standard 
deviation of current AFP measurements (expressed in MoM) for trisomy 18 pregnancies 
in the second trimester.  This translates into a logarithmic standard deviation of 0.1817.  
This value is included in the summary line in Table 3.2-1. 
 
 
Figure 3.2-2.  The variance of maternal serum AFP measurements in trisomy 18 
pregnancies by year of publication.  Each of the nine open circles shows an 
estimate from one of the large studies included in the analysis.  The dashed line 
shows the results of a weighted log-linear regression analysis on the eight 
observations between 1991 and 2002.   
 
The central estimate of maternal serum AFP in trisomy 18 pregnancies.  All studies 
reported the median (and/or logarithmic mean) AFP MoM value in the trisomy 18 
pregnancies.  As described previously, all but one reported a logarithmic standard 
deviation (or a value was computed from the reported raw data).  From this value and 
the number of cases, the standard error was computed.  For the study with a missing 
logarithmic standard deviation, the regressed estimate of 0.1817 was used 
(interpolated for Figure 3.2-2, Table 3.2-1).  The data were analyzed using a random 
effects model (Comprehensive Meta-Analysis V2.2, Biostat, Englewood, NJ).  In 
addition to an estimate of the central value (i.e., median, geometric mean), the model 
also was used to examine sources of heterogeneity.  Figure 3.2-3 shows data for 
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each of the 10 studies.  The weighted central estimate for the logarithmic mean is 
0.209 and is shown in the last line in the forest plot.  This corresponds to a median 
value of 0.62 MoM.  The test for heterogeneity was negative (Q=15, p=0.07, I2=43%), 
but the high I2 value is suggestive of underlying variability.  Among the excluded 
articles, 122 observations were available, and the weighted median value was 0.65 
MoM.  Even these more limited data were less well characterized and the data less 
reliable than those derived from larger, more focused studies. 
 
Analyzing sources of heterogeneity.  The last three columns of Table 3.2-1 provide 
stratifications of the data by three categorical variables: screened samples (none or 
fewer than 20% of samples identified as part of a serum screening program versus 
20% or more identified via screening), logarithmic standard deviation (SD), and year 
of publication (prior to 1995 versus 1995 and later).  Using a mixed-effects model, 
only one of these potential confounders appeared to be helpful in explaining the 
possible heterogeneity.  Figure 3.2-3 shows the stratification by method of identifying 
the sample for diagnosis (ID).  If trisomy 18 cases, even a proportion of the cases, 
were identified because of low maternal serum AFP measurements (i.e., screen 
positive for Down syndrome using maternal age and low AFP), one might expect that 
those studies would have a lower AFP median than the remaining studies that 
identified cases only through abnormal ultrasound, or after a live birth.  The six 
studies including pregnancies identified via serum screening had a median value of 
0.59 MoM (95% CI 0.55 to 0.64), with the remaining four studies at 0.66 MoM (0.61 
to 0.71) (overall, the estimate is 0.62 MoM, 95% CI 0.56 to 0.69).  Although 
suggestive, the test for heterogeneity between the two groups is still negative (Q=3.6, 
p=0.06).  However, given the plausibility of this finding, the higher estimate of 0.66 
(95% CI 0.61-0.71, logarithmic mean of -0.1830) will be used as the summary 
estimate for the central value for AFP measurements in trisomy 18 pregnancies. 
 
Chapter 3: Second Trimester Maternal Serum Markers for Trisomy 18 45 
 
Figure 3.2-3.  Maternal serum AFP measurements in trisomy 18 pregnancies.  
The central estimate (usually logarithmic mean) and associated 95% confidence 
intervals are shown for the 10 studies reporting AFP measurements from at least 19 
pregnancies affected with trisomy 18 (Table 3.2-1).  The solid line (MoM = 1.00) is 
the expected value for unaffected pregnancies.  The four studies on the left represent 
those in which samples were rarely identified via serum testing (see Table 3.2-1).  
The next six studies were often (more than 20% of the time) taken from pregnancies 
identified via serum testing for Down syndrome.  The overall summary estimate is 
0.62, but the reduced effect size of 0.59 MoM (95% CI 0.55 to 0.64) will be used in 
modeling. 
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3.3  Second trimester uE3 measurements  
There are fewer studies reporting uE3 measurements in trisomy 18 pregnancies.  A 
Medline search (trisomy 18, uE3, unconjugated estriol, second trimester) identified 46 
publications.  Inclusion criteria were similar to those described earlier for AFP 
measurements.  Three of these contained relevant information (Suzumori et al., 1997; 
Palomaki et al., 1995; Lambert-Messerlian et al., 1998).  Examining references in these 
papers identified additional potentially relevant publications.  One abstract was excluded 
(Darnule et al., 1990).  Ten studies contained 15 or fewer observations and were not 
included (Barkai et al., 1993; Greenberg et al., 1992; Staples et al., 1991; Canick et al., 
1990; Crossley et al., 1993; Heyl et al., 1990; Norgaard-Pedersen et al., 1990; Kim et al., 
2001; Suzumori et al., 1997; Palomaki et al., 1992).  The largest of these studies (Barkai 
et al., 1993) identified 15 cases that were, in part, screen positive using a triple marker 
algorithm (AFP, uE3 and hCG) and, therefore, likely to not represent an unbiased 
estimate.  The five remaining publications (Palomaki et al., 1995; Sancken et al., 1999; 
Leporrier et al., 1996; Bersinger et al., 1999; Lambert-Messerlian et al., 1998) formed the 
basis of the following uE3 analyses.  Overall, 280 observations were identified in all 15 
peer-reviewed publications.  The five publications included for analysis contained 201 of 
those observations (72%).  The 10 publications with smaller numbers of observations 
contained an additional 79 observations (28%).  Figure 3.3-1 provides a graphical 
summary of year of publication versus numbers of trisomy 18 observations reported, and 
notes those studies included (filled circles) and those not formally summarized (open 
circles).   
 
Two studies (Palomaki et al., 1995; Sancken et al., 1999) noted that the uE3 
measurements were not significantly different in pregnancies with open defects (spina 
bifida and ventral wall).  For this reason, trisomy 18 pregnancies with open defects were 
included.  The results of these analyses are presented below. 
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Figure 3.3-1.  Publications reporting maternal serum uE3 measurements in 
trisomy 18 pregnancies.  The horizontal dashed line is drawn at 19, a reasonable 
demarcation between small and large studies.  Five studies were considered large 
(between 20 and 89 affected pregnancies) and these were used in the analysis of 
uE3 measurements in trisomy 18 pregnancies. 
 
The central estimate of serum uE3 measurements in trisomy 18 pregnancies.  All five 
studies reported the median and/or logarithmic mean uE3 MoM value for the trisomy 
18 pregnancies studied, along with a logarithmic standard deviation.  A random 
effects model was used to estimate the median uE3 MoM (logarithmic mean) in 
trisomy 18 pregnancies (Figure 3.3-2).  The pooled logarithmic mean was found to be 
-0.4448, corresponding to a median value of 0.36 MoM.  The test for heterogeneity 
was not statistically significant, but did indicate the possibility of between study 
differences (Q=8.7, p=0.07, I2=54%).  Among the 79 usable observations from 
excluded studies, the weighted median MoM was 0.45.  The discrepancy may be at 
least partially explained by the majority of excluded studies being performed between 
1990 and 1995, when the uE3 assays were not optimized for the levels found in the 
second trimester. 
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Table 3.3-1.  Maternal serum uE3 measurements in trisomy 18 and unaffected pregnancies 
 
  Trisomy 18 pregnancies  Unaffected pregnancies 
Reference GA N uE3 Central Estimate (MoM)a 
uE3 Log 
SD  N 
Median uE3 
(MoM) uE3 Log SD 
         
(Sancken et al., 1999) 14-20 38 -0.5429  (0.31) 0.4213  29,081 1.00 0.1565 
(Bersinger et al., 1999) 15-20 20 -0.5151  (0.32) 0.2677  40 1.10 0.1719 
(Leporrier et al., 1996) 14-23 33 -0.4706  (0.37) 0.2619  3,000  1.00b 0.1625 
(Palomaki et al., 1995) 13-22 89 -0.3991  (0.43) 0.2938  NR NR NR 
(Lambert-Messerlian et al., 1998) 15-20 21 -0.3372  (0.46) 0.2655  105 1.00 0.1742 
         
Summary 
 
 
201 
 
-0.4448  (0.36) 
95% CI (0.31-0.42) 
0.2817 
   
0.1591 
 
 
NR = not reported, GA = gestational age, SD = standard deviation 
a  geometric mean (median).  If only one was reported, the other was directly computed. 
b  Information about uE3 measurements in control pregnancies reported in a separate reference (Herrou et al., 1992). 
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The logarithmic standard deviations for uE3 measurements in trisomy 18 
pregnancies.  In one study (Lambert-Messerlian et al., 1998), the raw data were 
obtained from the author, and the general formula for standard deviation was used 
(only 20 observations were included in that study, and no outliers were identified).  A 
previously published one-pass methodology (Palomaki et al., 2007) was used to 
identify and trim outlying variances.  Briefly, an F-value was computed using each 
individual variance divided by the pooled variance.  If the F-value was significant, that 
value was trimmed and the summary recomputed.  The weighted pooled standard 
deviation, prior to trimming, was 0.3131.  The logarithmic standard deviation from 
one study (Sancken et al., 1999) was identified as being an outlier, with a p-value of 
0.01 (F=1.81, df=38).  After removal, the trimmed pooled logarithmic standard 
deviation was 0.2817.  These standard deviations were not subjected to a temporal 
analysis for three reasons.  The timeframe over which the four studies took place 
was short (only four years), and the assay methodologies did not change over that 
time period.  Lastly, the four estimates remaining after trimming are similar. 
Figure 3.3-2.  Maternal serum uE3 measurements in trisomy 18 pregnancies.  The 
central estimate (usually logarithmic mean) and 95% confidence intervals are shown for 
the five studies reporting uE3 measurements from at least 19 pregnancies with trisomy 
18.  The solid line (MoM = 1.00) is the expected value for unaffected pregnancies.  The 
summary logarithmic mean is -0.4448 (uE3 median of 0.36 MoM, 95% CI 0.31-0.42). 
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3.4  Second trimester hCG measurements  
A Medline search (trisomy 18, hCG, human chorionic gonadotropin, second trimester) 
identified 92 publications.  Six of these contained relevant information (Palomaki et al., 
1995; Kim et al., 2001; Sancken et al., 1999; Suzumori et al., 1997; Canick et al., 1990; 
Lambert-Messerlian et al., 1998).  Examining references in these papers identified 
additional relevant papers and abstracts.  Inclusion criteria were similar to those 
described earlier for AFP measurements.  Two abstracts were excluded (Blitzer, 1991; 
Arab, 1988).  Twelve studies contained 14 or fewer observations and were also excluded 
(Greenberg et al., 1992; Bartels et al., 1990; Canick et al., 1990; Norgaard-Pedersen et 
al., 1990; Palomaki et al., 1992; Nebiolo et al., 1990; Kim et al., 2001; Heyl et al., 1990; 
Suchy and Yeager, 1990; Bogart et al., 1987; Suzumori et al., 1997; Crossley et al., 
1991).  There were seven larger studies (20 or more observations) that met inclusion 
criteria (Palomaki et al., 1995; Sancken et al., 1999; Kennedy et al., 2000; Leporrier et 
al., 1996; Bersinger et al., 1999; Aitken et al., 1996; Lambert-Messerlian et al., 1998), 
and these formed the basis of the hCG analyses.  Overall, a total of 334 observations 
were identified in the 19 publications.  The seven publications with 20 or more samples 
contained a total of 248 observations (74%), while the remaining 12 publications 
contained 86 observations (26%).  Figure 3.4 -1 provides a graphical summary of year of 
publication versus numbers of trisomy 18 observations reported, and notes those studies 
included (filled circles) and those not formally summarized (open circles).   
 
Two studies (Palomaki et al., 1995; Sancken et al., 1999) noted that the hCG 
measurements were not different in pregnancies with open defects.  For this reason, 
trisomy 18 pregnancies with open defects were included.  None of the studies included 
twin pregnancies.  The results of these analyses are presented below. 
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Figure 3.4-1.  Publications reporting maternal serum hCG measurements in 
trisomy 18 pregnancies.  The horizontal dashed line is drawn at 19, a reasonable 
demarcation between small and large studies.  Seven studies were considered large 
(between 20 and 89 affected pregnancies) and these were used in the analysis of 
hCG measurements in trisomy 18 pregnancies. 
 
The central estimate of serum hCG measurements in trisomy 18 pregnancies. 
All seven studies reported the median and/or logarithmic mean uE3 MoM value, and 
all but one (Aitken et al., 1996) also reported a logarithmic standard deviation (the 
trimmed pooled estimate of 0.3561 was used).  A random effects model was used to 
estimate the median hCG MoM (logarithmic mean) in trisomy 18 pregnancies (Figure 
3.4-2).  The pooled logarithmic mean was -0.4601, corresponding to a median value 
of 0.35 MoM.  The test for heterogeneity was significant (Q=18, p=0.007, I2=66%).  At 
least some of this heterogeneity is due to the estimate in the smallest study, 
consisting of 20 observations (Lambert-Messerlian et al., 1998), where the median is 
0.29.  However, the logarithmic mean corresponds to a median of 0.22.  Were the 
median of 0.29 to be used in the summary analysis instead, the test for heterogeneity 
would be reduced (Q=12, p=0.06, I2=51%).  Interestingly, this would have little effect 
on the summary MoM (from 0.35 to 0.36), and only a slight change in the logarithmic 
mean (from -0.4601 to -0.4442).  For these reasons, the original summary of 0.35 
MoM will be used.  The weighted median MoM from the 86 usable samples was 0.29.  
This lower median MoM may be due to several of the larger excluded studies being 
demonstration studies, which would be expected to produce a lower (biased) 
estimate. 
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Table 3.4-1.  Maternal serum hCG measurements in trisomy 18 and unaffected pregnancies 
 
  Trisomy 18 pregnancies  Unaffected pregnancies 
Reference GA N hCG Central Estimate (MoM)a uE3 Log SD  N 
Median uE3 
(MoM) uE3 Log SD 
         
(Lambert-Messerlian et al., 1998) 15-20   21 -0.6576  (0.29) 0.3550       100 1.00 0.2494 
(Sancken et al., 1999) 14-20   38 -0.5528  (0.28) 0.4734  29,081 1.05 0.2870 
(Aitken et al., 1996)   8-18   34 -0.5229  (0.30) NR       438 1.03 0.2196 
(Palomaki et al., 1995) 13-22   89 -0.4396  (0.36) 0.3772  NR NR NR 
(Bersinger et al., 1999) 15-20   20 -0.4278  (0.41) 0.3870         40 0.99 0.2168 
(Kennedy et al., 2000) 14-21   46 -0.3659  (0.43) 0.3245  48,150 1.01 0.2250 
(Leporrier et al., 1996) 14-23   33 -0.3294  (0.50) 0.3177    3,000 1.00a 0.2619 
         
Summary 
 
 
248 
 
-0.4123 (0.39) 
95% CI (0.29-0.41) 
0.3561 
    
 
NR = not reported, GA = gestational age, SD = standard deviation 
a  geometric mean (median).  If only one was reported, the other was directly computed. 
b  Information about hCG measurements in control pregnancies from another publication (Herrou et al., 1992). 
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The logarithmic standard deviation for hCG measurements The logarithmic standard 
deviation reported by the authors was used for six of the included studies.  In another 
study (Aitken et al., 1996), the focus was on Down syndrome and inhibin-A 
measurements, and no estimate for the standard deviation was possible.  The 
weighted pooled standard deviation, prior to trimming, was 0.3768.  The logarithmic 
standard deviation from one study (Sancken et al., 1999) was identified as being an 
outlier, with a p-value of 0.04 (F=1.58).  After this study was removed, the trimmed 
pooled logarithmic standard deviation was 0.3561.   
 
Figure 3.4-2.  Maternal serum hCG measurements in trisomy 18 pregnancies.  
The central estimate (usually logarithmic mean) and associated 95% confidence 
intervals are shown for the seven studies reporting hCG measurements from at least 
20 pregnancies affected with trisomy 18.  The solid line (MoM = 1.00) is the expected 
value for unaffected pregnancies.  The summary logarithmic mean is -0.4601 
(median of 0.35 MoM, 95% CI 0.29-0.41). 
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3.5  Second trimester free β hCG  
A Medline search (trisomy 18, free β hCG, human chorionic gonadotropin, second 
trimester) identified 33 publications.  Inclusion criteria were similar to those described 
earlier for AFP measurements.  Two of these contained relevant information (Muller et 
al., 2002; Spencer et al., 1999).  Examining references in these papers identified 
additional relevant papers.  Two studies included 12 or fewer observations (Staples et 
al., 1991; Wenstrom et al., 1998) and were excluded.  There were four large studies (20 
or more observations) that met inclusion criteria (Muller et al., 2002; Spencer et al., 
1999; Spencer et al., 1993; Aitken et al., 1996), and these formed the basis of the free β 
hCG analyses.  Overall, a total of 218 observations were identified in the six publications.  
The four publications included for analysis contained a total of 199 observations (91%), 
while the two publications with smaller numbers of observations contained the remaining 
19 observations (9%).  Figure 3.5-1 provides a graphical summary of year of publication 
versus numbers of trisomy 18 observations reported, and notes those studies included 
(filled circles) and those not formally summarized (open circles).   
 
The logarithmic standard deviations for free β hCG measurements in trisomy 18 
pregnancies.  The logarithmic standard deviation reported by the authors was used 
for three of the included studies.  In one study (Aitken et al., 1996), the focus was on 
Down syndrome and inhibin-A measurements and no estimate for the standard 
deviation was possible.  The weighted pooled standard deviation, prior to trimming 
was 0.4062.  No outliers were identified.   
 
The central estimate of serum free β hCG measurements in trisomy 18 pregnancies. 
All four included studies reported the median and/or logarithmic mean free β hCG 
MoM value for the trisomy 18 pregnancies studied, and all but one (Aitken et al., 
1996) also reported a logarithmic standard deviation.  For this study, the trimmed 
pooled estimate of 0.4062 was used to estimate standard error.  The standard error 
of the logarithmic mean was then computed, using the number of reported cases.  A 
random effects model was used to estimate the median free β hCG MoM (logarithmic 
mean) in trisomy 18 pregnancies (Figure 3.5-2).  The pooled logarithmic mean was -
0.6203, corresponding to a median value of 0.24 MoM.  The test for heterogeneity 
was significant (Q=17, p=0.001, I2=82%).  Among the excluded studies, only one 
provided an estimate of the median at 0.31 MoM based on 12 observations (Staples 
et al., 1991). 
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Figure 3.5-1.  Publications reporting maternal serum free β hCG measurements 
in trisomy 18 pregnancies.  The horizontal dashed line is drawn at 19, a reasonable 
demarcation between small and large studies.  Four studies were considered large 
(between 32 and 70 affected pregnancies) and these were used in the analysis of 
free β measurements in trisomy 18 pregnancies. 
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Table 3.5-1.  Maternal serum free β hCG measurements in trisomy 18 and unaffected pregnancies 
 
  Trisomy 18 pregnancies  Unaffected pregnancies 
Reference GA N Free β  Central Estimate (MoM)a 
Free β  
Log SD  N 
Median free β  
(MoM) 
Free  β Log 
SD 
         
(Aitken et al., 1996) 8-18   32 -0.8539   (0.14) NR  112 1.03 NR 
(Muller et al., 2002) early 2nd 45 -0.6198   (0.24) 0.4010  15,000 1.00 NR 
(Spencer et al., 1999) 14-19 70 -0.5300   (0.33) 0.3810  450 1.00 0.2600 
(Spencer et al., 1993) 14-21 52 -0.5025   (0.37) 0.4346  6,661 0.99 0.2583 
        
Summary 
 
 
199 
 
-0.6203   (0.24) 
95% CI (0.17-0,33) 
0.4062 
   
 
NR = not reported, GA = gestational age, SD = standard deviation 
a  geometric mean (median).  If only one was reported, the other was directly computed. 
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Figure 3.5-2.  Maternal serum free β hCG measurements in trisomy 18 
pregnancies.  The central estimate (usually logarithmic mean) and associated 
standard errors are shown for the four studies reporting free β hCG measurements 
from at least 20 pregnancies affected with trisomy 18.  The solid line (MoM = 1.00) is 
the expected value for unaffected pregnancies.  The summary logarithmic mean is -
0.6203 (free β hCG median of 0.24 MoM, 95% CI 0.17-0.33). 
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3.6  Second trimester inhibin-A measurements  
A Medline search (trisomy 18, inhibin-A, second trimester) identified 15 publications.  
Inclusion criteria were similar to those described earlier for AFP measurements.  Five of 
these contained relevant information (Hsu et al., 2003; Yoshida et al., 2000; Watanabe et 
al., 2002; Lambert-Messerlian et al., 1998; Aitken et al., 1996).  Examining references in 
these papers identified additional relevant papers.  Four studies included 13 or fewer 
observations (Wenstrom et al., 1998; Watanabe et al., 2002; Hsu et al., 2003; Yoshida et 
al., 2000).  Because of the small number of studies, these will be included in the data 
listings but not in the subsequent analyses.  There were only two larger studies (21 and 
32 observations) that met inclusion criteria (Lambert-Messerlian et al., 1998; Aitken et 
al., 1996), and these formed the basis of the inhibin-A analyses.  Overall, 78 
observations were identified in the six publications.  Figure 3.6-1 provides a graphical 
summary of year of publication versus numbers of trisomy 18 observations reported, and 
notes those two larger studies (filled circles) and the four smaller ones (open circles).   
 
The logarithmic standard deviations for inhibin-A measurements in trisomy 18 
pregnancies  The logarithmic standard deviation reported by the authors was used 
for the two largest studies.  The weighted pooled estimate is 0.2897.   
 
The central estimate of serum inhibin-A measurements in trisomy 18 pregnancies 
The standard error of the logarithmic mean was computed for the two largest studies 
using the number of reported cases and the reported standard deviation.  A random 
effects model was used to estimate the median inhibin-A MoM (logarithmic mean) in 
trisomy 18 pregnancies (Figure 3.6-2).  The pooled logarithmic mean was found to be 
-0.0392, corresponding to a median value of 0.91 MoM.  Neither study found a 
statistically significant difference, nor was the summary finding significantly different 
from 1.0 MoM (p=0.3).  The four smaller studies (Wenstrom et al., 1998; Watanabe et 
al., 2002; Hsu et al., 2003; Yoshida et al., 2000) are consistent with no effect.  The 
largest (Wenstrom et al., 1998) summarized results from 13 affected pregnancies 
and reported ‘no discrimination’, but no associated parameters or summary statistics.  
The three smallest studies all found point estimates above 1.00 MoM. 
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Figure 3.6-1.  Publications reporting maternal serum inhibin-A measurements 
in trisomy 18 pregnancies.  The horizontal dashed line is drawn at 19, a reasonable 
demarcation between small and large studies.  Two studies were considered large 
(between 21 and 32 affected pregnancies) and these were used in the analysis of 
inhibin-A measurements in trisomy 18 pregnancies.  Given the small number of 
studies and observations, all studies will be reviewed. 
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Table 3.6-1.  Maternal serum inhibin-A measurements in trisomy 18 and unaffected pregnancies 
 
  Trisomy 18 pregnancies  Unaffected pregnancies 
Reference GA N Inhibin-A  Central Estimate (MoM)a 
Inhibin-A  
Log SD  N 
Median Inhibin-A  
(MoM) 
Inhibin-A 
Log SD 
         
(Lambert-Messerlian et al., 1998) 15-20 21 -0.0560   (0.88) 0.3406  100 1.00 0.2634 
(Aitken et al., 1996) 15-18 32 -0.0340   (0.99) 0.2455  112 1.00 0.2967 
(Wenstrom et al., 1998) 14-20 13 NR    (NR)b NR  450 NR NR 
(Yoshida et al., 2000) 15-21   3  0.0253   (1.06) NR    71 1.00 NR 
(Watanabe et al., 2002) 15-17   5  0.0710   (1.20) 0.0695    56 1.00 NR 
(Hsu et al., 2003) 14-22   4 -0.0990   (1.04) 0.6210  160 1.00 0.2343 
        
Summary 
 
 
78 
 
-0.0392   (0.91) 
95% CI 0.77-1.09 
0.2897 
   
 
NR = not reported, GA = gestational age, SD = standard deviation 
 a  geometric mean (median).  If only one was reported, the other was directly computed. 
b  Reported there was ‘no discrimination’. 
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Figure 3.6-2.  Maternal serum inhibin-A measurements in trisomy 18 
pregnancies.  The central estimate (usually logarithmic mean) and associated 95% 
confidence intervals are shown for the two studies reporting inhibin-A measurements 
from at least 20 pregnancies affected with trisomy 18.  The solid line (MoM = 1.00) is 
the expected value for unaffected pregnancies.  The summary logarithmic mean is -
0.0392 (median of 0.91 MoM, 95% CI 0.77-1.09). 
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3.7  Second trimester PAPP-A measurements 
Measurements of pregnancy associated plasma protein-A (PAPP-A) are known to be the 
most effective serum marker in the late first trimester for Down syndrome (and trisomy 
18).  However, PAPP-A measurements have been shown to be of little value in the 
second trimester for Down syndrome.  For this reason, the expectation is for only a 
limited number of studies of second trimester PAPP-A and trisomy 18. 
 
A Medline search (PAPP-A, serum, second trimester, trisomy 18) identified 26 
publications.  Inclusion criteria were similar to those described earlier for AFP 
measurements.  Four of these contained relevant information (Muller et al., 2002; 
Spencer et al., 1999; Bersinger et al., 1999; Watanabe et al., 2002).  Examining 
references in these papers identified no additional relevant publications.  One of the four 
studies included only five observations and was excluded (Watanabe et al., 2002).  That 
left three large studies (20 or more observations) that met inclusion criteria, and these 
formed the basis of the PAPP-A analyses (Bersinger et al., 1999; Muller et al., 2002; 
Spencer et al., 1999).  Overall, 140 observations were identified in the four publications.  
The three publications included for analysis contained a total of 135 observations (96%), 
while the smaller publication contained the remaining 5 observations (4%).  Figure 3.7-1 
provides a graphical summary of year of publication versus numbers of trisomy 18 
observations reported, and notes those studies included (filled circles) and those not 
formally summarized (open circles).   
 
The logarithmic standard deviations for PAPP-A measurements in trisomy 18 
pregnancies  The logarithmic standard deviation was reported by all authors; the 
pooled estimate was 0.3894, with no outliers identified. 
 
The central estimate of serum PAPP-A  measurements in trisomy 18 pregnancies 
All three studies reported the median and/or logarithmic mean PAPP-A MoM value 
for the trisomy 18 pregnancies studied.  A random effects model was used to 
estimate the median PAPP-A MoM (logarithmic mean) in trisomy 18 pregnancies 
(Figure 3.7-2).  The pooled logarithmic mean was -0.9871, corresponding to a 
median value of 0.10 MoM.  The test for heterogeneity was borderline significant 
(Q=5.7, p=0.06, I2=65%).  Although there is some argument for heterogeneity, all 
three studies show an impressively low level of PAPP-A among trisomy 18 
pregnancies.  The excluded study (Watanabe et al., 2002) was consistent, with a 
reported median MoM of 0.33. 
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Figure 3.7-1.  Publications reporting maternal serum pregnancy associated 
plasma protein A (PAPP-A) measurements in trisomy 18 pregnancies.  The 
horizontal dashed line is drawn at 19, a reasonable demarcation between small and 
large studies.  Three studies were considered large (between 20 and 70 affected 
pregnancies) and these were used in the analysis of PAPP-A measurements in 
trisomy 18 pregnancies.  
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Table 3.7-1.  Maternal serum PAPP-A measurements in trisomy 18 and unaffected pregnancies  
 
  Trisomy 18 pregnancies  Unaffected pregnancies 
Author GA N 
PAPP-A Central 
Estimate (MoM)a 
PAPP-A 
Log SD 
 N 
Median PAPP-A 
(MoM) 
PAPP-A  
Log SD 
         
(Muller et al., 2002) early 2nd   45 -1.0969  (0.08) 0.3700  NR NR NR 
(Spencer et al., 1999) 14-19 70 -0.9490  (0.11) 0.3840  450 1.00 0.2560 
(Bersinger et al., 1999) 15-20 20 -0.8726  (0.11) 0.4408    40 1.35 0.2660 
        
Summary 
 
 
135 
 
       -0.9971  (0.10) 
95% CI (0.08-0.14) 
0.3994 
   
 
NR = not reported, GA = gestational age, SD = standard deviation 
a  geometric mean (median).  If only one was reported, the other was directly computed. 
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Figure 3.7-2.  Maternal serum PAPP-A measurements in trisomy 18 
pregnancies.  The logarithmic mean and 95% confidence intervals are shown for the 
three studies reporting PAPP-A measurements from at least 20 pregnancies affected 
with trisomy 18.  The solid line (MoM = 1.00) is the expected value for unaffected 
pregnancies.  The summary logarithmic mean is -0.9871 (PAPP-A median of 0.10 
MoM, 95% CI 0.08-0.14). 
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3.8  Population parameters for trisomy 18 and unaffected pregnancies 
This section summarizes the population parameters (logarithmic means, standard 
deviations) for second trimester maternal serum AFP, uE3, hCG, free β hCG and inhibin-
A in trisomy 18 pregnancies reviewed earlier.  To model screening performance, it is 
necessary to also have logarithmic means and standard deviations for unaffected 
pregnancies.  Lastly, pair-wise correlation coefficients for all of these markers in both 
trisomy 18 and unaffected pregnancies are required as well as truncation limits. 
 
Logarithmic means and standard deviations in trisomy 18 and unaffected 
pregnancies for six selected second trimester maternal serum analytes 
The medians, logarithmic means and standard deviations in trisomy 18 pregnancies 
in the left-hand side of Table 3.8-1 are taken directly from the summary tables in the 
preceding sections (3.1 through 3.7).  On the right hand side is a recent estimates of 
the logarithmic standard deviation in unaffected pregnancies for those same serum 
analytes from the SURUSS study (Wald et al., 2003; Wald, 2006).  
 
Figure 3.8-1 is a visual representation of the overlapping Gaussian curves 
represented by the parameters in Table 3.8-1, shown as thick solid lines.  For 
comparison, the thinner dashed lines are the trisomy 18 parameters from a 
commonly used publication (Palomaki et al., 1995).  The best marker for trisomy 18 
is PAPP-A, while the poorest is inhibin-A. 
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Table 3.8-1.  Summary of logarithmic means and standard deviations (SD) for six 
second trimester maternal serum analytes in trisomy 18 and unaffected pregnancies 
 
 Trisomy 18 pregnancies  Unaffected pregnanciesa 
Analyte Median Log meanb Log SD  Log SDb 
      
AFP 0.66 -0.1830     0.1817  0.1399 
uE3 0.36 -0.4448     0.2817  0.1142 
hCG 0.39 -0.4123     0.3561  0.2276 
free β hCG 0.24 -0.6203 0.4062  0.2577 
Inhibin-A 0.91 -0.0392 0.2897  0.2078 
PAPP-A 0.10 -0.9871 0.3894  0.2549 
 
AFP = alpha-fetoprotein, uE3 = unconjugated estriol, hCG = human chorionic gonadotropin, 
PAPP-A = pregnancy associated plasma protein-A, SD = standard deviation 
a  In unaffected pregnancies, the median is 1.00 and the logarithmic mean is 0.0000.  Only 
the logarithmic SD is reported. 
b  SURUSS – data from N Wald and colleagues (Wald et al., 2003; Wald, 2006) 
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Figure 3.8-1.  Overlapping Gaussian curves for six second trimester maternal serum 
markers in trisomy 18 and unaffected pregnancies.  All data are plotted on the same 
scale.  The height of the curves indicates the probability that an observation from that 
distribution will occur.  Data for all six curves are taken from Table 3.8-1 (thick solid and 
dashed lines).  The thin solid and dashed lines indicate the curves currently in used in 
most programs for second trimester trisomy 18 testing.  The dashed line(s) indicates the 
distributions in trisomy 18 pregnancies, while the solid lines indicate corresponding 
distributions in unaffected pregnancies.   
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Pair-wise correlation coefficients in trisomy 18 and unaffected pregnancies 
Table 3.8-2 contains the reported correlation coefficients in trisomy 18 and 
unaffected pregnancies from the studies included in Sections 3.1 to 3.7.  The 
estimates based on at least 40 observations in trisomy 18 pregnancies are bolded.  
Only three of the pair-wise comparisons are missing.  They all include free β hCG 
measurements (free β hCG versus uE3, hCG and PAPP-A).  These are unlikely to be 
of much consequence to clinical practice.  One would normally not measure both the 
free and intact molecules of hCG at the same time, inhibin-A measurements are not 
different in trisomy 18 pregnancies so would not be included in any algorithm, and 
uE3 is not often measured in laboratories that use free β hCG measurements.  In 
general, the correlation coefficients used by most laboratories to generate risk using 
AFP, uE3 and hCG (Palomaki et al., 1995) measurements are similar to other 
reported parameters or are centrally located with respect to multiple measurements.  
For free β hCG versus AFP, two studies (Spencer et al., 1993; Spencer et al., 1999) 
are consistent in their findings of a small correlation (between 0.12 and 0.20).  If 
PAPP-A measurements are considered the most promising as an addition in the 
second trimester, the needed correlation coefficients are all available, but from two 
additional separate studies (Bersinger et al., 1999; Spencer et al., 1999).  Because of 
this ‘mix-and-match’ for the correlation coefficients from three separate population 
studies, it will be important for modeling to ensure that computed risks are robust and 
reliable. 
 
In addition to the correlations in trisomy 18 pregnancies, correlation coefficients from 
unaffected pregnancies from large published studies are also needed for modeling 
and assigning trisomy 18 risk.  These estimates are contained in the second part of 
Table 3.8-2, with entries based on at least 1000 observations bolded.  Coefficients 
that are commonly used to assign risk for Down syndrome are also summarized 
(Knight et al., 1998; Haddow, 1998; Wald et al., 2003).  The advantage of the 
SURUSS parameters (Wald et al., 2003) is that they are comprehensive, but they 
have the disadvantage of being derived from a relatively small case/control study 
(<500 samples tested) with measurements occurring over a relatively short time 
frame. 
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Table 3.8-2.  Correlation coefficients between second trimester serum markers in trisomy 18 and in unaffected pregnancies 
 
 Second trimester serum markers in trisomy 18 pregnancies 
Marker uE3 hCG free β hCG PAPP-A Inhibin-A 
AFP 0.1676 (Lambert-Messerlian et 
al., 1998) 
0.2300 (Sancken et al., 1999) 
0.2501 (Palomaki et al., 1995) 
 
-0.1170 (Lambert-Messerlian 
et al., 1998) 
0.0314 (Palomaki et al., 1995) 
0.0541 (Kennedy et al., 2000) 
0.1251 (Sancken et al., 1999) 
0.1291 (Spencer et al., 1993) 
0.2360 (Spencer et al., 1999) 
 
0.2300 (Spencer et al., 1999) 0.1800 (Lambert-Messerlian et 
al., 1998) 
uE3  -0.2596 (Leporrier et al., 1996) 
0.0766 (Lambert-Messerlian et 
al., 1998) 
0.0944 (Palomaki et al., 1995) 
0.3500 (Sancken et al., 1999) 
NR -0.0413 (Bersinger et al., 1999) 
 
0.4609 (Lambert-Messerlian et 
al., 1998) 
hCG   NR (but ‘high’) 0.1824 (Bersinger et al., 1999) 0.2378 (Lambert-Messerlian et 
al., 1998) 
free β    0.3400 (Muller et al., 2002) 
0.3660 (Spencer et al., 1999) 
NR 
PAPP-A     0.2100 (Watanabe et al., 2002)
 
A bolded entry indicates that the estimate is based on 40 or more observations. 
Underlined estimates will be used in modeling and assigning risk for trisomy 18. 
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Table 3.8-2. (continued)  Correlation coefficients between second trimester serum markers in trisomy 18 and in unaffected 
pregnancies 
 
 Second trimester serum markers in unaffected pregnancies 
Marker uE3 hCG free β hCG PAPP-A Inhibin-A 
AFP 0.1981 (Wald et al., 2003) 
0.2223 (Knight et al., 
1998) 
0.2610 (Sancken et al., 1999) 
0.4737 (Lambert-
Messerlian et al., 1998) 
 0.1145 (Sancken et al., 1999) 
-0.1280 (Lambert-Messerlian 
et al., 1998) 
0.1535 (Wald et al., 2003) 
0.1560 (Knight et al., 1998) 
0.2300 (Aitken et al., 1996) 
0.0150 (Spencer et al., 1999) 
0.0204 (Spencer et al., 1993) 
0.0946 (Knight et al., 1998) 
0.0974 (Wald et al., 2003) 
0.1500 (Aitken et al., 1996) 
-0.0130 (Spencer et al., 1999) 
0.1918 (Wald et al., 2003) 
-0.0078 (Lambert-Messerlian 
et al., 1998) 
0.2033 (Wald et al., 2003) 
 
uE3  -0.0416 (Wald et al., 2003) 
-0.0790 (Sancken et al., 1999) 
-0.1400 (Knight et al., 1998) 
-0.1614 (Lambert-Messerlian 
et al., 1998) 
-0.0585 (Wald et al., 2003) 
-0.1451 (Knight et al., 1998) 
 
0.0983 (Wald et al., 2003) 
0.3102 (Bersinger et al., 1999) 
 
-0.1052 (Lambert-Messerlian 
et al., 1998) 
-0.0875 (Wald et al., 2003) 
hCG   0.8651 (Wald et al., 2003) 
0.8700 (Aitken et al., 1996) 
0.8757 (Knight et al., 1998) 
0.1623 (Bersinger et al., 1999) 
0.2838 (Wald et al., 2003) 
0.2297 (Lambert-Messerlian et 
al., 1998) 
0.4293 (Wald et al., 2003) 
 
free β    0.0270 (Spencer et al., 1999) 
0.2752 (Wald et al., 2003) 
0.4092 (Wald et al., 2003) 
PAPP-A     0.2530 (Wald et al., 2003) 
 
Bolded entries indicate that the estimate is based on 1,000 or more observations. 
Estimates from SURUSS (Wald et al., 2003) are underlined, and will be used for modeling and assigning risk. 
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3.9  Modeling performance of serum markers 
The truncation limits for each of the markers also need to be specified.  These are 
already available for AFP, uE3 and hCG measurements.  Table 3.9-1 provides 
reasonable truncation limits for Free β and PAPP-A measurements that are consistent 
with the methodology described in Chapter 3, Section 3.1.  These truncation limits can 
also be examined in relation to the overlapping curves shown in Figure 3.8-1.  At the 
upper and lower truncation limits, the height of the curves in unaffected and trisomy 18 
pregnancies are above baseline, indicating that these limits are not in the extreme tails of 
either of the distributions. 
 
Table 3.9-1.  Truncation limits (TL) for maternal serum markers 
 
  (Palomaki et al., 2005)  Recommended 
Marker   Lower TL Upper TL  Lower TL Upper TL 
       
AFP  0.33 2.00    
uE3  0.40 1.50    
hCG  0.20 2.50    
Free β  NR NR  0.20 2.50 
PAPP-A  NR NR  0.20 1.00 
 
 
The set of population parameters listed in the previous Sections (Tables 3.8-1, 3.8-2 and 
3.9-1), can now be combined with the age-associated risk for trisomy 18 to assign 
individual patient-specific risks.  By including the known distribution of maternal ages in a 
defined population, it is possible to construct a monte carlo simulation to model the 
trisomy 18 detection rate and associated false positive rates using trisomy 18 risk as the 
test result.  The distribution of maternal ages in England and Wales for 2006 through 
2008 can be used as a good approximation of the distribution of maternal ages in 
unaffected pregnancies, as the prevalence of age-associated disorders (e.g., Down 
syndrome and trisomy 18) are relatively rare.  Using a published equation to assign age-
related risk for trisomy 18 (Savva et al., 2010), one can also estimate the distribution of 
maternal ages for women with a trisomy 18 fetus at term.  These two overlapping 
distributions are shown in Figure 3.9-1.  Using these numbers, the overall birth 
prevalence is 2.9/10,000. 
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Figure 3.9-1.  Maternal age distribution in unaffected and trisomy 18 births.  The 
solid line is the observed distribution of maternal ages in England and Wales in 2006 
through 2008, derived from published data (Morris and Savva, 2008).  The dashed line is 
the expected distribution of trisomy 18 births in the absence of prenatal diagnosis and 
selective termination. 
 
 
Table 3.9-2 shows the results of modeling for six combinations of maternal age and 
serum markers.  Specifically, double markers (AFP and hCG, or AFP and free β), triple 
markers (double plus uE3) and quadruple markers (triple plus PAPP-A).  The table is 
further divided into two groups of rows.  The first group shows the false positive rates for 
these combinations at a fixed detection rate, while the second group shows detection 
rates at fixed false positive rates.  As the number of markers increases, overall test 
performance increases considerably.  For example, at a fixed detection rate of 80%, the 
inclusion of uE3 reduces the false positive rate from 9.0% to 0.3%, with a further 
reduction to <0.1% with the addition of PAPP-A measurements.  Replacing hCG 
measurements with those of the free β subunit improves performance a great deal for 
the double markers (9.0% versus 5.3% false positive rate for an 80% detection rate), but 
less so for triple and quadruple marker testing (0.3% versus 0.2% and <0.1% versus 
<0.1%, respectively). 
 
In Table 3.9-3, the modeling results for the same combinations are shown by risk cut-off 
level and include not only the detection and false positive rates, but also the odds of 
being affected given a positive result (OAPR).  Term risks are used to allow for 
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comparisons between these second trimester risks and those first trimester algorithms 
that will be evaluated later.  Performance for the double markers is limited, but 
reasonable cut-off levels for the triple and quadruple marker combinations might be term 
risks of 1:300 (second trimester risk of about 1:100).  The corresponding second 
trimester OAPRs are both very high at 1:5 and 1:2, respectively.  The major difference 
between the three and four marker algorithms is a three-fold reduction in the false 
positive rate (0.39% to 0.11%) with a concomitant improvement in detection rate (from 
81% to 88%.  These very low false positive rates may be somewhat misleading.  
Relatively rare events (e.g., existing fetal deaths, anencephaly) might also be 
preferentially assigned high risks, but would not be considered ‘false positives’ in the 
usual sense of the term.  Actual clinical performance will likely be associated with an 
additional two or three per 1000 more positive test results that those predicted based on 
modeling alone. 
 
A direct comparison can also be made between these modeling results and those 
reported in the literature (Palomaki et al., 1995) and summarized in Table 3.11-1.  Two 
clear points emerge.  First, the test performance is better.  Using triple marker testing 
with AFP, uE3 and hCG as an example, the 1995 modeling estimated a detection rate of 
60% at a false positive rate of 0.2%.  The current modeling estimates 80% detection at a 
false positive rate of 0.3%.  This improvement can be traced to two factors: the standard 
deviation of AFP measurements in affected pregnancies is considerably tighter than 
expected, and the standard deviation of uE3 measurements in unaffected pregnancies is 
also considerably tighter.  Some improvement may also be attributed to the underlying 
maternal age distribution used being considerably older than that used in 1995.  All of 
these factors will improve screening performance.   
 
The second point is that select performance occurs at quite different risk cut-off levels.  
For example, using the double test with AFP and hCG, the 1995 modeling estimated 
using a 1:100 second trimester risk cut-off level, the detection rate would be 30% and the 
false positive rate would be 0.2%.  This is similar to the performance seen for the current 
modeling (29% detection at 0.1% false positive rate from Table 3.9.3).  However, this 
performance estimate occurs using a second trimester risk cut-off of 1:18.  Although 
some of this could be attributed to improved performance, most is due to recent updates 
in the age-associated prior risk of trisomy 18 as well as the second trimester fetal loss 
rate.   
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Table 3.9-2.  Modeled trisomy 18 detection rates (DR) and false positive rates (FPR) using second trimester maternal serum markers 
 
 Maternal age and AFP, in combination with screening markers 
 hCG free β uE3 & hCG uE3 & free β uE3, hCG & PAPP-A uE3, free β  & PAPP-A
  
DR (%) False Positive Rate (%) 
50 0.7  0.3 <0.1 <0.1 <0.1 <0.1 
60 1.6  0.8 <0.1 <0.1 <0.1 <0.1 
70 3.8 2.0 <0.1 <0.1 <0.1 <0.1 
80 9.0             5.3 0.3 0.2 <0.1 <0.1 
90 >20           16 2.9 1.1   0.2   0.1 
       
FPR (%) Detection Rate (%) 
0.3 39 48 79 83 92 94 
0.5 45 54 82 86 94 96 
0.7 49 58 83 88 96 97 
1.0 54 62 84 90 97 97 
1.5 59 67 87 91 98 98 
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Table 3.9-3.  Modeled trisomy 18 detection rates (DR), false positive rates (FPR) and odds of being affected given a positive test 
result (OAPR) using second trimester maternal serum markers at selected trisomy 18 risk cut-off levels 
 
 Maternal age in combination with screening markers 
 Double Test  Triple test  Quadruple test 
Risk  AFP & hCG  AFP, uE3 & hCG  AFP, uE3, hCG & PAPP-A 
 at term (2nd)1 DR FPR OAPR2  DR (%) FPR (%) OAPR2  DR (%)  FPR (%) OAPR2 
            
1:  50 (1:  18) 29 0.10 1:  5  68     <0.10 -  76 <0.10 - 
1:100 (1:  35) 38 0.27 1:  9  73 0.12 -  81 <0.10 - 
1:150 (1:  53) 44 0.41 1:12  76  0.18 1:3  84 <0.10 - 
1:200 (1:  70) 48 0.63 1:17  78   0.26 1:4  85 <0.10 - 
1:250 (1:  88) 51 0.83 1:21  80  0.33 1:5  87 <0.10 - 
1:300 (1:105) 54 1.0 1:24  81  0.39 1:6  88   0.11 1:2 
1:350 (1:123) 57 1.2 1:27  81  0.45 1:7  88   0.12 1:2 
1:400 (1:140) 59 1.5 1:33  82  0.51 1:8  89   0.13 1:2 
 
1  assuming a  65% fetal loss from 16-18 weeks to term (Table 2.4-1) 
2 OAPR = second trimester odds of being affected given a positive result (assumes birth prevalence of 2.69/10,000, with adjustment for 65% 
fetal loss from 16-18 weeks to term). 
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Figure 3.9-2 shows the age-associated risk of trisomy 18, based on one-tenth the age-
associated term risk of Down syndrome (Hecht and Hook, 1996) as well as the risk 
based on a recent publication using direct observations of trisomy 18 birth pregnancies 
(Morris 2008).  At 25 and 40 years of age, for example, the current risk estimates (solid 
line) are higher by a factor of 1.6 (1:13,100 versus 8,350) and 2.3 (1:994 versus 1:435), 
respectively.  In 1995, these term risks were converted to second trimester using a fetal 
loss rate of 70% compared to the current estimate of 65%, increasing the difference 
even further.  Lastly, the general shifting towards older pregnancies will also cause the 
risk cutoff levels to shift towards higher values. 
 
However, the reasonable risk cutoff-level for both the old and new modeling for the triple 
test is a second trimester risk of about 1:100, easing the implementation of the new 
model.  The suggested changes in the underlying statistical parameters would not be 
noticeable to health providers, but the performance would improve, especially if PAPP-A 
measurements were to be included. 
 
Figure 3.9-2.  A comparison of two methods of assigning age-associated term 
risks for trisomy 18.  The solid line (Morris and Savva, 2008) shows the modeled 
age-specific trisomy 18 risk at term.  Prior to this, an alternative method was used to 
approximate trisomy 18 risk.  This was done by dividing the Down syndrome term 
risk (Hecht and Hook, 1996) by 10.  The factor 10 was the approximate ratio of term 
Down syndrome births to trisomy 18 births.  At 25 (A) and 40 years (B) of age, the 
corresponding risks are 1:8,350, 1:13,100 and 1:994, 1:435, respectively. 
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3.10  Demonstration studies using fixed MoM cut-offs 
In the 1980s, when only maternal age and AFP measurements were being used to 
screen for Down syndrome in the second trimester, there was no need for a separate 
algorithm for identifying pregnancies at high risk for trisomy 18.  This is because both 
Down syndrome and trisomy 18 pregnancies have lower AFP measurements, and both 
aneuploidies are associated with increasing maternal age.  If a woman is at increased 
risk of Down syndrome based on age and AFP measurements, then she would also be 
at increased risk of trisomy 18.  The information about increased risk for trisomy 18 was 
often provided as part of counseling women screen positive for Down syndrome, prior to 
diagnostic testing.  Two studies in the late 1980s included information about the 
identification of trisomy 18 pregnancies as part of a maternal age/AFP screening 
program for Down syndrome.  The Yale program screened 24,065 women under age 35 
for Down syndrome, with 6.0% of the population determined to be at or above the risk of 
a 35 year old woman (DiMaio et al., 1987).  Among these screen positive pregnancies, 
three were identified as having trisomy 18 at the time of amniocentesis.  A second 
multicenter trial in New England (Palomaki, 1989) enrolled 77,273 women under age 35 
from eight centers.  A total of 4.7% were screen positive for Down syndrome and four 
cases of trisomy 18 were identified.  Neither group attempted to determine a trisomy 18 
detection rate. 
 
At about the same time that these Down syndrome demonstration studies were being 
reported, new information about additional second trimester serum markers was 
emerging, including uE3, hCG and the free β subunit of hCG.  As documented earlier, 
some studies of these newer markers included reports of trisomy 18, and it soon became 
clear that the pattern of low, low, high (for AFP, uE3 and hCG) found in Down syndrome 
was not the same as the pattern seen in trisomy 18 pregnancies.  AFP and uE3 
measurements were still both low in trisomy 18 pregnancies, but hCG measurements 
were also low, not high.  Because of this important difference, double or triple marker 
algorithms for Down syndrome were less likely to also identify pregnancies with trisomy 
18.  A new algorithm targeted towards trisomy 18 was needed.  In 1990, Canick and his 
colleagues (Canick et al., 1990) published the levels of AFP, uE3 and hCG in a series of 
10 trisomy 18 pregnancies and proposed a simple algorithm based on reduced 
measurements of all three analytes.  Using fixed MoM cut-off levels of <0.75 MoM, <0.60 
MoM and <0.55 MoM for AFP, uE3 and hCG, respectively, they estimated that 60% of 
trisomy 18 pregnancies might be identifiable by offering amniocentesis to about 0.4% of 
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women.  In the second trimester, this would result in an odds of being affected given a 
positive result (OAPR) of about 1:16 (alternatively, a positive predictive value of 5.9%).  
Some argued that the fixed cut-off levels should be set higher, so that a higher detection 
rate could be achieved.  However, this would result in a higher false positive rate and, 
therefore, a lower OAPR.  The OAPR is directly translated into the number of procedures 
needed to identify a case of trisomy 18 in the second trimester.  Given the relatively low 
chance of survival to term, and the high rate of death among the few live births, it was 
decided to set the fixed MoM cut-offs to maintain a high target OAPR. 
 
The fixed MoM cut-off algorithm for the triple markers AFP, uE3 and hCG was widely 
adopted in the United States and used extensively in the 1990s.  The majority of studies 
reported trisomy 18 results as part of a Down syndrome demonstration study, but several 
focused only on trisomy 18 testing.  Because this algorithm is no longer in use, only 
summary information will be provided.  A total of 10 studies used AFP, uE3 and hCG 
(Palomaki et al., 1992; Burton et al., 1993; Bradley, 1994; Kellner et al., 1995; Benn et 
al., 1996; McDuffie et al., 1996; Yankowitz et al., 1998; Feuchtbaum et al., 2000; Hogge 
et al., 2001; Summers et al., 2003) and 2 used AFP and free β hCG (Seppo et al., 1999; 
Chao et al., 1999).  A total of 316,655 women were tested, and 0.29% (95% CI 0.21-
0.41%) had the high risk triple marker pattern.  Among these 1,639 women, 99 trisomy 
18 fetuses were identified for an OAPR of 1:15 (95% CI 1:10 to 1:26). 
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3.11  Demonstration studies using trisomy 18 risk 
The fixed MoM cut-off model does not account for the known age-associated change in 
the prior risk of trisomy 18.  More importantly, the results of the interpretation are 
dichotomous (positive, negative) and, therefore, cannot differentiate between those 
pregnancies that have markers near the cut-off levels or much below those levels.  
Clinicians and those involved in screening programs needed to be able to assign patient-
specific risks for trisomy 18 in much the same way as when screening for Down 
syndrome.  However, such a model would require a relatively large number of unbiased 
cases with AFP, uE3 and hCG measurements.  The cases would also need to have 
been identified without regards to the biochemistry results.  For example, stored serum 
samples collected prior to implementation of the fixed MoM cut-off trisomy 18 protocol 
from women whose pregnancy was later found to have trisomy 18.  Diagnostic testing 
might have been triggered by abnormal ultrasound findings or by clinical finding at the 
time of birth.  Other sources of unbiased samples would be those collected prior to 
amniocentesis performed due to maternal age or family history of aneuploidy. 
 
In 1995, a collaborative study of 94 second trimester serum markers in trisomy 18 
fetuses was published by our research group (Palomaki et al., 1995).  Of these, 89 were 
from pregnancies without an open defect.  All pregnancies had existing triple marker 
testing results.  A risk algorithm was developed, based on the same concept of 
overlapping Gaussian distributions as was used for assigning Down syndrome risk.  An 
important advantage of this dataset was the range of indications for diagnosis.  In 38%, 
the samples were collected due to age 35 or older, in another 17%, the indication was 
abnormal ultrasound, another 13% were live births, with the remaining 31% having only 
AFP screening.  This latter category was only included if the center was able to identify 
live-born/stillborn cases as well.  By comparing the serum marker measurements among 
these four groups, it was possible to determine whether any group differed in any 
important way from another.  Overall, no differences were found for the AFP or uE3 
measurements.  However, the group of older women did tend to have lower than 
expected hCG measurements (0.26 MoM vs. 0.42 MoM, p=0.05). 
 
Modeling based on these published parameters suggested that using the risk algorithm 
with triple markers would provide considerable improvement by both increasing the 
detection rate and reducing the false positive rate.  Table 3.11-1 summarizes the 
modeling results from that publication (Palomaki et al., 1995).  This algorithm is currently 
the standard of care for assigning trisomy 18 patient-specific risks in the second 
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trimester, with the boxed row indicating the most commonly used second trimester risk 
cut-off level of 1:100.  From this table, it is clear that a double marker algorithm (AFP and 
hCG, or AFP and the free β subunit of hCG) is less effective in identifying trisomy 18 
pregnancies than the triple test. 
  
The English literature was searched as described earlier.  Several of the studies (Benn 
et al., 1996; Summers et al., 2003) reported results for both the fixed MoM cut-off and 
risk protocols.  The majority of studies reported the trisomy 18 screening results as part 
of a Down syndrome demonstration study, but several focused only on trisomy 18.  All 
used patient-specific risks based on maternal age, AFP, uE3 and hCG measurements 
and used a published algorithm (Palomaki et al., 1995).  Figure 3.11-1 shows the six 
studies included in the analyses versus the year of publication (Benn et al., 1999; Hogge 
et al., 2001; Summers et al., 2003; Jaques et al., 2007; Breathnach et al., 2007; 
Wortelboer et al., 2008).  Since many laboratories were using fixed MoM cut-off levels 
routinely, it took several years for programs to switch methodologies, implement testing, 
and report results.  In some of the publications, the risks were assigned retrospectively, 
for samples collected prior to 1995 (Benn et al., 1999; Hogge et al., 2001). 
 
Table 3.11-1.  Test performance for trisomy 18 in the second trimester using maternal 
age and measurements of  maternal serum AFP, uE3 and hCG to assign patient-
specific risks 
 
Term (2nd trim) Maternal age in combination with 
Risk Cut-off AFP and hCG  AFP, uE3 and hCG 
(> 1:n) DR (%) FPR (%) OAPR  DR (%) FPR (%) OAPR  
        
1:  170 (1:  50)  22 0.1 1:11  33 <0.1 - 
1:  330 (1:100) 30 0.2 1:16  60  0.2 1:  8 
1:  500 (1:150) 38 0.5 1:32  65  0.3 1:12 
1:  670 (1:200) 43 0.7 1:39  68  0.4 1:14 
1:1000 (1:300) 49 1.2 1:59  70  0.6 1:21 
1:1300 (1:400) 54 1.7 1:76  73  0.8 1:26 
1:1700 (1:500) 57 2.3 1:97  76 1.0 1:32 
 
AFP = alpha-fetoprotein, uE3 = unconjugated estriol, hCG = human chorionic gonadotropin 
DR = detection rate, FPR = false positive rate, OAPR = odds of being affected given a 
positive result 
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Figure 3.11-1.  Publications reporting the results of second trimester trisomy 18 
demonstration studies that used patient-specific trisomy 18 risks.  The risk 
algorithm used in these reports was first published in 1995 (arrow).  All reported trials 
use maternal serum AFP, uE3 and hCG measurements.  None of the studies reported 
20 or more cases of trisomy 18 detected. 
 
Table 3.11-2 shows summary information from the six included studies.  Overall, the 
summary odds of being affected given a positive result (OAPR) is 1:14 (95% CI 1:8  to 
1:23) with considerable heterogeneity (Q=12, I2=66%, p=0.02).  This is somewhat lower 
than the predicted OAPR for this algorithm of 1:8 in Table 3.10-2 (Palomaki et al., 1995).  
There may be a reasonable explanation for the lower than expected OAPR.  The 
algorithm not only identifies trisomy 18, but also existing fetal deaths, anencephaly and 
other abnormalities (Palomaki et al., 1995; Benn et al., 1996).  Two of the intervention 
trials (Benn et al., 1996; Hogge et al., 2001) also reported the number of fetal 
deaths/abnormalities, and the revised positive rates are considerably lower (0.47% to 
0.35% and 0.55% to 0.41%, respectively).  These two studies had the lowest OAPR 
estimates of 1:21.6 and 1:31.3, and after removing fetal death/abnormalities, these were 
increased to 1:16 and 1:22, respectively.  A higher than expected number of ‘false 
positive’ are likely with the very specific trisomy 18 algorithms due to other true abnormal 
(but not trisomy 18) outcomes. 
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Table 3.11-2.  Trisomy 18 demonstration studies using patient specific risk  
 
 Years  Age 35 or Screen Positive  Number OAPR 
Study Included Number older (%) Number (%) Revised1  of T18 (1:n) 
          
(Benn et al., 1999) 92 to 97   41,565 NR 194 0.47 147    9 1:21.6 
(Hogge et al., 2001) 93 to 98   45,145 10.2 250 0.55 183    8 1:31.3 
(Summers et al., 2003) 98 to 00 107,240 16.2 223 0.21 NR  18 1:12.4 
(Jaques et al., 2007) 98 to 00   16,607 NR   41 0.25 NR    4 1:10.3 
(Breathnach et al., 2007) 99 to 02   35,120 NR 109 0.31 NR  13 1:  8.4 
          
All  245,677  817 0.33   52 1:14 
    (95% CI 0.22 – 0.51)   (95% CI 1:8 – 1:23)
      
(Wortelboer et al., 2008)2 91 to 05   42,554 NR NR NR NR  19 NR 
 
OAPR = odds of being affected given a positive result (equivalent to the positive predictive value) 
1  Number screen positive after other known abnormalities and existing fetal demises removed. 
2  Study not included in the summary analysis (All), due to limited data. 
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The analysis was performed on the logit of the PPV [ logit (PPV) = ln(PPV/(1-PPV)) ].  
The summary estimate based on the random effects modeling of these logit values was 
then converted back to an odds of being affected given a positive result (OAPR).  For 
example, the summary logit was -2.618.  The corresponding OAPR is 1:14 and is 
computed as follows: 
 
 PPV (as a risk) = exp(-2.618) / (1+exp(-2.618)) 
 PPV (risk) = 0.07295 / (1.07295) = 0.06799 
 PPV (as an odds) = 1:(1 - 0.06799)/(0.06799) = 1:14 
 
 
Figure 3.11-2.  The odds of being affected given a positive result (OAPR) for 
trisomy 18 screening trials using patient-specific risks.  These studies assigned 
risk using AFP, uE3 and hCG measurements.  The logit of the OAPR is analyzed 
using a random effects model, with the summary OAPR of 1:14 (logit of -2.618). 
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3.12  Conclusions 
Five questions were posed at the beginning of this section, and they can now be 
answered. 
 
Q1.  Based on observational studies, what are the summary population parameters for 
maternal serum markers in second trimester trisomy 18 pregnancies, and do they 
agree with those in wide use today (Palomaki et al., 1995)?   
 
Reasonable parameters are summarized in tables and figures contained in Section 
3.8.  The AFP, uE3 and hCG parameters derived from the literature are close to 
those used routinely for assigning trisomy 18 risk in clinical practice (Palomaki et al., 
1995), with the exception of a modest tightening of the AFP logarithmic standard 
deviation (from 0.2239 to 0.1817).  Although it is not necessary to revise the 
parameters for AFP, uE3 and hCG for trisomy 18, the updated population parameters 
could be used in clinical practice and would likely result in more appropriate patient-
specific risks.  Programs could also take this opportunity to update the age-specific 
term risks for trisomy 18, as well as the fetal loss rates from the early second 
trimester to term. 
 
Q2.  Do trisomy 18 demonstration studies using AFP, uE3 and hCG confirm the 
performance of the risk-based model (Palomaki et al., 1995), as defined by the false 
positive rate and positive predictive value? 
 
It is difficult to confirm a detection rate for trisomy 18 as part of a demonstration 
study, but the reported false positive rates and odds of being affected given a 
positive result (OAPR) meet expectations.  For example, the expected false positive 
rate for the risk-based algorithm was 0.2%, and the observed summary rate was 0.33 
(95% CI 0.22 – 0.51).  The expected OAPR was 1:8, and the observed rate was 1:14 
(95% CI 8 to 23).  Both of these rates are somewhat short of target, because this 
algorithm also preferentially identifies other abnormal pregnancies outcomes besides 
trisomy 18 (Section 3.10). 
 
Q3.  Are measurements of inhibin-A useful to add to the risk-based model?  If so, 
describe the algorithm and model the expected increase in performance.  
 
 
Chapter 3: Second Trimester Maternal Serum Markers for Trisomy 18 86 
Based on the two largest studies, the reduction in median inhibin-A levels in trisomy 
18 is only about 9% (0.91 MoM) and is not statistically significant.  Other smaller 
published studies report that the levels were ‘not different’, or were consistent with 
little or no change.  Inhibin-A does not appear to be useful for trisomy 18 testing in 
the second trimester. 
 
Q4.  Are there other serum markers that may be of use in a risk-based model?  If so, 
describe the algorithm and model the expected increase in performance. 
 
PAPP-A measurements are extremely low in trisomy 18 pregnancies in the early 
second trimester.  Were these measurements to be routinely available, performance 
would be significantly enhanced.  For example, at a detection rate of 80%, the false 
positive rate would drop from 1.5% to about 0.1%.  Screening programs would need 
to evaluate the costs of adding a second trimester PAPP-A against improved 
detection, reduced false positives, or a combination of the two.   
 
Although a complete cost benefit analysis is beyond the scope of this project, with 
some simplifying assumptions, one can determine whether more extensive analyses 
are warranted.  If the trisomy 18 detection rate were held constant at 80%, the 
expected false positive rate would be reduced from 3/1000 to 1/1000 (Table 3.9.2) by 
adding PAPP-A measurements.  Among a population of 10,000 pregnancies tested, 
this translates into detecting about 7 of the 8 cases occurring, while identifying 30 
false positive results using the triple test.  Adding PAPP-A reduces this to compared 
to 10 false positives with a savings of 20 amniocenteses / karyotypes.  A a cost of 
about $1000 each, this represents a $20,000 savings and translates into $2 per 
patient available for the PAPP-A measurement.  This is insufficient to cover the $5 or 
so needed to run a PAPP-A test.  However, contingent testing can greatly reduce the 
costs associated with testing everyone in the population while closely maintaining 
performance (Palomaki et al., 2006).  This is especially true when the marker is 
highly predictive, such as is in this scenario with PAPP-A.  Contingent models that 
include PAPP-A measurement on even one-quarter (or less) of the population would 
then be able to reduce the overall health care costs.  At the same time, fewer 
procedure-related losses would occur due to the 67% reduction in invasive 
procedures.  Given that many laboratories have PAPP-A assays available for first 
trimester testing, this is a real potential improvement in second trimester testing for 
trisomy 18.
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Chapter 4  First trimester maternal serum markers for trisomy 18 
 
4.1 Introduction 
The first reports for maternal serum markers for Down syndrome were made in the early 
1980s.  This was quickly followed by a large number of reports confirming the findings in 
the second trimester.  However, there are fewer earlier reports for first trimester markers 
for two reasons.  Second trimester screening was already established for neural tube 
defects at that time, so sample banks were readily available to document performance of 
Down syndrome markers.  In addition, diagnostic testing in the first trimester (chorionic 
villus sampling - CVS) was less commonly performed, and this led to fewer cases of 
aneuploidy being identified that could be used in research. In contrast to methods used 
to remove smaller studies from analysis for second trimester markers (Chapter 3), 
attempts were made to be as all inclusive as possible when examining first trimester 
serum markers.  Mainly, this was due to the smaller numbers of useable studies that, in 
general, had smaller numbers of cases examined.  Another clear finding was that the 
less common aneuploidies (e.g., trisomy 18 and trisomy 13) were far more prevalent in 
the first trimester than in the second trimester, or at term.  In Chapters 1 through 3, 
trisomy 18 was the sole focus.  However, because trisomy 13 (Patau syndrome) is more 
common in the first trimester and because both trisomy 18 and 13 are sometimes 
included together in relevant publications on serum and ultrasound markers, readily 
available information about those marker levels in trisomy 13 pregnancies will also 
summarized at the end of the chapter.  Rather than creating a separate algorithm for 
trisomy 13, it may be possible to model the proportion of these fetuses that might be 
identified as part of a risk algorithm for trisomy 18.   
 
Literature search 
A PubMed search was performed (through 2009) using search terms “trisomy 18”, “first 
trimester” and “serum”.  Identified abstracts were reviewed and selected articles 
retrieved.  Reference lists of identified articles were also searched for relevant articles.  
As before, many articles were aimed at Down syndrome screening and only tangentially 
referred to trisomy 18 (or trisomy 13).  The included articles were then stratified into two 
groups:  those in which the serum marker of interest was not used to assign risk for 
decision-making about diagnostic testing and/or other follow-up (e.g., assessment at 
birth), and the remaining articles.  This first group (32 articles) might be considered 
‘unbiased’, as they would likely represent the marker distribution in an unselected group 
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of affected pregnancies (Aitken et al., 1993; Akolekar et al., 2010; Bersinger et al., 1994; 
Biagiotti et al., 1998; Bogart et al., 1989; Brambati et al., 1994; Brizot et al., 1994; Brizot 
et al., 1995; Jauniaux et al., 1996; Johnson et al., 1991; Koster et al., 2010; Koster et al., 
2009; Kratzer et al., 1991; MacIntosh et al., 1993; Miell et al., 1997; Ozturk et al., 1990; 
Palomaki, 2004; Poon et al., 2009; Scott et al., 1996; Sifakis, 2010; Spencer et al., 1992; 
Spencer et al., 1997; Spencer et al., 2000b; Spencer et al., 2000a; Spencer et al., 
2001b; Spencer et al., 2001a; Spencer et al., 2007; Lambert-Messerlian, 2004b).  One 
additional study (Spencer et al., 1994) appears to duplicate data from another, more 
complete report (Aitken et al., 1993) and was not included.  
 
The second group of 20 or more articles was generally composed of demonstration 
studies and is not considered in this section.  They will be summarized in Chapter 6 
where first trimester intervention trials relying on both biochemistry and ultrasound 
measurements are reviewed.  These could be viewed as reporting ‘biased’ estimates of 
biochemistry distributions.  True positive results (pregnancies with abnormal marker 
levels) will be identified early, when the prevalence is higher.  In contrast, false negative 
results (pregnancies with more normal marker levels) will not usually be identified until 
birth, after many of the affected pregnancies have been spontaneously lost.  This “bias of 
ascertainment” is well described  for Down syndrome screening and is even more 
important when screening for trisomy 18 (or trisomy 13), due to the higher rate of fetal 
loss.  Figure 4.1-1 provides a schematic representation of this bias in a hypothetical 
cohort of 100 first trimester trisomy 18 pregnancies.   
 
Statistical methods are similar to those utilized in Chapter 4, including summary medians 
and rates determined using random effects modeling, and examining heterogeneity 
using the Q-statistic and I2.  Summary ROC curves were computed using public domain 
software (MetaDisc available at www.hrc.es/investigacion/metadisc.html).  Smaller 
studies that provided individual patient results were grouped together and fitted to a 
probability plot to estimate a representative log mean and log standard deviation for 
these data.
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60/(60+40)=60% 
 
60/(60+11)=85% 
 
 
 
 
Figure 4.1-1.  Schematic description of the ‘ascertainment bias’ present in 
demonstration studies.  Initially, 100 cases of trisomy 18 are known to be present in a 
population of women undergoing a first trimester screening test.  Assume that the test 
actually detects 60% of the cases (60 true positives in bold outline) and, therefore, 
misses 40% of the cases.  The fetal loss rate for trisomy 18 from the late first trimester to 
term is 72% (Morris and Savva, 2008) and is assumed, for now, to be independent of the 
test results.  Thus, of the 40 false negative cases, only 11 can be expected to survive 
and be diagnosed at term (bold outline).  However, the 29 false negative cases will not 
be identified, as they are spontaneously lost (dashed bold outline).  This leads to an 
overestimated detection rate of 85%, if the bias is not accounted for.  If, for example, the 
screening test were simply “How old are you?” with a cut-off of 35 years of age, then all 
60 true positive results would be in women age 35 and older, while the 40 false negative 
results would all occur in women under age 35.  However, as part of an demonstration 
study, only the 11 cases diagnosed at term would be counted, and it would appear as 
though 85% of women with trisomy 18 fetuses are age 35 or older, rather than the 
correct estimate of 60%.  This same phenomenon can occur with other markers (e.g., 
biochemical, ultrasound).  To obtain a correct distribution of results for the population 
(100 cases in this example), it is important to choose study designs that do not suffer 
from the bias of ascertainment described here, or account for it mathematically. 
100 1st trimester
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Characteristics of follow-up for included studies 
The group of 32 ‘unbiased’ studies of first trimester serum markers and trisomy 18 were 
then assigned to one of three categories, depending on study design and ascertainment 
methods. 
 complete ascertainment – in 19 studies all cases were identified, regardless of the 
analyte level (Aitken et al., 1993; Bersinger et al., 1994; Biagiotti et al., 1998; Bogart 
et al., 1989; Brambati et al., 1994; Brizot et al., 1994; Brizot et al., 1995; Jauniaux et 
al., 1996; Johnson et al., 1991; Kratzer et al., 1991; MacIntosh et al., 1993; Ozturk et 
al., 1990; Palomaki, 2004; Scott et al., 1996; Spencer et al., 1992; Spencer et al., 
2000a; Van Lith, 1992; Zaragoza et al., 2009; Zimmermann et al., 1996).  For 
example, serum samples were collected routinely from women of advanced maternal 
age prior to a CVS.  Although this group has a higher rate of trisomy 18 due to age, 
there is no evidence suggesting that phenotypic presentation is dependent on the 
mother’s age. 
 Screened, but not correlated – in 12 studies some form of phenotypic screening has 
occurred, but the marker used is known to be uncorrelated (or have low correlation) 
with the marker of interest (Akolekar et al., 2010; Koster et al., 2010; Koster et al., 
2009; Miell et al., 1997; Poon et al., 2009; Sifakis, 2010; Spencer et al., 1997; 
Spencer et al., 2000b; Spencer et al., 2001b; Spencer et al., 2001a; Spencer et al., 
2007; Tul et al., 1999).  For example, serum samples were collected from women 
screen positive due to a combination of maternal age and NT measurements.  NT 
measurements have been shown to be independent of biochemistry for Down 
syndrome and other aneuploidies.  Another example would be serum samples from a 
combined testing program (NT, PAPP-A and free β) that examined the performance 
of ADAM-12, and found low correlations with the other markers. 
 Screened, but follow-up occurs later – in one study (Lambert-Messerlian, 2004b) first 
trimester screening results were not acted upon until the second trimester.  At that 
time, women were also provided with their second trimester screening test results 
(quadruple test).  This protocol will detect a very high proportion of cases and, 
therefore, will not be subject to a strong effect of ascertainment bias. 
 
Included studies and associated numbers of affected pregnancies 
Overall, 30 of the 32 included publications provided 28 datasets that totaled 508 trisomy 
18 pregnancies (open circles in Figure 4.1-2).  Two sets of paired studies used the same 
dataset to examine different markers (Brizot et al., 1994; Brizot et al., 1995; Spencer et 
al., 2001b; Spencer et al., 2001a) and these will be displayed only once.  One dataset 
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was published only in abstract form (Palomaki, 2004), and another is unpublished data 
from the FASTER trial (Lambert-Messerlian, 2004b).  Raw data were available from both 
of these studies for analysis.  Data from the included studies most often provide 
information on one or more of the three most common first trimester serum markers for 
Down syndrome (i.e., PAPP-A, free β hCG, and intact/total hCG), but data are also 
available for 14 other first trimester biochemical markers.   
 
Of the 32 publications, 17 also reported marker levels in 232 trisomy 13 affected 
pregnancies (Figure D.1) (Akolekar et al., 2010; Bersinger et al., 1994; Bogart et al., 
1989; Brambati et al., 1994; Brizot et al., 1995; Johnson et al., 1991; Koster et al., 2009; 
Koster et al., 2010; Kratzer et al., 1991; MacIntosh et al., 1993; Poon et al., 2009; 
Spencer et al., 1997; Spencer et al., 2000b; Spencer et al., 2000a; Spencer et al., 2007; 
Zaragoza et al., 2009).  Again, two sets of paired studies used the same dataset to 
examine different markers (Brizot et al., 1994; Brizot et al., 1995; Spencer et al., 2000b; 
Spencer et al., 2000a).  Although this number appears quite large, the majority of 
included publications for trisomy 13 did not focus on the more common first trimester 
markers.  Instead, this literature is dominated by relatively recent, large studies of ‘fringe’ 
markers using stored samples collected during first trimester combined demonstration 
studies (from the ‘screening but not correlated’ group) (Akolekar et al., 2010; Koster et 
al., 2010; Poon et al., 2009; Spencer et al., 2007; Zaragoza et al., 2009).  Unfortunately, 
due to the biases mentioned earlier, these reports cannot be utilized for the marker 
levels used in the interpretive algorithm (e.g., PAPP-A, free β hCG).  Only 93 affected 
pregnancies are available, at most, for the common markers; 65 coming from only two 
datasets (Koster et al., 2009; Spencer et al., 2000b; Spencer et al., 2000a).   
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Figure 4.1-2.  Relevant publications for biochemical marker levels in 1st 
trimester pregnancies affected with trisomy 18 or trisomy 13.   Open circles 
indicate the number of trisomy 18 pregnancies, while the open squared indicate 
trisomy 13 pregnancies.  Some of the largest studies are for rarely used markers. 
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4.2  Common first trimester serum markers 
Table 4.2-1 summarizes the numbers of included studies in the first phase of analysis, 
along with the number of cases of trisomy 18 and 13, and the median MoM levels for the 
three common first trimester serum markers (free β, hCG and PAPP-A).  Each of these 
had at least five published reports for trisomy 18.  In general, these findings provided 
consistent estimates of effect size, even though some included a relatively small number 
of cases.  Overall, 13 studies reported the free β subunit of hCG measurements in 195 
trisomy 18 pregnancies affected with trisomy 18.  The overall estimate for free β was 
about 0.28 MoM.  A total of 10 studies reported intact (or total) hCG measurements in 
130 pregnancies with trisomy 18, with a summary of 0.37 MoM.  For PAPP-A 
measurements, there were seven studies of 149 women with a summary MoM of 0.21.  
These estimates will be further refined in subsequent sections. 
 
The data are sparser for trisomy 13 and these serum markers.  For the free β subunit of 
hCG, there are three studies with 29 samples having a summary of 0.43 MoM.  There 
were five studies reporting levels of hCG, with 60 samples having a summary MoM of 
0.49.  Only two studies reported PAPP-A levels in trisomy 13, with the summary of 0.24 
MoM based on 21 samples (20 coming from one study).  It is this lack of unbiased (or 
only modestly biased) data that makes confident modeling of trisomy 13 difficult. 
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Table 4.2-1.  Summary of biochemical markers for trisomy 18 (and trisomy 13) in the late first trimester having five or more included 
studies of any size  
 
 First   Trisomy 18 Trisomy 13 
Marker Author Country GA (range) Number MoM Number MoM 
        
Free β hCG (Brambati et al., 1994) Italy   8 - 12   2 0.13   1 0.15 
 (Aitken et al., 1993) UK   6 - 14   5 0.15   0 - 
 (Lambert-Messerlian, 2004a) US/multiple 10 - 13 14 0.15   0 - 
 (Spencer et al., 1992) UK   7 - 13   5 0.17   0 - 
 (Jauniaux et al., 1996) Belgium 10 - 11   5 0.19   0 - 
 (Koster et al., 2010) Netherlands 11 - 13 43 0.22 20 0.49 
 (Palomaki, 2004) US/multiple   9 - 13 12 0.23   0 - 
 (Spencer et al., 1997) UK 10 – 14   7 0.24   5 0.64 
 (Tul et al., 1999) UK 11 - 13 50 0.28   0 - 
 (Scott et al., 1996) Australia 10 - 13   4 0.30   0 - 
 (Zimmermann et al., 1996) Switz/Austria 10 - 13   5 0.33   0 - 
 (Biagiotti et al., 1998) Italy   8 - 13 23 0.34   0 - 
 (Ozturk et al., 1990) Italy/Neth   8 - 12   8 0.48   0 - 
 (Brizot et al., 1995) UK 10 - 13 19 0.50   8 0.30 
         
 All    202 0.28 34 0.46 
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Table 4.2-1.  (continued) 
 
 First   Trisomy 18  Trisomy 13 
Marker Author Country GA (range) Number MoM  Number MoM 
         
Intact hCG (Bogart et al., 1989) US/CA   9 - 11   2 0.12    2 3.42 
 (Aitken et al., 1993) UK   6 - 14   5 0.27    0 - 
 (Jauniaux et al., 1996) Belgium 10 - 11   5 0.36    0 - 
 (Van Lith, 1992) Netherlands   9 - 11   6 0.81    0 - 
 (Johnson et al., 1991) US/PA 10 - 11   7 0.32    5 0.65 
 (Kratzer et al., 1991) US/CA   9 - 12   7 0.32    3 0.34 
 (Palomaki, 2004) US/multiple   9 - 13 12 0.37    0 - 
 (Lambert-Messerlian, 2004a) US/multiple 10 - 13 14 0.27    0 - 
 (Brizot et al., 1995) UK 10 - 13 19 0.40    8 0.30 
 (Spencer et al., 2000b) UK 10 - 13 53 0.38  42 0.38 
         
 All   130 0.37  60 0.49 
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Table 4.2-1.  (continued) 
 
 First   Trisomy 18  Trisomy 13 
Marker Author Country GA (range) Number MoM  Number MoM 
         
PAPP-A (Brambati et al., 1994) Italy   8 - 12   2 0.51    1 0.59 
 (Zimmermann et al., 1996) Switz/Austria 10 - 13   5 0.08    0 - 
 (Benacerraf et al., 1994) UK 10 - 14   9 0.07    4 0.28 
 (Palomaki, 2004) US/multiple   9 - 13 12 0.28    0 - 
 (Lambert-Messerlian, 2004a) US/multiple 10 - 13 14 0.23    0 - 
 (Brizot et al., 1994) UK 10 - 13 19 0.17    8 0.25 
 (Biagiotti et al., 1998) Italy   8 - 13 23 0.25    0 - 
 (Koster et al., 2010) Netherlands 11 - 13 43 0.19  20 0.22 
 (Tul et al., 1999) UK 11 - 13 50 0.18    0 - 
         
 All   177 0.20  33 0.25 
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4.3  Other first trimester serum markers 
Table 4.3-1 shows data for the 14 additional markers identified in the literature search, in 
alphabetical order.  Both AFP and the free alpha-subunit of hCG have results from four 
studies.  For AFP, the results from the 80 observations are variable, ranging from 0.62 to 
1.25 MoM.  For free alpha, there are 22 observations from four studies, with results 
ranging from 0.98 to 2.09 MoM.  Neither appears to be useful for trisomy 18 in the late first 
trimester.  All of the remaining 12 markers have one (9 markers) or two (3 markers) 
included studies.  Due to these limited data, the reported estimates for these should be 
considered preliminary.  Of interest, however, is the single finding of very low uE3 
measurements (0.34 MoM) (Aitken et al., 1993).  However, this was based on only five 
observations and needs confirmation.   
 
Also included in Table 4.3-1 are the corresponding results for trisomy 13 pregnancies.  
Several relatively large studies for selected markers in this category are promising.  In two 
studies (80 cases), ADAM-12 median MoM levels were 0.58 and 0.66 (Poon et al., 2009; 
Spencer et al., 2007).  Several other markers had low levels reported (e.g., PlGF, PP13), 
but each was based on a single study. 
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Table 4.3-1.  Summary of other biochemical markers for trisomy 18 (and trisomy 13) in the late first trimester having fewer than five 
included studies  
 
 First  GA Trisomy 18  Trisomy 13 
Marker Author Country  (range) Number MoM  Number MoM 
         
Activin-A (Spencer, 2001) UK 10 - 13 45 1.23  0 - 
         
A disintegrin and metalloprotease (Poon et al., 2009) UK 11 - 13 28 0.70  20 0.58 
(ADAM-12) (Spencer et al., 2007) UK 10 - 13 0 -  60 0.66 
         
Alpha-fetoprotein (AFP) (Zimmermann et al., 1996) Switz/Austria 10 - 13 5 0.62  0 - 
 (Aitken et al., 1993) UK 6 - 14 5 0.71  0 - 
 (Spencer et al., 2000a) UK 10 - 13 53 0.91  42 0.92 
 (Johnson et al., 1991) US/PA 10 - 11 7 1.25  5 0.50 
          
Free-alpha subunit of hCG (Bogart et al., 1989) US/CA 9 - 11 2 0.98  2 1.25 
 (Kratzer et al., 1991) US/CA 9 - 12 7 1.01  3 0.32 
 (Jauniaux et al., 1996) Belgium 10 - 11 5 1.58  0 - 
 (Ozturk et al., 1990) Italy/Nether. 8 - 12 8 2.09  0 - 
         
human Placental Lactogen (hPL) (Sifakis, 2010) UK 11 - 13 28 0.62  0 - 
         
IGFBP-1 (Miell et al., 1997) UK 11 - 13 19 2.78  0 - 
          
IGFBP-2 (Miell et al., 1997) UK 11 - 13 19 0.39  0 - 
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Table 4.3-1.  (continued) 
 
 First   Trisomy 18  Trisomy 13 
Marker Author Country GA (range) Number MoM  Number MoM 
         
Dimeric Inhibin-A (Spencer et al., 2001a) UK 10 - 13 45 0.74    0 - 
 (Lambert-Messerlian, 2004a) US/multiple 10 - 13 14 0.78    0 - 
          
hyperglycosoylated hCG (Palomaki, 2004) US/multiple 9 - 13 12 0.15    0 - 
          
Placental growth factor (PlGF) (Zaragoza et al., 2009) UK 11 - 13 28 0.48  19 0.4 
 (Spencer et al., 2001b) UK 10 - 13 45 0.89    0 - 
          
Placental protein 13 (PP13) (Koster et al., 2009) Netherlands 8 - 14 38 0.64  23 0.46 
          
Progesterone (Kratzer et al., 1991) US/CA 9 - 12   7 0.63    3 0.60 
          
Schwangerschafts protein 1 (Bersinger et al., 1994) UK 10 - 14   9 0.62    4 0.70 
(SP1) (MacIntosh et al., 1993) Italy 6 - 11   8 1.15    1 0.46 
          
unconjugated estriol (uE3) (Aitken et al., 1993) UK 6 - 14   5 0.34    0 - 
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4.4  Population parameters for first trimester serum markers 
Introduction 
Table 4.2-1 provided central estimates for the three common first trimester markers 
(PAPP-A, free β and total/intact hCG).  In this section, those estimates will be refined, 
and additional population parameters (logarithmic standard deviations, correlation 
coefficients and truncation limits) will be estimated.  These parameters, along with age-
associated birth prevalences and fetal loss rates set the stage for modeling patient-
specific risks for trisomy 18.  It is current practice to not offer stand-alone serum 
screening for trisomy 18 (i.e., without nuchal translucency – NT measurements), but 
these parameters will be used in Chapter 7 for modeling combined (and eventually 
integrated) testing. 
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PAPP-A measurement in late first trimester trisomy 18 pregnancies 
 
Seven studies reported PAPP-A measurements (Biagiotti et al., 1998; Brambati et al., 
1994; Koster et al., 2010; Palomaki, 2004; Tul et al., 1999; Zimmermann et al., 1996; 
Lambert-Messerlian, 2004b).  Of these, three reported over 20 cases (total of 116 cases) 
as well as summary population parameters (Biagiotti et al., 1998; Koster et al., 2010; Tul 
et al., 1999).  The remaining four studies (33 cases) provided sufficient information to 
estimate the individual MoM levels and thus estimate a combined ‘small study’ dataset.  
Figure 4.4-1 shows a probability plot for the 33 cases comprising the small study dataset.  
The resulting four sets of parameters (from the three larger studies and the small study 
combined dataset) are summarized in Table 4.4-1.  One of the estimates of the standard 
deviation (Koster et al., 2010) is much larger than the other three (i.e., 0.42 versus about 
0.31).  No probability plot or other descriptions of the data were provided, except for 
listing the parameters.    
 
 
Figure 4.4-1.  Probability plot for PAPP-A measurements in first trimester 
trisomy 18 pregnancies from four smaller studies (33 observations).  The 
straight line indicates the regression line for the observed data (Table 4.4-1).  The 
median MoM level in the general population (1.00) is shown as a horizontal dashed 
line. 
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Free β hCG measurement in late first trimester trisomy 18 pregnancies 
 
Thirteen studies reported free β measurements (Aitken et al., 1993; Biagiotti et al., 1998; 
Brambati et al., 1994; Brizot et al., 1995; Jauniaux et al., 1996; Koster et al., 2010; 
Ozturk et al., 1990; Palomaki, 2004; Scott et al., 1996; Spencer et al., 1992; Tul et al., 
1999; Zimmermann et al., 1996; Lambert-Messerlian, 2004b).  Of these, three reported 
over 20 cases (total of 116 cases) as well as summary population parameters (Biagiotti 
et al., 1998; Koster et al., 2010; Tul et al., 1999).  The remaining nine studies (79 cases) 
provided sufficient information to estimate the individual MoM levels and thus estimate a 
combined ‘small study’ dataset.  Figure 4.4-2 shows a probability plot for the 79 cases 
comprising the small study dataset for free β.  The resulting four sets of parameters 
(from the three larger studies and the small study combined dataset) are summarized in 
the second section of Table 4.4-1.   
 
 
Figure 4.4-2.  Probability plot for free β hCG measurements in first trimester 
trisomy 18 pregnancies from 10 smaller studies (79 observations).  The straight 
line indicates the regression line for the observed data (Table 4.4-1).  The median 
MoM level in the general population (1.00) is shown as a horizontal dashed line. 
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hCG in measurement in late first trimester trisomy 18 pregnancies 
 
Ten studies reported total/intact hCG measurements (Aitken et al., 1993; Bogart et al., 
1989; Brizot et al., 1995; Jauniaux et al., 1996; Johnson et al., 1991; Kratzer et al., 1991; 
Palomaki, 2004; Spencer et al., 2000a; Van Lith, 1992; Lambert-Messerlian, 2004b).  Of 
these, only one reported over 20 cases (53 cases) as well as summary population 
parameters (Spencer et al., 2000a).  Eight of the remaining nine studies (70 cases) 
provided sufficient information to estimate the individual MoM levels and thus estimate a 
combined ‘small study’ dataset.  One study (Kratzer et al., 1991) did not provide 
individual data.  Figure 4.4-3 shows a probability plot for the 70 cases comprising the 
small study dataset.  The resulting two sets of parameters (from the one large study and 
the small study combined dataset) are summarized in the final section of Table 4.4-1.   
 
 
Figure 4.4-3.  Probability plot for intact/total hCG measurements in first 
trimester trisomy 18 pregnancies from 9 smaller studies (70 observations).  The 
straight line indicates the regression line for the observed data (Table 4.4-1).  The 
median MoM level in the general population (1.00) is shown as a horizontal dashed 
line. 
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Table 4.4-1 contains the population summary information for PAPP-A, free β and hCG 
measurements in trisomy 18 pregnancies based on the previous analyses, along with the 
corresponding information from the both the large and smaller ‘combined’ studies.  
Based on these data, and additional information from the original studies in Table 4.2-1, 
it is possible to create Forest plots for these three markers showing the variability in the 
median levels for each of the studies used (Figure 4.4-4).  Some of the included studies 
are small and/or did not provide an estimated of the SD.  For that reason, a pooled SD 
was used to estimate the confidence interval.  For all three markers, the estimates from 
all studies are below the median MoM value of 1.00, the expected level in unaffected 
pregnancies. 
 
Table 4.4-1.  Population parameters for three commonly reported first trimester serum 
markers of trisomy 18 
 
Data source Number Median Log mean (antilog) Log SD 
     
Pregnancy associated plasma protein-A (PAPP-A)  
(Tul et al., 1999) 50 0.18 -0.7040   (0.20) 0.3060 
(Koster et al., 2010) 43 0.19 -0.6500   (0.22) 0.4200 
(Biagiotti et al., 1998) 23 0.25 -0.6020   (0.25) 0.3090 
‘Combined’1  (various) 33 0.20 -0.6989   (0.20) 0.3207 
All2 149 0.20 -0.6759   (0.21) 0.3432 
     
Free β hCG     
(Tul et al., 1999) 50 0.28 -0.5540   (0.28) 0.3219 
(Koster et al., 2010) 43 0.22 -0.6600   (0.22) 0.4100 
(Biagiotti et al., 1998) 23 0.34 -0.4690   (0.34) 0.3839 
‘Combined’1 various 79 0.22 -0.5992   (0.25) 0.3246 
All2 195 0.25 -0.5861   (0.26) 0.3508 
      
human chorionic gonadotropin (hCG)   
(Spencer et al., 2000a) 53 0.35 -0.4693   (0.38) 0.2686 
‘Combined’1   (various) 70 0.38 -0.3790   (0.35) 0.3195 
All2  124 0.37 -0.4179   (0.38) 0.2986 
 
1 Combination of individual data from 4, 10 and 9 smaller studies, for PAPP-A, free β hCG 
and hCG, respectively. 
2 Weighted summary estimates (square root of weighted variances for log SD) 
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Figure 4.4-4.  Forest plots for 
first trimester maternal serum 
markers in trisomy 18 
pregnancies.  The central 
estimate (usually logarithmic 
mean) and associated 95% 
confidence intervals are shown 
for PAPP-A (upper figure), the 
free β subunit of hCG (middle 
figure) and intact hCG (lower 
figure).  The solid line (MoM = 
1.00) is the expected value for 
unaffected pregnancies.  The 
summary median levels are 
shown as a horizontal dotted line.   
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Correlations between the three common markers in first trimester trisomy 18 pregnancies 
Five studies provided correlation coefficients (or sufficient data to compute it) in at least 
10 trisomy 18 pregnancies (Biagiotti et al., 1998; Koster et al., 2010; Palomaki, 2004; Tul 
et al., 1999; Lambert-Messerlian, 2004b).  Other reports based on fewer samples, or 
those that did not provide multivariate results, were excluded.  All five studies provided 
correlations for PAPP-A and free β hCG measurements.  Three showed little correlation 
(-0.07 to 0.07), one a modest correlation (0.19), and a third showed a moderate 
correlation (0.44).  As a way to help resolve this variability, the largest collection of 
trisomy 18 results was examined (Kagan et al., 2008b).  This study was excluded from 
this analysis, as the data were collected as part of a demonstration study that utilized 
both PAPP-A and free β measurements to assign risk.  However, among the 122 trisomy 
18 pregnancies identified, the PAPP-A/free β correlation was 0.386.  This is similar to the 
highest of the five unbiased estimates (0.44).  The potential bias of ascertainment in this 
large study is unlikely to have a important impact on the correlation.  In conclusion, there 
is wide variability in the correlation reported between PAPP-A and free β measurements 
in first trimester trisomy 18 pregnancies.  The weighted summary of the included studies 
is 0.1286, and this will be used in modeling.  However, this could be an underestimate 
and should be explored further.   
 
Less data are available for the other two correlations.  In all previous reports, the free β 
and intact/total hCG measurements are highly correlated in both cases and controls, and 
the two available datasets confirm this (summary r = 0.9033).  Conflicting results occur 
between PAPP-A and intact/total hCG, with one study showing low and the other 
moderate correlation.  Using well defined parameters in the past (e.g., for Down 
syndrome, unaffected pregnancies), one would expect this correlation to be similar to 
that found for PAPP-A and free β.  The summary of 0.2255 meets this expectation and 
will be used in future modeling. 
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Table 4.4-2.  Summary of the correlation coefficients in trisomy 18 pregnancies 
 
  Correlation coefficient 
Study Number PAPP-A / free β PAPP-A / hCG free β / hCG 
      
(Biagiotti et al., 1998) 23 0.0770 NR NR 
(Koster et al., 2009) 43 0.1980 NR NR 
(Lambert-Messerlian, 2004a) 14 -0.0772 0.0587 0.8616 
(Palomaki, 2004) 12 0.4490 0.4200 0.9520 
(Tul et al., 1999) 50 0.0735 NR NR 
     
All 142 0.1286 0.2255 0.9033 
     
(Kagan et al., 2008b)1 122 0.3860 NR NR 
 
NR = not reported 
1 Not included in the analysis, but used to help resolve the wide variability in the  
PAPP-A/free β correlation coefficients from the five included studies. 
 
 
Parameters in first trimester unaffected pregnancies 
Although it might seem best if the parameters for unaffected pregnancies were derived 
from the same dataset as the cases, there are advantages to obtaining these parameters 
elsewhere.  Some of the included trisomy 18 studies are relatively old, and 
improvements in assays and interpretive refinements (e.g., maternal weight adjustment) 
may have resulted in more refined parameter estimates.  I have chosen the SURUSS 
parameters (Wald et al., 2003), because they are: 
 Complete – they include all three common parameters, as well as first trimester NT 
measurements and second trimester measurements (useful later for integrated 
testing) 
 Up-to-date – the assays were performed after 2000, and revised parameters for NT 
measurements have just been published (Bestwick et al., 2010) 
 Verified – originally collected in the UK, a similar study in the US (FASTER) (Malone 
et al., 2005) has confirmed the parameters as being reasonable using even more 
recent data from the United States 
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Table 4.4-3 contains a summary of all the first trimester serum parameters needed for future 
modeling for both trisomy 18 and unaffected pregnancies.  It also contains a summary 
estimate of the screening potential for the three markers.  The separation between the 
markers (on a logarithmic scale) is divided by the log standard deviation in unaffected 
pregnancies.  This z-score indicates that the ‘best’ marker is PAPP-A, followed by the two 
hCG-related markers that have similar, but lower, z-scores. 
 
Table 4.4-3.  Summary of population distribution parameters for first trimester 
maternal serum markers in trisomy 18 and unaffected pregnancies 
 
   Correlation coefficients 
Marker Log mean Log SD PAPP-A Free β hCG 
      
Unaffected pregnancies     
PAPP-A 0.0000 0.2495 - 0.1395 0.2198 
Free β 0.0000 0.2651 - - 0.7178 
hCG 0.0000 0.1950 - - - 
      
Trisomy 18 pregnancies     
PAPP-A -0.6989 0.3207 - 0.1286 0.2255 
Free β -0.5992 0.3255 - - 0.9033 
hCG -0.4179 0.2986 - - - 
      
Truncation limits     
PAPP-A 0.3 – 0.7     
Free β 0.3 – 1.2     
hCG 0.4 – 1.2     
      
Separation in marker levels in case and control pregnancies, expressed as Z-score  
PAPP-A -2.80     
Free β -2.26     
hCG -2.14     
 
SD = standard deviation 
Chapter 4.  First Trimester Maternal Serum Markers for Trisomy 18    109 
 
Distribution of first trimester serum markers in trisomy 18 and unaffected pregnancies 
Figures 4.4-5 (a through c) display the overlapping Gaussian curves in trisomy 18 and 
unaffected pregnancies for measurements of maternal serum PAPP-A, free β and hCG, 
respectively.  The figures are plotted on a logarithmic scale.  The separation is best for 
PAPP-A measurements.  At a 5% false positive rate, the univariate detection rates for 
the three markers are 82%, 69% and 63%, respectively.  These can be seen in the 
figure, using the thin vertical line as the guide.  The false positive rate of 5% is to the left 
of the vertical line under the unaffected distribution (dashed curved line).  The 
corresponding detection rate is to the right of the line under the trisomy 18 distribution 
(solid curved line).  At a fixed 60% detection rate, the corresponding false positive rates 
are 0.7%, 2.6% and 4.0%, respectively.  Multivariate modeling for biochemistry and 
biochemistry plus first trimester ultrasound markers will be presented in Chapter 6. 
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Figure 4.4-5.  Overlapping Gaussian distributions in unaffected and trisomy 18 
pregnancies.  Marker levels for pregnancy associated plasma protein-A (PAPP-A), 
the free β subunit of hCG (free β hCG) and for total/intact human chorionic 
gonadotropin (hCG) are expressed as multiples of the median (MoM) on the 
horizontal logarithmic axis.  The relative distributions of results (population density) 
are shown as varying heights of the curves.  For all three markers, trisomy 18 is 
associated with reduced levels (left bell-shaped curve).  The vertical line is drawn at 
a 5% false positive rate. 
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4.5.  First trimester markers in trisomy 13 pregnancies 
Tables 4.2-1 and 4.3-1 also contain estimates for the median PAPP-A, free β and 
total/intact hCG measurements for trisomy 13 pregnancies (0.25, 0.46 and 0.49 MoM, 
respectively).  For PAPP-A and free β, the majority of samples (20/33 and 20/34, 
respectively) come from one study (Koster et al., 2010).  The corresponding logarithmic 
standard deviations were 0.43 and 0.30, respectively, and these will be used in any 
modeling.  They are consistent with the logarithmic standard deviation estimated on the 
5th to 95th centiles reported in that same study (0.43 and 0.25, respectively).  This study 
also reported the correlation coefficient between PAPP-A and free β to be 0.198.  For 
intact/total hCG measurements, a different study (Spencer et al., 2000a) dominates the 
results (42/60 observations).  The reported logarithmic standard deviation was 0.2656.  
No correlations between intact/total hCG and PAPP-A were reported in any included, or 
excluded, study.  For any modeling, the correlation for trisomy 18 will be used (0.2255).  
The PAPP-A measurements in trisomy 18 and 13 are similar, but there is less separation 
for both free β and hCG.  How this might impact the coincidental detection of trisomy 13 
during a trisomy 18 risk assessment will be discussed further in Chapter 6, after first 
trimester ultrasound markers have been examined.
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Chapter 5  First trimester ultrasound markers for trisomy 18 
5.1  Introduction 
Hundreds of published reports are available documenting the association between 
various ultrasound measurements and aneuploidy in the late first trimester of pregnancy.  
By far the most widely studied marker is the measurement of the width of the translucent 
space between the fetal spine and skin.  This is referred to as the nuchal translucency, 
or NT, and its measurement is now widespread as part of routine prenatal care.  Other 
ultrasound markers are considerably less well developed, with few actually having been 
introduced into routine practice outside of a few high risk centers.  Many of the reports on 
these newer ultrasound markers (e.g., the presence or absence of the nasal bone, or the 
shape of ductus venous blood flow on Doppler imaging), were based on cohorts that 
included women referred because of elevated fetal NT measurements or because higher 
NT measurements contributed to a high Down syndrome risk.   
 
Many of the first trimester ultrasound studies are subject to important biases which can 
make interpretation of results difficult or even impossible.  One of these is trimester of 
ascertainment.  When this source of bias is present, it causes the detection rate to be 
overestimated, especially in demonstration studies.  This is especially important, 
because few observational studies of NT have been published.   
 
Another important bias that mainly affects the detection rate for NT measurements or 
other ultrasound markers is the proportion of ultrasound referral patients in a cohort.  
Several research groups active in this area are located in ‘high risk’ centers, where it 
may be difficult to distinguish between the women who have never been tested, and 
those who have been referred to that high risk center because an increased NT was 
identified in a primary care setting.  For example, assume the median NT (expressed in 
MoM) was 2.0 for Down syndrome pregnancies with a corresponding 1.0 MoM in 
unaffected pregnancies.  Also, assume that 2.0 MoM is about the 95th centile in 
unaffected pregnancies, and that women above this level would be routinely offered 
diagnostic testing.  In a population undergoing primary ultrasound screening, the median 
MoM in the Down syndrome pregnancies would be expected to be 2.0 and 5% of women 
would have NT measurements above 2.0.  However, if half of the women seen at a 
hypothetical high risk center were actually referrals (most having values above 2.0 
MoM), then these observations will substantially increase the observed median NT MoM 
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in the Down syndrome pregnancies that are identified.  This would result in an 
overestimate of both the observed and modeled detection rates.   
 
A third potential bias occurs when the cohort of women studied is preselected by a factor 
that is correlated with the test of interest.  For example, later in this chapter there will be 
data showing a clear correlation between measurements of NT and absence of the fetal 
nasal bone.  As NT increases, it becomes more likely that the nasal bone will be absent.  
This effect occurs in both affected and unaffected pregnancies.  Thus, a study of women 
with elevated NT measurements will overestimate the performance of nasal bone 
visualization.  This problem does not occur, if the two factors are unrelated.  For 
example, there is no correlation between NT and maternal age.  Thus, a cohort of 
unscreened women over age 35 will be expected to have the same distribution of NT 
measurements in affected and unaffected pregnancies as a cohort of unscreened 
women under age 35. 
 
Separate PubMed literature searches were performed for three selected first trimester 
ultrasound markers (NT, nasal bone, and ductus venosus).  The aim for NT was to 
create distribution parameters suitable for multivariate modeling.  For nasal bone and 
ductus venosus, the aim was to create univariate likelihood ratios for these categorical 
tests and determine whether they are independent of NT measurements.  If not, it would 
be more difficult to include them in modeling, as the necessary between-marker 
correlations for trisomy 18 would be based on limited data.  For other less commonly 
reported markers, a short informal summary was prepared, but parameters were not 
included, and these markers will not be part of future modeling.  Methods for combining 
results from multiple studies are the same as those used in earlier chapters. 
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5.2  Nuchal translucency (NT) measurements  
Introduction:   
In a sagittal view of the fetus, a translucent space between the spine and skin can be 
seen in all fetuses in the late first trimester.  A third echogenic line indicating the amnion 
should also be visualized, as care must be taken to ensure that the distance from the 
spine to the skin is measured, rather than the spine to the amnion.  The NT 
measurement is different from the second trimester finding of nuchal skin fold thickness, 
in which the actual thickness of the skin is measured (Benacerraf et al., 1985).  In the 
original description of Down syndrome (Down, 1866), he describes the skin as being 
“deficient in elasticity, giving the appearance of being too large for the body”.  This is 
likely the observation of skin fold thickening.  Nuchal translucency may be a precursor of 
this finding. 
 
One of the first groups to describe the specific finding of nuchal translucency (NT), rather 
than the more classic findings of cystic hygroma (fluid filled sacs) or hydrops 
(generalized fluid accumulation) (Szabo and Gellen, 1990), found “accumulation of 
subcutaneous fluid in various amounts in the nuchal region” in all seven cases of Down 
syndrome identified through CVS, but in only one of 105 matched control pregnancies.  
This was later confirmed by several groups (Hewitt, 1993; Savoldelli et al., 1993; 
Nicolaides et al., 1992a).  However, there were initial problems with some groups 
replicating the findings (Bewley et al., 1995; Kornman et al., 1996; Haddow et al., 1998) 
leading to the development of specific training programs (Fetal Medicine Foundation in 
mid-1990s and the Nuchal Translucency Quality Review Program in 2005) that included 
formal coursework, testing, submission of sonographic images, and credentialing 
(www.fetalmedicine.com and www.ntqr.org).  An innovative aspect in both of these 
existing programs is the use of external quality assessment to help identify sonographers 
who may not be performing as expected (Palomaki et al., 2008; Cuckle, 2010). 
 
In brief, a proper NT study requires that the sonographer obtain a true sagittal section 
with the image magnified to include only the head and thorax (Figure 5.2-1).  The head 
should be in the neutral position, and the spine, skin and amnion should be visualized.  
The calipers are then placed in a specific manner (referred to as ‘on-to-on’) to obtain at 
least 3 measurements, with the largest of the three used for interpretation.  Some groups 
have suggested using the median of the three observations.  For long-term assessment 
of performance, individual NT results are collected and epidemiological monitoring is 
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carried out to determine the weekly increase in NT measurements (expected 20 to 25% 
per week), the median NT MoM (expected 1.00) and logarithmic standard deviation 
(between about 0.09 and 0.13).  Usually, selected images are also reviewed for 
sonographer adherence to protocols. 
 
 
 
 
 
Figure 5.2-1.  Sonographic image of a late first trimester fetal head and thorax 
showing the correct measurement of nuchal translucency.  The calipers (+) are 
placed on the fetal spine and skin in the ‘on to on’ position.  This indicates that the lower 
edge of the horizontal line in the ‘+’ is on the lower edge of the fetal spine, and the upper 
edge of the horizontal line for the lower marker is on the upper edge of the fetal skin.  
Note the amnion visible below these two structures.
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Literature search: 
A literature search using the search phrase ‘[(nuchal translucency OR nuchal edema OR 
cystic hygroma) AND (Down syndrome or trisomy 18 or aneuploidy) AND first trimester]’ 
was performed on PubMed; 682 references were identified.  After reviewing titles, over 
100 papers were examined for relevance, and reference lists were searched for 
additional publications.  Case reports, studies that did not include any fetus affected with 
trisomy 18, reviews and publications in foreign languages were excluded.  The usual 
protocol would then be to identify observational studies or those in which NT was not 
used in offering diagnostic testing.  This helps avoid ascertainment bias.  Unfortunately, 
only a few very early studies (usually referring to cystic hygroma) satisfied these criteria 
(Gembruch et al., 1988; Bronshtein et al., 1989; Cullen et al., 1990; Droste et al., 1991; 
MacLeod and McHugo, 1991; Shulman et al., 1992; van Zalen-Sprock et al., 1992; Ville 
et al., 1992; Hewitt, 1993; Nadel et al., 1993; Savoldelli et al., 1993; Trauffer et al., 1994; 
Podobnik et al., 1995; Nicolaides et al., 1992a; Cullen et al., 1995), and they did not 
contain sufficient observations to allow appropriate population parameters to be derived.  
Early studies also suffered from non-standard measurement of NT and did not account 
for the increase in NT measurements by gestational age. 
 
Many of the studies that included large numbers of affected pregnancies appear to be 
strongly influenced by biases, especially referral bias.  For example, consider a series of 
papers from Kings College (Nicolaides et al., 1994; Pandya et al., 1994; Sherod et al., 
1997; Nicolaides et al., 1992a; Pandya et al., 1995).  This group first reported initial 
experiences and then issued updated reports derived from their expanding database.  In 
earlier publications (Pandya et al., 1994; Pandya et al., 1995) they declared that a high 
proportion of their samples were referred due to elevated NT from surrounding practices 
(23% and 30%, respectively).  Later, the proportion was not reported, but it seems likely 
that referrals continued.  A high rate of referrals can also be inferred from the very high 
rate of trisomy 18 reported (1:18 and 1:20, respectively) that would be unlikely, even if 
the women were of advanced maternal age.  Studies with clear referral bias are 
unsuitable for creating population parameters, as high NT measurements are 
overrepresented and identifying which cases might or might not be referred is not 
possible.   
 
In this situation, a potential alternative to a formal summary of the literature might be to 
identify a single study that had limited biases.  If these biases could be accounted for by 
analysis, then the resulting parameters may be suitable for future modeling and 
assignment of risks.  The study would need to be relatively large, occur at a time when 
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the technique of NT measurements was well described, come from a site that had 
demonstrated compliance with the techniques, and would be subject to few, if any, other 
biases.  The only bias that can be readily accounted for is trimester of ascertainment.  
One study demonstrated how this bias could be accounted for when screening for Down 
syndrome (Nicolaides et al., 1998).  A random subset of observations with positive NT 
measurements was removed from the dataset, and the log means and standard 
deviations were recalculated.  The proportion of samples removed was equivalent to the 
fetal loss expected from the late first trimester to term.  I have also applied that 
methodology to another Down syndrome/NT dataset with trimester of ascertainment bias 
(Spencer et al., 2003).  The resulting ‘adjusted’ distribution parameters (Palomaki et al., 
2007) agree well with another parameter set derived from a general screening study 
(Wald et al., 2003; Wald, 2006).   
 
Figure 5.2-2 shows a hypothetical distribution of 100 NT observations derived from a log 
Gaussian distribution with a median NT MoM of 2.0, and a logarithmic standard deviation 
of 0.12 (these are actually representative values for Down syndrome pregnancies; the 
distribution for trisomy 18 is, as yet, considered unknown).  Further, assume that these 
observations are followed to term without diagnostic testing or selective terminations.  In 
Chapter 2, it was found that 72% of trisomy 18 pregnancies do not survive to term.  The 
72 of 100 observations that will not survive are shown in the second panel of Figure 5.2-
2 as open circles.  The filled circles represent the 28 of 100 observations that will survive 
to term (panel 3).  Although fewer observations are present at term, the distribution of NT 
measurements is essentially unchanged and either would provide a more unbiased 
estimate for the NT distribution. 
 
However, it is not possible to know about all 100 cases in the first trimester, and it is also 
now routine for diagnostic testing to occur and for identified trisomy 18 pregnancies to be 
selectively terminated.  In Figure 5.2-3, the same 100 trisomy 18 pregnancies are 
observed in the late first trimester (panel 1).  However, in this scenario, all will have NT 
measurements, with an NT above 2.0 MoM resulting in diagnostic testing and likely 
termination of the pregnancy.  Since the median of the distribution is 2.0, half will be 
above, and half below, this value.  In panel 2, we see that all of the affected pregnancies 
above 2.0 MoM have been identified via NT testing, regardless of whether or not they 
would have survived to term.  However, among the cases with NT levels below 2.0 MoM, 
only the filled circles (those 28% destined to go to term) will be identified at birth.  The 
trisomy 18 pregnancies that are spontaneously lost (open circles below 2.0 MoM in panel 
2 of Figure 5.2-2) will not be identified.  Panel 3 shows the resulting distribution of NT 
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measurements among those with lower levels that go to term, and those with higher 
levels that were identified in the late first trimester.  This is the ‘trimester of ascertainment 
bias’ and its presence results in the distribution of NT measurements being skewed 
towards higher values and a smaller standard deviation (notice the distribution of panel 3 
in the Figure 5.2-3 appears ‘tighter’ than the corresponding distribution in Figure 5.2-2). 
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Figure 5.2-2.  Hypothetical distribution of NT measurements in trisomy 18 pregnancies in the absence of screening and selective 
termination.  In the left figure is the distribution of NT measurements in the first trimester, centered at 2.0 MoM.  The middle figure shows 
those pregnancies that will survive to term (filled) versus those that will be spontaneously lost (filled).  The right figure shows the distribution of 
NT measurements at term.  The distribution, although based on smaller numbers, is equivalent to the left figure for mean and SD.  
 
 
Figure 5.2-3.  Hypothetical distribution of NT measurements in trisomy 18 pregnancies in the presence of screening and selective 
termination.  In the left figure is the distribution of NT measurements in the first trimester.  The half that are screen positive (filled squares) will 
be diagnosed in the first trimester.  The middle figure shows the expected losses for those below 2.0 MoM (as in the upper figure), and what 
would have occurred would those with the higher levels not have been terminated.  The right figure shows the distribution of NT measurements 
at term, now centered at 3.0 rather than 2.0 MoM.  This latter distribution suffers from trimester of ascertainment bias.  Methods described in 
the text can help overcome this problem.
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Results 
With this as background, one study (Tul et al., 1999) appears suitable to apply a 
methodology for adjusting for trimester of ascertainment bias, in order to estimate a more 
unbiased distribution of NT measurements in late first trimester trisomy 18 fetuses.  It 
comes from a site that adheres to the Fetal Medicine Foundation methodology for NT 
measurements (thus reliable measurements), is reasonably large (50 trisomy 18 fetuses) 
and is subject only to the trimester of ascertainment bias.  Figure 5.2-4 shows the 
probability plot of the 50 cases from that study, as they were reported on the left-hand 
side of the page.   
 
In order to ‘unbias’ the data, it is necessary to selectively remove “about half of those 
terminated in the first trimester and one-third of those terminated in the second 
trimester“(Nicolaides et al., 1998).  Without direct access to the individual pregnancy 
outcome, this is not possible, so a statistical approach will be taken instead.  Few 
terminations would have likely occurred among screen negative women, and the majority 
of women with screen positive results would have diagnostic testing.  Since this cohort of 
women was screened using maternal age and NT measurements (the aim of the study 
was to find the distribution of serum markers in trisomy 18), the NT measurements will 
dominate the Down syndrome risk calculation.  For example, in a 20 year old and a 40 
year old, NT measurements above 1.9 and 1.2 MoM, respectively would be considered 
screen positive (term risk greater than or equal a 38 year old woman).  Thus, affected 
fetuses with NT MoM levels below 1.2 would have likely been screen negative and have 
been diagnosed at term, while those above 1.9 would likely have been diagnosed in the 
late first or early second trimester.  Together, an estimated 72% (of these early detected 
cases would have been spontaneously lost (Table 2.4-1, (Morris and Savva, 2008)).  In 
order to ‘unbias’ this selection of trisomy 18 cases, each case falling above 1.9 MoM will 
have a 72% random chance of being removed from the analysis.  For the few samples 
falling between 1.2 and 1.9 MoM, a linear extrapolation from 72% to 0% removal was 
applied.  None of those falling below 1.2 MoM would be removed, because the 
assumption is that they were identified at term.   
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Figure 5.2-4.  The effect of accounting for bias of ascertainment on the NT distribution parameters for trisomy 18.  On the left side is 
the dataset as published (Tul et al., 1999).  On the right side, an unbiasing technique has been applied (see text for a full description).  In that 
technique, a high proportion (72%) of elevated NT measurements have been removed (likely to have been diagnosed in the first trimester, but 
not likely to go to term), while those with lower measurements have been retained (likely to have gone to term).  In this adjusted dataset, the 
median is considerably lower (2.17 versus 2.94), while the standard deviation is higher (0.3151 versus 0.2540).
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This technique was then performed 10 times, with the overall median MoM and log 
standard deviation being 2.17 (log mean 0.3373 or 2.16) and 0.3151, respectively.  
Figure 5.2-4 shows (on the right) one of the 10 sample datasets from that exercise.  
Although the number of observations is reduced considerably (in the 10 simulations, N 
ranged from 14 to 22).  The slope of the straight line indicates the summary standard 
deviation, and goes through the summary log mean of 0.3373 (2.16 MoM).  These data 
fit a straight line far better than in the original plot (left figure in 5.2-4).  The distribution’s 
median value is lowered, from about 2.94 to 2.17, while the logarithmic standard 
deviation increases from 0.2540 to 0.3151. 
 
Table 5.2-1 examines the effect of these changes in NT parameters when interpreting 
NT measurements for trisomy 18 risk.  These are univariate detection and false positive 
rates and do not include maternal age or other markers.  Distribution parameters for 
unaffected pregnancies (log SD 0.1105 at 11 weeks) are from a recent update (Bestwick 
et al., 2010).  When comparing the two parameter sets, the detection rate for NT 
measurements alone at a 1% false positive rate is 80% (Tul et al., 1999), versus 60% 
after the unbiasing procedures.  Similar differences are seen at higher false positive 
rates.  When detection rates are held constant (bottom of Table 5.2-1), the differences 
are also clearly visible, with false positive rates of 0.1% and 6%, respectively, at a 
detection rate of 70%.   
 
At least two publications (Wald et al., 2003; Hyett et al., 1996) have reported that both 
unaffected and affected pregnancies (usually Down syndrome) have a higher rate of 
spontaneous fetal loss as the NT measurement increases.  In SURUSS, for example 
(Wald et al., 2003) women with NT MoMs above the 95th centile, or about 1.5 MoM, had 
twice the rate of fetal loss than those with lower levels.  This indicates a potential for the 
trisomy 18 cases identified via high NT measurements to be lost at even a higher rate 
than the 72% used in modeling.  However, this is unlikely to have any important effect on 
the revised parameters computed here, because 44 of the 56 cases of trisomy 21 in the 
dataset (Tul et al., 1999) were at or above 1.5 MoM.  There are too few data to suggest 
that one can further stratify levels above the 95th centile into a dose-response effect.  
Thus, this refinement to the model is unnecessary. 
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Table 5.2-1.  Performance of NT measurement in identifying trisomy 18 in the late first 
trimester, according to one dataset before and after an unbiasing protocol was 
applied 
 
False positive rate Detection rate 
(Original) 
Detection rate 
(Adjusted) 
    Change (%) 
    
1% 80% 60% -20% 
2% 83% 64% -19% 
3% 85% 66% -19% 
4% 86% 68% -18% 
5% 87% 69% -18% 
    
Detection rate False positive rate 
(Original) 
False positive rate 
(Adjusted) 
    Change  (%) 
    
60% <0.1%   1.0%   0.9% 
65% <0.1%   2.5%   2.4% 
70%   0.1%   6.0%   5.9% 
75%   0.4% 13.0% 12.6% 
80%   1.1% 25.6% 24.5% 
 
If the biases act as expected on the distribution of NT measurements in trisomy 18 
fetuses, then a dataset with both trimester of ascertainment bias (as described earlier) 
and referral bias should deviate even more from a Gaussian distribution and provide 
even higher estimates of test performance.  Referral bias occurs when a tertiary care site 
receives patients that have already been tested, and are being referred because of an 
abnormal measurement.  In this setting, it might be primary care practices performing NT 
measurements, but referring those with elevated measurements to a ‘high risk’ practice 
for confirmation and diagnostic testing. 
 
Figure 5.2-5 shows a paired set of probability plots, the left being a repeat of the 
uncorrected dataset with only ascertainment bias (Tul et al., 1999).  The right is a larger 
dataset of 106 cases of trisomy 18 from a high risk center published two years earlier 
(Sherod et al., 1997), that acknowledged high NT referrals to that center in earlier, 
overlapping publications (Pandya et al., 1994; Pandya et al., 1995).  The median (3.20 
MoM), geometric mean (2.82 MoM) and logarithmic standard deviation (0.2528) have 
been derived from the Figure and were not reported. 
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Figure 5.2-5.  The effect on the NT distribution parameters for trisomy 18 of including a referral population with increased NT 
measurements.  On the left side are data shown earlier with suspected bias of ascertainment (Tul et al., 1999).  On the right side, are data 
from a study suspected to have both ascertainment and referral biases (Sherod et al., 1997).  In this larger dataset, the deviation from the 
straight line (representing a log Gaussian distribution) is more pronounced, even though the geometric mean and log SD are similar to that 
found in the smaller dataset on the left.
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Conclusions 
At least two important biases, trimester of ascertainment and referrals, cause problems 
in determining the distribution parameters for NT measurements in trisomy 18 
pregnancies.  Although these biases exist when testing for Down syndrome as well, the 
problem is exacerbated when dealing with trisomy 18 because the fetal losses during 
pregnancy are so much higher than for Down syndrome (78% versus 32%).  It was 
possible to identify one relatively large dataset that appeared to have only the bias of 
ascertainment.  A previously described statistical method was used in an attempt to 
account for the impact of the bias on the reported distribution.  The adjusted parameters 
indicate that the separation between NT measurements in trisomy 18 and unaffected 
pregnancies is less than published estimates, and revisions in the logarithmic standard 
deviation are also needed.  This is especially important given the recent publication of a 
‘mixture model’ designed to better fit the distribution of NT measurements in affected 
pregnancies (Wright et al., 2008).  These authors rely on the ‘non-Gaussian’ appearance 
of the data (like that shown in Figure 5.2-5 in the right scatterplot) as the justification for 
more complex modeling.  They do not appear to have considered that the deviations 
might be due to well described biases.  This effort appears to be a futile modeling 
exercise aimed at fitting biased data that does not represent the distribution of NT 
measurements in a general pregnancy population.  Others in this research group in 
London have ‘confirmed’ the improvement of the mixture model on an independent 
dataset (Kagan et al., 2008a).  However, that new dataset was also subject to the same 
two biases, so the finding of a ‘good fit’ is both expected, and irrelevant for trisomy 18 
testing in the general pregnancy population. 
 
In the next Chapter (6), results from the review of the first trimester serum markers for 
trisomy 18 (Chapter 4) will be combined with these NT results to model how maternal 
age in combination with, PAPP-A, free hCG and NT measurements might perform.   
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5.3  Nasal bone  
Definition: 
Among the findings first described by Langdon Down in 1886 (Down, 1866) is one that 
reads: “The nose is small”.  As with excess skin at the back of the neck leading to 
measurement of nuchal thickness in the second trimester, and nuchal translucency in the 
first trimester, this statement suggests that the nasal bone is early pregnancy might be 
smaller, or even absent in the presence of Down syndrome.  Radiographic post-mortem 
studies 15 to 40 weeks’ gestation provided evidence that the nasal bone is absent in 
25% of Down syndrome fetuses.  This finding was rare among normal fetuses (Stempfle 
et al., 1999). 
The first study to report on nasal bone (NB) measurements (Cicero et al., 2001) noted 
that the methodology for identifying the presence/absence of the NB was not 
straightforward. 
For examination of the fetal nose, a mid-sagittal view of the fetus was obtained, with the 
beam of the ultrasound transducer being parallel to the nasal bone.  In this position, the 
skin of the nose produces an echogenic line, which can be misinterpreted as the nasal 
bone.  To avoid this mistake, the ultrasound transducer was gently tilted from side to side 
to ensure that the nasal bone was seen separate from the nasal skin.   
That same author (Cicero et al., 2006) elaborated on the methodology five years 
later. 
For examination of the nasal bone, the image was magnified so that the head and upper 
thorax only were included in the screen and a midsagittal view of the fetal profile was 
obtained.  The ultrasound transducer was parallel to the direction of the nose and the 
probe was gently tilted from one side to the other of the fetal nose.  When these criteria 
were satisfied, 3 distinct lines were seen at the level of the fetal nose.  The first 2, which 
are proximal to the forehead, are horizontal and parallel to each other, resembling an 
“equal sign”.  The top line represents the skin and the bottom one, which is thicker and 
more echogenic than the overlying skin, represents the nasal bone.  A third line, almost in 
continuity with the skin, but at a higher level, represents the tip of the nose.  The nasal 
bone is considered to be present if it is more echogenic than the overlying skin and absent 
if it is either not visible or its echogenicity is the same or less than that of the skin. 
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Figure 5.3-1 shows an appropriate view of the fetal head, with the clearly visible 
“equal sign”.  From this image, the nasal bone is clearly “present” (lower line in the 
equals sign). 
 
Figure 5.3-1.  An ultrasound image showing a fetal head in the late first 
trimester, along with the identification of the nasal bone.  In this midsagittal view, 
the “equal sign” is clearly visible, made up of the nasal bone (lower line) and the skin 
on the nose (upper line).  The tip of the nose is also visible.  These three landmarks 
indicate an appropriate view for detecting the presence (or absence) of the nasal 
bone (image courtesy of Dr. Alan Donnenfeld). 
 
Literature search 
A literature search was performed using the terms “nasal bone”, “Down syndrome” and 
“Trisomy 18” and 21 references were identified.  After abstract review, potentially 
relevant articles were obtained in full and the reference lists searched for other relevant 
Tip of nose
Skin at nasal bridge 
Nasal bone
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articles.  In order to be included, sufficient data needed to be present to describe the 
clinical scenario (prior to CVS after a positive screening test) and the proportion with an 
absent nasal bone.  If data were available for Down syndrome and/or trisomy 13 
pregnancies, these were included in the summaries.  In four studies, trisomy 18 
pregnancies were included, but the proportion of cases with an absent NB was not 
reported (Kozlowski et al., 2006; Peralta et al., 2005; Prefumo et al., 2005; Weingertner 
et al., 2006).  A total of 12 publications provided NB information in at least one first 
trimester fetus with trisomy 18 (Cicero et al., 2001; Otano et al., 2002; Cicero et al., 
2003; Orlandi et al., 2003; Viora et al., 2003; Wong et al., 2003; Zoppi et al., 2003; 
Cicero et al., 2004; Malone et al., 2004; Cicero et al., 2006; Kagan et al., 2009a; 
Sepulveda et al., 2010).  Figure 5.3-2 shows the number of reported trisomy 18 (and 
trisomy 13) cases by year having nasal bone measurements, with the first report 
appearing in 2001.  One group in the UK has published extensively on nasal bone, and 
their reports include overlapping datasets (Cicero et al., 2001; Cicero et al., 2003; Cicero 
et al., 2004; Cicero et al., 2006; Kagan et al., 2009a).  These publications are connected 
by a thin dotted line.  Circles and squares are used to indicate trisomy 18 and trisomy 13 
cases, respectively.  Filled symbols indicate that most, if not all, of the study participants 
were screen positive, usually by a combination of nuchal translucency and maternal age.  
 
Results 
Table 5.3-1 shows relevant data on trisomy 18 and nasal bone from the 12 included 
studies.  All were subject to important potential biases that have been described earlier.  
Data for trisomy 13 and Down syndrome are also listed for comparison.  All studies 
restricted gestational age to 11 to 14 weeks’ gestation, but few observations were 
actually later than 13 completed weeks’.  The four studies presenting overlapping data 
are listed at the bottom of the table and are not included in the analysis.  In the remaining 
eight studies, nasal bone measurements were obtained in between 77% and 99% of 
fetuses examined.  The summary estimate was 96.2% (95% CI 88.8% to 98.8%) but 
there was considerable heterogeneity (Q=1020, p<0.001, I2=99%).  Although the 
FASTER study estimate of 77% was the lowest (Malone et al., 2004) another study also 
reported a relatively low success rate of 83% (Wong et al., 2003).   
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Figure 5.3-2.  A summary of trisomy 18 (and trisomy 13) observations available 
to determine associations with absent nasal bone.  Circles and squares are used 
to indicate trisomy 18 and trisomy 13 cases, respectively.  Filled symbols indicated 
that most, if not all, of the study participants were screen positive, usually by a 
combination of nuchal translucency and maternal age.  One group in the UK has 
published extensively on this topic, and their reports tend to include overlapping data.  
These publications are connected by a thin dotted line  
 
 
The nasal bone was absent in between 0.6 and 4.4% of unaffected fetuses.  The 
summary estimate was 0.9% (95% CI 0.5 – 1.5%), but heterogeneity was again high 
(Q=95, p<0.001, I2=96%).  This heterogeneity is also seen in the multiple reports from 
the UK group; where one study reports a rate of about 2.6% (Cicero et al., 2003; Cicero 
et al., 2004; Kagan et al., 2009a) while the remaining two have rates of about 0.5% 
(Cicero et al., 2006; Cicero et al., 2001).  
The proportions of Down syndrome, trisomy 18 and trisomy 13 fetuses with absent nasal 
bone are all shown in Table 5.3-1, to ensure that the rates in trisomy 18 and 13 are put in 
the context of the larger experience in Down syndrome screening.  The highest detection 
rate (69%) is found for Down syndrome in 401 reported cases.  The detection rates are 
significantly lower for trisomy 18 (56% in 194 cases) and trisomy 13 (33% in 44 cases).  
Taken as a whole, the likelihood ratios associated with absent NB in the three major 
trisomies are 76, 62 and 37, respectively. 
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The majority of studies were, however, performed in settings that included women who 
were already screen positive, usually by a combination of maternal age and nuchal 
translucency.  This would not bias the information about NB, unless the absence of the 
NB were correlated with NT measurements in unaffected pregnancies, affected 
pregnancies, or both.  There are too few reported pregnancies affected with trisomy 18 
or 13 to examine the NB/NT relationship, but sufficient numbers do exist for Down 
syndrome pregnancies.  Some early reports (Cicero et al., 2001; Orlandi et al., 2003) 
stated that the two markers were completely independent.  With experience, however, a 
clear relationship was found (Zoppi et al., 2003; Cicero et al., 2004; Cicero et al., 2006).  
As NT levels increase, the proportion of Down syndrome (and control) pregnancies with 
absent NT also increases.  Unfortunately, there are no sufficiently large datasets that 
performed NB measurements as a screening test in all women that could document the 
association across the range of NT values.  One study included mainly older women 
(Orlandi et al., 2003) in their cohort of over 1000 pregnancies, but only 15 cases of Down 
syndrome and 3 cases of trisomy 18 were studied.  In a much larger study of women 
screen positive using maternal age and NT (Cicero et al., 2004), the proportion of Down 
syndrome fetuses with an absent NB showed a modest increase from about 60% near 
the 95th centile of NT to nearly 80% when the NT were above 5.5 mm.  However, few of 
these women actually had NT measurements in the normal range, as all were screen 
positive.  Among the unaffected pregnancies, the change was more dramatic.  The false 
positive rate (absent NB) was about 2% at the 95th centile of NT, but 15% for the few 
unaffected pregnancies with an NT above 5.5 mm.  Due to the much larger change in the 
false positive rate in unaffected pregnancies, the likelihood ratio for NB becomes lower 
as the NT increases, with a reported range of 37 (in women near the 95th centile) to 5 (in 
women with NT >5.5 mm).  Whether there is an association between NB and NT in 
trisomy 18 pregnancies has not been reported, but it would be reasonable to assume 
that it could be similar to that found for Down syndrome.  
Identifying the nasal bone (or its absence) is considered by experienced sonographers to 
be more difficult than performing NT measurements (Cicero et al., 2003; Senat et al., 
2003).  One study (Senat et al., 2003) compared three operators’ measurements using 
657 prerecorded loops.  They found inter-operator kappa values of about 0.3 and intra-
operator values of about 0.4.  Both would be considered poor to fair.  The operators 
agreed on only about 80% of the assessments (present, absent, uncertain).  Another 
(Bekker et al., 2004) compared the results of a 2D and 3D ultrasound and found fair to 
good correlations as well as a clear gestational age relationship with the length of the 
nasal bone.  Adding to the difficulty in interpreting NB testing is a potential racial effect 
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(Cicero et al., 2003; Prefumo et al., 2005).  In one of these reports (Cicero et al., 2003), 
for example, 10.4% of unaffected fetuses of Afro-Caribbean ancestry had an absent NB, 
compared to only 2.5% in their Caucasian counterparts (2.5%).   
One study examined the effect of NB measurements on the biochemistry results (Cicero 
et al., 2005).  They reported no significant difference in PAPP-A or free β hCG 
measurements in trisomy 18 pregnancies with absent (N=19) or present (N=15) NB.  The 
point estimates do appear to be quite different between the groups, but the differences 
are not statistically significant.  This may be due to the small sample size.  Even if the 
differences were to be statistically significant, there is likely to be little impact on overall 
test performance, as one marker (free β hCG) is in the direction of lower risk, while the 
other PAPP-A) is in the direction of increased risk. 
Summary   
Specialized training is needed for reliable ultrasound detection (or measurement) of NB.  
Oversight is also necessary and would require more than monitoring of the rate of absent 
NB.  The proper interpretation of NB would require adjustment for gestational age, the 
associated NT measurement, and race/ethnicity.  The reported test performance is likely 
to be overestimated, due to trimester of ascertainment bias, and by the inclusion of 
referral patients in the population.  Without adjusting for these biases, the univariate 
likelihood ratios associated with absent NB are 76, 62 and 37, for Down syndrome, 
trisomy 18 and trisomy 13, respectively.  Demonstration projects performed in an 
unbiased low risk population, after appropriate training and oversight, have been 
recommended (Rosen et al., 2007).
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Table 5.3-1.  Summary of published studies reporting nasal bone (NB) measurements in unaffected and common trisomic 
pregnancies between 11 and 14 weeks’ gestation 
 
   NB NB Absent 
Author Country Study type1 Success  Unaffected (%) Down S (%) T18 (%) T13 (%) 
        
(Otano et al., 2002) Argentina MR cohort NR     1/     175 (0.6)     3/    5 (60)     1/    1 (100) 0 
(Orlandi et al., 2003) Italy MR cohort   94%   10/  1,000 (1.0)   10/  15 (67)     2/    3 (  67)   0/  2 (  0) 
(Viora et al., 2003) Italy HR cohort   92%   24/  1,709 (1.4)     6/  10 (60)     1/    4 (  25)   1/  2 (50) 
(Wong et al., 2003) Hong Kong HR cohort   83%     1/     114 (0.9)     0     0/    1 (    0) 0 
(Zoppi et al., 2003) Italy MR cohort   99%   34/  5,525 (0.6)   19/  27 (70)   19  /27 (  70)   0/  2 (  0) 
(Cicero et al., 2004) UK HR cohort   99% 129/  5,223 (2.5) 229/333 (69)   68/124 (  55) 13/38 (34) 
(Malone et al., 2004) US LR cohort   77%   21/  4,790 (0.4)     0/  11 (  0)     1/    2 (    0) 0 
(Sepulveda et al., 2010) Chile Case only NR 0    0   17/  32 (  53) 0 
All (random effects model)  96.2% 220/18,536 (0.9) 266/401 (68) 109/194 (  56) 14/44 (33) 
95% CI   (88.8 – 98.8) (0.5 – 1.5) (63 – 72) (49 – 63) (21 – 48) 
        
Studies with data included in Cicero S, 2004 (included above)     
(Cicero et al., 2001) UK HR cohort 100%     3/     603 (0.5)   43/  59 (73)   11/  20 (  55)   2/  8 (24) 
(Cicero et al., 2003) UK HR cohort 100%   93/  3,358 (2.8) 161/242 (67)   48/  84 (  57)   7/22 (32) 
(Cicero et al., 2006) UK HR cohort   98% 113/20,165 (0.6)   98/142 (69)   22/  40 (  55)   3/12 (25) 
(Kagan et al., 2009a) UK HR cohort   99% 513/19614 (2.6)   73/122 (60)   19  /36 (  53)   9/20 (45) 
 
1 HR = high risk, indicating that all, or nearly all women were screen positive, usually by NT and maternal age,  MR = moderate risk, 
indicating that at most, a small portion were screen positive, but many were age 35 or older, LR = low risk, indicating close to a general 
pregnancy population.
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5.4  Ductus Venosus 
Introduction 
Heart defects are commonplace in both Down syndrome and trisomy 18 fetuses 
(Chapter 1).  There also appears to be a linkage between certain types of heart defects 
and increased nuchal translucency (NT) measurements (Hyett et al., 1997).  This led to 
observations of abnormal ductus venosus flow in chromosomally abnormal fetuses with 
increased NT measurements (Matias et al., 1998; Kiserud, 1997).  The ductus venosus 
is present only in the fetus and allows up to 80% of the umbilical vein blood flow to go 
directly into the fetal circulation.  Using color Doppler ultrasound imaging techniques, it is 
possible to identify and quantify abnormalities in the flow.  Figure 5.4-1 is a stylized 
diagram of the three main ductus venosus waveforms observed in the late first trimester. 
 
There are several methods for identifying abnormal ductus venosus flow.  The simplest 
is to classify the waveforms as in Figure 5.4-1: positive, absent or reversed.  Some 
researchers measure the height of the A-wave (in cm/sec).  Still others compute a 
pulsatility index for veins (PIV) for the ductus venosus.  Both of these latter methods aim 
to quantify how abnormal the waveform might be.   
 
 
 
Figure 5.4-1.  Three ductus venosus Doppler waveforms demonstrating 
differences in the A-wave.  In these three figures, time is on the x-axis, and venous 
blood flow is on the vertical axis.  The baseline indicates no blood is flowing.  In the 
left figure, the arrow points to a tracing showing a positive A-wave, in the middle 
figure, the A-wave is absent, and in the right figure, the A-wave is reversed 
(negative), indicating venous blood flow going to the placenta.  The positive A-wave 
is considered normal, while the absent or reversed A-wave is considered abnormal 
(figures courtesy of Dr. Tony Borrell). 
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Figure 5.4-2.  A ductus venosus waveform showing the components needed to 
compute the pulsatility index for veins (PIV).  The A-wave height is 11 cm/sec 
(lower horizontal dashed line) while the maximum S-wave height is 45 cm/s (upper 
horizontal dashed line).  The average height of the waveform integrated over time is 
31 cm/sec.  The PIV is computed as (S-A)/average.  In this example, the PIV is 1.10 
(45-11)/31 (Figure adapted from one provided by Dr. Tony Borrell). 
 
Figure 5.4-2 shows how the PIV is calculated.  For positive A-wave findings, the PIV will 
be relatively small (e.g., 1.10).  If the A-wave is reversed, the A-wave value will be 
negative, resulting in larger PIV values.  For example, the negative A-wave on the right 
side of Figure 5.4-2, might have an S-wave of 45, an A-wave of -15, with a time 
averaged height of 21.  This would result in a PIV of 2.76 and be considered abnormally 
high. 
 
As with measurement of NT and NB, there is expert guidance in the performance of 
reliable ductus venous measurements.  Specifically, the fetus should be quiescent with a 
sagittal view of the entire trunk.  Pulsed Doppler is applied with a minimal insonation 
angle.  The sweep speed should be sufficiently high to accurately capture the waveform.  
When performing measurements (A-wave height or PIV), some groups suggest 
performing the study three times and taking the mean value for interpretation.  Due to 
concerns about fetal safety, the time spent in the Doppler imaging mode is usually 
restricted to 5 or 10 minutes, or less. 
 
averaged 
height 
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Literature search 
A literature search using the terms “ductus venosus”, “Down syndrome” and “trisomy 18” 
was performed, and 8 references were identified.  After abstract review, potentially 
relevant articles were obtained and the reference lists searched for other relevant 
articles.  In order to be included, sufficient data needed to be present to describe the 
clinical scenario (prior to CVS after a positive screening test) and the proportion with an 
abnormal ductus venosus (DV) blood flow.  If data were available for trisomy 18 and/or 
trisomy 13, these and any associated Down syndrome pregnancies were included in the 
summaries.  One study (Prefumo et al., 2005) measured DV blood flow in 12 trisomy 18 
and 5 trisomy 13 pregnancies, but did not report any of those results and was excluded.  
A total of 11 publications satisfied inclusion criteria (Huisman and Bilardo, 1997; 
Montenegro et al., 1997; Matias et al., 1998; Antolin et al., 2001; Bilardo et al., 2001; 
Mavrides et al., 2002; Murta et al., 2002; Borrell et al., 2003; Toyama et al., 2004; Maiz 
et al., 2009; Zoppi et al., 2002).  In two of these studies, results were not reported 
separately for each aneuploidy (Mavrides et al., 2002; Borrell et al., 2003) but are 
included in the data listings, given that DV blood flow is considered to be equally 
effective for identifying all three aneuploidies.   
 
Figure 5.4-3 shows the number of reported trisomy 18 (and trisomy 13) cases by year, 
with the first report appearing in 1997.  Circles and squares are used to indicate trisomy 
18 and trisomy 13 cases, respectively.  Filled symbols indicate that most, if not all, of the 
included study participants were screen positive, usually by a combination of nuchal 
translucency and maternal age.  Open symbols indicate populations with a lower 
prevalence of aneuploidy and fewer participants subject to preliminary screening tests. 
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Figure 5.4-3.  A summary of trisomy 18 (and trisomy 13) observations available 
to determine associations with abnormal ductus venosus flow.  Filled symbols 
indicated that most, if not all, of the study participants were already screen positive 
for Down syndrome, usually by a combination of nuchal translucency and maternal 
age.  
 
Results 
Table 5.4-1 shows relevant DV data for pregnancies affected with trisomy 18 from the 11 
studies.  Many of these studies suffer from important potential biases that have been 
described earlier.  Data for Down syndrome and trisomy 13 are also listed, when 
reported.  All studies restricted gestational age to 11 to 14 weeks’ gestation, but a few 
observations were later than 13 completed weeks’.  There are 12 datasets, as one study 
reported results for both A-wave height and DV-PIV (Borrell et al., 2003).  The upper half 
of the table includes studies of the A-wave only (using categories of positive versus 
absent or reversed, or the equivalent group of the height of the A-wave).  The lower half 
of the table shows study results for those using the DV-PIV. 
 
Table 5.4-1 shows the reported false positive rates, ranging from 1.9% to 17%.  The 
overall false positive rates in the two groups of studies, and overall, are 4.0%, 8.4% and 
5.8%, respectively.  All of these estimates are associated with high heterogeneity (Q>60, 
p<0.001 and I2>90% for each).  Two studies (Bilardo et al., 2001; Zoppi et al., 2002) had 
unusually high false positive rates of 13% and 17%, respectively, and both reported 
results as PIV.  However, these studies were not associated with higher detection rates, 
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compared to the studies with lower false positive rates.  This may indicate a difference in 
technique or cut-off level that was not apparent in the reports.  With these two studies 
removed, the range of false positive rates is 1.9 to 8.4%, with all but two between 3.1 
and 6.6%.  Summary detection rates for Down syndrome, trisomy 18 and trisomy 13 are 
shown in the last three columns.  Individual rates generally fall between 60 and 90%.  
Overall detection rates for these three aneuploidies are 74%, 67% and 56%, 
respectively, but due to the relatively small sample sizes (94, 74 and 47 cases, 
respectively), these rates are not significantly different (Q=3.8, p=0.15).  Using the 
summary false positive rate of 8.4%, the likelihood ratios for the three aneuploidies are 
12, 11 and 10, respectively.  Were a more conservative false positive rate of 5% to be 
used (the median of the rates after excluding the two high estimates), the likelihood 
ratios would increase to 15, 13 and 11, respectively. 
 
In order for DV measurements to be useful in routine clinical practice, it is important that 
the test results be reproducible both within and between sonographers.  Three studies 
examined this aspect of testing (Mavrides et al., 2002; Prefumo et al., 2001; Borrell et al., 
2007).  The Italian group (Prefumo et al., 2001) collected four repeated measurements in 
22 fetuses for the PIV, S-wave, A-wave, and time averaged maximum velocity, with 
corresponding coefficients of variation (CVs) of 10%, 13% 22% and 13%, respectively.  
Between-observer differences for an average result for the same four measurements 
resulted in CVs of 9%, 14%, 27% and 15%, respectively.  All sonographers provided the 
sample normal/abnormal classifications for all fetuses examined.  At about the same 
time, a group in England (Mavrides et al., 2001) found good with-in observer 
performance for PIV (9%), but less good performance for S-wave, A-wave and S/A ratios 
(19%, 29% and 25%, respectively).  The CVs between observers are also less good, 
ranging between 12 and 47%.  They concluded that only the PIV measurement could be 
considered reproducible.  More recently, a group from Catalonia (Borrell et al., 2007) 
examined reproducibility of the A-wave and the PIV and confirmed that PIV is the most 
reliable DV measure.  
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Summary 
A ductus venosus blood flow test can be reliably measured and is associated with an LR 
of about 12 (range 10 to 15).  This finding appears to be consistent in both high risk and 
lower risk settings, and varies only slightly for the three aneuploidies studied.  Some 
unusually high false positive rates for DV-PIV measurements were reported by some 
groups.  However, other studies provide some evidence that the DV-PIV may be more 
reliable and more predictive than measuring the A-wave height or categorizing the 
direction of flow.  Such testing could potentially be used in routine testing, but its overall 
complexity, required equipment, extensive training and continuing external oversight 
makes the test more appropriate for high risk referral centers.  
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Table 5.4-1.  Summary of published studies reporting Ductus Venosus (DV) measurements in unaffected and common trisomic 
pregnancies between 11 and 14 weeks’ gestation. 
 
  Study DV Abnormal Ductus Venosus Flow 
Author Country type1 Success Unaffected (%) Down S (%) T18 (%) T13 (%) 
        
Ductus Venosus (A wave absent or negative)      
(Huisman and Bilardo, 1997) Netherlands Case study NR NR 0   1/  1 (100) 0 
(Montenegro et al., 1997) Portugal HR Cohort NR NR     4/    4 (100)   1/  1 (100) 0 
(Matias et al., 1998) Portugal/UK HR Cohort 100%   13/     423 (  3.1)   35/  38 (  92) 12/12 (100) 5/  7 (  72) 
(Mavrides et al., 2002) UK HR Cohort 98%   10/     204 (  4.9) 302 52 42 
(Murta et al., 2002) Brazil HR Cohort    99.7%     6/     321 (  1.9)   17/  18 (  94)   1/  1 (100) 2/  2 (100) 
(Borrell et al., 2003) Catalonia MR Cohort NR 162/  3,248 (  5.0)   28/  48 (  58)   7/123 ( 58) 7/123 (  58) 
(Toyama et al., 2004) Brazil LR Cohort NR   79/  1,195 (  6.6)     5/    7 (  71)   3/  5 (  60) 1/  1 (100) 
(Maiz et al., 2009) UK LR Cohort NR 622/19,614 (  3.2)   81/122 (  66) 21/36 (  58) 11/20 (  55) 
(excludes T18/13 combined data from Mavrides 2002) 
                            
920/25,502 (  4.0)   
(2.7 – 5.8) 
217/284 (  75) 
(62 - 85) 
46/68 (  62) 
(46 - 75) 
26/42 (  61) 
(43 - 76) 
         
Ductus Venosus (pulsatility index for veins or PIV)     
(Antolin et al., 2001) Spain LR Cohort 100%   68/  1,351 (  5.0)   6/    7 (  86)   4/  4 (100) 0 
(Bilardo et al., 2001) Netherlands HR Cohort   86% 22/     130 (17 ) 12/  19 (  63)   9/11 (  92) 1/  6 (  17) 
(Zoppi et al., 2002) Italy HR Cohort   98% 38/     292 (13 ) 14/  20 (  70)   6/  7 (  86) 1/  1 (100) 
(Borrell et al., 2003) Catalonia MR Cohort NR 162/  3,249 (  5.0) 36/  48 (  75)   7/12 (  58)  7/12 (  58) 
     
290/  5,012 (  8.4) 
(5.5 – 12.7) 
68/  94 (  72) 
(56 - 84) 
26/34 (  74) 
(55 – 87) 
9/19 (  47) 
(24 - 71) 
      
All1   
5.8% 
(2.8 – 11.7) 
74%  
(64 – 82) 
67%  
(54 – 77) 
56%  
(40 – 70) 
 
1 HR = high risk (prevalence of Down syndrome of about 1:20 or higher), MR = moderate risk (prevalence 1:20 to 1:100), LR = low risk 
(prevalence <1:100 and includes few, if any, screen positive women. 
2 Individual rates for the three aneuploidies were not reported, but the overall rate was 58%. 
3 14 of 24 trisomy 18/13 had abnormal flow patterns, and the rates for the three aneuploidies were said to be ‘nearly equal’. 
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5.5  Other ultrasound markers in the first trimester 
Fetal heart rate, crown rump length, and tricuspid regurgitation have also been reported 
to be associated with trisomy 18 fetuses in the late first trimester of pregnancy.   
Studies are subject to the many of the same biases that were discussed earlier 
(especially trimester of ascertainment, referral, and correlation).  No attempt has been 
made to provide an unbiased estimate of performance.  Instead, the effect is described 
for each marker and a general introduction to the literature is provided.  Several other 
markers were mentioned in the literature, but these had either low predictive ability, few 
affected fetuses examined, or both (e.g., reversed umbilical vein blood flow, gestational 
sac volume, choroid plexus cysts, and specific heart defects).  These will not be 
reviewed. 
 
 Fetal heart rate:  The fetal heart rate is known to vary by gestational age in the late 
first trimester.  In a report from a series of 25,000 high risk pregnancies seen in a 
referral center, the fetal heart rate (FHR) declined from about 168 beats per minute 
(bpm) at a CRL of 40 mm to 155 bpm at 80 mm (FHR = 181.41 – 0.324*CRL_in_mm, 
r= -0.44) (Liao et al., 2000).  The group then compared the proportions of Down 
syndrome (N=554), trisomy 18 (N=219) and trisomy 13 (N=95) fetuses with bpm 
below the 5th, above the 50th and above the 95th centiles of the unaffected 
distribution.  That distribution had a constant standard deviation of 6.6 bpm.  The 
distribution of FHRs in Down syndrome fetuses was only slightly higher than that 
found in unaffected fetuses (5.2% < 5th centile, 54% > 50th centile, and 9.7% > 95th 
centile).  This results in less than a two-fold increase in risk of Down syndrome, 
should the FHR be above the 95th centile.  However, the FHR in trisomy 18 fetuses 
were somewhat lower than expected (19.7%, 39.7%, and 4.5%, respectively).  Thus, 
an FHR below the 5th centile would result in a four-fold increase in risk for a trisomy 
18 pregnancy.  The distribution was more abnormal for trisomy 13, with those 
pregnancies having higher FHRs (2%, 90%, and 64%, respectively).  Thus, an FHR 
above the 95th centile would represent a nearly 13-fold increase in risk for trisomy 13.   
 
One more recent study examined FHR measurements in the context of other 
ultrasound and serum markers (Kagan et al., 2008b).  When the FHR was included 
with the combined test (maternal age, NT, PAPP-A and free β hCG) at a 5% false 
positive rate, the increases in detection for Down syndrome, trisomy 18 and trisomy 
13 were 0%, -2% and 5%, respectively.  This confirms that measuring FHR might be 
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beneficial only for identifying  trisomy 13.  Others have also reported FHR in 
aneuploid pregnancies, although with much smaller numbers.  Two studies found 
higher odds ratios (10-fold and 4-fold) for Down syndrome and elevated FHR (Hyett 
et al., 1996; Martinez et al., 1998).  One of these studies (Hyett et al., 1996), 
confirmed that trisomy 18 fetuses had lower, and trisomy 13 higher, FHR.  
 
Given that FHR measurements are of real value only for detecting trisomy 13, it is 
unlikely that they would be routinely measured as part of a screening program.   
 
 Crown rump length (CRL):  First trimester growth delay was reported in five trisomy 
18 fetuses (Lynch and Berkowitz, 1989).  All were five days earlier than by LMP 
dating, and four were more than seven days early.  Later, a study found that Down 
syndrome and trisomy 13 fetuses were not growth retarded, but among trisomy 18 
fetuses, 34% were at or below the 5th centile for CRL (Kuhn et al., 1995).  A much 
larger trisomy 18 case-only report (Sherod et al., 1997) found a 1.1 standard 
deviation reduction in CRL, with 20% below the 5th centile.  Another case-only report 
identified trisomy 18 as having the greatest growth delay, with an OR of 14 for a 20% 
or more reduction in the expected CRL (Bahado-Singh et al., 1997).  Finally, a UK 
group (Falcon et al., 2005) reported the greatest mean difference in CRL 
measurement (-12.3 mm) for trisomy 18 fetuses.  Smaller CRL differences of -5.9 
and -0.8 were reported for trisomy 13 and Down syndrome fetuses.   
 
All of these studies relied on women reporting reliable menstrual dates, which limited 
the usefulness of CRL in predicting aneuploidy.  However, there is a consistent 
finding that trisomy 18 fetuses are the most severely growth retarded, followed by 
trisomy 13.  Down syndrome does not appear to be associated with growth 
retardation at this time in pregnancy. 
 
 Tricuspid regurgitation (TR): In a small proportion of fetuses, some blood leaks 
back into the right atrium during the contraction of the right ventricle.  This leakage is 
called tricuspid regurgitation, as it occurs through the tricuspid valve.  During fetal 
echocardiography, a pulsed wave Doppler study of the tricuspid valve can be used to 
diagnosis TR.  The association between heart defects and chromosome 
abnormalities is well documented.  A UK group used a strict definition of TR 
(regurgitation lasting at least half of the systole and having a peak of 80 cm/sec or 
greater) to survey a high risk population (Faiola et al., 2005).  Overall, a TR 
measurement was attainable in 97% of the fetuses and was present in 8.5% of 
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unaffected pregnancies.  Among Down syndrome (N=83) and trisomy 18/trisomy 13 
(N=51) fetuses, the corresponding detection rates were 65% and 53%, respectively.  
There was a positive correlation with elevated NT measurements.  That same group 
updated their work a year later in another dataset (Falcon et al., 2006), with 12 
obstetricians performing the ultrasound exams who were trained in fetal 
echocardiographs.  The false positive rate was lower (4.4%), the Down syndrome 
detect rate was similar (67% of 114 cases), and the detection rate for trisomy 18 
fetuses alone was provided (33% of 42 cases).  The agreement between the 
observers was high (kappa = 0.9).  They again found a positive correlation between 
TR and NT measurements.   
Another group in the UK reported the results of tricuspid regurgitation in a more 
routine setting (Kagan et al., 2009b).  A lower false positive rate was found (0.9%), 
and this may be due to the lower proportion of women with elevated NT 
measurements in this non-referral, but high risk setting (about one Down syndrome 
per 108).  However, detection rates for Down syndrome (56% of 122) were 
somewhat lower.  Trisomy 18 (33% of 36) and trisomy 13 (30% of 20) detection rates 
were similar.  Adding TR to combined testing in a contingent protocol was found to 
be of little use for either trisomy 18 or trisomy 13, but did improve Down syndrome 
detection.  
Tricuspid regurgitation appears to be associated with all three chromosomal 
abnormalities, but the strongest association is with Down syndrome.  Studies were 
performed in high risk settings with experienced fetal echocardiologists and may not 
be suitable for routine practice, where sonographers are not experienced in Doppler 
heart studies.
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Chapter 6.  Combining first trimester markers  
6.1  Introduction 
First trimester testing for Down syndrome and other autosomal trisomies is often 
portrayed as being better than second trimester testing because of the potential for 
earlier diagnostic testing and, if an abnormality is identified, earlier termination of 
pregnancy.  This would be true, if access to the first trimester diagnostic test (chorion 
villus sampling or CVS) were as available, safe and reliable as second trimester 
amniocentesis.  In the U.S, CVS is less available, is generally considered to be 
associated with a higher procedure-related fetal loss, and is less reliable than 
amniocentesis.  Given this, the performance of first trimester testing would need at least 
similar performance compared to the corresponding testing in the second trimester.  For 
this reason, neither NT testing alone, nor biochemistry alone, would be considered 
sufficiently powerful to be offered as a routine first trimester test.  The following sections 
will provide estimates of performance for various combinations of markers, but only 
those with both NT and biochemistry would be considered suitable for introduction as a 
first line test for Down syndrome; the major focus of such testing. 
 
6.2  Modeling test performance 
Chapter four provided the parameters necessary to describe the performance of serum 
screening markers for trisomy 18, with the best performers being PAPP-A, free β and 
intact hCG measurements.  Chapter five provided similar information for ultrasound 
markers, with only NT measurements being suitable for routine use.  Based on a 
multivariate overlapping Gaussian model, a monte carlo simulation was performed as a 
way to estimate screening performance of a combined (serum + ultrasound) model for 
identifying trisomy 18.  The age-associated risk at term, and the proportion of affected 
fetuses spontaneously lost are taken from Chapter 2.  Table 6.2-1 examines four tests, 
all of which use maternal age and PAPP-A measurements.  Two are serum only, with the 
addition of either free β or hCG, while the latter two add NT measurements to these 
serum markers.  Clinical testing would be expected to concentrate only on the last two 
columns, as these are needed for Down syndrome screening.  The top half of the table 
shows false positive rates at fixed detection rates, while the bottom shows detection 
rates at fixed false positive rates. 
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Table 6.2-1.  Modeled trisomy 18 detection rates (DR) and false positive rates (FPR) using first trimester maternal serum markers with 
and without ultrasound measurements of nuchal translucency (NT) 
 
 Maternal age in combination with 
 PAPP-A & free β PAPP-A & hCG PAPP-A, free β & NT PAPP-A, hCG & NT 
DR (%)     
50 0.2 0.4 <0.1 <0.1 
60 0.4 0.7 <0.1 <0.1 
70 0.6 1.0 <0.1 <0.1 
80 1.4 2.4 0.1 0.1 
90 4.2 6.3 0.5 0.8 
     
FPR (%)     
0.3 53 46 87 85 
0.5 63 52 90 87 
0.7 73 60 91 89 
1.0 77 70 93 91 
1.5 81 74 95 93 
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Testing using only serum markers is somewhat better with the use of free β than with hCG 
measurements.  For example, at a detection rate of 80%, the combination of maternal age, 
PAPP-A and free β would require a 1.4% false positive rate.  If hCG were to replace free β 
measurements, the false positive rate would increase to 2.4%.  However, when NT 
measurements are also included, a false positive rate of only about 0.1% would be required 
for both combinations of serum markers. 
 
Table 6.2-2 shows the results of modeling stratified by the trisomy 18 risk cut-off level and 
included an estimate of the odds of being affected given a positive test result (OAPR) in the 
first trimester.  The risk cut-off levels are shown both at term, and in the second trimester.  
Term results allow comparison of test performance with that found for second trimester 
markers (Chapter 3), while the first trimester risks are probably more appropriate for clinical 
use.  The combined test performance at a term risk of 1:100 (first trimester risk of about 
1:30) yields about an 85% detection rate for a 0.2% to 0.3% false positive rate, regardless of 
which hCG marker is used.  The corresponding OAPRs are in the order of 1:2 to 1:4.  If 
higher performance was needed, a term risk cut-off of 1:200 would improve detection to 
90%, but with a doubling of the false positive rate to about 0.5%.  The corresponding OAPR 
would be about 1:6. 
 
As shown in second trimester demonstration studies (Chapter 3.11), trisomy 18 test 
performance is extremely good, with high detection rates at very low false positive rates, 
usually below 0.3% (3 per 1000 false positives).  At such low rates, the model will not agree 
well with rates found in practice.  This is because other relatively rare outcomes (e.g., fetal 
death, anencephaly) that the trisomy 18 algorithms preferentially identify can result in a 
noticeable increase in the false positive rate (i.e., from 0.1% to 0.3%).  However, most of 
these additional ‘false positives’ are not unaffected pregnancies.   
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Table 6.2-2.  Modeled first trimester trisomy 18 screening performance at selected trisomy 18 risk cut-off levels 
 
 Maternal age in combination with 
Risk (1:n) PAPP-A & free β  PAPP-A & hCG  PAPP-A, free β & NT  PAPP-A, hCG & NT 
at term (in first1) DR FPR OAPR2 DR FPR OAPR2 DR FPR OAPR2 DR FPR OAPR2 
             
1:  20   (1:  6) 36 <0.1 >1:  3 29 0.1 1:  4 71 <0.1 >1:  2 66 <0.1 >1:  2 
1:  50   (1:14) 56 0.4   1:  7 47 0.3 1:  7 79 0.1 1:  1 77 0.1   1:  1 
1:  70   (1:20) 70 0.6   1:  9 56 0.5 1:  9 83 0.1 1:  1 80 0.2    1:  3 
1:100   (1:29) 74 0.8   1:11 69 0.9 1:14 86 0.2 1:  2 83 0.3   1:  4 
1:120   (1:35) 77 1.1   1:15 71 1.1 1:16 87 0.3 1:  4 85 0.3   1:  4 
1:150   (1:43) 80 1.4   1:18 75 1.4 1:19 88 0.3 1;  4 86 0.4   1:  5 
1:200   (1:60) 83 2.0   1:25 78 2.0 1:27 90 0.4 1:  5 88 0.6   1:  7 
 
 
1  assumes 72% fetal loss from 11-13 weeks to term (Table 2.4-1) 
2 with a first trimester prevalence of 9.61/10,000 (term = 2.69/10,000) 
DR = detection rate, FPR = false positive rate, OAPR = first trimester odds of being affected given a positive result  
The shaded rows indicate two potential cut-off levels that could be used for the first trimester combined test for trisomy 18
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6.3  Summary of demonstration studies 
Literature search:  The literature was search for demonstration studies containing a 
prospective implementation of a trisomy 18 (or trisomy 18/13) specific protocol in the late 
first trimester.  Most reports of trisomy 18 testing are contained within a report on Down 
syndrome screening performance.  In addition to reporting the results of a prospective 
application of a trisomy 18 specific protocol using biochemistry and NT measurements in 
the late first trimester, it was necessary for the publication to provide the needed 
information to estimate both the detection rate and the false positive rate (no study was 
excluded because they did not report the detection rate).  Studies that combined trisomy 
18 and 13 together in either the algorithm or in computing the detection rate were 
included.  The identification of demonstration studies was performed using the results of 
the NT literature search (Section 5.2).  A total of 33 publications were individually 
reviewed and eight were found to be suitable for analysis (Orlandi et al., 1997; Krantz et 
al., 2000; Spencer et al., 2000c; Wapner et al., 2003; Stenhouse et al., 2004; Breathnach 
et al., 2007; Jaques et al., 2007; Schaelike et al., 2009).  All used a combination of 
maternal age, PAPP-A, free β and NT measurements in the late first trimester.  There 
were 25 excluded studies (Nicolaides et al., 1994; Scott et al., 1996; Zimmermann et al., 
1996; Taipale et al., 1997; Theodoropoulos et al., 1998; O'Callaghan et al., 2000; Acacio 
et al., 2001; Brizot et al., 2001; Niemimaa et al., 2001; Schuchter et al., 2001; Tsai et al., 
2001; Wayda et al., 2001; Bindra et al., 2002; von Kaisenberg et al., 2002; Chasen et al., 
2003; Cheng et al., 2003; Spencer et al., 2003; Borrell et al., 2004; Nicolaides et al., 
2005; Wojdemann et al., 2005; Dhaifalah et al., 2006; Kim et al., 2006; Perni et al., 2006; 
Leung et al., 2007; Torring, 2009).  The main reasons for excluding these studies were: 
no specific trisomy 18 algorithm, no biochemistry, and a retrospective application of an 
algorithm that was developed using the same dataset (over-fitting).  Because elevated 
NT measurements are a strong predictor of both trisomy 18 and Down syndrome, some 
programs did not think it was necessary to have a test interpretation focused on trisomy 
18/13.  Figure 6.3-1 shows the date of publication versus the number of trisomy 18 
pregnancies studied.  
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Figure 6.3.1  Summary of publications included in the analysis of 
demonstration studies for first trimester combined testing for trisomy 18. 
 
Results:  Table 6.3-1 shows relevant information about these eight publications, 
including the observed false positive rates and corresponding detection rates.  The table 
is sorted in order of increasing false positive rates.  Overall, 103 trisomy 18 pregnancies 
were identified in the eight studies, among over 87,000 women tested.  One study 
(Schaelike et al., 2009) included trisomy 13 and trisomy 18 together.  In a general 
population of first trimester pregnancies, one would expect the trisomy 18 prevalence to 
be approximately 9.6/10,000, or about 1:1000 (see Table 6.2-2 footnote for the 
derivation).  The overall rate in the eight studies was about 1:690.  However, four studies 
appeared to have included referral patients many more older women, or both, as their 
rates were between 1:300 and 1:400 (Orlandi et al., 1997; Krantz et al., 2000; Spencer et 
al., 2000c; Schaelike et al., 2009).  No single summary estimate for the detection rate 
and false positive rate are provided, as there is a clear relationship between increasing 
false positive rates and increasing detection rates.  
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Table 6.3-1.  Results of eight demonstration studies of combined testing for trisomy 18. 
 
Author 
False 
Positive 
True 
Negative 
False Positive 
Rate (%) 
 True 
Positive 
False 
Negative 
Detection Rate 
(%) 
Prevalence 
(1:n) 
         
(Breathnach et al., 2007) 116 35,793 0.32  19 30     63.3 1:1201 
(Jaques et al., 2007)   56 15,947 0.35  10 15     66.7 1:1071 
(Schaelike et al., 2009)   74 10,485 0.70  21 321     65.6 1:  332 
(Krantz et al., 2000)   44   5,675 0.77  16 16 100 1:  360 
(Stenhouse et al., 2004)   53   4,921 1.07    7   8     87.5 1:  628 
(Spencer et al., 2000c)   45   3,717 1.20    8     9     88.9 1:  423 
(Orlandi et al., 1997)   36   1,956 1.81    5   6     83.3 1:  338 
(Wapner et al., 2003) 163   7,981 2.00  10 11     90.9 1:  755 
         
All 587 87,062   96 103  1:  690 
 
1 includes both trisomy 18 and trisomy 13 
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Figure 6.3-2.  Trisomy 18 detection rate and associated false positive rate from 
eight demonstration studies of first trimester combined test.  The open circle 
indicates the point estimate, with the thin lines indicating the corresponding 95% 
confidence interval.  The dashed curve indicates the average performance over the 
eight studies.  The dashed line indicated a ‘useless’ test, where the detection rate is 
equal to the false positive rate. 
 
Figure 6.3-2 is a receiver operator characteristic (ROC) curve that summarizes the 
performance of the eight studies shown in Table 6.3-1.  Since detection rate estimates 
are based on between 4 and 32 cases, they are broad compared to estimates of the 
false positive rates.  This performance is not as high as that predicted by modeling 
(Table 6.1-1), where detection rates from 80% to 90% could be achieved with false 
positive rates below 0.5%.  The most important observation, however, is the high false 
positive rates reported in the studies.  Only two studies were below a 0.5% false positive 
rate and these were both published recently (Breathnach et al., 2007; Jaques et al., 
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2007).  The most recent report was only slightly higher at 0.7% (Schaelike et al., 2009).  
This might indicate that the earlier studies did not choose an optimal risk cut-off level.  It 
is also clear that not all of pregnancies associated with a ‘false positive’ result have 
normal fetuses.  Elevated NT measurements are clearly associated with heart defects 
and other abnormalities and this may be another reason why the modeled false positive 
rates should be viewed with caution.  It is expected that the false positive rates in 
practice will be higher than the modeled rates by at least a few tenths of a percent.  This 
was clearly demonstrated in the evaluation of second trimester serum-based testing for 
trisomy 18 (Section 3.11). 
 
Excluded studies:  To help clarify why studies were excluded, two examples were 
chosen for further examination.  Excluding a study does not imply that it is a poor study.  
It only suggests that that study did not provide reliable data suitable to answer the 
question posed.  The recent study from Denmark (Torring, 2009) provides an overview of 
44,537 singleton pregnancies screened between 8 and 13 completed weeks.  Over 80% 
of the data were collected at 8-10 weeks, outside of the window chosen for study.  In 
additon, the author grouped trisomy 18, trisomy 13 and triploidy together.  Lastly, there 
was no clear algorithm specified.  Rather, this group of defects were identified by ‘clincal 
data and biochemistry, or clinical data and nuchal translucency measurements’.  The 
study with the largest number of cases (61) was from the UK (Nicolaides et al., 2005) 
and it applied only a Down syndrome risk protocol and then reported detection rates only 
for the combination of trisomy 18 and 13. 
   
Summary:  Based on included studies, a combination of maternal age, PAPP-A, free β 
(or intact hCG) and NT measurements can detect 80% to 90% of trisomy 18 pregnancies 
in the late first trimester with fewer than 0.5% of the population having a screen positive 
result.  Many of these women will also be screen positive for Down syndrome, as the 
marker patterns for the two abnormalities are similar; only the free β measurements differ 
(elevated for Down syndrome, but reduced for trisomy 18).  Given the similarity of the 
pattern for trisomy 18 and trisomy 13, it is reasonable to assume that the majority of 
trisomy 13 pregnancies will also be identified as part of either the Down syndrome or 
trisomy 18 risk interpretations.  Due to a lack of relatively unbiased data for NT 
measurements in trisomy 13 pregnancies, it is not possible to be more specific.  
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Chapter 7  Integrated testing for trisomy 18 
7.1 introduction 
In the 1990s there was a real division in prenatal care providers between those offering 
serum-based second trimester testing for Down syndrome, and others who were 
convinced that first trimester NT measurements w/wo biochemistry was at least as 
efficient, and provided an opportunity for earlier diagnostic testing.  In 1999, Wald and 
colleagues (Wald et al., 1999) redirected the discussion from first or second trimester 
testing, to a combination of first and second trimester testing.  He theorized that if both 
first and second trimester screening were each effective tests, then the combination of 
the two must be even better.  Interpreting biochemical and/or ultrasound marker results 
from both trimesters into a single interpretation for Down syndrome was called 
‘integrated’ testing and is covered by patent (U.S. Pat No. 6,573,103, issued 6/3/03 to 
Nicholas J. Wald).   
 
Integrated testing comes in two flavors, serum integrated, where NT measurements are 
not included and full integrated, when NT measurements are included in the 
interpretation.  Although not in this chapter, additional twists in implementation include 
sequential and contingent integrated testing (Chapter 10).  In the original description of 
integrated screening, no interpretation is provided until all data is available for the 
interpretation in the second trimester.  Waiting until the second trimester has been 
criticized for two reasons.  First, it does not allow for any first trimester diagnostic testing, 
a leading reason for combined testing in the first trimester.  Second, it can appear to 
some that the laboratory is ‘withholding’ information from the woman that could be useful 
in decision-making.  Sequential testing avoids much of the controversy by allowing for a 
very high risk group (usually about 0.5%) to receive their results after first trimester 
testing is completed (Palomaki et al., 2006).  In order to be efficient, an NT measurement 
is required for sequential testing.  In this group, nearly 50% of the Down syndrome cases 
can be detected.  The remainder of the population (99.5%) received a full integrated test, 
as planned.  Contingent testing goes a step further, but not only having  a high risk cut-
off, but also a low risk cut-off (usually about 1:2000 to 1:5000).  Women with first 
trimester risks below this level are told that testing is completed and there is no need to 
return for the second trimester portion of the test.  Sequential testing, when implemented 
correctly, is nearly as efficient as full integrated testing and is becoming more commonly 
offer as part of routine prenatal care in the US.  Contingent screening is not as widely 
used. 
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7.2 Modeling serum integrated test performance 
Serum integrated screen for Down syndrome has been reported from Maine (Knight et 
al., 2005), and a serum integrated algorithm for trisomy 18 has been published 
(Palomaki et al., 2003).  That modeling relied on first trimester PAPP-A measurements 
along with second trimester AFP, uE3 and hCG measurements from a previous 
publication (Palomaki et al., 1995).  Performance was estimated to be 90% at a 0.1% 
false positive rate.  This is similar to the performance estimated for the quadruple test for 
trisomy 18 in the second trimester (AFP, uE3, hCG and PAPP-A) of 90% at 0.2% (Table 
3.9-2).  However, it is better than the performance of the combined test in the first 
trimester 0.5% to 0.8%, depending on the hCG subunit tested (Table 6.2.-1).  The 
advantage of a serum integrated test over the second trimester quadruple test for 
trisomy 18 is that an additional assay (PAPP-A in the second trimester) is not necessary.   
 
The one missing parameter is between trimester correlation coefficients for trisomy 18.  
In the previous modeling (Palomaki et al., 2003) it was assumed that the correlation 
coefficients between trimesters for these markers was 0.  For unaffected pregnancies, 
data now exist (Wald et al., 2003) that show the correlations are low (first trimester 
PAPP-A correlations with second trimester AFP, uE3, free β, and hCG were all positive 
and less than 0.12).  For trisomy 18 pregnancies, unpublished data are available from 
the FaSTER Study (Malone et al., 2005) to determine the correlation coefficients 
between PAPP-A in the first trimester and AFP, uE3 and hCG measurements in the 
second trimester (personal communication, Dr Geralyn Messerlian-Lambert).  Figure 7.2-
1 shows this data collected from 12 trisomy 18 pregnancies having both first and second 
trimester serum samples obtained and tested as part of that study.  For comparison, the 
93 available matched controls for these 12 trisomy 18 pregnancies had correlations of -
0.0625, 0.01777 and 0.1251, respectively.  The modeling uses correlations in unaffected 
pregnancies as derived in the SURUSS report (Wald et al., 2003), and the values are 
0.0114, 0.1003 and 0.2198, respectively.  This high level of agreement in the unaffected 
pregnancies provides some additional confidence that the correlations found for the 12 
trisomy 18 pregnancies are accurate, albeit, imprecise. 
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Figure 7.2-1  Correlation between first trimester PAPP-A and second trimester AFP, uE3 and hCG measurements from 12 trisomy 
18 pregnancies.  The three figures show the pair-wise correlation coefficients (after a logarithmic transformation) and the exclusion of the 
paired observations.  All the correlations are relatively small.  The vertical and horizontal dotted lines are shown at the median level for 
unaffected pregnancies.  All of the markers examined are significantly lower than 1.00 MoM. 
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Table 7.2-1 shows the detection and false positive rates for serum integrated testing for 
trisomy 18 using updated age related risks (Chapter 2) and serum parameters (Chapters 
3 and 6) and the between-trimester correlations in unaffected pregnancies from 
SURUSS (Wald et al., 2003) and in affected pregnancies as shown in Figure 7.2-1.  At a 
second trimester risk cut-off level between 1:70 and 1:140, the detection rates are in the 
mid 80% range, with about a 0.2% false positive rate.  The OAPR is about 1:2 or 1:3.  As 
described earlier, it is likely that the observed positive rate in practice will be higher that 
the modeling suggests, due to the identification of other abnormalities, such as existing 
fetal deaths.  
 
There is insufficient information to create the corresponding model using free β 
measurements instead of total or intact hCG measurements in the second trimester.  
However, were the correlations assumed to be the same for PAPP-A and free β as for 
PAPP-A and hCG, the performance would only be slightly improved (e.g., at a given 
false positive rate, the detection would be, at most, 1% or 2% higher (modeling results 
not shown). 
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Table 7.2-1.  Serum integrated testing for trisomy 18: Modeled detection rates (DR) 
and false positive rates (FPR) 
 
 DR (%) FPR (%) OAPR2 
DR (%)    
50 - <0.1 >1:  3 
60 - <0.1 >1:  2 
70 - <0.1 >1:  2 
80 -   0.1   1:  2 
90 -   0.6   1:  9 
    
FPR (%)    
0.3 87 -   1:  4 
0.5 89 -   1:  7 
0.7 92 -   1:10 
1.0 93 -   1:14 
1.5 94 -   1:21 
    
Risk cut-off level    
at term (in second1)    
1:100   (1: 35) 76 <0.10 >1:  2 
1:150   (1: 52) 80 <0.10 >1:  2 
1:200   (1: 70) 82   0.10   1:  2 
1:250  (1:  88) 83   0.13   1:  2 
1:300  (1:105) 84   0.16   1:  3 
1:350  (1:123) 85   0.19   1:  3 
1:400  (1:140) 86   0.21   1:  3 
 
Serum integrated testing is defined as a first trimester PAPP-A measurement combined 
with second trimester AFP, uE3 and hCG measurements 
1  assuming a  65% fetal loss from 16-18 weeks to term (Table 2.4-1) 
2 OAPR = second trimester odds of being affected given a positive result (assumes 
1:1300, derived from the birth prevalence of 2.69/10,000, with adjustment for 65% 
fetal loss from 16-18 weeks to term). 
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7.3 Modeling full integrated test performance 
The same parameters using in modeling serum integrated performance (Chapter 7.2) 
can be used to model full integrated performance, with the addition of information about 
NT distributions in trisomy 18 and unaffected pregnancies (Chapter 5.2).  Studies have 
consistently found that NT measurements have little or no correlation with serum 
markers in either unaffected or unaffected pregnancies, and the model will assume these 
correlations are zero.  Given that the ultrasound measurement of NT is the strongest 
predictor of trisomy 18, the full integrated test should have the highest possible 
performance. 
 
Table 7.3-1 shows the results of modeling full integrated test performance for trisomy 18.  
The detection rates are 90% or higher, with corresponding false positive rates of 0.2% or 
lower.  Expected OAPRs are on the order of 1:2, but in practice, lower odds might be 
expected due to other outcomes with this pattern such as fetal death. 
 
Comparing this performance with first trimester combined testing 
Full integrated screening can detect 90% of trisomy 18 at a 0.1% false positive rate, 
but requires waiting until the second trimester for the interpretation and subsequent 
offering of diagnostic testing.  To achieve a 90% detection rate in the first trimester, 
the false positive rate is higher at 0.5%.  Although there are 5 times as many false 
positives, the advantage is that diagnostic testing can be offered several weeks 
earlier, sometimes in the first trimester.  Fortunately, there is a way to keep the higher 
performance of full integrated screening while allowing for most of the diagnoses to be 
made in the first trimester.  Conceptually, the first step of integrated testing identifies 
pregnancies at very high risk and offers first trimester diagnostic testing immediately.  
That cut-off is so high that subsequent testing in the second trimester would be 
unlikely to re-classify them as being test negative.  Such a protocol has been labeled 
‘sequential’ and has been well described for Down syndrome screening (Palomaki et 
al., 2006).  That paper demonstrates that it is always possible to create a sequential 
strategy with only slightly lower performance than full integrated, and that such a 
protocol usually results in most cases identified in the first trimester.  In Section 10, 
modeling sequential testing for trisomy 18 is performed and compared with full 
integrated as well as first trimester testing.   
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Table 7.3-1.  Full integrated testing for trisomy 18: Modeled detection rates (DR) 
and false positive rates (FPR) 
 
 DR (%) FPR (%) OAPR2 
DR (%)    
50 - <0.1 >1:  3 
60 - <0.1 >1:  2 
70 - <0.1 >1:  2 
80 - <0.1 >1:  2 
90 -   0.1   1:  1 
    
FPR (%)    
0.3 94 -   1:  4 
0.5 95 -   1:  7 
0.7 96 -   1:  9 
1.0 97 -   1:13 
1.5 98 -   1:20 
    
Risk cut-off level    
at term (in second1)    
1:100  (1:  35) 84 <0.1 >1:  2 
1:150  (1:  52) 86 <0.1 >1:  2 
1:200  (1:  70) 88 <0.1 >1:  2 
1:250  (1:  88) 89 <0.1 >1:  2 
1:300  (1:105) 89 <0.1 >1:  2 
1:350  (1:123) 90 <0.1 >1:  2 
1:400  (1:140) 91     0.11   1:  2   
 
Full integrated testing is defined as first trimester PAPP-A and NT measurements combined 
with second trimester AFP, uE3 and hCG measurements. 
1  assuming a  65% fetal loss from 16-18 weeks to term (Table 2.4-1) 
2 OAPR = second trimester odds of being affected given a positive result (assumes 1:1300, 
derived from the birth prevalence of 2.69/10,000, with adjustment for 65% fetal loss from 
16-18 weeks to term). 
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Chapter 8  Second trimester ultrasound markers for trisomy 18 
8.1  Introduction 
In many developed countries, a second trimester ultrasound examination at 18 to 22 
weeks’ gestation is recommended as part of routine prenatal care to identify major 
structural anomalies.  It is scheduled at this relatively late gestational age, because some 
of the targets (e.g., heart defects, face, hand and foot) are more easily visualized.  At a 
somewhat earlier time in pregnancy (15 to 20 weeks’ gestation), ultrasound is also 
commonly performed prior to amniocentesis.  Thus, there is an existing literature 
regarding the ability of early second trimester ultrasound markers to identify fetuses with 
aneuploidy.  Although the major focus of this literature is on Down syndrome, some 
information is available concerning trisomy 18.  This chapter will focus on ultrasound 
performed between 15 and 20 weeks’ gestation, but will include some later second 
trimester, and even third trimester, results to aid in determining whether individual 
markers may be gestational age dependent.  Lastly, it is important to acknowledge that 
the majority of observations will be made in high risk pregnancies, where the ultrasound 
is performed as part of a diagnostic testing protocol.  This has the strength of having the 
availability of a routine karyotype, but is associated with several important limitations that 
might bias performance estimates.  The most important of these include: the indication 
for amniocentesis is sometimes because of an ultrasound marker, and the result of the 
ultrasound and subsequent counseling might influence the uptake of amniocentesis, thus 
missing cases that do not have that marker. 
 
For this review, ultrasound markers have been stratified into two separate groups: 
structural anomalies and non-structural anomalies.   
 Structural anomalies are real fetal defects that will be maintained during pregnancy 
and will usually result in birth defects.  These include: open defects (abdominal and 
spinal), cardiac defects, and anomalies of the hand and foot (clenched fingers, rocker 
bottom feet, talipes).  Some groups only reported ‘gross’ abnormalities that could 
include combinations of these outcomes.   
 Non-structural anomalies will usually not result in birth defects, but may be found in 
association with aneuploidy during pregnancy or even after delivery.  These include: 
choroid plexus cysts, nuchal skinfold thickening, shortened long bone 
measurements, echogenic bowel and pyelectasis. 
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For each of these ultrasound markers, a structured literature search was conducted that 
included a review of the reference lists from retrieved articles.  The Medline search 
strategy included the names (or names) of the marker, and the terms ‘second trimester 
or mid-trimester’, ‘aneuploidy’ and ‘trisomy 18’.  Case reports are not included.  Studies 
were included if they provided gestational age, study type (e.g., case/control, cohort, 
case only), whether the population was at high, population or low risk for trisomy 18, and 
a suitable description of the ultrasound marker(s) studied.  Relevant information is shown 
in an evidence table, and summary detection and false positive rates are estimated using 
a random effects model.  Overall heterogeneity is evaluated, and sources for that 
heterogeneity are examined (e.g., year of publication, study type, and gestational age).  
In general, gestational ages are grouped into earlier (15 to 20 weeks’ gestation, 
inclusive), moderate (15 through 23 weeks) and later (15 through 24 weeks and later) 
categories.  The lower limit of the gestational age is less important than the upper in this 
classification scheme.  For example, a study of 13 through 22 weeks will be classified as 
moderate, while a study of 17 through 20 will be considered early.  If studies provided 
information on individual pregnancies, the summary used may differ from that published.  
For example, if a study reported the individual ultrasound marker results for 20 
pregnancies from 15 through 30 weeks’ gestation, it might be possible to create two 
summary detection rates.  One for the early group (15 to 20 weeks), with the remaining 
pregnancies (21 to 30 weeks) assigned to the late grouping. 
 
Although all of the included studies provided an estimate of the detection rate, many did 
not provide sufficient information for the associated false positive rate.  Sometimes this 
was due to study design (e.g., case only), but not always.  In general, studies reporting 
both detection and false positive rates were examined separately from the studies 
reporting only a detection rate.  Table 8.1-1 summarizes the 46 included publications for 
10 of the 11 second trimester ultrasound markers summarized in this chapter.  The 
publications for choroid plexus cysts (CPCs) are not included in the Table, as many of 
them focus exclusively on CPCs (Figure 8.3.1-2).  Unlike previous chapters, some of the 
results have been stratified by study design and/or whether the population studied was 
high-risk or low-risk.  This allowed for evaluation of heterogeneity and examine potential 
biases. 
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Table 8.1-1.  Included publications for second ultrasound markers and trisomy 18, excluding those for choroid plexus cysts  
 
 Structural anomalies  Non-structural anomalies 
 
Reference 
Gross 
defect 
Open 
defect 
Cardiac 
defect 
Hands 
& feet 
 Nuchal 
Skinfold 
Long 
bone 
Hyper. 
bowel 
Pyele-
ctasis 
2 vessel 
cord 
 
EICF 
            
(Bahado-Singh et al., 2003) X X  X      X  
(Benacerraf et al., 1988) X X X X        
(Benacerraf et al., 1990) X X X X        
(Benacerraf et al., 1992) X X X   X X     
(Benacerraf et al., 1994) X X X X  X X X X   
(Benacerraf et al., 1994)      X      
(Borrell et al., 1997)      X      
(Bottalico et al., 2009) X     X X X X  X 
(Bronsteen et al., 2004) X  X X        
(Brumfield et al., 2000) X X X X      X  
(Bundy et al., 1986)       X     
(Cheng et al., 2006)            
(Cho et al., 2009) X  X X  X X X X X X 
(Coco and Jeanty, 2004)            
(DeVore, 2000) X  X   X  X X   
(Dicke et al., 1989)       X     
(Droste et al., 1990)       X     
(Drugan et al., 1996)      X  X X   
(Ghidini et al., 2000)            
(Ginsberg et al., 1990)      X X     
(Grandjean et al., 1998) X           
(Gray et al., 1996)  X  X        
(Gupta et al., 1997) X X X X        
(Havutcu et al., 2002)         X   
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Table 8.1-1.  (Continued)  
 
 Structural anomalies  Non structural anomalies 
 
Reference 
Gross 
defect 
Open 
defect 
Cardiac 
defect 
Hands 
& feet 
 Nuchal 
Skinfold 
Long 
bone 
Hyper. 
bowel 
Pyele-
ctasis 
2 vessel 
cord 
 
EICF 
            
(Jelliffe-Pawlowski et al., 2008)   X         
(Lubusky et al., 2007)          X  
(Moran et al., 2002) X           
(Nadel et al., 1992)       X     
(Nicolaides et al., 1992b)   X X        
(Nyberg et al., 1993) X X X X        
(Papp et al., 2007) X X X X    X   X 
(Papp et al., 2008)       X  X   
(Picklesimer et al., 2005) X           
(Roberts et al., 1993) X           
(Saller et al., 1990)          X  
(Seoud et al., 1994)   X   X X X X   
(Sepulveda et al., 1995)           X 
(Shields et al., 1998) X X X X        
(Taslimi et al., 2005) X           
(Tongsong et al., 2002) X X X X        
(Viora et al., 2007)  X X X    X    
(Watson et al., 1994)      X      
(Watson et al., 2008)  X X X        
(Watson et al., 2008)       X X  X  
(Wax et al., 2000)           X 
(Yeo et al., 2003)  X X X    X X  X 
Total number (46) 20 15 19 17  11 12 10 9 6 6 
 
ICEF = intracardiac echogenic focus, hyper = hyperechoic bowel 
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8.2  Structural anomalies  
This section includes three structural anomalies associated with trisomy 18 in early 
second trimester sonographic examinations and a ‘summary’ grouping including any 
structural anomaly.  The three individual defects include: open ventral/neural tube 
defects (most often omphalocele), cardiac structural anomalies (excluding blood flow 
anomalies), and hand/feet anomalies (including clenched hands, overlapping digits, club 
feet).  Since some studies did not always report individual defects, an additional group 
designated as a ‘any structural defect’ was also included.  In general, structural 
anomalies have moderate sensitivity, but high specificity for trisomy 18 (or other 
aneuploidies).   
 
Overview of the literature search:  A total of 26 publications (1988 to 2009) were 
identified that satisfied inclusion criteria and reported structural anomalies in trisomy 18 
pregnancies.  These were found via formal literature searching (described in Chapter 
8.1) and examining the lists of retrieved publications (Bahado-Singh et al., 2003; 
Benacerraf et al., 1988; Benacerraf et al., 1990; Benacerraf et al., 1992; Benacerraf et 
al., 1994; Bottalico et al., 2009; Bronsteen et al., 2004; Brumfield et al., 2000; Cho et al., 
2009; DeVore, 2000; Grandjean et al., 1998; Gupta et al., 1997; Jelliffe-Pawlowski et al., 
2008; Moran et al., 2002; Nicolaides et al., 1992b; Nyberg et al., 1993; Papp et al., 2007; 
Picklesimer et al., 2005; Roberts et al., 1993; Seoud et al., 1994; Shields et al., 1998; 
Taslimi et al., 2005; Tongsong et al., 2002; Viora et al., 2007; Watson et al., 2008; Yeo et 
al., 2003).  Inclusion criteria have been specified earlier.  Two studies were excluded 
because they required that an ultrasound finding (choriod plexus cysts) be present in all 
included patients (Gray et al., 1996; Nadel et al., 1992).  If a study contained no 
instances of a specific structural anomaly in cases or controls, it was assumed that data 
were not collected, unless the Methods clearly stated that it was reportable.  For 
example, if a study contained no cases or controls with an omphalocele, this category 
would be left blank, unless methods explicitly stated that omphalocele was considered a 
reportable outcome.   
 
Figure 8.2-1 shows the number of trisomy 18 pregnancies reported by each of the 26 
included studies, along with the study design (shape of the symbol) and whether the 
study was derived from a high risk population (filled symbols) or a general pregnancy 
population (open symbols).  No study was performed in a low risk population (i.e., an 
important proportion of trisomy 18 pregnancies identified and removed from the 
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population earlier in pregnancy).  Not all studies provided information on all four 
structural anomaly groups included in this analysis, but each contributed at least one.  
Only three of 26 studies reported structural anomalies on fewer than 10 cases; seven 
studies reported on 50 or more cases.  The majority of these ultrasound studies are 
case-only.  The most common scenario was the review of an existing clinical database, 
with ultrasound information extracted only on pregnancies diagnosed with trisomy 18. 
 
A pair of articles (Papp et al., 2007; Papp et al., 2008) are also of interest, as they 
compare the results of routine US in trisomy 18 pregnancies, with the corresponding 
second trimester autopsy results following termination of pregnancy.  Some of the US 
findings were found to be extremely reliable (e.g., hydrops, CNS defects), while others 
were quite poor (e.g., only four of the 70 trisomy 18 fetuses had hand/feet anomalies 
identified by ultrasound, but 46 of 70 had such findings at autopsy). 
 
Figure 8.2-1.  The included articles of structural anomalies among trisomy 18 
fetuses.  Each symbol represents a single study, with the shape indicating the study 
design.  The symbol is filled if the study was performed in a high risk population 
(usually prior to amniocentesis), and open if performed in a general population.   
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8.2.1  Open fetal defects 
 
Definition:  This category mainly includes omphalocele and open spina bifida, 
which were sometimes reported as an ‘abdominal wall defect’ or ‘neural tube 
defect’.  Occasionally other open defects were also reported and included in this 
category (e.g., anencephaly).  
 
Literature review:  Based on a structured literature search, fifteen studies met 
inclusion criteria on the proportion of trisomy 18 pregnancies with open fetal 
defects (Bahado-Singh et al., 2003; Benacerraf et al., 1990; Benacerraf et al., 
1988; Benacerraf et al., 1994; Benacerraf et al., 1992; Brumfield et al., 2000; Gray 
et al., 1996; Gupta et al., 1997; Nyberg et al., 1993; Papp et al., 2008; Shields et 
al., 1998; Tongsong et al., 2002; Viora et al., 2007; Watson et al., 2008; Yeo et al., 
2003).   
 
Results:  Table 8.2.1-1 provides a listing of the 15 studies, the observed number of 
trisomy 18 pregnancies, the number and proportion with open fetal defects.  It also 
includes the approximate time in gestation the ultrasound study was performed 
(early, middle and late as defined earlier).  Figure 8.2.1 -1 shows a forest plot for 
the proportion of trisomy 18 fetuses associated with open defects for the 15 
studies.  The summary estimate is 23%, (95% CI 18% to 28%).  Heterogeneity is 
moderate (Q=20, I2=29%, p<0.001).  There is no difference in detection rates in the 
19 estimates by study design (p = 0.8), but there is some indication that the rate is 
slowing decreasing over time (p = 0.055, for slope).  There is a much stronger 
effect seen when the rates are stratified by the time in gestation when the 
ultrasound was performed.  Among the seven estimates from studies with early 
results (<20 weeks), the detection rate is 27% (95% CI 19% to 37%), similar to the 
results found for the six middle estimates of 25% (95% CI 20% to 31%).  Overall, 
the rate is 26% (95% CI 21% to 31%) for these 13 studies.  However, the two 
studies that included results from the late second trimester (no upper gestational 
age limit) were quite low, 10% (95% CI 6% to 17%).  These differences are 
significant (p = 0.003).  Each of the larger groups are homogeneous (I2=0% and 
10%, respectively).  It is possible that the later two studies were performed in 
populations where open fetal defects were identified much earlier in pregnancy and 
would not represent results found in the 15 to 20 week period.  Results from the 15 
studies were also examined for publication bias using two methods.  Neither was 
statistically significant (Eggers regression intercept, p = 0.9, trim and fill method 
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estimates a positive bias of 3%).  Only two studies reported the rates of open fetal 
defects in the control population, and there were too few for reliable estimates.  
However, a reasonable estimate from the literature for the combination of open 
neural tube and ventral wall defects is about 1:500 (0.2%).   
 
Summary:  A total of 15 articles was identified and included for analysis of open 
fetal defects, with information on 441 cases of trisomy 18.  There was a change in 
detection rate by gestational age, but among the 13 studies reporting ultrasound 
exams in the early to mid second trimester, the proportion of 18 fetuses with an 
open defect was constant at 26%.  Two studies including later ultrasound exams 
found a much lower rate of 10%.  When two late gestational age studies with very 
low detection rates (10%) were removed, the detection rate remained constant over 
time (p=0.8).  No differences by study type were noted.  Few studies reported the 
rate of open defects in the population without any chromosome abnormalities.  Best 
estimate would be 26% detection at a 0.2% false positive rate. 
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Table 8.2.1-1.  Rates of open fetal defects in trisomy 18 and control pregnancies  
 
 
Author 
 
Location 
 
Design (prev)1 
Gestational 
Age (weeks)2 
Trisomy 18 
positive / total (%) 
Controls 
positive / total 
(%) 
      
(Gupta et al., 1997) UK Ca only         (high) 16 – 20    E   4/19      21%  
(Benacerraf et al., 1990) US/MA Ca only         (high) 13 – 20    E   3/13      23%  
(Benacerraf et al., 1988) US/MA Ca only         (high) 15 – 19    E   2/  8      25%  
(Nyberg et al., 1993) US/WA Ca only         (high) 15 – 19    E   5/20      25%  
(Gray et al., 1996) US/MO Ca only         (high) 14 – 20    E   3/11      27%  
(Benacerraf et al., 1992) US/MA Ca only         (high) 14 – 20    E   3/  9      33%  
(Yeo et al., 2003) US/NJ Ca only         (high) 15 – 19    E   6/16      38%  
(Brumfield et al., 2000) US/AL Ca only         (high) 14 – 22    M   3/30      10%  
(Viora et al., 2007) Italy Ca only         (high) 16 – 23    M   6/27      22%  
(Watson et al., 2008) US/NC Ca only         (high) 15 – 21    M 23/98      23%  
(Shields et al., 1998) US/WA Ca only         (high) 14 – 22    M 10/35      29%  
(Benacerraf et al., 1994) US/MA Case/Cont    (high) 14 – 21    M   4/13      31% 0 /    106    0.0% 
(Tongsong et al., 2002) Thailand Ca only         (high) 16 – 22    M   9/25      36%  
(Papp et al., 2007) Hungary Ca only         (high) 13 – 24    L   5/70        7%  
(Bahado-Singh et al., 2003) US/CT Case/Cont    (high) 14 – 24    L   6/47      13% 2 / 1,214    0.2% 
      
All Studies    92/441      23% 2 / 1320     0.2% 
    (95% CI 18% to 28%)  
 
1 prev = population prevalence.  High = referral population, general = unscreened population with background risk   
2 first and last completed week, or mean (SD).  The letters indicate a gestational age grouping (E=early, M=moderate, L=late) 
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Figure 8.2.1-1.  Forest plot showing the proportion of trisomy 18 pregnancies 
with open fetal defects.  Two studies that included third trimester studies or 
observations are not included.  Among the remaining 13 studies, the summary 
detection rate is 26%. 
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8.2.2  Cardiac defects 
 
Definition: There was more variability in the reporting of this category, most likely 
due to improvement in ultrasound imaging equipment over time.  The more recent 
studies routinely reported 4-chambered views of the heart prior to 20 weeks’ 
gestation.  The most commonly reported anomaly was a ventricular septal defect 
(VSD), but other descriptions include ‘cardiac abnormalities’, ‘cardiac structural 
problems’, ‘heart defects’, and ‘major abnormalities of the heart’.  When possible, 
cases having only an abnormal Doppler flow result were excluded, as these would 
probably not be part of routine testing, due to availability, costs and expertise in 
interpretation. 
 
Literature search:  Nineteen studies reported the proportion of trisomy 18 
pregnancies with cardiac defects (Benacerraf et al., 1990; Benacerraf et al., 1994; 
Benacerraf et al., 1992; Bronsteen et al., 2004; Brumfield et al., 2000; Cho et al., 
2009; DeVore, 2000; Gupta et al., 1997; Jelliffe-Pawlowski et al., 2008; Nyberg et 
al., 1993; Papp et al., 2008; Seoud et al., 1994; Shields et al., 1998; Tongsong et 
al., 2002; Viora et al., 2007; Watson et al., 2008; Yeo et al., 2003).   
 
Results:  Table 8.2.2-1 provides a listing of the 15 studies, the observed number of 
trisomy 18 pregnancies, the number and proportion with open fetal defects.  It also 
includes additional information, including the approximate time in gestation (15-20 
weeks - early, 15 through 24 weeks - middle and 15 through 40 weeks - late), as 
defined previously, as well as the study design and prevalence of trisomy 18 in the 
population studied.  Figure 8.2.2-1 shows a forest plot for the proportion of trisomy 
18 fetuses associated with heart defects for the 19 studies, as shown in Table 
8.2.2-1.  In one study (Benacerraf et al., 1988), it was possible to divide the data 
into two groups by gestational age.  The overall summary estimate is 49%, (95% CI 
31% to 67%).  Heterogeneity is high (Q=61, I2=69%, p<0.001).  When grouped by 
study design, the summary detection rate for the 15 case-only studies is 40%.  This 
is confirmed by the two cohort studies (42%), but the findings for the three 
case/control studies are much higher (69%).  This difference is statistically 
significant (p=0.04).  When the results were regressed by year of publication, there 
was a positive, but non-significant, slope (p = 0.13).  There are also important 
differences by time in gestation when the ultrasound was performed.  Among the 
six early estimates, the detection rate is 38% (95% CI 26% to 51%).  The nine 
middle and five late estimates both showed a 47% detection rate.  These 
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differences are not significant (p = 0.56).  There is significant heterogeneity in both 
the earlier and middle gestational age groups (I2=72% and 80%, respectively).  
Results from the 19 studies were also examined for publication bias using two 
methods; neither was statistically significant (Eggers regression intercept, p = 0.2, 
trim and fill method found no imputed values). 
 
Five of the studies were either of case/control or cohort design and, therefore, both 
the detection and false positive rates could be compared.  One study (DeVore, 
2000) stands out as having a high rate of heart defects in control pregnancies 
(5.9%), compared to the other four studies (1.2% or lower).  It is also associated 
with the highest detection rate (80%), compared to the other four studies (38%, 
46%, 54% and 67%).  This may be an indication that those sites reporting high 
detection rates may be defining ‘heart disease’ in a different way, and are including 
heart defects that are either not considered major findings or, perhaps, these 
authors are using a more refined technique.  One case-only study (Yeo et al., 
2003) also reported a high detection rate (81%).  In that study, nearly all cases 
were associated with multiple major and minor malformations, perhaps indicating a 
referral population or, again, a differing technique.  However, these two studies are 
not solely responsible for the high heterogeneity.  If they were to be removed, 
heterogeneity would be reduced from an I2 value of 69% to 60%.  Results from the 
17 studies were also examined for publication bias.  None was found to be 
statistically significant (Eggers regression intercept, p = 0.2).  The trim and fill 
method (Duval and Tweedie, 2000) imputed four studies to the right of the mean, 
changing the detection rate from 61% to 62%, a negligible bias. 
 
Summary:  A total of 19 articles (20 datasets) were identified and included for 
analysis of heart defects, with information on 315 cases of trisomy 18.  All studies 
were performed in a high risk setting.  An estimated 44% of trisomy 18 fetuses can 
be identified as having a heart defect by 20 weeks’ gestation.  However, there is 
considerable heterogeneity.  The sources of this heterogeneity may be due to: 1) 
the gestational age at testing, with lower rates associated with earlier scanning; 2) 
improvement in equipment/technique, with more recent studies showing somewhat 
higher rates; 3) differences in the definition of a major heart defect; and 4) other 
less well described factors.  This latter group could include sonographer 
experience, whether the site receives ultrasound referrals and other, yet unknown 
factors.  Publication bias is unlikely to influence the effect size.  A conservative 
detection rate to use is the rate found in the early studies (38%  95% CI 26% to 
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51%), as these are less likely to be referrals, more likely to reflect general practice 
and are more relevant to the setting of prenatal screening for trisomy 18.  The 
corresponding rate of heart defects seen in pregnancies without trisomy 18 is about 
1.5%.  Thus, a reasonable estimate in non-specialized centers is a detection rate of 
36% and a false positive rate of 1.5%.  
 
 
Figure 8.2.2-1.  Forest plot showing the proportion of trisomy 18 pregnancies 
with a major cardiac defect.  The summary detection rate among all studies (except 
the three case/control studies) is 40%, but with considerable heterogeneity.  The first 
group of studies (Case only) are stratified by gestational age (early, middle, later). 
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Table 8.2.2-1.  Rates of cardiac defects in trisomy 18 and control pregnancies  
 
 
Author 
 
Location 
 
Design (prev)1 
Gestational 
Age (weeks)2 
Trisomy 18 
positive / total (%) 
Controls 
positive / total (%) 
      
(Nyberg et al., 1993) US/WA Ca only         (high) 15 – 19     E   1/20        5%  
(Benacerraf et al., 1988) (early) US/MA Ca only         (high) 15 – 19     E   1/  8      13%  
(Benacerraf et al., 1990) US/MA Ca only         (high) 13 – 20     E   4/13      31%  
(Gupta et al., 1997) UK Ca only         (high) 16 – 20     E   6/19      32%  
(Benacerraf et al., 1992) US/MA Ca only         (high) 14 – 20     E   4/  9      44%  
(Yeo et al., 2003) US/NJ Ca only         (high) 15 – 19     E 13/16      81%  
(Brumfield et al., 2000) US/AL Ca only         (high)  14 – 22     M   4/30     13%  
(Viora et al., 2007) Italy Ca only         (high)  16 – 23     M   8/27      30%  
(Shields et al., 1998) US/WA Ca only         (high)  14 – 22     M 10/27      37%  
(Tongsong et al., 2002) Thailand Ca only         (high)  16 – 22     M   9/24      38%  
(Watson et al., 2008) US/NC Ca only         (high)  15 – 21     M 62/98      63%  
(Nicolaides et al., 1992b) UK Ca only         (high) 14 – 39     L 37/83      45%  
(Benacerraf et al., 1988) (late) US/MA Ca only         (high) 20 – 38     L   3/  7      43%  
(Bronsteen et al., 2004) US/MI Ca only         (high) 15 – 24     L 25/54      46%  
(Papp et al., 2007) Hungary  Ca only         (high) 13 – 24     L 33/70      47%  
(Jelliffe-Pawlowski et al., 2008) US/CA Cohort           (high) Early 2nd    M 30/80      38% 191 / 20,005  1.0% 
(Cho et al., 2009) US/CA Cohort           (high)  15 – 21     M 26/56      46% 108 /   8,606  1.2% 
(Benacerraf et al., 1994) US/MA Case/Cont     (high)  14 – 21     M   7/13      54%     1 /     106  0.9% 
(DeVore, 2000) US/CA Case/Cont     (high)  15 – 23     M 24/30      80% 118 /   2,000  5.9% 
(Seoud et al., 1994) US/VA Case/Cont     (high)   22 / 5      L   8/12      67%     0 /        50  0.0% 
      
All Studies    315/696      46%  
(random effects)    (95% CI 42% to 50%)  
      
Studies with controls     87/179      56% 418/30,868  1.4% 
    (95% CI 39% to 71%) (95% CI 1.2% to 1.5%) 
 
1  prev = population prevalence.  High = referral population, general = unscreened population with background risk   
2 first and last completed week, or mean/SD.  The letters indicate a gestational age grouping (E=15-20 weeks, M=15-24 and L=15-40) 
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8.2.3  Hand and foot anomalies 
 
Definition:  Most study protocols attempted to visualize both hands to look for clenched 
fists and overlapping fingers.  Highly correlated with these findings are problems with 
the feet, including clubbing.  In addition to these specific terms, alternative descriptions 
include ‘defects of the extremities’, ‘abnormal extremities’, and ‘abnormal hands/feet’.  
 
Literature search:  Seventeen studies reported the proportion of trisomy 18 
pregnancies with abnormalities of the hand and foot (Bahado-Singh et al., 2003; 
Benacerraf et al., 1988; Benacerraf et al., 1990; Benacerraf et al., 1994; Bronsteen 
et al., 2004; Brumfield et al., 2000; Cho et al., 2009; Gray et al., 1996; Gupta et al., 
1997; Nyberg et al., 1993; Papp et al., 2008; Shields et al., 1998; Tongsong et al., 
2002; Viora et al., 2007; Watson et al., 2008; Yeo et al., 2003).   
 
Results:  Table 8.2.3-1 provides a listing of the 17 studies, the observed number of 
trisomy 18 pregnancies, the number and proportion with hand and foot anomalies.  
It also provides additional information, including the approximate time in gestation 
(15-20 weeks - earlier, 15-24 weeks - middle and 15-40 weeks - later), as defined 
earlier.  In one study (Benacerraf et al., 1988), it was possible to divide the data 
into two groups by gestational age.  Figure 8.2.3-1 shows a forest plot for the 
proportion of trisomy 18 fetuses associated with hand and foot anomalies.  The 
summary is 51%, (95% CI 38% to 63%).  Heterogeneity is high (Q=95, I2=83%, 
p<0.001).  When grouped by study design, the detection rates for the 15 case-only 
study estimates (51%) and two case/control study estimates (37%) are not 
significantly different (p=0.11).  When the results were regressed by year of 
publication, there was a negative and significant, slope (p = 0.007, -0.04117 per 
year of the logit of the slope, intercept=82.388).  This translates into about an eight 
to 10% decline every five years.  There does not appear to be clear trend by time in 
gestation when the ultrasound was performed.  Among the six studies performed 
earlier in gestation, the detection rate is 41% (95% CI 22% to 64%).  The eight 
middle and three later gestational age group studies showed increasing rates at 
50% and 70%, respectively.  However, these differences are not significant (p = 
0.40), perhaps due to the high heterogeneity in all three groups (I2=56%, 94% and 
81%, respectively).  Results from the 17 studies were also examined for publication 
bias and none was found (Eggers regression, p = 0.6; trim and fill method did not 
produce any imputed values). 
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Only three of the studies reported associated rates of hand and feet abnormalities 
in the control population, with a summary rate of 0.06% (6 per 10,000).  This 
indicates that the presence of such an abnormality provides a high suspicion of an 
affected pregnancy.  Of interest is the trend towards higher detection rates with 
advancing gestational age.  Although not statistically significant, this may be an 
indication that as the fetus becomes larger, it is easier to visualize the fetal 
extremities and identify these abnormalities. 
 
Summary:  A total of 17 articles were identified and included for analysis of hand 
and feet abnormalities, with information on 615 cases of trisomy 18.  For ultrasound 
exams performed between 15 and 20 weeks’ gestation, the detection rate was 
41%.  However, there was a change in detection rate over time, with lower rates 
reported in more recent studies.  This is likely to indicate both an improvement in 
equipment, and a general awareness among sonographers of the importance of 
examining the fetal extremities.  Hand and feet anomalies such as described here, 
are rare in the few control populations examined, with a rate of about 6 per 10,000.  
In most setting, it should be possible to achieve a detection rate of about 41% at a 
false positive of 0.06%.
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Table 8.2.3-1.  Rates of hand and foot anomalies in trisomy 18 and control pregnancies  
 
 
Author 
 
Location 
 
Design (prev)1 
Gestational 
Age (weeks)2 
Trisomy 18 
positive / total (%) 
Controls 
positive / total (%) 
      
(Nyberg et al., 1993) US/WA Ca only         (high) 15 – 19     E   5/20      25%  
(Gupta et al., 1997) UK Ca only         (high) 16 – 20     E   5/19      26%  
(Gray et al., 1996) US Ca only         (high) 14 – 20     E   3/11      27%  
(Benacerraf et al., 1990) US/MA Ca only         (high) 13 – 20     E   6/13      46%  
(Benacerraf et al., 1988) (early) US/MA Ca only         (high) 15 – 19     E   4/  8      50%  
(Yeo et al., 2003) US/NJ Ca only         (high) 15 – 19     E 16/16    100%  
(Brumfield et al., 2000) US/AL Ca only         (high) 14 – 22     M   3/30      10%  
(Cho et al., 2009) US/CA Cohort           (high) 15 – 21     M 20/56      36% 6 / 8,707   0.1% 
(Tongsong et al., 2002) Thailand Ca only         (high) 16 – 22     M 10/25      40%  
(Watson et al., 2008) US Ca only         (high) 15 – 21     M 43/98      44%  
(Benacerraf et al., 1994) US/MA Case/Cont     (high) 14 – 21     M   6/13      46% 0 /    106   0.0% 
(Viora et al., 2007) Italy Ca only         (high) 16 – 23     M 22/27      81%  
(Shields et al., 1998) US/WA Ca only         (high) 14 – 22     M 16/18      89%  
(Papp et al., 2007) Hungary Ca only         (high) 13 – 24     L   4/70        6%  
(Bahado-Singh et al., 2003) US/CT Case/Cont     (high) 14 – 24     L 16/47      34% 0 / 1,214   0.0% 
(Bronsteen et al., 2004) US/MI Ca only         (high) 15 – 24     L 31/54      57%  
(Nicolaides et al., 1992b) UK Ca only         (high) 14 – 39     L 71/83      86%  
(Benacerraf et al., 1988) (late) US/MA Ca only         (high) 20 – 38     L   7/  7    100%  
      
All Studies    288/615      51% 6 / 10,027   0.06% 
(random effects)    (95% CI 38% to 63%) (95% CI 0.02% to 1.3%) 
 
1 prev = population prevalence.  High = referral population, general = unscreened population with background risk   
2 first and last completed week.  The letters indicate a gestational age grouping (E=15-20 weeks, M=15-24, L=15-40) 
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Figure 8.2.3-1.  Forest plot showing the proportion of trisomy 18 pregnancies 
with hand and foot anomalies.   The summary detection rate for ultrasound exams 
done between 15 and 20 weeks’ gestation is 41%, with high unexplained 
heterogeneity.  The proportion of trisomy 18 pregnancies with hand and foot anomalies 
is significantly higher, when exams are performed later in gestation. 
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8.2.4  Any structural anomaly 
 
Definition:  Descriptions for this category include non-specific terms for structural 
anomalies: ‘gross defect’, ‘major defect’, any ‘structural defect’, and ‘structural 
abnormality’.  This often included multiple outcomes (e.g., both a heart defect and club 
feet).  Specifically excluded were any non-structural anomalies covered in a later 
section (e.g., choroid plexus cysts, nuchal skin fold thickness).   
 
Literature search:  Twenty articles reported the proportion of trisomy 18 pregnancies 
with any structural anomaly (Bahado-Singh et al., 2003; Benacerraf et al., 1994; 
Benacerraf et al., 1992; Benacerraf et al., 1988; Bottalico et al., 2009; Bronsteen et al., 
2004; Brumfield et al., 2000; Cho et al., 2009; DeVore, 2000; Grandjean et al., 1998; 
Gupta et al., 1997; Moran et al., 2002; Nyberg et al., 1993; Papp et al., 2008; 
Picklesimer et al., 2005; Roberts et al., 1993; Shields et al., 1998; Taslimi et al., 2005; 
Tongsong et al., 2002).  In two of these studies, it was possible to divide the reported 
cases into two separate gestational age groups (Bahado-Singh et al., 2003; Benacerraf 
et al., 1988), resulting in a total of 22 estimates of the detection rate.   
 
Results:  Table 8.2.4-1 provides a listing of the 20 studies and 22 datasets, the 
observed number of 18 trisomy pregnancies, the number and proportion with gross 
abnormalities as well as additional information, including the approximate time in 
gestation (early, middle and late), as defined earlier.  The entries are ordered by 
increasing detection rate, within the three gestational age groupings.  Among the 588 
trisomy 18 pregnancies, 428 were reported to also have any structural anomaly.  The 
summary estimate for the detection rate is 71%, (95% CI 61% to 79%).  Heterogeneity 
is high (Q=85, I2=75%, p<0.001).  Two of the three general population studies have 
very low detection rates, even though all three were in the late gestational age 
grouping.  One from Australia (Roberts et al., 1993) found 11% and another from 
Ireland (Moran et al., 2002) found 33%.  This is in contrast to the third from France 
(Grandjean et al., 1998) that reported 79%.  The difference between these findings 
may be that, in France, there is a systematic program of routine ultrasound aimed at 
identifying structural abnormalities in aneuploidies.  This was not true for the two other 
general population studies.  Because of this, it may reasonable to remove the other two 
studies because they do not represent routine practice at a referral center (Roberts et 
al., 1993; Moran et al., 2002).  There is also one very high detection rate of 97% from a 
large US study (DeVore, 2000).  This group is known for its intensive surveillance that 
is demonstrated by their associated false positive rate of over 15% (last column, Table 
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8.2.1-1).  Other centers report false positive rates of about 1% to 3%.  This level of 
surveillance is unlikely to represent routine practice at an average referral site, and it 
was also removed for the subsequent analyses.  Figure 8.2.4-1 shows a forest plot for 
the trisomy 18 detection rates shown in Table 8.2.4-1, after these three outlying 
datasets were removed.  The summary detection rate is now 72.4%.  Among these 
remaining 19 estimates (17 studies), there is no difference in the detection rates by 
study design (p = 0.5), or when the results were regressed by year of publication (p = 
0.8, for significant slope).  However, there are important differences by time in 
gestation when the ultrasound was performed.  Detection rates are 60% (95% CI 44% 
to 74%), 68% (95% CI 51% to 81%), and 83% (95% CI 72% to 90%) among the 7, 5 
and 7 studies in the early, moderate and late gestational age groupings, respectively  
These differences are significant (p=0.01).  However, there remains important 
unexplained heterogeneity in all of the groups (p-values 0.07, 0.01 and 0.001, with I2 
values of 49%, 44% and 80%, respectively).  The 19 datasets were also examined for 
publication bias using two methods, but neither was statistically significant (Eggers 
regression intercept, p = 0.4, and the trim and fill method estimated a positive bias of 
2% (observed detection of 72%, adjusted rate of 70%).  Using all five reports for the 
rate in control pregnancies, the summary estimate is 2.6% (95% CI 0.8% to 8.3%) with 
very high heterogeneity (Q=510, I2=99%, p<0.001).  Were the one high estimate 
(DeVore, 2000) to be removed, the estimate is reduced to 1.6% (95% CI 0.8% to 
3.2%), but the heterogeneity is still relatively high (Q=19, I2=85%, p<0.001).   
 
Summary:  A total of 20 articles were identified and 22 datasets were included for 
analysis, with information on 588 cases of trisomy 18.  When restricted to reports of 
routine and standardized ultrasound at an average referral center (average defined as 
finding 1% to 3% of chromosomally normal fetuses having any structural anomaly), 
60% of trisomy 18 fetuses would be detected between 15 to 20 weeks’ gestation.  This 
rate has remained constant from the late 1980s to present.  The detection rate for 
trisomy 18 appears to increase as the ultrasound exams are performed later in 
gestation, reaching a maximum of about 83% by the early third trimester.  The 
remaining unexplained heterogeneity is likely due to the definition of gross anomalies, 
and/or sonographer(s) training, expertise or experience.  The false positive rate is 
highly heterogeneous, but with one outlying high value removed, a reasonable 
estimate is 1.6%.  In most settings, the detection rate is expected to be 60% at a 1.6% 
false positive rate.
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Table 8.2.4-1.  Rate of ‘any structural anomaly’ in trisomy 18 and control pregnancies  
 
Author 
 
Location 
 
Design (prev)1 
Gestational 
Age (weeks)2 
Trisomy 18 
positive / total (%) 
Control 
positive / total (%) 
      
(Gupta et al., 1997) UK Case only     (high) 16 – 20     E   6/19      32%  
(Bahado-Singh et al., 2003) US/CT Case/Cont    (high) 14 – 17     E 14/29      57%      9 / 1,214      0.7% 
(Picklesimer et al., 2005) US/NC Case only     (high) 14 – 17     E   6/10      60%  
(Benacerraf et al., 1988) US/MA Case only     (high) 15 – 19     E   5/  8      63%  
(Nyberg et al., 1993) US/WA Case only     (high) 15 – 19     E 15/20      75%  
(Benacerraf et al., 1994) US/MA Case/Cont     (high) 15 – 19     E 10/13      77%   2 /    106      1.9% 
(Brumfield et al., 2000) US/AL Case only     (high)  14 – 22     M        10/30      33%  
(Cho et al., 2009) US/CA Cohort          (high)  15 – 21     M 36/56      64% 244 / 8,707      2.9% 
(Taslimi et al., 2005) US/IL Case only     (high)  15 – 23     M 19/28      68%  
(Benacerraf et al., 1990) US/MA Case/Cont    (high)  14 – 21     M   9/13      69%  
(Shields et al., 1998) US/WA Case only     (high)  14 – 22     M 30/35      86%  
(Bottalico et al., 2009) US/NJ Cohort          (high)  15 – 22     M   7/  8      88%   9 /    628      1.4% 
(Tongsong et al., 2002) Thailand Case only     (high)  16 – 22     M 24/25      96%  
(DeVore, 2000) US/CA Case/Cont    (high)  14 – 23     M 29/30      97% 314 / 2,000    15.7% 
(Roberts et al., 1993) Australia Case only     (gen) 16 – 24     L   1/  9      11%  
(Moran et al., 2002) Ireland Case only     (gen) 2nd  trim.    L   7/16      44%  
(Bahado-Singh et al., 2003) US/CT Case/Cont    (high) 18 – 24     L 13/18      72%     9 / 1,214      0.7% 
(Grandjean et al., 1998) France Case only     (gen) 20 (7.1)    L 64/81      79%  
(Papp et al., 2007) Hungary Case only     (high) 13 – 24     L 61/70      87%  
(Bronsteen et al., 2004) US/MI Case only     (high) 15 – 24     L 47/54      87%  
(Benacerraf et al., 1992) US/MA Case only     (high) 20 – 38     L   8/  9      89%  
(Benacerraf et al., 1988) US/MA Case only     (high) 20 – 34     L   7/  7    100%  
      
All    
  428/588      71% 
 95% CI (61 - 79%) 
587/13,869    2.6% 
95% CI (0.8% to 8.3%) 
 
1  prev = population prevalence.  High = referral population, general = unscreened population with background risk   
2 first and last completed week, or mean (SD).  The letters indicate a gestational age grouping (E=earlier, M=moderate, L=later) 
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Figure 8.2.4-1.  Forest plot showing the proportion of trisomy 18 pregnancies 
with any structural anomaly.  Results are after excluding three datasets (two low, 
one high).  Although the summary detection rate is 72% (not shown), some of the 
heterogeneity is explained by the gestational ages at the time of ultrasound that are 
included.  The solid line is the estimate relevant to early second trimester ultrasound 
testing for trisomy 18 (solid summary line at 60%).  Higher proportions are found 
when later ultrasound studies are also included in the publications (dashed summary 
lines at 68% and 83%). 
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8.3  Non-structural Anomalies 
 
The non-structural anomalies in this section are sometimes referred to as ‘soft’ 
ultrasound markers.  They differ from structural anomalies (Chapter 8.2), in that they do 
not, by themselves, cause problems for the fetus or newborn.  Most of these markers 
were originally studied because of a relationship with Down syndrome.  Often, these are 
physical characteristics known to manifest in children with Down syndrome and/or 
trisomy 18.  For example, children with Down syndrome and trisomy 18 are growth 
retarded at birth, and this has led to the observation of shortened long bone 
measurements in the second trimester (e.g., humerus, femur).  Another example is the 
excess skin at the back of the neck in newborns and children with Down syndrome.  This 
led to measuring the nuchal skin fold (NSF) thickness in Down syndrome and in other 
fetuses with chromosomal abnormalities.  The exception to this rule is the finding of cysts 
in the choroid plexus (CPC).  CPCs are generally considered benign and usually resolve 
by late in the second trimester.  In general, these non-structural anomalies can be 
characterized as being of moderate sensitivity, but low specificity. 
 
8.3.1  Choriod plexus cyst (CPC)  
Definition: The first identification of a CPC in a fetus was reported in 1984 from a 
group in London, England (Chudleigh et al., 1984) using early second trimester 
ultrasound.  Their description reads: 
 
Ultrasound scanning during the second trimester pregnancy revealed cysts of the 
choroid plexus in the posterior horn of the lateral ventricle.  In two (of the five) 
cases, they were obviously bilateral.  Careful follow up high resolution ultrasound 
examination showed that all the cysts disappeared spontaneously between 20 -23 
weeks’ gestation and in no cases was there any suggestion of hydrocephaly.  
 
The choroid plexuses are located in the lateral ventricles and are responsible for 
the production of cerebrospinal fluid.  In about 1 to 3% of fetuses, there is an 
echoic region within the choroid plexus – a CPC.  Figure 8.3.1-1 shows an 
ultrasound image of a choroid plexus cyst (CPC). 
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Figure 8.3.1-1.  Choriod plexus cyst (CPC).  A cross-sectional view of a fetal head 
at 17.9 weeks’ gestation showing the outline of the skull, the lateral ventricles, and, 
within the choroid plexus, two large cysts (from Alan Donnenfeld, M.D, personal 
communication). 
 
Publications, study designs and confounders:  Sonographers in the mid 1980s 
thought CPCs were rare, and suggested that the benign nature of the cysts might 
warrant a repeat ultrasound examination at 24 weeks’ gestation to confirm their 
disappearance (Chudleigh et al., 1984).  Over the next five years, at least 12 
studies were published that looked at the presence of CPC in the second trimester 
and associated abnormalities; mainly trisomy 18 (Figure 8.3.1-1).  The number of 
publications now exceeds 60, and to make sense of them, it is necessary to stratify 
results by study design.  The following sections define three main study designs: 
cohort, case/control, and those studies in which all enrollees have an identified 
CPC (e.g., test positives only).  Since all of these women are, in a sense, screen 
positive, the term for this type of study will be ‘screen positive’.  Each of these 
designs has been used in both general population and high risk settings (e.g., 
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referred pregnancies, women over age 34).  Several additional covariates will be 
also be included in the analyses.  All of these factors combine into making the 
interpretation of the literature on CPC and trisomy 18 difficult, and give rise to the 
multitude of conflicting summary analyses that characterize this literature. 
Impact of various study designs 
 Cohort:  a consecutive series of pregnant women having ultrasound testing in a 
given region or at a given center.  In these studies, it is possible to determine 
the false positive rate (proportion of women without trisomy 18 or other 
aneuploidy) with a CPC, as well as the detection rate (proportion of trisomy 18 
cases with a CPC) and OAPR (odds for the women with a CPC having a fetus 
with trisomy 18).  The prevalence of trisomy 18 in the population can also be 
determined.  
 Case/control:  a series of ultrasound results from women with a trisomy 18 
pregnancy are compared to a matched (or unmatched) series of results from 
women without trisomy 18 pregnancies.  Both detection and false positive rates 
can be determined, but OAPR and prevalence cannot be computed directly. 
 Case-only:  a series of ultrasound results from women with an affected 
pregnancy are collected.  Only the detection rate can be computed.   
 Screen positive: a series of women whose ultrasound shows a CPC are all 
followed to determine pregnancy outcome (e.g., trisomy 18, normal).  Only the 
OAPR (and perhaps the false positive rate) can be computed.  Neither the 
detection rate nor prevalence can be computed.  Comparison of these rates to 
those derived from other study types is problematic. 
 
Impact of the prevalence of trisomy 18 in the population studied 
 General population:  an unselected pregnancy population in which the 
incidence of trisomy 18 should be representative (i.e., about 1:1,500 in the 
second trimester). 
 High risk: a selected population that is likely to have either a higher rate of CPC 
than expected (due to referrals) and/or a higher rate of trisomy 18 (due to 
indications for referral such as maternal age, positive serum biochemistry, or 
ultrasound finding of gross abnormalities). 
 Low risk: a selected population that is likely to have a lower rate of trisomy 18 
than expected, usually due to active screening (either biochemical or ultrasound 
based) that occurs earlier in the pregnancy (e.g., screen negative results for the 
first trimester combined testing). 
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Consideration of other important covariates 
 Improvement in technique/equipment:  There is little question that the 
equipment has vastly improved since the 1984 report of second trimester CPC 
identification (Chudleigh et al., 1984).  This may allow the detection of smaller 
or less well-defined CPC, resulting in a higher proportion of the population 
being screen positive.  Earlier studies rarely included CPC that did not measure 
at least 4 to 5 mm in diameter.  As equipment improved, CPC of 1 or 2 mm 
could be visualized and were reported.  Currently, there are formal 
recommendations to ignore these small CPCs.  In 2005, for example, the 
Society of Obstetricians and Gynecologists of Canada suggested that anything 
smaller than 3 mm not be considered a CPC (www.SOGC.org).  Thus, the 
definition of a CPC may have changed over time from rather large and easy to 
distinguish to all sizes visualized, and now to only those of a certain size being 
considered. 
 Isolated CPC versus CPC with other US findings (non-isolated):  After the first 
flurry of reports, some researchers began to look for patterns that might 
subdivide pregnancies with a CPC into higher and lower risk.  Such findings 
included laterality, size and whether or not the CPC was associated with 
another US finding.  Only isolated/non-isolated seems to be of importance.  
However, given the improvement of equipment, it is also possible that the 
definition of ‘isolated’ has changed over time, with earlier studies more often 
unable to locate other abnormalities.  In addition, the definition and number of 
‘abnormalities’ is changing.  Originally, only gross structural defects were 
considered (e.g., omphalocele, major heart defect, clenched fist), while some 
more recent studies include several of the ‘soft’ ultrasound markers (e.g., femur 
length, nuchal fold thickness) as abnormalities. 
 Prospective/retrospective:  Many authors pay careful attention to the nature of 
the observations, but do not correctly classify them.  Often, a large series of 
non-structural anomalies and pregnancy outcomes are available.  These could 
be collected with the intent of performing an analysis involving CPC where the 
US information is recorded prior to the collection of outcome (prospective 
collection/analysis).  However, it is more common that both findings have been 
recorded in a retrospective analysis of prospectively collected data (US 
information recorded prior to knowledge of the outcome).  True retrospective 
studies (finding those with/without trisomy 18 and then interpreting the results of 
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the stored US image) are relatively rare.  Such studies might be subject to a 
strong reviewer bias.  Blinding would not be sufficient, as the US would contain 
strong indications of trisomy 18 (e.g., gross structural anomalies) that might 
influence the interpretation of the CPC.   
 Trimester of ultrasound:  Many of the non-structural anomalies are more, or 
less, likely to occur (or be identified) as gestation advances.  Heart defects are 
hard to identify early in the second trimester because the heart is relatively 
small.  This is the reason behind the anomaly scan being generally targeted at 
20 weeks’ gestation.  However, CPCs usually disappear by 24 to 28 weeks’ 
gestation, and any study looking at this later time period might fail to find the 
association.  For this reason, the current analysis focuses only on the 15 to 20 
week time period.  If the mean gestational age or range is outside of this 
window for more than a small proportion, the study might be eliminated.  
Alternatively, if sufficient individual data are presented, a subset of cases can 
be analyzed that do fall within the targeted range. 
 Timing of diagnosis: in many of the case/control or case-only studies, the 
women were at high risk and had already chosen amniocentesis.  This has the 
advantage of knowing about all cases of trisomy 18 regardless of associated 
defect, but has the disadvantage of selection bias.  For example, if women 
know about gross abnormalities found prior to the procedure, their choice will 
almost certainly be influenced towards acceptance of amniocentesis based on 
the non-structural anomalies.  This would result in a higher proportion of trisomy 
18 pregnancies having amniocentesis also having any structural anomaly.  In a 
cohort study the result could be unbiased, if the women who do not choose 
amniocentesis eventually have the diagnosis made at or near birth.  However, 
given the high rate of spontaneous loss for trisomy 18 pregnancies, this would 
be unlikely. 
  
Figure 8.3.1-2 displays the 61 studies that will be included in the analysis of CPC 
and trisomy 18 by year of publication and also shows the type of study (symbol) 
and whether it was performed in a general (larger and open) or high risk (smaller 
and filled) population.  As expected, some designs will have relatively large 
numbers of trisomy 18 pregnancies studied (e.g., case/control, case-only), while 
others will have smaller numbers of affected fetuses (e.g., cohort or screen 
positive).  In general, the studies using the screen positive study design were 
focused only on CPC and not other abnormalities, while most of the case-only and 
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case/control studies provided information on other possible trisomy 18 markers 
(both structural anomalies and non-structural anomalies). 
 
 
Figure 8.3.1-2.  Sixty-one published studies regarding choroid plexus cysts 
(CPC) and trisomy 18.  Each symbol represents a single publication.  Open symbols 
indicate studies performed in the general population (background risk of both CPC 
and trisomy 18), while filled symbols indicate those studies that have a high risk (of 
either CPC, trisomy 18, or both).  Circles indicate cohort or case/control studies, 
squares indicate studies that reported only on pregnancies in which a CPC had been 
identified (screen positive design), and diamonds indicate studies that only included 
pregnancies with trisomy 18 (case-only).  A horizontal dotted line is drawn at 10 
cases to indicate studies with relatively low power.   
 
 
Results:  Population-based cohort studies   
Table 8.3.1-1 shows the four population-based cohort studies of CPCs and trisomy 
18 (Cheng et al., 2006; Coco and Jeanty, 2004; Ghidini et al., 2000; Gray et al., 
1996).  The one ‘case-only’ study from the general population has also been 
included in the analysis of the detection rate (Gupta et al., 1997).  Among the four 
cohort studies, a total of 53,151 women in the early second trimester of pregnancy 
(usually <20 weeks’ gestation) were scanned for CPCs.  Overall, 47 cases of 
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trisomy 18 were identified.  Among these five studies the rate of CPCs was 1.4% 
(range 0.98% to 2.9%).  The analysis shows high heterogeneity between these 
rates (Q=247, I2=99%).  One way to validate the general population nature and 
completeness of follow-up for these studies is to examine the prevalence of trisomy 
18.  Overall the second trimester prevalence is expected to be about 1:1500, and 
the observed rate of 1:1300 is consistent with that expectation.  All five studies in 
Table 8.3.1-1 can be used to determine the overall, detection rate of 29% for any 
CPC and trisomy 18.  The estimates have low heterogeneity (Q=1, I2=0%, p=NS), 
perhaps due to the small number of cases analyzed.  When CPCs are the only 
finding (i.e., isolated), the likelihood of identifying trisomy18 appears low (none 
observed in 765 pregnancies with isolated CPCs).  However, the rate is not likely to 
be zero, as the one included case-only study reported two trisomy 18 fetuses 
where CPC was isolated.  On the other hand, when CPCs were associated with 
another ultrasound abnormality (usually a structural anomaly), the likelihood of 
trisomy 18 fetus was high (15 cases in 89 pregnancies).   
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Table 8.3.1-1.  Choroid plexus cysts (CPCs) and trisomy 18:  Population based cohort studies 
 
  GA Number  Trisomy 18  OAPR for CPC 
Study Location weeks Total CPC Rate Total Prev (1:n) w/CPC (%)  Isolated w/abnorm 
            
(Cheng et al., 2006) Taiwan 16-20 7,795 98 1.3% 10 1:   780 3   (30)  0/  82 3/13  (1:  4) 
(Coco and Jeanty, 2004) Italy 16-18 12,670 364 2.9%   6 1:2,112 2   (33)  0/311 2/51  (1:25) 
(Ghidini et al., 2000) Italy 16-23 23,842 199 0.8% 20 1:1,192 7   (35)  0/181 7/11  (1:  2) 
(Gray et al., 1996) US  14-201 18,844 208 1.1% 11 1:1,713 3   (27)  0/191 3/14  (1:  5) 
          
All (random effects)   53,151 869 1.4% 
(0.7%-2.5%) 
47 
(66) 
1:1300 
(1:880-1:1900) 
19   (32) 
(20% -47%) 
 0/765 
<1:765 
15/89 (1: 3) 
(1:1 - 1:15) 
          
(Gupta et al., 1997)2 UK 14-20  19  43  (21)    2/ NR3 2 / NR3 
 
GA = gestational age, Prev = prevalence, OAPR = odds of being affected given a positive result, w/abnorm = other important ultrasound 
abnormality identified during the same examination. 
1  Originally 14-26 weeks, but trisomy 18 cases after 20 weeks have been removed 
2  Case-only design from the general population.  Data not included in the analyses 
3  Two of these four were isolated CPCs 
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Results:  Population-based ‘screen positive’ studies:   
Table 8.3.1-2 summarizes the 16 studies reporting on the results of a routine 
ultrasound finding of CPCs in a general pregnancy population.  They contain the 
outcomes for only those with a CPC identified (e.g., screen positive for CPCs) 
(Achiron et al., 1991; Camurri and Ventura, 1989; Chinn et al., 1991; Chitty et al., 
1998; Clark et al., 1988; Digiovanni et al., 1997; Geary et al., 1997; Howard et al., 
1992; McHugo et al., 1991; Ostlere et al., 1990; Perpignano et al., 1992; Reinsch, 
1997; Twining et al., 1991; Beke et al., 2008; Gupta et al., 1995; Walkinshaw et al., 
1994).  One of these studies (Gupta et al., 1995) reports on separate populations 
from Dundee and Yorkshire that are listed separately, yielding 17 datasets for 
analysis.  Three identified studies were not included in the analysis:  two did not 
report the number of women with a CPC identified (Ricketts et al., 1987; Hertzberg 
et al., 1989) and one reported on gestational ages outside of the early second 
trimester (Chitkara et al., 1988).   
 
These studies reported results in over 375,000 early second trimester pregnancies 
with widely varying definitions of a CPC.  Overall, CPCs were identified in 0.8%, 
with high heterogeneity (Q=1830, I2=98%, p<0.001).  This is somewhat lower than 
the 1.4% found in the cohort studies (Table 8.3.1-1).  This difference may be 
related to the dates of publication.  The median year of publication for the screen 
positive studies is 1992, while the earliest publication date for the general 
population cohort studies is 1996.  Figure 8.3.1-3 shows a meta-regression of 
publication year versus proportion of pregnancies with a CPC for the 21 datasets 
(17 screen positive and 4 cohort).  There is a statistically significant relationship 
(slope=0.11454, intercept=-233.637) that predicts CPC rates of 0.6%, 1.0% and 
1.8% in 1995, 2000 and 2005, respectively.  This relationship is potentially 
explained by the changing definition for a CPC.  In the late 1980s and early 1990s, 
it was common to define CPCs as being 3, 4 or even 5 mm or larger.  Now, the 
definition usually includes CPCs as small as 2 or 3 mm.  For example, an earlier 
report (Gupta et al., 1995) used a definition of >5 mm (expanding it later in the 
study to smaller cysts) and reported a rate of 0.3%.  In a more recent study (Beke 
et al., 2008), the definition of >2mm was used, with a reported rate over 10 times 
higher (4.0%).  Among those pregnancies identified with a CPC, an average of 
2.2% were identified with trisomy 18 with low heterogeneity between studies 
(Q=17, I2=6%, p=NS).   
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Not all of the studies reported whether the CPC occurred as an isolated finding, or 
in combination with one or more additional non-structural anomalies (last two 
columns in Table 8.3.1-2).  Among the 12 studies reporting this information, 13 of 
the 44 cases of trisomy 18 (30%, 95% CI 17% to 45%) were found to have CPCs 
as the only finding.  Half of the studies found at least one instance of a fetus with 
trisomy 18 having CPCs as the only ultrasound finding.  The prevalence of trisomy 
18 among pregnancies with isolated CPCs was 1:217 (95% CI 1:125 – 1:400).  
Among those with ultrasound anomalies in addition to CPCs the prevalence was 
much higher 1:10 (95% CI 1:7 – 1:15).  Although this is similar to the pattern found 
in the population cohort studies (Table 8.3.1-1), there is a less striking difference 
between isolated and non-isolated CPCs in these studies from the general 
population. 
 
 
Figure 8.3.1-3.  Relationship between the proportion of women with a CPC 
identified and year of publication, for studies in the general population.  The 
darkness of the data points indicates the relative weight (darker circles indicating 
studies with more observations). 
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Table 8.3.1-2.  Choroid plexus cysts (CPCs) and trisomy 18:  General population ‘screen positive’ studies 
 
  GA CPC Number All CPCs All T18  OAPR for CPC 
Study Location Weeks1 Size2 studied N (%) N    (%)  Isolated w/abnorm 
          
(Achiron et al., 1991) Israel 20 / NR >8 mm 5,400   30 (0.6)   2   (6.7)  1: NR 1: NR 
(Beke et al., 2008) Hungary 15 -21 >2 mm 10,875 436 (4.0)   6   (1.4)  3:278 3:112 
(Camurri and Ventura, 1989) Italy 16-20 NR 3,000   10 (0.3)   1   (10 )  0: NR 1: NR 
(Chinn et al., 1991) US/CA 15-24 >2 mm 1,045   38 (3.6)   0   (0.0)  0:  36 0:    2 
(Chitty et al., 1998) UK 14-24 >3 mm 101,600 658 (0.6) 12   (1.8)  2:603 10:  55 
(Clark et al., 1988) US/UT 16-22 >3 mm 2,820     5 (0.2)   0   (0.0)  NR NR 
(Digiovanni et al., 1997) US/IL 15-22 NR 8,270   89 (1.1)   3   (3.4)  NR NR 
(Geary et al., 1997) UK 18-20 pres/abs 13,690   84 (0.6)   3   (3.6)  0:  78 3:    6 
(Gupta et al., 1995) Dundee 16-21 NR 7,250   71 (1.0)   1   (1.4)  1:  62 0:    9 
(Gupta et al., 1995) Yorkshire 16-20 >5, any 151,000 524 (0.3)   7   (1.3)  0:486 7:  38 
(Howard et al., 1992) UK 18-20 NR 4,765   51 (1.1)   1   (1.2)  NR NR 
(McHugo et al., 1991) UK mid-trim. pres/abs 4,984   19 (0.4)   0   (0.0)  NR NR 
(Ostlere et al., 1990) UK 16-18 pres/abs 11,700 100 (0.9)   3   (3.0)  0: NR 3: NR 
(Perpignano et al., 1992) US/NY 18 / 2.7 >2 mm 8,769   87 (1.0)   4   (4.6)  3: NR 1: NR 
(Reinsch, 1997) US/CA 18-21 pres/abs 16,059 301 (1.9)   2   (0.7)  0:263 2:  38 
(Twining et al., 1991) UK 18-20 >3 mm 4,541   19 (0.4)   1   (5.3)  NR NR 
(Walkinshaw et al., 1994) UK 17-19 >5 mm 15,565 152 (1.0)   3   (2.0)  3:151 0:    1 
         
  377,621 2,715 (0.8) 
(0.5 - 1.3%) 
49   (2.2) 
(1.7 – 3.0%)
 9:1,957 
1:217 (114 – 475) 
25:261 
1:10 (7 – 16) 
 
1 Gestational age range, or mean / standard deviation 
2 lower cutoff (e.g., >3 mm), lowest reported size (e.g., 8 mm) or not specified (i.e., presence/absence) 
NR = not reported 
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Results - High risk case/control and cohort studies:   
The next series of studies is from high risk populations (e.g., screen positive via 
biochemistry, advanced maternal age).  Table 8.3.1-3 summarizes the data from 
eight studies (Bahado-Singh et al., 2003; Benacerraf et al., 1994; DeVore, 2000; 
Seoud et al., 1994; Bottalico et al., 2009; Cho et al., 2009; Watson et al., 2008; 
Goetzinger et al., 2008).  One study (Bahado-Singh et al., 2003) provided sufficient 
data so that the data could be separated into those less than 17.5 weeks, and 
those at or beyond 17.5 weeks.  Thus, nine datasets were available for analysis.  
One study (Drugan et al., 1996) was excluded because sufficient information could 
not be obtained from the report.  Case control and cohort studies were reported 
and analyzed separately.  Only one study specified the size of >3 mm (Bottalico et 
al., 2009), but since most of the studies were performed after 1999, it is likely they 
used a relatively consistent definition of greater than 2 or 3 mm. 
 
Among the four case/control studies (five datasets), a total of 3,370 unaffected 
pregnancies were included, with a rate of CPCs of 4.4%.  One study (Seoud et al., 
1994) had a relatively high rate of 18%, but this estimate was based on only 50 
observations.  It is mainly responsible for the identified heterogeneity (Q=30, 
I2=87%, p<0.001).  These four studies also included 102 trisomy 18 pregnancies 
(prevalence 1:33).  Among these cases, 43% (44 cases) had a CPC identified 
during the ultrasound examination.  Heterogeneity was low (Q=2.5, I2=0%, p=0.6).   
 
The three cohort studies included 148,484 unaffected pregnancies, with a 3.5% 
rate of CPCs (Q=100, I2=97%, p<0.001).  The smallest study (Bottalico et al., 2009) 
reported a high rate of 8.3%, but included only 628 unaffected pregnancies.  Two of 
these studies reported CPC measurements on a total of 112 trisomy 18 
pregnancies (prevalence 1:707).  CPCs were identified in 47% (52 cases).  
Heterogeneity was again low (Q=1.3, I2=22%, p=0.3).   
 
Although there were some differences in the rate of identifying CPCs in the 
unaffected population, the overall rate for all eight studies is 4.0% (I2>90%).  There 
is, however, good consistency among the detection rates, with 43% of cases 
having a CPC identified via ultrasound (Q=4.7, I2=0%, p=0.7). 
 
It is possible to stratify the results further, based on whether the CPC was an 
isolated finding.  Three studies reported whether the CPC was an isolated finding, 
for both the cases and controls (Benacerraf et al., 1994; Cho et al., 2009; 
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Goetzinger et al., 2008).  Among the 114 trisomy 18 fetuses, 7% (seven cases) had 
an isolated CPC, and the associated heterogeneity was low (Q=3.8, I2=58%, 
p=0.15).  According to these studies, about 1 in 14 second trimester trisomy 18 
fetuses might have CPCs as the only ultrasound finding.  Among the corresponding 
70,924 unaffected pregnancies, 0.19% had isolated CPCs.  Heterogeneity of this 
finding was also low (Q=0.3, I2=0%, p=0.8).   
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Table 8.3.1-3.  Choroid plexus cysts (CPCs) and trisomy 18:  High risk case/control and cohort studies 
 
  GA1 Unaffected pregnancies  Trisomy 18  Isolated CPC 
Study Location weeks Total CPC Rate (%)  Total Prev w/CPC (%)  T18 UA 
             
Case/control             
(Bahado-Singh et al., 2003) US/CT 14-17.5    767   24   3.1%    29 1:    26   9 (  31)    
(Bahado-Singh et al., 2003) US/CT 17.6-24    447   21   4.7%    18 1:    25   8 (  44)    
(Benacerraf et al., 1994) US/MA 14-21    106     2   1.9%    13 1:      8   6 (  46)  1/  13 2/    106 
(DeVore, 2000) US/CA 14-23 2,000   56   2.8%    30 1:    67 15 (  50)    
(Seoud et al., 1994) US/VA 22 / 5      50     9 18.0%    12 1:      4   6 (  50)    
Subtotal 
(random effects)  
3,370 
 
112 
 
  4.4% 
(2.7-7.2)  
102 
 
1:    33 
 
44 (  43) 
(34-53)    
             
Cohort             
(Bottalico et al., 2009) US/NJ 15-22      628      52 8.3%      7    1:    90 NR    
(Cho et al., 2009) US/CA 15-21   8,707    221 2.5%    56    1:  155 29 (  52)  6/  45 167/  8707 
(Goetzinger et al., 2008) US/MO 15-21 63,222 1,322 2.1%    56    1:1,129 23 (  41)  1/  56 111/62111 
Subtotal 
(random effects) 
 
 
72,557
 
1,595 
 
3.5% 
(2.0-5.9) 
 112 
 
   1:   605 
 
52 (  47) 
(37-56) 
   
              
All2 
(random effects) 
 75,927
 
 
1,707 
 
 
4.0% 
(2.8-5.7) 
 
 214 
 
  
96 (45) 
(38-52) 
 
 7/114 
7.2% 
(2.2-21) 
280/70924 
0.19% 
(0.17-0.21) 
 
1 Gestational age range, or mean / standard deviation 
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Results - High risk ‘screen positive’ studies:   
The next series of 17 studies (Table 8.3.1-4) reported only on women who had a 
CPC identified as part of the second trimester ultrasound study (i.e., screen 
positive only).  The first seven studies (Chan et al., 1989; DeRoo et al., 1988; 
Gabrielli et al., 1989; Kupferminc et al., 1994; Morcos et al., 1998; Platt et al., 1991; 
Porto et al., 1993) report the total number of pregnancies scanned (denominator), 
while the latter 10 do not (Bakos et al., 1998; Benacerraf et al., 1989; Bird et al., 
2002; Chudleigh et al., 1984; Gross et al., 1995; Nadel et al., 1992; Nava et al., 
1994; Oettinger et al., 1993; Thorpe-Beeston et al., 1990; Jou, 1997). 
 
The first seven studies reported the number of women scanned in the second 
trimester (30,325) and found 492 (1.6%) with CPCs (95% CI 1.1% - 2.4%).  
Heterogeneity was high (Q=102, I2=94%, p<0.001).  Among these 429 fetuses, 
trisomy 18 was diagnosed in 25 (5%).  In the remaining 10 studies, a total of 1,687 
women with a CPC were identified, and 39 (2%) were diagnosed with trisomy 18.  
Among all 17 studies, eight provided information on other non-structural anomalies 
in addition to CPCs for both cases and controls.  One study (Gabrielli et al., 1989) 
reported this information for cases only and, therefore, is not included in the 
analysis.  The odds for trisomy 18 among fetuses with an isolated CPC are 1:156, 
compared to 1:7 when additional ultrasound anomalies are present. 
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Table 8.3.1-4.  Choroid plexus cysts (CPCs) and trisomy 18:  High risk ‘screen positive’ studies 
 
  GA1 CPC Number N (%) N    (%)  Isolated w/abnormality
Study Location (weeks) Size Studied All CPCs All T18  OAPR for CPC 
          
(Chan et al., 1989) US/PA 15-24 >3 mm      513   13  (2.5) 11 (85)  -  
(DeRoo et al., 1988) US/NH 14-21 >2 mm   1,565   12  (0.8)   0 (  0)  -  
(Gabrielli et al., 1989) US/Italy 16-28 NR      933   21  (2.3)   4 (19)  0 /  NR 4 /  NR 
(Kupferminc et al., 1994) US/IL 19.5/2.8 NR   9,100 102  (1.1)   3 (  3)  1 /   98 2 /   4 
(Morcos et al., 1998) US/CA 2nd trim >2 mm   7,617 210  (2.8)   1 (<1)  0 / 181 1 /  29 
(Platt et al., 1991) US/CA 15-22 NR   7,350   71  (1.0)   3 (  4)  -  
(Porto et al., 1993) US/CA 15-22 >2 mm   3,247   63  (1.9)   3 (  5)  -  
Subtotal 
 
   30,325 492  (1.6) 
(1.1 – 2.4) 
25 (  5)    
          
(Bakos et al., 1998) Sweden 11-20 >3 mm - 50   1 (  2)  -  
(Benacerraf et al., 1989) US/MA 16-18.4 NR - 14   0 (  0)  -  
(Bird et al., 2002) US/CA 2nd trim NR - 395 10 (  3)  1 /  341 1 / 54 
(Chudleigh et al., 1984) UK 17-19 NR - 5   0 (  0)  -  
(Gross et al., 1995) US/TN 14-22 NR - 80   1 (  1)  0 /   74 1 /   6 
(Jou, 1997) Taiwan 13-24 NR - 108   7 (  7)  5 /   95 2 /   6 
(Nadel et al., 1992) US/MA 14-22 NR - 234 10 (  4)  0 / 220 10 / 14 
(Nava et al., 1994) US/PA 19.6/3 >4 mm - 211   4 (  2)  1 / 193 3 / 18 
(Oettinger et al., 1993) Israel 2nd trim NR - 14   1 (  7)  -  
(Thorpe-Beeston et al., 1990) UK 15-18 >3 mm - 83   5 (  6)  0 /   49 5 / 34 
Subtotal     1,687 39 (  2)    
          
All     2,179 64 (  3)  8 / 1,251 
1:156 
25 / 165 
1:7 
 
1  Gestational age range, or mean/standard deviation 
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Results - High risk case-only studies  
The next series of CPC studies is case-only, performed in a high risk setting.  A 
total of 13 second trimester studies were identified (Benacerraf et al., 1990; 
Bronsteen et al., 2004; Brumfield et al., 2000; Bundy et al., 1986; Fitzsimmons et 
al., 1989; Nicolaides et al., 1992b; Papp et al., 2008; Shields et al., 1998; 
Tongsong et al., 2002; Viora et al., 2007; Yeo et al., 2003; Nyberg et al., 1993; 
Watson et al., 2008) (Table 8.3.1-5).  Among the 568 cases, 41% were found to 
have CPCs.  Heterogeneity was low (Q=14, I2=14, p=0.3).  Eight of these studies 
reported whether the CPC was an isolated finding.  Overall, 8% of the 260 cases 
from these studies had a CPC as the only ultrasound finding.  Two of these studies 
(Papp et al., 2008; Shields et al., 1998) reported 10 of the 14 cases with isolated 
CPCs.  One possibility for this might be that both studies included a small number 
of pregnancies prior to 15 weeks’ gestation, when some of the other non-structural 
anomalies in trisomy 18 fetuses are difficult to visualize and/or measure.  
Regardless, the heterogeneity was still low (Q=11, I2=34%, p=0.2). 
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Table 8.3.1-5.  Choroid plexus cysts (CPCs) and trisomy 18:  High risk positive case only studies 
 
  GA CPC Trisomy 18 
Study Location (weeks) size Total CPC CPC (%) Isolated CPC    N  (%) 
         
(Benacerraf et al., 1990) US/MA 13-20 NR 13   4 31%   1   8% 
(Bronsteen et al., 2004) US/MI 15-24 NR 54 22 41% NR NR 
(Brumfield et al., 2000) US/AL 14-22 NR 21   9 43% NR NR 
(Bundy et al., 1986) US/MA 15-18 NR   6   1 17%   1 17% 
(Fitzsimmons et al., 1989) US/WA 18-19 NR   2   2 100%   1 50% 
(Nicolaides et al., 1992b) UK 14-39 NR 83 39 47% NR NR 
(Nyberg et al., 1993) US/WA 15-19 NR 20   7 35%   1   5% 
(Papp et al., 2008) Hungary 13-24 NR 70 27 39%   5   7% 
(Shields et al., 1998) US/WA 14-22 NR 35 15 43%   5 14% 
(Tongsong et al., 2002) Thailand 16-22 NR 25 10 40% NR NR 
(Viora et al., 2007) Italy 16-23 NR 27   8 30% NR NR 
(Watson et al., 2008) US/MN 15-21 NR 98 39 40% 0   0% 
(Yeo et al., 2003) US 15-19 AIUM 16 16 100% 0   0% 
         
All 
(random effects) 
  
568 
 
238 
 
41% 
(36 – 46) 
14 
 
  8% 
(4 to 16) 
 
AIUM = American Institute of Ultrasound Medicine 
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Conclusions: trisomy 18 and CPCs:   
Given the large number of studies with widely varying designs, settings, equipment 
and sonographer training, it can be difficult to come to a simple conclusion.  
However, two findings are clear: 
 Prospective population-based studies find both a lower detection rate (29%) 
and false positive rate (0.8% to 1.4%) than do studies in high risk settings 
(detection rates of 44%, 52% and 41% at false positive rates of 3.5%, 2.1% 
and 1.6%).  This is most likely due to the setting, as population-based studies 
are more likely to rely on less comprehensive ultrasound scans being done by 
less skilled personnel with equipment that may not be as up-to-date.  The 
data from the prospective studies will be used as the summary estimates, 
appropriate for use in the general population. 
 The finding that isolated CPCs are far less likely to be associated with trisomy 
18 is obvious, once the evidence on associated anomalies is taken into 
account.  Over time, with the addition of more ‘soft’ markers, improved 
equipment and sonographer training, the likelihood of not finding at least one 
other marker in a fetus with trisomy 18 is becoming smaller. 
 
In reviewing the data on CPCs as a marker for trisomy 18, several reports provide 
insight and are summarized below: 
 Equipment:  In one study (Ostlere et al., 1990), an older Hitachi EUB 25 
ultrasound machine found a rate of 1:300 for CPC.  However, the same 
sonographers using a higher resolution Hitachi EUB 340 in the same 
population found a rate of 1:90, three times higher. 
 Bilateral CPC/Persistence:  Several studies provide evidence that neither 
size, bilaterality, nor persistence of isolated CPCs are indicators of a trisomy 
18 fetus (Kupferminc et al., 1994; Nava et al., 1994; Perpignano et al., 1992). 
 CPCs and Down syndrome:  A 1998 review of CPC and Down syndrome 
(Chitty et al., 1998) identified 32 studies reporting on 4,342 fetuses.  The 
overall incidence of Down syndrome was 1:150.  However, since some of 
those studies were in high risk populations due to maternal age, non-
structural anomalies and serum screening results, this rate is difficult to 
interpret.  If the data are restricted to the 13 studies performed in the general 
pregnancy population (1,494 CPC in 247,406 women), the incidence is 
considerably lower (1:239).  In that same group of studies, the risk for Down 
syndrome among women with isolated CPC is only 1:1,962.  This provides 
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strong evidence that the association of CPC, especially isolated CPC, with 
Down syndrome is relatively weak. 
 Long-term follow-up:  One group followed the children of women with isolated 
CPCs and normal karyotypes after birth (Digiovanni et al., 1997).  Among 76 
children followed between one and five years, all had normal early childhood 
development as measured by the modified Denver II Developmental 
Screening Test.  
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8.3.2  Nuchal skin fold thickness (NSF) 
 
Definition:  Thickening of the skin at the back of the neck is a common finding in 
newborns and infants with trisomy 18 (earlier analysis).  By 1990, sonographers 
were looking for this finding in the early second trimester.  NSF thickening was 
described in 1992 as (Benacerraf 1992): 
 
“Measurement from the outer limit of the occipital bone to the skin edge using a 
modified transverse view of the fetal head, which included the brain stem, 
cerebellum and occipital bone 
 
 
Figure 8.3.2-1.  Ultrasound measurement of nuchal skin fold (NSF) thickness.  
Ultrasound image at 19 weeks, 6 days (personal communication, Alan Donnenfeld, 
MD).  The white oval visible in the center of the image is a cross-sectional view of the 
fetal skull.  The white bar in the upper left quadrant indicates the NSF measurement 
of 7.4 mm.  In most centers, this would be considered a positive NSF measurement
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Literature search:  A total of 16 studies was identified that reported NSF 
measurements in trisomy 18 pregnancies in the early second trimester (Borrell et al., 
1997; Benacerraf et al., 1992; Ginsberg et al., 1990; DeVore, 2000; Seoud et al., 
1994; Gupta et al., 1997; Tongsong et al., 2002; Papp et al., 2008; Viora et al., 2007; 
Yeo et al., 2003; Nicolaides et al., 1992b; Drugan et al., 1996; Cho et al., 2009; 
Bottalico et al., 2009; Watson et al., 1994; Benacerraf et al., 1994) (Table 4.3.2-1).  
All of the studies were performed in a high risk setting (usually prior to amniocentesis 
due to maternal age or positive biochemistry testing).  Three distinct study types 
were represented (cohort, case/control and case only).  Each of these is presented 
separately in Table 8.3.2-1, so that differences can be seen. 
 
Results:  Among the four cohort studies, three reported the rate of elevated NSF 
thickness measurements in unaffected pregnancies to be 1.2% (95% CI 0.9% - 
1.8%).  Heterogeneity is high (Q=7.9, I2=75%, p=0.02).  A lower rate for NSF 
elevations of 0.3% (95% CI 0.2% - 0.6%) was found in the six case/control studies.  
Heterogeneity was low (Q=2, I2=0%, p=0.8).  For all nine studies combined, the rate 
was 0.6% (95% CI 0.2% – 2.4%), with high heterogeneity (Q=30, I2=74%, p<0.001).  
The point estimate for all three cohort studies is higher than the highest estimate 
among the case/control studies, indicating that study design is related to variability.  
Fifteen studies reported the rate of elevated NSF thickness and trisomy 18.  There 
were clear differences by study design.  Among the three cohort studies, one 
increased NSF thickness was identified among 63 trisomy 18 (1.6%, 95% CI <0.1% 
to 8.5%).  The six case/control studies found 20 of 70 identified (30%, 95% CI 20% - 
44%), while the six case only studies found 24 of 240 cases (12%, 95% CI 6.7% - 
16%).  The overall estimate of 15% (95% CI 9.5% - 24%) is heterogeneous (Q=30, 
I2=56%, p=0.005).   
 
Summary:  A total of 16 studies reported NSF thickening measurements on 373 
cases of second trimester trisomy 18 fetuses.  The best test performance was 
reported by case/control studies, with the lowest false positive rate (0.3%) along with 
the highest detection rate (30.3%).  This leads to an overall likelihood ratio (LR) of 
10.  However, the corresponding LR in the cohort studies is about 1 (1.2% and 1.3%, 
respectively).  With no explanation for this high heterogeneity, the routine use of 
second trimester NSF thickening may not be a suitable test for trisomy 18 in the early 
second trimester.  To be conservative, the rates from the cohort studies will be used 
as the summary estimate.
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Table 8.3.2-1.  Nuchal skin fold thickness (NSF) and trisomy 18 
 
  Gestational Defined Unaffected pregnancies  Trisomy 18 
Study Location Age (wks) NSF+ NSF + Total Rate (%)  NSF+ Total Rate (%) 
           
Cohort           
(Bottalico et al., 2009) US/NJ 15-22 >6 mm     4      628 0.6%  NR   
(Cho et al., 2009) US/CA 15-21 >6 mm   94   8,707 1.1%    1 56 1.8% 
(Drugan et al., 1996) US 15-19 >5 mm       0   1 0.0% 
(Watson et al., 1994) US/SD 14-21 >6 mm   27   1,453 1.9%    0   6 0.0% 
Subtotal   125 10,788 1.2%    1 63 1.6% 
    (95% CI 0.9-1.8%)   (95% CI 0.1-8.5%)
           
Case/control           
(Benacerraf et al., 1994) US/MA 14-21 >6 mm     0    102 0.0%    4 13 30.8% 
(Benacerraf et al., 1992) US/MA 14-20 >6 mm     2    588 0.3%    5   9 55.6% 
(Borrell et al., 1997) Spain 15-18 >6 mm     2 1,365 0.1%    2   7 28.6% 
(DeVore, 2000) US/CA 14-23 >6 mm     7 2,000 0.4%    5 30 16.7% 
(Ginsberg et al., 1990) US 14-20 >6 mm     0    212 0.0%    2   4 50.0% 
(Seoud et al., 1994) US/VA 22/5 >5 mm     0      50 0.0%    2   7 28.6% 
Subtotal   11 4,317 0.3%  20 70 30.3% 
    (95% CI 0.2-0.6%)  (95% CI 20-44%)
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Table 8.3.2-1.  (continued) 
 
  Gestational Defined Unaffected pregnancies  Trisomy 18 
Study Location Age (wks) NSF+ NSF+ Total Rate (%)  NSF+ Total Rate (%) 
           
Case only           
(Gupta et al., 1997) UK 16-20 >5 mm       1   19   5.3% 
(Nicolaides et al., 1992b) UK 14-39 NR       5   83   6.0% 
(Papp et al., 2008) Hungary 13-24 >6 mm     12   70 17.1% 
(Tongsong et al., 2002) Thailand 16-22 NR       2   25   8.0% 
(Viora et al., 2007) Italy 16-23 >6 mm       3   27 11.1% 
(Yeo et al., 2003) US/NJ 15-19 NR       1   16   6.3% 
Subtotal        24 240 10.5% 
         (95% CI 6.7-16%)
            
All    136 15,105 0.6%  45 373 12% 
  (95% CI 0.4-1.1%) (95% CI 3.8 – 33%)
 
1  expressed as range (13-19) or average/standard deviation (18.3/1.7) 
NR = not reported 
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8.3.3  Fetal long bone measurements 
 
Definition:  Trisomy 18 newborns are small for gestational age, and intrauterine 
growth retardation is often a finding by the third trimester.  These early findings 
support the effort to search for shortened long bone measurements in the early 
second trimester.  By the early 1990s, sonographers were reporting results on 
shortened femur and humeral bone measurements.  However, there was not a 
generally accepted definition of a ‘shortened’ long bone measurement.  Some 
sonographers used selected centiles or multiples of the standard deviation in 
known unaffected pregnancies.  Others used a cut-off for the ratio of observed to 
expected length, given the gestational age of the fetus.  The two major long bones 
studied most often are the humerus and the femur, and the relevant studies will be 
summarized separately. 
 
Humeral length 
Literature search:  A total of seven studies were identified that reported humeral 
bone measurements in second trisomy 18 pregnancies (Benacerraf et al., 1992; 
Benacerraf et al., 1994; Bottalico et al., 2009; Bundy et al., 1986; Cho et al., 2009; 
Dicke et al., 1989; Droste et al., 1990; Ginsberg et al., 1990; Nadel et al., 1992; 
Papp et al., 2008; Seoud et al., 1994; Watson et al., 2008) (Table 8.3.3-1).  
Although there are varied study designs and definitions for a shortened humeral 
bone, there are too few datasets and no clear pattern.  Thus, no stratified analyses 
will be performed. 
 
Results:  Six of the studies reported humeral bone length measurements in 153 
second trimester trisomy 18 fetuses.  Twenty-three (19%) had shortened humeral 
bone lengths.  Heterogeneity was moderate (Q=10, I2=50%, p=0.08).  Five studies 
reported the corresponding rate of shortened humeral bones in 11,491 unaffected 
pregnancies to be 2.5%.  Heterogeneity was high (Q=47, I2=91%, p<0.001).  At 
least some of the heterogeneity is due to the definition of ‘shortened’.  For example, 
one group (Cho et al., 2009) used a cut-off of less than 0.85 for the 
observed/expected ratio.  This led to a lower detection and false positive rate.  
Removal of this study reduces heterogeneity and produces a summary likelihood 
ratio of 7.6 (22% / 2.9%).  A reasonable summary estimate for detection and false 
positive rates are 19% and 2.5%, respectively. 
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Table 8.3.3-1.  Fetal long bone (humeral) measurements and trisomy 18 
 
 
Author 
 
Location 
 
Design 
Definition 
of ‘shortened’ 
Gestational 
Age (weeks)1 
Trisomy 18 
positive / total (%) 
 Controls 
positive / total (%) 
        
(Bottalico et al., 2009) US/NJ Cohort O/E < .90 15-22 NR /  7      8/   628  (1.3%) 
(Cho et al., 2009) US/CA Cohort O/E < .85 15-21   3 /56  (  5%)  144/ 8,707 (1.7%) 
(Benacerraf et al., 1994) US/MA Case / Cont O/E < .90 14-21   2 /  9  (22%)      3 /     84  (3.6%) 
(Benacerraf et al., 1992) US/MA Case / Cont O/E < .90 14-20   3 /  9  (33%)    34/   588  (5.8%) 
(Droste et al., 1990) US/WI Case / Cont O/E < -2SD 18-19   2 /  3  (67%)      4/   174  (2.5%) 
(Bundy et al., 1986) US/MA Case only NR 15-18   1 /  6  (17%)  NR 
(Papp et al., 2008) Hungary Case only <10th 13-24 12 /70  (17%)  NR 
         
All 
(random effects) 
    
23 / 153 (19%)2 
(95% CI 10 - 34%) 
 
150 / 11,491 (2.5%) 
(95% CI 1.2 to 5.1) 
 
O/E = observed / expected, SD = standard deviation 
1  expressed as the range of completed weeks 
2  excluded Bottalico 2009  
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Femur length  
Literature search:  A total of 11 studies were identified that reported measurements 
of femur length in trisomy 18 pregnancies (Benacerraf et al., 1994; Benacerraf et 
al., 1992; Bottalico et al., 2009; Cho et al., 2009; Dicke et al., 1989; Droste et al., 
1990; Ginsberg et al., 1990; Nadel et al., 1992; Papp et al., 2008; Seoud et al., 
1994; Watson et al., 2008) (Table 4.3.3-2).  Six of these studies were of 
case/control design; the other five were of various other designs.  One report 
(Nadel et al., 1992) reported only on women who were identified with a CPC 
(screen positive study design) and was not included. 
 
Results:  Eleven studies reported that the proportion of the 284 trisomy 18 
pregnancies with a shortened femur length was 33%.  Heterogeneity was high 
(Q=32, I2=72%, p<0.001).  When stratified into the five case/control studies versus 
other study designs, there was a significant difference.  Case/control studies alone 
had a rate of 54% (95% CI 40% -68%), while other study types had a lower rate of 
16% (12% - 21%).  Remaining heterogeneity was low in both groups. 
 
Seven studies reported the proportion of 11,491 unaffected pregnancies with 
shortened femurs to be 5.2%.  Heterogeneity was high (Q=124, I2=95%, <0.001).  
The five case/control studies had a summary rate of 8.2% (5.4% – 12%) versus 
2.0% (1.1% – 3.8%) in the two remaining studies.  Heterogeneity was low in both 
groups. 
 
Two separate likelihood ratios can be generated.  Data from the case/control 
studies indicate an LR of 6.6 (54%/8.2%) while the corresponding LR for other 
study types is 8 (16%/2%).  The differences do not appear to be due to varying 
definitions/cut-off levels.  However, there is a clear temporal difference.  The 
case/control studies were all published between 1989 and 1994, while four of the 
five remaining studies were published in 2008 or later.  Given this information, the 
best LR estimate to use may be the 8.0, based on the non case/control studies. 
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Table 8.3.3-2.  Fetal long bone (femur) measurements and trisomy 18 
 
 
Author 
 
Location 
 
Design1 
 
Definition2 
Gestational 
Age (weeks)3 
Trisomy 18 
positive / total (%) 
 
Controls 
positive / total (%) 
        
(Bottalico et al., 2009) US/NJ Cohort O/E < .91 15-22 NR      7 /   628  (1.1%) 
(Cho et al., 2009) US/CA Cohort O/E < .85 15-21 10 / 56  (18%)  245 / 8707  (2.8%) 
(Watson et al., 2008) US/MN Cohort < 5th 15-21 13 / 98  (13%)  NR 
(Benacerraf et al., 1994) US/MA Case / Cont O/E < .91 14-21   8 / 13  (62%)      4 /   106  (3.8%) 
(Benacerraf et al., 1992) US/MA Case / Cont O/E < .91 14-20   5 /   9  (55%)    63 /   588  ( 11%) 
(Dicke et al., 1989) US/MO Case / Cont O/E < .91 14-21   5 / 10  (50%)    10 /   142  (7.0%) 
(Droste et al., 1990) US/WI Case / Cont O/E > -2 SD 18-19   3 /   4  (75%)  NR 
(Ginsberg et al., 1990) US/IL Case / Cont BPD/FL < 1.5 SD 14-20   3 /   4  (75%)    14 /   212  (6.6%) 
(Seoud et al., 1994) US/VA Case / Cont BPD/FL < 1.5 SD 22 / 5   3 / 10  (30%)      7 /     50  (14%) 
(Papp et al., 2008) Hungary Case only < 10th 13-24 12 / 70  (17%)  NR 
(Nadel et al., 1992) US/MA Screen pos NR 14-22   2 / 10  (20%)  NR 
        
All 
(random effects) 
    
64 / 284 (33%) 
(95% CI 21-49%) 
 
150 / 11,491 (5.2%) 
(95% CI 2.7 to 9.8) 
 
O/E = observed / expected, SD = standard deviation, BPD = biparietal diameter, FL = femur length, NR = not reported 
1 All studies were in populations with a high prevalence of trisomy 18 
2 Expressed as range (13-19) or average/standard deviation (18.3 / 1.7) 
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8.3.4  Hyperechoic bowel 
 
Definition:  Hyperechoic (or echogenic) bowel occurs when the brightness of the 
scanned bowel meets or exceeds the echogenicity (brightness) of nearby bone 
(Figure 8.3.4-1).  This definition is generally accepted and widely applied. 
 
Literature search:  A total of 10 studies was identified that reported echogenicity of 
the bowel in second trimester trisomy 18 fetuses (Benacerraf et al., 1994; Bottalico 
et al., 2009; Bromley et al., 1994; Cho et al., 2009; DeVore, 2000; Gupta et al., 
1997; Papp et al., 2008; Seoud et al., 1994; Viora et al., 2007; Watson et al., 2008; 
Yeo et al., 2003; Drugan et al., 1996) (Table 8.3.4-1).  Although the definition of 
echogenic bowel was not reported for four of these studies, it is likely that they 
used the definition provided above.  All studies were performed in high risk 
settings. 
 
Results:  Among the ten studies, 322 trisomy 18 fetuses were scanned, and 7.1% 
were found with echogenic bowel (Table 8.3.4-1).  There was high heterogeneity 
among the study estimates (Q=17, I2=59%, p=0.02).  Five of those studies also 
reported the rate of echogenic bowel in unaffected pregnancies.  The summary 
was 1.5%.  Again, the heterogeneity was high (Q=78, I2=95% p<0.001).  The 
summary likelihood ratio was 4.7, but the high heterogeneity hinders routine 
application of this ultrasound finding to identify trisomy 18. 
 
 Chapter 8. Second Trimester Ultrasound Markers for Trisomy 18 210 
 
 
 
Figure 8.3.4-1.  Echogenic bowel.  Early second trimester ultrasound scan, in which 
the bowel (arrow) appears to be as bright as adjacent bone.(echogenic).  The fetal 
spine can be seen across the bottom of the image. 
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Table 8.3.4-1.  Hyperechoic bowel and trisomy 18 
 
 
Author 
 
Location 
 
Design 
 
Definition 
Gestational 
Age (weeks)1 
Trisomy 18 
positive / total (%) 
 
Controls 
positive / total (%) 
        
(Bottalico et al., 2009) US/NJ Cohort > bone 15-22 NR  10 /   628  (1.6%) 
(Cho et al., 2009) US/CA Cohort > bone 15-21 2 / 56  (   4%)  69 / 8707  (0.8%) 
(Drugan et al., 1996) US/MI Cohort NR 15-19 0 /   1  (    0%)  NR 
(Watson et al., 2008) US/MN Cohort NR 15-21 1 /  98  (   1%)  NR 
(Benacerraf et al., 1994) US/MA Case / Cont > bone 14-21 0 /  13  (   0%)  1 /   106  (0.9%) 
(DeVore, 2000) US/CA Case / Cont > bone 14-23 4 /  30  ( 13%)  70 / 2000  (3.5%) 
(Seoud et al., 1994) US/VA Case / Cont bone 22 / 5 4 /  11  ( 36%)  0 /     50  (0.0%) 
(Papp et al., 2007) Hungary Case only NR 13-24 5 /  70  (   7%)  NR 
(Viora et al., 2007) Italy Case only bone 16-23 1 /  27  (   4%)  NR 
(Yeo et al., 2003) US/NJ Case only NR 15-19 1 /  16  (   6%)  NR 
        
All 
(random effects) 
    
18 / 322 (7.1%) 
(95% CI 3.2-15%) 
 
150 / 11,491 (1.5%) 
(95% CI 0.6 to 3.8) 
 
NR = not reported 
1  expressed as range (13-19) or average/standard deviation (18.3 / 1.7) 
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8.3.5  Pyelectasis 
 
Definition:  Pyelectasis is defined as the diameter of the renal pelvis (anterior to 
posterior measurement) being greater than a certain size, usually 4 mm.  Some 
sonographers use a higher cut-off level of 5 mm or even greater. 
 
Figure 8.3.5-1.  Pyelectasis in the early second trimester.  The left sonogram 
shows the normal sized renal pelvis, while the left photo shows a large dilation of the 
renal pelvis (pyelectasis).  
 
Literature search:  A total of nine studies were identified that reported pyelectasis in 
trisomy 18 pregnancies (Benacerraf et al., 1994; Bottalico et al., 2009; Cho et al., 
2009; DeVore, 2000; Havutcu et al., 2002; Papp et al., 2008; Seoud et al., 1994; 
Yeo et al., 2003; Drugan et al., 1996).  Three were cohort studies, three were 
case/control studies, two were case only, and one only followed women whose 
scan indicated pyelectasis (screen positive).  All studies were performed in a high 
risk setting, except for the screen positive study (Havutcu et al., 2002). 
 
Results:  All nine studies provided the proportion of the 198 trisomy 18 pregnancies 
identified with pyelectasis, but in two studies (Drugan et al., 1996; Havutcu et al., 
2002), only one, or no trisomy 18 pregnancies were reported (Table 4.3.5-1).  
Overall, the detection rate was 11% (21 with pyelectasis).  Heterogeneity was high 
(Q=14, I2=65%, p=0.01).  Six of the nine studies reported the rate of pyelectasis 
among the 37,077 unaffected pregnancies.  The summary was 1.5%, with high 
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heterogeneity identified (Q=10 I2=52% p=0.06).  The summary likelihood ratio for 
pyelectasis based on these rates is 7.3 (11% / 1.5%).  However, only one of the 
nine studies actually provided detection and false positive rates with at least one 
instance of pyelectasis in both groups (Cho et al., 2009) resulting in a likelihood 
ratio of 2.9.  The summary estimates of 11% and 1.5% are reasonable estimates 
for detection and false positive rates for pyelectasis. 
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Table 8.3.5-1.  Pyelectasis and trisomy 18 
 
 
Author 
 
Location 
 
Design 
 
Definition 
Gestational 
Age (weeks)1 
Trisomy 18 
positive / total (%) 
 
Controls 
positive / total (%) 
        
(Bottalico et al., 2009) US/NJ Cohort >4 mm 15-22 NR      9  /   628  (1.4) 
(Cho et al., 2009) US/CA Cohort >4 mm 15-21 3  /  56  (  5%)  146  /8.707  (1.7) 
(Drugan et al., 1996) US Cohort >5 mm 15-19 0  /    1  (  0%)   
(Benacerraf et al., 1994) US/MA Case / Cont >4 mm 14-21 0  /  13  (  0%)      0  /   106  (  0) 
(DeVore, 2000) US/CA Case / Cont >4 mm 14-23 0  /  30  (  0%)    33  /2,000  (1.7) 
(Seoud et al., 1994) US/VA Case / Cont >4 mm 22 / 5 5  /  12  (42%)      0  /     50  (  0) 
(Papp et al., 2008) Hungary Case only NR 13-24 12  /   70  (17%)   
(Yeo et al., 2003) US/NJ Case only NR 15-19 1  /  16  (  6%)   
(Havutcu et al., 2002) UK Screen pos (low) >5 mm 18-24 0  /    0  (  0%)  320 / 25,586  (1.3) 
        
All 
(random effects) 
    
     21 / 198  (11%) 
(95% CI 4 – 25%) 
 
   308 / 37,077 (1.5%) 
(95% CI 1.2 – 1.8%) 
 
NR = not reported, mm = millimeters 
1  expressed as range (13-19) or average/standard deviation (18.3 / 1.7)  
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8.3.6  Two-vessel cord 
 
Definition:  In normal pregnancies, the umbilical cord is composed of three vessels; 
one vein and two arteries.  In some instances, only two vessels are present (one 
vein and one artery).  This is labeled a two-vessel cord.  Some studies distinguish 
between whether the right or left artery is absent, but this does not seem to be 
strongly associated with karyotype. 
 
Figure 8.3.6-1.  Two vessel cord.  A third trimester black & white version of a color 
Doppler image of the cross-sectional view of an umbilical cord (personal 
communication, Alan Donnenfeld, MD).  A normal umbilical cord has 3 vessels (2 
arteries and a vein).  This image shows only two vessels (indicated by the white 
ovals), one would be colored red and the other blue.   
 
Literature search:  A total of seven studies were identified that reported two-vessel 
cords in trisomy 18 pregnancies.  All occurred in high risk settings, usually prior to 
amniocentesis (Bahado-Singh et al., 2003; Brumfield et al., 2000; Cho et al., 2009; 
Watson et al., 2008; Lubusky et al., 2007; Saller et al., 1990).  One of these studies 
(Bahado-Singh et al., 2003) could be stratified into an early and late gestational 
age groups resulting in the analysis of four datasets. 
 
Red
Blu
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Results: The six datasets included 231 fetuses with trisomy 18, and a two-vessel 
cord was identified in an estimated 14% (Table 8.3.6-1).  Heterogeneity was low 
(Q=2.9, I2=0%, p=0.7).  Four studies also reported the false positive rates.  The 
summary estimate is 1.2% (95% CI 0.3% to 4.6%), with high heterogeneity (Q=135, 
I2=98, p<0.001).  One study had a very high rate of 4% (Lubusky et al., 2007).  If 
this were removed, the estimate would be reduced to 0.7% (95% CI 0.4% to 1.4%).  
The heterogeneity is reduced, but still high (Q=7.6, I2=74%, p=0.02).  Using these 
summary estimates for two-vessel cord, the corresponding likelihood ratio would be 
20 (14%/0.7%).  
 
 
 Chapter 8. Second Trimester Ultrasound Markers for Trisomy 18 217 
 
Table 8.3.6-1.  Two-vessel cord and trisomy 18 
 
 
Author 
 
Location 
 
Design 
Gestational 
Age (weeks)1 
Trisomy 18 
positive / total (%) 
 Unaffected 
positive / total (%) 
       
(Cho et al., 2009) US/CA Cohort 15-21   6  /  56  (11%)  38  / 8,707 (0.4%) 
(Lubusky et al., 2007) Czech Rep Cohort Early 2nd trimester   8  /  16  (50%)  81  / 2,020 (4.0%) 
(Bahado-Singh et al., 2003) US/CT Case / Cont 14-17.5   3  /  25  (12%)    6  /     767 (0.8%) 
(Bahado-Singh et al., 2003) US/CT Case /Cont 17.6-24   3  /  22  (14%)    6  /     447 (1.3%) 
(Brumfield et al., 2000) US/AL Case only 14-22   1  /  21  (  5%)  NR 
(Saller et al., 1990) US/MD Case only    2  /    9  (22%)  NR 
(Watson et al., 2008) US/MN Case only 14-21 16  /  98  (17%)  NR 
        
All 
(random effects) 
   31  /231  (14%) 
(95% CI 10-19%) 
 131  / 11,941 (1.2%) 
 (95% CI 0.5-1.5%) 
 
NR = not reported 
1  expressed as range (13-19) or average/standard deviation (18.3/1.7)  
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8.3.7  Echogenic intra-cardiac focus (EICF) 
 
Definition:  Echogenic intra-cardiac focus was reported in the literature as early as 
1988 (Levy and Mintz, 1988) and was initially thought to be benign.  The EICF is a 
bright spot (as bright as bone), usually observed in the left ventricle during a four-
chambered view of the heart.  It may be due to calcification, thickening, or incomplete 
penetration of the papillary muscles or chordate tendineae (Wax et al., 2000). 
 
Figure 8.3.7-1  Echogenic intra-cardiac focus (EICF).  This ultrasound image 
shows the fetal heart with a bright spot (arrow) in the left ventricle – the echogenic 
intra-cardiac focus.   
 
Literature search:  A total of six relevant articles was identified (Bottalico et al., 2009; 
Cho et al., 2009; Papp et al., 2008; Sepulveda et al., 1995; Wax et al., 2000; Yeo et 
al., 2003).  All were performed in a high risk setting, three were of case only design 
and the three others were cohort studies. 
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Results:  The data are summarized in Table 8.3.7-1.  The gestational ages are, in 
general, early second trimester.  For the five studies reporting the detection rates, the 
summary rate was 1.9% (95% CI 0.4% to 5.5%, based on the binomial distribution); 
rates ranged from 0 to 8%.  The observed rate was used, because two of the five 
studies detected no cases (Wax et al., 2000; Papp et al., 2008).  For the three 
studies reporting false positive rates, the summary using a random effects model was 
3.8% (95% CI 2.9% to 4.8%), with high heterogeneity (Q=4, I2=61%, p=0.08).  The 
summary likelihood ratio is 0.50 (1.9%/3.8%).  Only one study had sufficient data 
(Cho et al., 2009) to compute an individual OR (0.55, 95% CI 0.08 to 3.7, p=NS).  In 
summary, the data are highly variable with an overall estimate of 1.9% detection rate 
with a 3.8% false positive.  In reality, it is likely that there is little or no association 
between EICF and trisomy 18. 
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Table 8.3.7-1.  Echogenic intra-cardiac focus (EICF) and trisomy 18 
 
 
Author 
 
Location 
 
Design 
Gestational 
Age (weeks)1 
Trisomy 18 
positive / total (%) 
 Controls 
positive / total (%) 
       
(Bottalico et al., 2009) US/ Cohort 15-22 NR    30 /    628    (4.8) 
(Cho et al., 2009) US/CA Cohort 15-21 1 /   56      (2)  280 / 8,707    (3.2) 
(Wax et al., 2000) US/CT Cohort 18.3/1.7 0 /     2      (0)    27 /    682    (4.0) 
       
(Papp et al., 2007) Hungary Case only 13-24 0 /   70      (0)  NR 
(Sepulveda et al., 1995) UK Case only mid-trimester 1 /   13      (8)  NR 
(Yeo et al., 2003) US/NJ Case only 15-19 1 /   16      (6)  NR 
       
All 
(fixed and random effects) 
   3 / 157    (1.9) 
(95% CI 0.4 – 5.5) 
 337 / 10,017    (3.8) 
(95% CI 2.9 - 4.8) 
 
NR = not reported 
1 expressed as average/standard deviation (e.g., 18.3/1.7) or range (e.g., 13-24) 
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8.3.8  Less commonly reported non-structural anomalies 
 
Several other non-structural anomalies for Down syndrome have been reported, 
including iliac wing, heart rate, polyhydramnios, ear length, and renal anomalies.  
These may, or may not, be useful in screening for trisomy 18.  They were not 
included, either because there are relatively few data available for these markers in 
Down syndrome, or because the reported effect is small. 
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8.4  Summary of second trimester ultrasound markers 
 
Table 8.4-1 summarizes the findings regarding the structural anomalies and non-
structural anomalies that could be potentially used to help identify fetuses with trisomy 18 
during the early second trimester.  For each ultrasound marker, the number of included 
studies, as well as total number of unaffected and trisomy 18 pregnancies reported are 
presented.  The reported trisomy 18 detection and false positive rates are the most 
relevant, and do not necessarily use data from all included studies.  For example, the 
detection and false positive rates for ‘any structural anomaly’ relies only on those studies 
reporting their cases between 15 and 20 completed weeks’ gestation.  The summary 
likelihood ratio is then provided along with the setting in which it might be acheived.   
 Structural anomalies.  All four groupings had high likelihood ratios (25-690), but the 
performance estimates for two of them (cardiac defects and hand/foot anomalies) 
would be unlikely to be met outside of a high risk referral center.  Since these 
anomalies are all considered serious, their identification is important, regardless of 
karyotype.  The classification of ‘false positives’ is misleading, but in an 
epidemiological context is appropriate for evaluation purposes. 
 Non-structural anomalies.  Only two of the eight ultrasound markers in this category 
were considered to be suitable for use.  The long bone measurement (femur) could 
be reliably measured in routine settings, but the two-vessel cord requires Doppler 
ultrasound that may only be available from referral centers. 
 
Summary:  Overall, the large literature base is mostly composed of opportunistic study 
populations that were not properly designed or powered to provide reliable and clinically 
relevant conclusions.  Along with evolving ultrasound techniques and equipment, this 
results in heterogeneous findings making subsequent evaluation and recommendations 
difficult.  Given the high detection and low false positive rates achievable in the second 
trimester (maternal age in combination with AFP, uE3, hCG and PAPP-A 
measurements), the first trimester (maternal age in combination with NT, PAPP-A and 
hCG or free β measurements), or with an integrated test (combinations of the first and 
second trimester markers), the addition of second trimester ultrasound measurements 
does not appear needed, especially in light of the pressure to have the ‘anomaly scan’ at 
19 weeks or later.  However, such ultrasound scans clearly have a role in identifying 
important structural defects such as cardiac anomalies.  The next section shows 
examines the whether an earlier version of such testing might be useful among those 
with positive serum test results. 
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Table 8.4-1.  Summary of association of second trimester ultrasound markers with trisomy 18 
 
Ultrasound Marker (page) Number of  Relevant estimates for  
 Studies T18 UA  DR (%) FPR (%)  (LR) Estimates appropriate for 
Structural anomaly         
Hand/foot anomalies (174) 17 615 10,027  41   0.06 680 Referral centers, 15 - 20 wks  
Open fetal defects (166) 15 441   1,320  26 0.2 130 All settings, 15 - 20 wks 
Any structural anomaly (178) 20 588 13,869  60 1.6   38 All settings, 15 - 20 wks 
Cardiac defects (171) 19 696 30,868  38 1.5   25 Non-specialized centers, 15 - 20 wks 
         
Non-structural anomaly         
Two-vessel cord (216)   7 231     9,921  14 0.7      20 Referral centers, 15-20 wks  
Long bone – humeral (205)   7 153   11,491  19 2.5 8 All settings, 15 - 20 wks 
CPC - all (199) 61 942 536,960  29 1.4      21 Not usable: highly variable 
Pyelectasis (213)   9 198   37,077  11 1.5   7.3 Not usable: variable, poor performance 
Hyperechoic bowel (209) 10 322   11,491       7.1 1.5   4.7 Not usable: variable, poor performance 
Nuchal skin fold (202) 16 373   15,105  1.6 1.2   1.3 Not usable: variable, poor performance 
CPC - isolated1 (200) - - -  low low      ~1 Not usable: poor performance 
EICF (219   6 157   10,017       1.9 3.8    0.5 Not usable: poor performance 
 
UA = unaffected, DR = detection rate, FPR = false positive rate, LR = likelihood ratio  
CPC = choroid plexus cysts, EICF = echogenic intra-cardiac focus 
1  With current practice (especially at referral centers), few, if any, truly isolated CPCs would be identified among trisomy 18 pregnancies 
 Chapter 8. Second trimester ultrasound markers for trisomy 18 224 
8.5  Combining second trimester ultrasound markers  
 
The usual method of combining serum markers is to identify those markers that provide 
reasonable separation between unaffected and affected pregnancies, determine whether 
those markers are independent of each other, and evaluate various combinations to 
determine which should be included in a test offering.  Ultrasound markers are different 
in that the sonographer will, during the course of the examination, identify markers that 
may, or may not, be useful.  Thus, a ‘set’ ultrasound test is more difficult to create.  One 
must also keep in mind that the ultrasound scan is not designed solely to identify trisomy 
18, but a whole host of findings relating to overall fetal well-being.  
 
Structural anomalies:  The most obvious first combination of tests is the identification of 
any structural anomaly.  Earlier data showed that the combination of open fetal defects, 
cardiac defects and other gross anomalies can identify over half of trisomy 18 fetuses.  
In addition, the ‘false positives’ are not really unaffected pregnancies.  They really do 
have, for the most part, an important fetal defect that is worthwhile identifying, even if the 
karyotype is normal.  It is clear from the data, that an examination of the hands and feet 
can be quite useful in identifying trisomy 18 (but not Down syndrome).  This requires 
time and high resolution equipment and may be an example of an anomaly that cannot 
be easily translated into routine practice.  
 
Non-structural anomalies.  The literature regarding these markers is characterized by 
high heterogeneity, even when attempting to account for potentially important covariates.  
One unexpected finding is the high likelihood ratio found for 2 vessel cords, along with 
moderate to low heterogeneity.  This suggests that it may have potential as a widely 
applicable test if Doppler analysis is available.  The various long bone measurements 
are surely correlated to some extent, and the literature suggests that both the femur and 
humeral bone measurements are equally predictive.  However, there is more 
heterogeneity present when the femur is used, suggesting that humeral bone 
measurements might be preferred.  Pyelectasis and hyperechoic bowel could also be 
potentially useful, with moderate predictive power, but are associated with unexplained 
high heterogeneity.  Identifying CPCs are not very useful as they are not associated with 
Down syndrome and are, as equipment improves, less likely to be found in isolation.  
Nuchal skin fold measurements appear far too variable for routine use.  It is possible that 
standardization, such as that currently employed for nuchal translucency measurements, 
may solve this problem.  Until then, NSF measurements do not appear ready for routine 
use.  ECIF appears to be of limited use in testing for trisomy 18. 
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US screening performance:  The screening performance of individual markers (Table 
8.4-1) can be used to estimate a combined marker panel by assuming independence of 
markers.  This is reasonable, if careful choices are made.  First, the estimate for the 
combination of structural anomalies (identified in the literature and this review as ‘gross 
anomalies’) can be used.  This accounts for interdependences among those markers 
and is likely to be more reproducible than difficult measurements made in referral 
centers.  Second, the number of non-structural anomalies can be limited, and those that 
are likely to show correlation (e.g., both humerus and femur length) would not be 
included together.  A monte carlo simulation can then generate thousands of 
combinations of markers in both affected and unaffected pregnancies and use the 
associated detection and false positive rates to estimate combined performance.  Using 
a combination of gross anomalies (at 15 – 20 weeks’ gestation), two vessel cord, 
humerus length and pyelectasis, the model predicts an 87.6% detection rate with a 
corresponding 8.8% false positive rate.   
 
Combining US and biochemistry:  Could second trimester ultrasound markers be 
combined with serum markers to screen for trisomy 18?  The answer from a statistical 
point of view is yes.  A routine scan looking for gross abnormalities and two or three non-
structural anomalies (i.e., 2 vessel cord, humerus length and pyelectasis) could 
potentially be helpful in identifying trisomy 18 in the second trimester.  Although some 
additional information would be needed to develop a reliable model, screening 
performance could be improved by combining the two strategies rather than choosing 
one or the other.  The real problem is timing, reliability and the necessary resources for 
the ultrasound.  Unlike biochemistry, there are no savings in scale for ultrasound.  Most 
professional organizations for sonographers recommend waiting until 19 weeks or later 
for an anomaly scan, so that features are more easily visualized.  This is too late for a 
trisomy 18 scan to be part of routine practice.  There are also not sufficient numbers of 
trained sonographers to handle the 2 to 4 million pregnant women that would be 
potential candidates for such testing.  Thus, it is likely that second trimester ultrasound 
and biochemistry will not be combined into a ‘one step’ trisomy 18 test. 
 
US markers as a follow-up test:  Performing an ultrasound scan among women already 
screen positive for trisomy 18 via second trimester biochemistry is routine in many 
referral centers.  The stated aim of the scan is to ‘refining the assigned risk’.  However, 
follow-up screening tests must be highly sensitive (i.e., high detection rate) in order that 
women with affected fetuses would not be missed on the follow-up testing.  Structural 
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anomalies are highly specific, but not highly sensitive.  The addition of several non-
structural anomalies would increase the detection rate, but probably not to the level 
required (95% detection rate or higher).  Figure 8.5-1 shows that follow-up ultrasound 
testing does not have sufficiently high detection to stratify screen positive women into a 
low risk group that would not benefit from diagnostic testing.   
 
Second trimester biochemistry can identify a group of women at an odds of 1:16 (or 
higher) of having trisomy 18 (Chapter 3, Sections 3.10 and 3.11).  Among the 
hypothetical group of 17,000 screen positive women, 1,000 women would be carrying a 
trisomy 18 fetus.  Of these, 876 will have one or more US markers positive (87.6% 
detection rate as described above), along with 1,408 women with normal pregnancies 
(8.8% of the 16,000).  The risk in screen positive women is now about 1:2 and the offer 
of diagnostic testing/karyotyping is clearly warranted.  However, the risk in the women 
with a negative ultrasound is about 1:120.  Significantly lower, but not so low as to not 
offer amniocentesis, especially since these women have already been told of their 
increased risk of trisomy 18.  Thus, reclassification using second trimester ultrasound is 
not sufficiently sensitive to use in determine which of these ‘high risk’ women should be 
offered ultrasound.  However, many of these fetuses will have a structural anomaly 
and/or an ultrasound finding.  One could respond that relatively few of the trisomy 18 
fetuses that would be missing would be likely survive to term, and even fewer would 
survive more than a few days.  However, evidence presented in Chapter 2 indicates that 
the more severely affected fetuses (such as those identified with gross abnormalities) 
are more likely to be lost and more likely to survive for a shorter time period.  Thus, those 
that are ‘missed’ via a second trimester ultrasound scanning protocol as shown in Figure 
8.5-1,  may actually be more likely to survive, making their identification via diagnostic 
testing especially important. 
 
Thus, the literature supports the assertion that several of the second trimester ultrasound 
markers are associated with trisomy 18.  However, that data generally is available later 
(19 weeks or later) than the biochemistry window (15-17 weeks) making it difficult to 
combine the two into a single interpretation sufficiently early in the second trimester to be 
clinically useful.  Even  a combination of second trimester ultrasound markers are not 
sufficiently sensitive (high enough detection) to allow their use among biochemistry 
screen positive women.  Although not suitable for routine use in screening for trisomy 18 
(or Down syndrome), second trimester ultrasound testing may still have use in the 
detection of other structural anomalies.
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Figure 8.5-1.  A hypothetical cohort of 17,000 women at high risk for trisomy 18 in 
the second trimester showing the effect of follow-up ultrasound testing.  The top 
three entries show the 1000 case, and 16,000 control pregnancies.  At that point, all 
undergo a second trimester ultrasound test that includes gross anomalies (at 15 – 20 
weeks’ gestation), two vessel cord, humerus length and pyelectasis.  The third row 
shows the results grouped into positive (solid outlined boxes) and negative (dashed 
boxes) ultrasound exams.  The final row shows the computation of the odds of being 
affected given a positive result for those with positive and negative test results.  Those 
women screen negative still have a relatively high risk (1:120) of having an affected 
fetus, and an offer for diagnostic testing still appears warranted. 
  
Screen positive by 
2nd trimester biochemistry
17,000 (1:16 OAPR)
trisomy 18
880 (88%)
trisomy 18
120 (12%)
unaffected
1,408 (8.8%)
unaffected
14,592 (91.2%)
trisomy 18
1,000
Not trisomy 18
16,000
screen positive
880:1,408
~1:2
Screen negative
120:14,592
~1:120
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Chapter 9  Diagnostic testing for trisomy 18 
9.1 Diagnostic procedures: amniocentesis 
Introduction: An amniocentesis procedure involves the use of a small gauge needle 
inserted through the woman’s abdomen to withdraw a small amount of amniotic fluid 
(about 10 mL) from the amniotic sac.  This fluid contains fetal cells that can be used to 
diagnose aneuploidy (e.g., trisomy 18), along with other chromosomal disorders.  The 
amniotic fluid contains additional analytes that can be used to diagnose other conditions.  
For example, measuring alpha-fetoprotein and acetylcholinesterase in the amniotic fluid 
is diagnostic for open neural tube and ventral wall defects (Brock and Sutcliffe, 1972).  
Historically, amniocentesis was occasionally performed in the 19th century in women with 
polyhydramnios, but it was not used for diagnostic purposes until the 1960s (Jacobson 
and Barter, 1967). 
 
Indications:  Because of the invasive nature, availability and cost of the procedure 
(currently several hundred dollars), amniocentesis is generally available only to women 
with pregnancies at risk of a diagnosable condition.  Beginning in the 1960s, when 
amniocentesis became available, the main indications for the procedure were a previous 
history of aneuploidy (or other inherited chromosomal disorder) and advanced maternal 
age.  As ultrasound improved and became widespread, abnormal anatomical findings 
were also considered an indication for diagnostic testing.  Beginning in the mid 1970s, 
women with elevated maternal serum AFP test results were offered amniocentesis for 
open neural tube defects (Wald et al., 1977; Haddow et al., 1983).  More recently, these 
women would not be offered invasive testing, as ultrasound visualization has improved 
and specific markers for open neural tube defects have been discovered.  These findings 
included the lemon and banana sign in the fetal brain (Nicolaides et al., 1986).   
 
Beginning in the mid 1980s, the association between serum AFP markers and Down 
syndrome was reported (Merkatz et al., 1984) and soon implemented (Palomaki and 
Haddow, 1987).  Women with Down syndrome risks above a certain threshold were 
offered amniocentesis and diagnostic testing.  As serum and ultrasound markers 
improved, it became clear that the rationale behind offering diagnostic testing to all 
women of advanced maternal age was not justified, and, in 2007, the American College 
of Obstetricians and Gynecologists recommended offering screening to women of all 
ages (ACOG, 2007a; ACOG, 2007b).  Currently, the indications for amniocentesis in 
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high risk centers around the world are, in rough order, women screen positive via serum 
screening (including ultrasound NT testing), advanced maternal age, abnormal 
ultrasound findings without serum test results, and a positive family history.  According to 
anecdotal data from prenatal diagnostic centers, the proportion of women receiving 
amniocentesis in the early second trimester has fallen precipitously over the last five 
years, from 10% or more ten years ago, to a current level of 5% or fewer.  This is most 
likely due to improvement in screening tests (higher detection rates with lower false 
positive rates), as well as the slow change away from routinely offering diagnostic testing 
women of advanced maternal age.   
 
The procedure:  Amniocentesis is generally performed for prenatal diagnosis between 15 
and 22 weeks’ gestation (Figure 9.1-1).  Amniocentesis is performed later in pregnancy 
for other indications, such as determining lung maturity, determining Rh compatibility and 
diagnosing infection.  Once the fluid is obtained, the cells are isolated for testing by one 
of several methods described in later sections of this chapter.  
 
 
Figure 9.1-1.  A diagram showing an ultrasound guided amniocentesis procedure.  
Ultrasound is initially used to identify the location of the fetus and placenta and then to 
guide the needle to obtain amniotic fluid containing fetal cells.  Figure courtesy of 
Genetics and IVF Institute, Fairfax, Virginia. 
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Reliability:  In experienced hands, the procedure will yield an acceptable sample more 
than 99% of the time.  If oligohydramnios is present, it may be difficult to obtain the 
required amount of amniotic fluid and, subsequently, sufficient fetal cells for diagnostic 
testing.  In a small percentage of procedures, the needle does not puncture the amniotic 
sac, but pushes the membrane aside (tenting).  The result is that no amniotic fluid is 
obtained (a dry tap).  Very occasionally the maternal bladder will be punctured and urine 
will be drawn instead of amniotic fluid.  No fetal cells will be present and the procedure 
considered a failure. 
 
Safety:  The complications associated with the procedure include bleeding, rupture of the 
membranes and infection.  In some instances, the fetus may be injured by the needle, 
but real time ultrasound guidance has reduced this risk considerably over the past two 
decades.  Other fetal complications such as prematurity are also a concern.  Higher 
rates of these complications are associated with multiple needle insertions, experience of 
the operator and position of the placenta.  Only one randomized trial of the procedure-
related loss associated with early second trimester amniocentesis has been performed 
(Tabor et al., 1986) and it documented about a 1% extra fetal loss rate attributable to the 
procedure.  The study has been criticized on several points (e.g., needle size, younger 
population), but it remains the definitive report (Tabor et al., 1988).  The Cochrane 
Collaboration (Alfirevic, 2008) bases its conclusion of about 1% additional risk of fetal 
loss on this study, as well. 
 
Early amniocentesis:  One drawback to amniocentesis at 15 weeks and later is that the 
diagnostic test result (e.g., karyotype) may not be available for at least a week, leaving 
less time for crucial decision-making by the couple.  Another important factor is that 
women prefer the methods used in first trimester termination to those utilized later in 
pregnancy and there is more of sense of privacy regarding their decision-making.  In 
response to the perceived need to move the procedure earlier in pregnancy, some 
groups began performing amniocenteses at between 11 and 14 weeks’ gestation.  A 
Canadian collaborative study (CEMAT, 1998) definitively showed the increased risk 
associated with the procedure being performed this early in pregnancy.  They not only 
found an increased rate of procedure-related loss (7.6% versus 5.9%, RR 1.29, 95% CI 
1.03 to 1.63) but also an increased risk of talipes compared to CVS (another first 
trimester procedure, chorionic villus sampling) (RR 4.6).  Based on these results, there 
are few, if any, amniocenteses being performed prior to 15 weeks, and virtually none 
prior to 14 weeks’ gestation.   
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9.2 Diagnostic procedures: chorionic villus sampling (CVS) 
Introduction:  Amniocentesis is a relatively safe and widely available procedure, and the 
fetal cells collected are reliable for diagnostic testing for fetal aneuploidy.  However, the 
procedure is relegated to 14 or 15 weeks’ gestation or later.  There is need for diagnostic 
procedures to collect appropriate samples earlier in pregnancy.  Chorionic villus 
sampling can be performed late in the first trimester.  One important difference between 
amniocentesis and CVS is that amniocentesis collects fetal cells from the amniotic fluid, 
while the CVS procedure aims at collecting placental tissue.  In 98% or more of 
pregnancies, the karyotype of the fetus and placenta are the same.  However, in 1 to 2% 
of pregnancies, they are different, and this can complicate the interpretation of the 
downstream diagnostic test. 
 
Indications:  The indications for CVS are similar to those for amniocentesis and include 
increased risk of Down syndrome or other aneuploidy and abnormal ultrasound findings.  
The costs for CVS are also similar to those for amniocentesis, but the procedure is 
considered to have a steeper learning curve than amniocentesis.  Since it is less 
commonly performed in the United States, finding sufficient numbers of experienced 
providers can be difficult, especially outside of metropolitan areas. 
 
The procedure:  There are two separate routes for the CVS procedure; transabdominal 
and transcervical (Figure 9.2-1).  In both, an ultrasound guided catheter is inserted and 
chorion villae are aspirated by an attached syringe.  The choice is often the one the 
operator is most experienced and comfortable performing.  Known venereal diseases or 
vaginal bleeding are contraindications for the transcervical route.  Transabdominal CVS 
can be performed later in pregnancy, even into the second trimester.  Transcervical CVS 
is generally considered more difficult to perform. 
 
Reliability:  Transcervical CVS is associated with more procedure failures than 
transabdominal CVS (Alfirevic, 2008).  It is unclear whether sampling failures are more 
or less common for CVS versus amniocentesis.  One study from Finland (Ammala et al., 
1993; Alfirevic, 2008) found transcervical CVS to have a somewhat lower procedure 
failure rate compared to amniocentesis (RR=0.55, p=0.1), but the overall rates for both 
procedures was quite high (2.5% for CVS and 4.5% for amniocentesis).  In a much larger 
study (MRC, 1991), the opposite effect was found (RR 3.09, p<0.001), with important 
differences in the absolute rates at 4.8% and 1.6%, respectively.  These differences may 
be due to operator skill and experience. 
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Figure 9.2-1  A diagram showing an ultrasound guided chorion villus sampling 
procedure.  Ultrasound is initially used to identify the location of the fetus and 
placenta and then to guide the catheter to obtain placenta tissue.  The procedure can 
be performed transabdominally (A) or transcervically (B).  Figure courtesy of 
Genetics and IVF Institute, Fairfax, Virginia.  
 
Safety:  It has been difficult to directly compare CVS in the late first trimester to 
amniocentesis in the early second trimester.  Two studies (Rhoads et al., 1989; CEMAT, 
1998) each found a slightly higher fetal loss rate for CVS than second trimester 
amniocentesis.  A third study (MRC, 1991) found a 4.4% higher loss rate for CVS.  There 
was some criticism of this latter study that the providers of CVS were not as well trained 
and experienced as those in the US and Canadian studies.  Overall, CVS does appear to 
have a slightly higher procedure-related loss rate than amniocentesis.  Several studies 
have compared the two approaches to CVS and tend to find little or no difference 
(Jackson et al., 1992; Brambati et al., 1990).  However, a Danish study (Smidt-Jensen et 
al., 1992) found a much higher loss rate for transcervical CVS.  This finding has been 
criticized because the experience of the providers was mainly with the transabdominal 
route.  The Cochrane Collaboration Review (Alfirevic, 2008) concludes that 
transabdominal is safer than transcervical, but that experience is an important factor in 
overall safety. 
 
A second important issue with early CVS (prior to 10 weeks’ gestation) was first reported 
in 1991 (Firth et al., 1991) and involves severe limb reduction abnormalities.  These CVS 
procedures were performed between 8 and 9 weeks’ gestation and 5 of 289 fetuses 
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were associated with this relatively rare abnormality.  Another large study in the US of 
394 infants found another four instances of limb abnormalities (Burton et al., 1992).  
Larger studies showed clear associations between the gestational age at the time of the 
procedure and the risk and severity of limb abnormalities (Mastroiacovo et al., 1992).  
Large collections of CVS procedures did not necessarily confirm these findings made by 
single groups.  For example, the WHO review of 216,381 CVS cases concluded that 
“CVS carries no increased risk for fetal loss or congenital malformation, including limb 
reduction defects” (WHO/PAHO, 1999).  This issue of limb reductions associated with 
early CVS procedures has, in effect, set a lower limit of 10 completed weeks’ gestation. 
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9.3 Other invasive procedures 
Introduction:  Amniocentesis and chorionic villous sampling are, by far, the most 
common methods of obtaining fetal material for diagnostic testing.  Occasionally, special 
circumstances would permit use of other invasive procedures (Shulman, 2008).  These 
include:  
percutaneous umbilical blood sampling (PUBS) involves the collection of fetal blood 
by ultrasound guided needle aspiration.  This is a relatively specialized procedure 
that may be associated with higher fetal loss but is useful in at least two, and 
potentially, a third setting.  As one example, if a late unscreened pregnancy (e.g., 20 
weeks or later) is found to have specific ultrasound anomalies associated with 
chromosome abnormalities (e.g., heart defect and clenched hands/feet).  In many 
centers, this is too late for CVS, and an amniocentesis/karyotype would take too 
long.  Since there is a high chance of an affected pregnancy, the risk of procedure-
related loss might be considered acceptable.  The fetal blood can be directly 
observed for chromosome abnormalities.  Another instance when PUBS might be 
considered would be an equivocal mosaic karyotype.  A direct observation of the fetal 
blood might shed light on the expected fetal phenotype.  A few trials have 
administered treatments directly into the fetus using the PUBS technique.   
 
Fetal tissue biopsy involves ultrasound guided collection of tissues via forceps.   In 
the past, skin biopsies were a common requirement for diagnosing certain severe 
skin disorders in the fetus.  More recently, DNA analysis has replaced the need for 
biopsies.  In certain circumstances, DNA testing for Duchene’s muscular dystrophy 
would not be informative and a muscle biopsy required for definitive diagnosis.  
These procedures would generally not be used in diagnosing autosomal aneuploidy 
(the exception being exploring fetal mosaicism). 
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9.4 Diagnostic testing: karyotype 
Introduction:  In order for a karyotype to be produced, the cells must be in mitosis.  This 
is accomplished by placing the cells collected from amniocentesis or CVS in a culture 
medium and growing them in specific conditions over one to two weeks.  The cells are 
then stained (or banded), with darker staining indicating that the DNA has a higher 
concentration of adenine-thymine bonding.  The most common G-banding (Giemsa) 
produces several hundred bands.  The chromosomes are then identified based on size 
(e.g., chromosome 1 is the largest), the centromere position (e.g., chromosome 1 is 
metacentric with the centromere near the center of the chromosome) and the banding 
pattern.  Prior to the mid 1990s, photomicrographs were cut by hand and arranged into a 
karyotype.  Now this is done by computer recognition and visual verification.  Both 
methods allow for counting of the number of chromosomes and identifying Down 
syndrome, trisomy 18 and trisomy 13.   
 
Figure 9.4-1.  A karyotype of a fetus with trisomy 18.  Note the three chromosome 
18s at the end of the third row. 
Other features such as large deletions, translocations or duplications can also be 
identified via karyotyping.  Clinically, several colonies of cells are grown, and multiple 
cells from each colony are karyotyped.  In some instances, there are discrepancies such 
as one or two cells from one colony being abnormal.  This mosaicism may represent the 
true karyotype or be an artifact of the cell growth in culture.  It can also be due to the 
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growth of maternal rather than fetal cells.  This is most commonly seen in the karyotype 
of a male fetus that has a low level of female mosaicism considered to be maternal cell 
contamination.  Specific technical/laboratory practice guidelines help define when the 
mosaicism is likely to be clinically relevant. 
 
Reliability:  When performed by experienced laboratories, karyotyping for aneuploidy is 
considered to be the gold standard of diagnostic tests.  Except for sample mix-up, the 
detection rate approaches 100% with very few false positives.  In the 1990s, the reported 
error rates were 0.01 to 0.02%, with the majority of errors being incorrect sex assignment 
due to maternal cell contamination (Benn, 2010).  The few false negative cases of Down 
syndrome were karyotyped as 46, XX, again indicating maternal cell contamination.  
These could be considered errors of collection, rather than errors of karyotyping.  
Failures are infrequent.  Using modern techniques with robotic harvesting of cells, 
failures could be as low as 1 in 500 samples (van Dyke, 2010). 
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9.5 Diagnostic testing: FISH 
Introduction:  The main limitation to karyotyping is the delay of 10 days to two weeks or 
more between sample collection and the availability of the diagnostic test result.  This 
complicates decision-making and may cause problems with access to terminations, 
should an abnormal karyotype be identified.  Fluorescent in situ hybridization (FISH) 
testing can be performed on uncultured whole cells in interphase, and results can be 
available in one or two days.  In the 1990s, researchers investigate the use of DNA-
based probes directed at unique sequences on specific chromosomes (Klinger et al., 
1992).  These probes usually target only specific chromosomes responsible for the 
majority of major aneuploidies, namely chromosomes 21, 18, 13, X and Y.  Each probe 
is attached to a specific phosphor that will emit a unique color when excited by a laser.  
Using this technique, each cell should have two ‘dots’ of light representing the normal 
two 21 chromosomes (perhaps red), while the two probes for 18 might fluoresce green.  
Not all probes need be used on each cell.  Figure 9.5-1 shows two cells, one normal, and 
one trisomy 21 (Down syndrome).   
 
 
 
 
 
 
 
 
 
 
 
Figure 9.5-1.  Two pictures of interphase cells tested with FISH probes.  On the 
left is a normal cell with two 21 (green, with arrows), two 18 (blue), two 13 (red) and 
two 22 (gold) chromosomes.  On the right is an abnormal cell with three 21 
chromosomes, but a normal complement of 18, 13 and 22.  Pictures courtesy of the 
University of Rochester Medical School (www.urmc.rochester.edu) 
  Chromosome 21
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Reliability:  By the late 1990s, commercial reagents were available allowing for wide-
spread testing in diagnostic laboratories.  In a 2007 summary paper (Shaffer and Bui, 
2007), 19 publications of FISH testing for major aneuploidies in high risk cohorts had 
been published.  Overall, over 26,000 FISH tests had been performed and validated 
against karyotyping.  There was a 3.3% failure rate for the test, varying from 0% (even in 
some large studies) to up to 16%.  Among the 1,640 detectable aneuploidies having 
successful FISH testing, 1,619 (98.7%) had positive test results.  The 21 false negatives 
occurred in 9 of the 19 studies.  Among the approximately 23,600 pregnancies without a 
detectable aneuploidy, four had false positive results (0.02%).  These occurred in four 
different studies.  The prior risk in these high risk cohorts was about 1:14.  The odds 
among those with a positive test result were over 400:1 (1619:4), while the odds among 
those with a negative test result were about 1:1100 (23,600:21).  While being close to 
diagnostic, many clinical FISH reports today suggest clinicians not take “irreversible 
clinical actions” until the results of the karyotype are available.  FISH testing is not 
generally considered a replacement for karyotyping, but may be considered diagnostic in 
the presence of other indications of abnormalities (e.g., heart defect, clenched hands). 
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9.6 Diagnostic testing: qfPCR 
Quantitative florescence polymerase chain reaction (qfPCR) measures the florescence 
intensity of highly polymorphic short tandem repeats (STRs) located on the 
chromosome(s) of interest.  The first report of qfPCR for detecting aneuploidy during 
pregnancies was in the early 1990s (Mansfield, 1993).  Figure 9.6-1 is a sample result 
from one STR (D13S252) that is located on chromosome 13.  There are two clear peaks 
with equal height.  One is 279 base pairs long, while the other (located on the second 
chromosome 13) is 303 bp.  In this instance, the STR is heterozygous (2 different sizes) 
and the marker is said to be informative.  If, for example, an STR is homozygous, only 
one peak would appear and that STR would be considered uninformative.  Generally, 2 
to 5 STRs will be targeted for each chromosome of interest, so that at least one would be 
informative. 
 
Figure 9.6-1.  The result of a normal STR measurement on chromosome 13.  In 
this electrophoretogram, the STR D13S252 is heterozygous.  Since the two heights 
(florescence) are equal, there are two copies of chromosome 13 in the sample.  
Figure courtesy of the University of Leeds (www.leedsteachinghospitals.com). 
 
 
When there are three chromosomes, the STR measurements may be 
homozygous/uninformative, may have three peaks (indicating varying STR lengths on all 
three chromosomes), or may have two peaks, but one is twice the height of the other.  
This later occurs when the STR on one pair of chromosomes is of equal length, but 
these are both different from the length on the third chromosome.  Figure 9.6-2, shows 
examples of these abnormal qfPCR results.  
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Figure 9.6-2.  Abnormal qfPCR results.  On the left are results from STR 
D21S1409 on chromosome 21.  That STR is heterozygous over the three copies of 
the chromosome, indicated by relatively equal heights of the peaks.  On the right are 
results from D21S1411 where one of the peaks (316 bps) is twice the height of the 
allele with 307 bps.  Both results indicate the sample was from a Down syndrome 
fetus.  Figure courtesy of the University of Leeds (www.leedsteachinghospitals.com). 
 
 
Reliability  The advantage of qfPCR is that testing is able to be done at much higher 
throughput levels, resulting in its being less expensive.  It can also be performed on 
many sample types collected via amniocentesis, CVS, and fetal tissue.  In a summary of 
16 studies published between 1999 and 2006 (Shaffer and Bui, 2007), a total of nearly 
42,000 samples have been tested via qfPCR and confirmed via karyotype.  Among the 
1,936 detectable abnormal karyotypes, 1,922 were found by qfPCR (99.3%).  Among the 
14 false negative results, more than half (8) occurred among the 310 fetuses with sex 
aneuploidies.  Given the high performance, cost and throughput, qfPCR is often used in 
parallel with karyotyping, especially in Europe, to provide early indication of fetal 
abnormalities.  In some countries, qfPCR alone is used for diagnostic testing after a 
screen positive test for Down syndrome. 
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9.7 Diagnostic testing: Other methods 
Several other diagnostic testing methods exist, but are not generally targeted at 
identifying aneuploidy.  All of these methods currently require the collection of fetal tissue 
via invasive procedures.   
 
MLPA 
Multiplex ligation–dependent probe amplification (MLPA) is a method used to identify 
gene dosage differences for multiple targeted segments of a patient’s genome.  In 
MLPA, the probes are amplified via PCR rather than the patient DNA.  Each probe can 
be targeted for a specific region in the genome, and up to 45 probes can be combined 
in a single multiplex test.  The probes hybridize to the target sequence and then 
amplified.  The relative amount of the product is an indication of the number of copies 
of that target region.  If probes were designed for chromosome 18, then the triple dose 
of targets on that chromosome would identify trisomy 18.  Such probes are 
commercially available for the common aneuploidies (MLPA kit P095, MRC-Holland, 
Amsterdam, Holland). 
 
Array CGH 
Array-based comparative genomic hybridization (array CGH), or microarray analysis, is 
a method used to compare a patient’s whole genome to a standard normal genome to 
identify chromosome imbalances.  Findings include deletions, duplications, copy 
number variants and aneuploidy.  These findings are the same as that of a karyotype, 
except the resolution of an array CGH is far higher.  A karyotype can identify deletions 
that are 5 megabases or larger, while array CGH can find deletions that are under 100 
kilobases (more than 50 times smaller).  A simplest interpretation is that the array CGH 
is a ‘super’ karyotype.  However, this high resolution also has disadvantages.  
However, an array CGH test cannot identify balanced translocations, but a karyotype 
can because each chromosome is visualized   Neither array CGH nor karyotyping can 
identify point mutation.  Applying array CGH testing to apparently normal individuals 
finds that most carry 30 or more small copy number variants (CNVs), most of which do 
not result in any phenotypic changes.   
 
At this time, insufficient data are available to clarify which of the CNVs might be 
associated with mild or even serious problems.  This is an especially important issue 
when performing prenatal testing, when identifying these CNVs would result in difficult 
decision-making for virtually every patient.  For this reason, targeted arrays have been 
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developed that can either focus on regions known to have clinical implications, or be 
designed in such a way that the small CNVs are not identified.  Many commercial and 
academic laboratories are now offering prenatal array CGH testing.  An expert in the 
field believes that targeted prenatal array CGH testing will replace karyotyping within 
the next few years because it is easier to perform, quicker and more informative than a 
karyotype (Petrone, 2010). 
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9.8 Fetal cells and free nucleic acids in maternal circulation 
 
Introduction.  Although karyotyping remains the gold standard, both FISH and qfPCR 
testing still require invasive procedures for sample collection.  A test that can provide 
diagnostic, or near diagnostic, results early in pregnancy, without the need for invasive 
testing, has been sought for decades.  By the late 1960s, fetal cells were known to be 
present in the maternal circulation (Walknowska et al., 1969).  However, successful 
isolation of these cells was not accomplished until the early 1990s (Simpson and Elias, 
1993).  These cells are rare, and difficult to find and test.  In 1997, cell free fetal DNA 
and RNA was identified in the maternal circulation (Lo et al., 1997).  The advantage of 
cell free fetal nucleic acids over fetal cells is that the concentration relative to maternal 
free nucleic acis is much higher than for fetal cells.  The disadvantage is that without the 
cells, it can be difficult to determine numerical chromosome abnormalities.  The next two 
sections provide an overview of fetal cells in maternal circulation (9.8.1) and fetal nucleic 
acids in maternal circulation (9.8.1). 
 
9.8.1  Fetal cells in maternal circulation    
Several fetal cell types are present, but the one of most interest is nucleated 
erythrocytes, because they are present early in gestation, cross the placenta, and 
have characteristics that help make them distinguishable from maternal cells.  There 
are several methods that can be used to identify fetal cells.  After the blood is 
processed, the first step is to use a density gradient to concentrate the cell type of 
interest.  Then, using fetal-specific antigens (e.g., CD71, HbF) as markers, magnetic-
activated cell sorting (MACS) or fluorescence-activated cell sorting (FACS) techniques 
are used to identify potential candidate cells.  It is now estimated that fetal cells occur 
in less than one per million maternal cells (Simpson and Elias, 1993), so any 
successful methodology must be extremely accurate to both not miss the few fetal 
cells, and remove from consideration the vast number of maternal cells. 
 
Rather than review the entire literature, a single larger experience from a national trial 
will be reviewed.  The NIH-sponsored NIFTY trial (Bianchi et al., 2002) began in 1995 
and recruited patients for five years.  Various changes in blood collection, processing 
and testing methodologies occurred over time, complicating the analysis.  The two 
main outcomes of interest were the identification of male cells in the maternal 
circulation, and the identification of common aneuploidies (21, 18 and 13).  
Confounding variables included the method of separation (MACS versus FACS), the 
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gestational age (<14 weeks versus > 14 weeks).  Among the samples from women 
with singleton male fetuses, at least one male cell was detected 42% of the time.  
Among the women with singleton female fetuses, a male cell was identified 11% of the 
time (false positive rate).  Testing for aneuploidy was performed prospectively in only 
11 cases, and four (36%) were correctly identified.  The associated false positive rate 
was 0.6%.  When known cases were blindly submitted with a limited number of 
controls, the detection rate improved to 87.5%, but the false positive rate also 
increased to 4.1%.   
 
Given the poor results and unresolved problems with the limited number of target cells 
and the difficulty and costs associated with testing, there has been a marked reduction 
in research in the area of fetal cells in maternal circulation. 
 
9.8.2  Free fetal DNA/RNA in maternal circulation   
Beginning in the late 1990s, several reports showed the presence of tumor-derived 
DNA in the circulation of patients with cancer (Chen et al., 1996; Nawroz et al., 1996; 
Gonzalez et al., 2000).  This line of research led to the finding that cell-free fetal DNA 
and RNA was found in the maternal circulation (Lo et al., 1997).  It was previously 
thought that these nucleic acids would have a short half-life in circulation, but they 
apparently can survive for appreciable periods of time due to protection by particulate 
matter (Ng et al., 2002).  This allows for the collection of nucleic acids from maternal 
circulation using existing plasma sampling methodologies.  The fragments are 
relatively short, on average measuring 180 base pairs.  These nucleic acids do not 
survive in the maternal circulation for more than one day after delivery.  On average, 
about 5% to 10% of the free circulating nucleic acids are derived from the fetus.  Most 
of the ‘fetal’ content is actually derived from the placenta.  Maternal and fetal DNA are, 
in general, not distinguishable by their DNA or RNA sequence.  Instead, epigenetic 
changes or differences can be utilized to determine aneuploidy status of the fetus.  
Lastly, the whole genome is represented by these fragments, in rough proportion to the 
size of each chromosome (i.e., more fragments are expected for chromosome 1 than 
for chromosome 22).  These circulating cell free fetal nucleic acids are already being 
used to determine fetal sex (Costa et al., 2001; Mazza et al., 2002) and to diagnose 
fetal Rh incompatibility (Lo, 2001; Legler et al., 2002).  However, detecting aneuploidy 
is more difficult, and more creative methods must be employed.  Three of these are 
reviewed below.  The last one discussed, massively parallel sequencing, is currently 
closest to becoming available as a clinical test. 
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RNA based SNP allelic ratios 
The methodology relies on the premise that there are genes that are activated in the 
fetal/placental unit, but not in the mother (Lo et al., 2007).  Thus, circulating mRNA 
must be derived from the placenta and not the mother.  If a highly polymorphic SNP 
(single nucleotide polymorphism) can be identified on a gene located on 
chromosome 21, then an information test for Down syndrome could be created for 
pregnancies in which the fetus is heterozygous for that SNP.  Figure 9.8.2-1 shows 
how this might work. 
 
Figure 9.8.2-1.  Schematic showing how the RNA SNP allelic ratio method of 
aneuploidy detection.  In step 1, the DNA from a Down syndrome fetus (top 
gray rectangle) and from a normal fetus (bottom gray rectangle) are both 
heterozygous.  This is indicated by the G and A single base pair difference.  The 
Down syndrome fetus carries 3 copies of chromosome 21, while the normal 
carries only 2 copies.  The RNA is transcribed (step 2) and enters the maternal 
circulation (step 3).  At that point, a detection method would find equal numbers 
of each SNP allele (G/A ratio of 1.0) while the ratio in the Down syndrome sample 
would be 1:2.  Alternatively, the Down syndrome sample could be 2:1, if the G 
allele were duplicated rather than the A allele.  
 
 
In 2007, a proof-of-concept paper was published demonstrating the potential for this 
method to identify Down syndrome using free circulating RNA in maternal plasma 
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collected in the first and second trimester (Lo et al., 2007).  Using a single SNP 
(rs8130833) on the PLAC4 gene (placental-specific protein 4), 10 of 21 cases and 57 
of 98 control samples were found to be heterozygous (informative).  Of these 57 
informative control samples, two were outside of the 95% prediction limits (Figure 
9.8.2-2) indicating a false positive rate of about 4%.  Among the 10 informative 
cases, nine had ratios significantly higher, or lower, than that found in euploid 
pregnancies, give a detection rate of 90%.  This figure is misleading, as only 9 of the 
21 original cases were actually detected; 11 received no result as they were 
homozygous for the PLAC4 SNP.  
 
 
Figure 9.8.2-2.  Scatterplot showing the results of an RNA-based SNP allelic 
ratio test for Down syndrome.  A single SNP on the PLAC4 gene was tested for 
the G to A allelic ratio.  If the pregnancy was Down syndrome, the G/A ratio 
should be higher, or lower, than that found in euploid pregnancies. 
 
 
For this test to be clinically useful, several important advances need to occur.  There 
need to be more genes identified that are differentially active in the placenta.  
Alternatively, more SNPs might be identified on such genes.  This would allow for an 
interpretation for all pregnancies tested.  It was also found that the SNP allele 
frequencies differed dramatically by race/ethnicity.  Thus, a set of SNPs that might 
provide coverage for 98% for Caucasian pregnancies might only provide informative 
results for 50% of Asian pregnancies.  So far, it has not been possible to identify 
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multiple genes/SNPs that provide wide coverage for a diverse population while 
retaining high performance. 
 
In addition, the processing required to retain the RNA for testing must be done in a 
short time frame (< 6 hours) and the samples must be frozen at -20°C or colder 
immediately after processing.  That means that the samples would need to be 
shipped on dry ice.  Such requirements could limit availability and adversely affect 
the cost of testing. 
 
The platform used in the proof-of-concept report (Lo et al., 2007) was the MassArray 
(Sequenom, Inc., San Diego, CA).  Costs and turn-around time could, with sufficient 
numbers, make a methylation-based test competitive with current screening tests.  
The available data allow this test to be classified as being in the research and 
development phase. 
 
 
DNA methylation-based differences 
The RNA method described above relies on differences in the production of a gene-
specific RNA between the feto-placental unit and the mother.  This methods relies on 
identifying differences in DNA methylation between the feto-placental unit and the 
mother.  Again, a gene must be found that is highly methylated in the mother and 
unmethylated in the fetus, or vice versa.  In a proof of concept publication (Tong et 
al., 2006), the SERPINB5 gene promoter (maspin) was unmethylated in the placenta 
(turned on), but methylated (turned off) in the mother.  SERPINB5 is located on 
chromosome 18, so this testing would be directed at identifying trisomy 18.  Using a 
methylation-specific PCR methodology, it is possible to measure a SNP allelic ratio, 
similar to the approach described in Figure 9.8.2-1.  Figure 9.8.3-1 shows the results 
of such testing of maternal plasma from two second trimester trisomy 18 
pregnancies.  Controls consisted of one second trimester pool and eight near term 
euploid pregnancies. 
 
Although the data are sparse, the methylation methodology has an advantage in a 
more stable sample type (DNA versus RNA).  However, it still requires that 
heterozygous SNPs be present in the selected differentially methylated genes, so 
race/ethnic coverage remains an issue.  It should be possible to identify differentially 
methylated genes on other chromosomes (e.g, 21 and 13) in order that other 
common autosomal aneuploidies could also be identified.  The platform used in the 
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proof-of-concept report (Tong et al., 2006) was the MassArray (Sequenom, Inc., San 
Diego, CA).  Costs and turn-around time could, with sufficient numbers, make a 
methylation-based test competitive with current screening tests.  The available data 
allow this test to be classified as being in the research and development phase. 
 
Figure 9.8.2-3.  Scatterplot showing the results of a DNA-based methylation-
specific SNP allelic ratio test for trisomy 18.  A single SNP in the unmethylated 
maspin region of the SERPINB5 gene was tested for the G to A allelic ratio.  The 
unmethylated maspin will be feto-placental.  The maternal DNA would be methylated 
and not included in the SNP ratio.  If the pregnancy was trisomy 18, the A/C ratio 
should be higher, or lower, than that found in euploid pregnancies. 
 
 
Massively parallel sequencing (MPS) 
The third methodology takes on a more brute force approach to using circulating fetal 
DNA to identify Down syndrome.  Two groups, almost simultaneously, published 
proof-of-concept papers demonstrating the use of third-generation sequencing as a 
viable methodology (Chiu et al., 2008; Fan et al., 2008).  The underlying concepts to 
this test can be described in the following way.  Consider a euploid pregnancy with a 
fixed proportion of fetal to maternal DNA in the mother’s circulation.  The number of 
DNA fragments originating from both the mother and the fetus are known.  Now if this 
same pregnancy were to be affected with Down syndrome, there would be slightly 
more DNA contributed to the fetal DNA in circulation due to the extra 21 
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chromosome.  The problem would then be to find a methodology to quantify this 
increase.  Of course, this scenario can’t exist, but it would still be possible if two 
further conditions were met.  First, although the amount and proportion of circulating 
maternal and fetal DNA differs from woman to woman, the proportion of the DNA that 
derives from each chromosome (or at least chromosome 21) must be quantifiable 
and very constant.  The increase in the proportion of trisomy 21 DNA must be 
different enough that it can be distinguished from that constant proportion seen in 
euploid pregnancies. 
  
The following more detailed description of the theoretical basis behind MPS test 
relies on figures originally presented by the group from the Chinese University of 
Hong Kong (Chiu et al., 2008).  The bullets are linked to the highlighted text in 
Figures 9.8.2-4 through 9.8.2-6. 
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In Figure 9.8.2-4: 
 DNA fragments in maternal plasma -  the large rectangle represents the maternal 
circulation, with both maternal (thin) and fetal (thick) DNA fragments.  The dashed 
box indicates the sample of plasma collected for testing.  It is important to 
remember that there is no way (and no need) to distinguish fetal from maternal 
DNA. 
 Sequence and align – for each of these fragments, 36 base pairs (bp) are 
sequenced, and that sequence is then is aligned with the human genome to 
determine which chromosome was the source for the fragment.  In some 
instances the fragment won’t match anywhere in the genome, and if so, it is not 
considered further.  In others, the fragment might match locations in two separate 
chromosomes and, if so, it would also not be considered further.  Perfect and 
unique matches are sought.  However, due to the presence of SNPs throughout 
the genome, a 36 bp sequence would only need to match on 35 of the bps to be 
considered a true match. 
 
 
Figure 9.8.2-4.  A cartoon showing the first two steps in massively 
parallel sequencing of free DNA in the maternal circulation.  The content 
is described in the text. 
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In Figure 9.8.2-5: 
 Sequence counting -  for each matched sequence, the corresponding 
chromosome count is increased by one.  For example, among all 24 
chromosomes shown, there have been a total of 51 fragments already counted 
(each fragment indicated by a small circle.  For chromosome 21, only 1 fragment 
has been found so far. 
 % representation of unique sequences mapped to a chromosome – rather than 
representing the result as absolute counts of matches, the count for any given 
chromosome will be represented as a percentage.  In this example, the 
proportion associated with chromosome 21 is 1/51 or about 1.96%.  In practice, 
the X and Y chromosome counts are not included in the denominator, so the 
percentage could also be represented as 1/49 or 2.04. 
 
  
 
Figure 9.8.2-5.  A cartoon showing the next two steps in massively 
parallel sequencing of free DNA in the maternal circulation.  The content 
is described in the text. 
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In Figure 9.8.2-5: 
 Disease status determination - once a large number of euploid pregnancies have 
been tested, it would be possible to compute the mean and standard deviation for 
the percentage of counts for any chromosome of interest, like chromosome 21.  
Assume, for example that the mean value for the percentage of chromosome 21 
is, in fact 2.01%, and that this value is highly repeatable, with a standard 
deviation of 0.02%.  If the next, unknown sample were to have a chromosome 21 
percentage of 2.11%, this could be represented as a z-score of 5.0 (calculation 
shown in the figure). 
 Bar chart graphic – given all of the earlier assumption, one would expect a series 
of test results to look something like the small bar in the figure.  The small bars (A 
through D) that fall slightly above, or below, a z-score of 0 indicate results 
expected for euploid pregnancies.  The larger positive bars (E through H) indicate 
results expected in Down syndrome pregnancies. 
 
 
Figure 9.8.2-6.  A cartoon showing the last step in massively parallel 
sequencing of free DNA in the maternal circulation.  The content is 
described in the text. 
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Figure 9.8.2-7 shows the data collected as part of one of the proof-of-concept publication 
(Lo et al., 2007).  The MPS was performed on the Illumina platform (Illumina Inc, San 
Diego, CA).  The observed detection rate was 100% (14/14) and the false positive rate 
was 0 (0/14).  In this small, select dataset, MPS was able to correctly distinguish 
between Down syndrome and unaffected pregnancies.  
 
 
Figure 9.8.2-7.  Chromosome 21 z-scores for 28 maternal plasma 
samples undergoing massively parallel sequencing.  The horizontal lines 
indicate the normal range (+/- 3 standard deviations).  Of the 28 samples, 14 
were from Down syndrome pregnancies, and all had chromosome 21 z-
scores above 3.  Of the 14 samples from euploid pregnancies, none were 
outside the normal range. 
 
Massively parallel sequencing has several advantages.  It is based on the more 
stable DNA fragments and, unlike the previous methods, does not require 
heterozygous SNPs be identified for appropriate coverage.  Essentially, all samples 
tested will get a result.  It is also not limited to Down syndrome, as the collected 
could, in theory also identify trisomy 18 and trisomy 13 simply by performing another 
series of computations.  However, no paper yet has shown it feasible to identify 
trisomy 18 or 13 using MPS. 
 
On the other hand, massively parallel sequencing is extremely complex, requiring 
highly trained molecular technologists working on expensive equipment in tightly 
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controlled environments.  This, along with reagent costs result in test that would be 
expected to cost $1,000 or more per woman tested and take up to a week to 
complete.  Other limitations exist.  The amount of data to be collected and interpreted 
is staggering.  Over 1 terabyte of data are collected for each flow cell.  High 
performance computer clusters can take several days to complete the processing.  
Lastly, if the fetal fraction of the DNA were to become to low (e.g., <5%), it would 
become difficult to resolve the small differences between a mother with a normal 
pregnancy with one having a Down syndrome pregnancy.  Whether this limit can be 
lowered remains to be seen.  Other improvements that could be anticipated to 
improve the potential for MSP would be multiplexed samples.  Rather than running 
only one patient per lane, multiplexing allows running 2, 4 or even 8 or more patients 
mixed together in that same single lane.  This improved throughput and reduces 
costs.  Spin-offs from the $1,000 genome initiative would likely reduce the resources 
required to run MPS and fourth generation sequencing platforms are beginning to 
emerge. 
 
Several groups around the world are actively pursuing the development of MPS tests 
suitable for introduction into clinical practice.  Whether or not this test can be 
translated from the bench to the clinical laboratory is not yet known.  Even if it can be 
implemented clinically, it is not yet clear how MPS testing (or another free DNA/RNA 
test) might fit into the complex world of prenatal testing and diagnosis. 
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Chapter 10.  Summary 
As with Down syndrome, there is a strong positive association between maternal age 
and increasing birth prevalence of trisomy 18, with rates of 1:8,350 and 1:994 at 25 and 
40 years of age, respectively.  There is also an important increase in the spontaneous 
rate of fetal loss, with an estimated 72%, 65% and 52% of trisomy 18 fetuses lost from 
about 12, 17 and 28 weeks’ of gestation to term, respectively.  Table 10-1 and Figure 10-
1 provide these maternal age and gestational age specific results, along with the 
equations and values needed for computation. 
 
 
 
Figure 10-1.  Prevalence of trisomy 18 by maternal age, at three selected times in 
gestation.  The solid line provides the prevalence at term.  The dashed and dotted lines 
provide estimates at 18 and 12 weeks’ gestation, respectively.  Fetal loss rates of 65% 
and 72% were used (Morris and Savva, 2008).  The prevalence (as a probability) is 
computed using the following equation   p = 1/(1+exp(a-(b/(1+exp(c*(age-38.9)))))), 
where a, b and c are 9.11, 4.27 and -0.324, respectively (Savva et al., 2010).
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Table 10-1.  Prevalence of trisomy 18 by maternal age, at three selected times in 
gestation. 
 
Decimal maternal Prevalence of trisomy 18, expressed as an odds (1:n) 
age at delivery At Delivery At 18 weeks At 12 weeks 
    
20.5 8,947 3,131 2,505 
21.5 8,909 3,118 2,495 
22.5 8,858 3,100 2,480 
23.5 8,788 3,076 2,461 
24.5 8,692 3,042 2,434 
25.5 8,562 2,997 2,397 
26.5 8,388 2,936 2,349 
27.5 8,155 2,854 2,283 
28.5 7,848 2,747 2,197 
29.5 7,451 2,608 2,086 
30.5 6,950 2,432 1,946 
31.5 6,336 2,218 1,774 
32.5 5,614 1,965 1,572 
33.5 4,806 1,682 1,346 
34.5 3,954 1,384 1,107 
35.5 3,118 1,091    873 
36.5 2,358    825    660 
37.5 1,722    603    482 
38.5 1,228    430    344 
39.5    870    304    244 
40.5    622    218    174 
41.5    457    160    128 
42.5    349    122      98 
43.5    277        97      78 
44.5    230      81      64 
45.5    198      69      56 
46.5    177      62      50 
47.5    162      57      45 
48.5    152      53      42 
49.5    145      51      40 
50.5    139      49      39 
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The most common clinical abnormalities apparent in the fetus are heart defects (e.g., 
ventricular septal defects) and abnormalities of the hands and feet.  Among live born 
trisomy 18, half die within one week of delivery and only 1 in 20 (mostly females) survive 
the first year.  All fail to thrive and all survivors will have moderate to serious mental 
retardation.  Low birthweight is common, and fetal distress at delivery may result in 
unnecessary cesarean sections.  It is this latter problem that makes the identification of 
trisomy 18 of potential benefit to the mother.  Additional information can be found in 
Chapter 2. 
 
Low levels of early second trimester ‘triple test’ markers (AFP, uE3, and hCG / free β 
subunit of hCG) have been used to assign risk for trisomy 18 for over 25 years, with 
detection and false positive rates of 81% and 0.4%, respectively.  The algorithms have 
been validated by demonstration studies, and new data show the existing parameters 
need only minor, if any, revisions.  Of interest is the finding that second trimester PAPP-
A measurements are extremely low in trisomy 18 pregnancies (median MoM 0.10).  
These measurements are not, however, used in everyday practice, as they are not 
different in Down syndrome pregnancies.  If they were used, a second trimester 
quadruple marker algorithm (triple test + PAPP-A) would improve trisomy 18 detection to 
an estimated 88%, while simultaneously reducing the false positive rate to about 0.1%.  
Table 10-2 provides expected detection and false positive rates for three combinations of 
tests at selected term risk cut-off levels (more complete modeling results are in Tables 
3.9-2 and 3.9-3). 
 
 
Table 10-2.  Modeled trisomy 18 detection rates (DR) and false positive rates (FPR) 
using second trimester maternal serum markers at four risk cut-off levels 
 
 Maternal age in combination with screening markers 
 Double Test  Triple test  Quadruple test 
Risk  AFP & hCG  Double test + uE3  Triple test + PAPP-A 
 at term (2nd) DR (%) FPR (%)  DR (%) FPR (%)  DR (%) FPR (%) 
         
1:100 (1:  35) 38 0.27  73 0.12  81 <0.10 
1:200 (1:  70) 48 0.63  78   0.26  85 <0.10 
1:300 (1:105) 54 1.0  81  0.39  88 0.11 
1:400 (1:140) 59 1.5  82  0.51  89 0.13 
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Table 10-3 provides the population parameters and truncation limits used in this 
modeling.  These can also be recommended for assigning patient-specific risks for the 
second trimester serum markers.  Age-related trisomy 18 risks were computed as 
described in Figure 10-1.  The maternal age distribution used was for England and 
Wales in 2006 through 2008 (Figure 3.9-1).  A more complete discussion of the 
modeling, sources of data and other markers that could be used (e.g., free β 
measurements) are found in Tables 3.8-1 and 3.8-2 and the associated text. 
 
Table 10-3.  Modeling parameters for four second trimester maternal serum 
analytes in trisomy 18 and unaffected pregnancies 
 
 Trisomy 18 pregnancies  Unaffected pregnancies 
Analyte Median Log mean Log SD  Log SD 
      
AFP 0.66 -0.1830      0.1817   0.1399 
uE3 0.36 -0.4448      0.2817   0.1142 
hCG 0.39 -0.4123      0.3561   0.2276 
PAPP-A 0.10 -0.9871  0.3894   0.2549 
      
  Pair-wise correlations 
AFP uE3   0.2501   0.1981 
AFP hCG   0.0314   0.1981 
AFP PAPP-A   0.2300   0.1536 
uE3 hCG   0.0944  -0.0416 
uE3 PAPP-A  -0.0413   0.0983 
hCG PAPP-A   0.1824   0.2838 
    
   Truncation limits 
AFP   0.33 – 2.00 
uE3   0.40 – 1.50 
hCG   0.20 – 2.50 
PAPP-A   0.20 – 1.00 
 
AFP = alpha-fetoprotein, uE3 = unconjugated estriol, hCG = human chorionic 
gonadotropin, PAPP-A = pregnancy associated plasma protein-A, SD = standard 
deviation 
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Late first trimester serum markers for trisomy 18 are also well described, but care must 
be taken to avoid study bias.  This occurs when abnormal levels of a marker, (e.g., low 
PAPP-A) are used to identify high risk pregnancies that are then offered early diagnostic 
testing and subsequent early identification.  Affected pregnancies associated with more 
normal marker levels would continue, but they are subject to high rates of spontaneous 
loss during the remaining weeks of pregnancy.  The resulting over-selection of 
pregnancies with low PAPP-A compared to the under-selection of pregnancies with 
normal measures results in a bias that will overestimate the strength of association.  The 
most commonly used markers are PAPP-A and free beta (or total hCG).  However, the 
performance of these markers alone (70% detection at a 0.6% false positive rate) is not 
as good as the performance of the second trimester markers.  Of some interest is one 
study showing trisomy 18 associated with very low uE3 measurements at this time in 
pregnancy, but there have been no confirmatory studies.  Additional information can be 
found in Chapter 4. 
 
First trimester nuchal translucency (NT) measurements are increased in pregnancies 
with trisomy 18.  However, there are no sufficiently large, observational studies that can 
be used to reliably determine the population parameters.  Instead, the analyses in this 
thesis rely on an ‘unbiasing’ technique using data from an ongoing clinical service.  This 
technique randomly removed a proportion of the observations from pregnancies with 
‘positive’ test results that were diagnosed in the first trimester, in order to properly 
balance these observations from pregnancies with ‘negative’ test results that were 
diagnosed at term.  Applying this technique resulted in a reduction in the median NT 
MoM from 2.94 to 2.17.  More information can be found in Chapter 5. 
 
When these revised NT population parameters were added to the first trimester serum 
markers together making the ‘combined’ test.  The resulting detection improved to an 
estimated 83%, with a reduction in the false positive rate to about 0.1%.  Table 10-4 
provides estimated detection and false positive rates for three combinations of tests at 
selected term risk cut-off levels (more complete modeling results are in Tables 6.2-1 and 
6.2-2).  These more conservative trisomy 18 modeling results are in agreement with 
performance reported from first trimester demonstration studies of the combined test.  
Table 10-5 provides the population parameters and truncation limits used in this first 
trimester modeling.  These can also be recommended for assigning patient-specific 
trisomy 18 risks for the combined test.  A more complete discussion of the modeling, 
sources of data and other markers that could be used (e.g., intact/total hCG 
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measurements) are found in Table 4.4-3, Figure 5.2-4 and the associated text.  More 
information can be found in Chapter 6. 
 
Table 10-4.  Modeled trisomy 18 detection rates (DR) and false positive rates (FPR) 
using first trimester serum and ultrasound markers at four risk cut-off levels 
 
 Maternal age in combination with 
Risk (1:n) PAPP-A & free β  PAPP-A, free β & NT 
at term (in first) DR (%) FPR (%)  DR (%) FPR (%) 
      
1:  50   (1:14) 56 0.4  79 0.1 
1:100   (1:29) 74 0.8  86 0.2 
1:150   (1:43) 80 1.4  88 0.3 
1:200   (1:60) 83 2.0  90 0.4 
 
PAPP-A = pregnancy associated plasma protein-A, free β = the free subunit of hCG,  
NT = nuchal translucency 
 
 
Table 10-5.  Modeling parameters for three first trimester maternal serum / 
ultrasound markers (combined test) in trisomy 18 and unaffected pregnancies 
 
 Trisomy 18 pregnancies  Unaffected pregnancies 
Analyte Median Log mean Log SD  Log SD 
      
PAPP-A 0.20 -0.6989 0.3207  0.2495 
Free β 0.25 -0.5992 0.3255  0.2651 
NT 2.17 0.3365 0.3151  0.1105 
      
  Pair-wise correlations 
PAPP-A Free β  0.1286   0.1395 
PAPP-A NT  0.0000  0.0000 
Free β NT  0.0000  0.0000 
    
   Truncation limits 
PAPP-A   0.30 – 0.70 
Free β   0.40 – 1.20 
NT   0.50 – 2.00 
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An integrated test combines information from both the first trimester combined test and 
the second trimester triple test.  If only serum markers (without duplication of the hCG 
subunit) were used, estimated detection and false positive rates would be  82% at about 
0.1%, respectively.  Thus, the serum integrated test is better than the second trimester 
serum triple test or the first trimester combined test.  If first trimester NT measurements 
were included to form the full integrated test, detection improves to 91% at the same 
false positive rate, the highest performance achieved yet.  Table 10-6 provides expected 
detection and false positive rates for serum and full integrated tests at selected term risk 
cut-off levels (more complete modeling results are in Tables 7.2-1 and 7.3-1).  All 
necessary parameters have already been provided in this Chapter.  More information 
regarding integrated testing for trisomy 18 is contained in Chapter 7. 
 
Table 10-6.  Modeled trisomy 18 detection rates (DR) and false positive rates (FPR) 
using serum integrated and full integrated testing, at four risk cut-off levels 
 
 Serum integrated  Full Integrated 
 DR (%) FPR (%)  DR (%) FPR (%) 
      
1:100  (1:  35) 76 <0.10  84 <0.1 
1:200  (1:  70) 82   0.10  88 <0.1 
1:300  (1:105) 84   0.16  89 <0.1 
1:400  (1:140) 86   0.21  91 0.11 
 
Serum integrated = maternal age in combination with 1st trimester PAPP-A and second 
trimester triple test (AFP, uE3 and hCG)measurements  
Full integrated = serum integrated and 1st trimester NT measurements 
 
Second trimester ultrasound markers have been widely studied and reported over the 
last three decades, but the literature is difficult to interpret.  Results are confounded by 
the gestational age at which the ultrasound was performed, the equipment available at 
the time, as well as differences in training and technique among centers and 
sonographers.  In general, a fetal anomaly scan is targeted between 18 and 20 weeks’ 
gestation, a relatively late time in pregnancy to be determining trisomy 18 risks, when 
reliable and less expensive methods of identifying pregnancies at risk are widely 
available.  This is not to say that second trimester ultrasound does not have a place in 
prenatal care, just that identifying trisomy 18 would not be a major factor in its routine 
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use.  More information regarding second trimester ultrasound testing can be found in 
Chapter 8. 
 
For all of these methods of assigning pregnancy risk for trisomy 18, it is necessary to 
offer follow-up diagnostic testing.  At this time, diagnostic testing requires an invasive 
test, either chorionic villus sampling between 11 and 14 weeks’ gestation or 
amniocentesis between 14 and 20 weeks’ gestation.  Each has an associated risk of 
procedure-related loss.  The diagnostic tests available have expanded since the 1980s 
when only karyotyping was available.  Now, molecular-based tests such as quantitative 
PCR (qfPCR) or fluorescent in situ hybridization (FISH) can be performed in a few days, 
with fewer resources, but with high reliability.  Newer methods like array comparative 
genomic hybridization (array CGH) may even replace the gold standard karyotype in the 
near future. 
 
In the future, it may be possible to create a diagnostic (or near diagnostic) test by relying 
on cell free fetal nucleic acids in the maternal circulation.  Fetal sex and fetal Rh status 
can already be confidently diagnosed using a maternal plasma sample.  Several proof of 
concept tests using cell free fetal DNA or RNA have been published, and large scale 
studies are underway.  Whether this will be feasible and affordable remains to be seen.  
More information on diagnostic procedures as well as current and future methods for 
diagnostic or near diagnostic testing can be found in Chapter 9. 
 
Trisomy 18 testing does not occur in isolation.  It is, in fact, a reinterpretation of existing 
measurements that were justified for Down syndrome and open neural tube defect 
screening.  Given the relatively low prevalence and poor survival after birth, any 
interpretation for trisomy 18 must be extremely efficient, resulting in a small number of 
procedures per case detected.  Given this as background, there are several 
considerations for Down syndrome screening programs when reviewing and updating 
their protocols to identify trisomy 18 pregnancies.  These include: 
 
 Regardless of the Down syndrome test offered, if a trisomy 18 interpretation is to be 
made, the age-associated prior risks and fetal loss coefficients by gestational age 
should be updated to the most currently available information. 
 Patient and provider materials should be reviewed to ensure that the natural history 
is correctly portrayed and variability in phenotype considered. 
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 If first trimester combined Down syndrome screening is offered, trisomy 18 
interpretations can be provided, but updating NT parameters is critical for assigning 
reliable risks.  Programs should also review their expected performance claims 
against those provided here. 
 Available evidence suggests that a similar percentage of first trimester trisomy 13 
pregnancies will be coincidentally detected by the trisomy 18 risk interpretation. 
 There is insufficient information to recommend the routine use of other first trimester 
ultrasound markers (e.g., nasal bone, ductus venosus) for trisomy 18. 
 If second trimester Down syndrome triple marker testing is offered, trisomy 18 
interpretations can be provided using updated parameters.  However, consideration 
should also be given to strategies that could utilize PAPP-A measurements from that 
sample. 
 Routine use of second trimester ultrasound makers as part of routine testing for 
trisomy 18 does not appear useful.  Modifying trisomy 18 risks using these ultrasound 
markers is also problematic, as it would reduce the high detection already present 
with excellent available serum/NT testing.  
 If full integrated Down syndrome screening is offered, trisomy 18 interpretations 
could utilize first trimester PAPP-A and NT measurements, along with second 
trimester triple markers, using the updated parameter sets. 
 If serum integrated Down syndrome screening is offered, trisomy 18 interpretations 
should utilize first trimester PAPP-A, along with second trimester triple markers using 
updated parameters. 
 The performance of sequential testing for trisomy 18 can approach that for full 
integrated testing.  However, such testing would likely occur only if the laboratory 
utilized sequential testing for Down syndrome. 
 
The best practices for identifying trisomy 18 can be summarized in four distinct 
categories that can co-exist in clinical practice.  For those women presenting prior to 14 
weeks’ gestation and who have access to reliable NT measurements, the full integrated 
test has the highest performance.  However, the performance of a ‘sequential’ integrated 
test is essentially the same and has an advantage in identifying a high proportion of 
trisomy 18 fetuses in the first trimester rather than in the second trimester.  Sequential 
testing involves setting a very high risk cut-off level in the first trimester to interpret the 
NT, PAPP-A measurements (with or without the hCG subunit measurement).  The 
reason for this is that the risk is so high, that the additional information available in the 
second trimester (AFP, uE3 and hCG measurements) would be unlikely to reclassify this 
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pregnancy as being at low risk.  Thus, action can be taken earlier in pregnancy in this 
small group.  The vast majority of pregnancies that are not at this very high risk, continue 
with an integrated test, only receiving their risk after the second trimester testing has 
been completed.  If NT is not available in this group of women presenting early for 
prenatal care, serum integrated testing is the next best option.  For those women 
presenting later in pregnancy, the ‘triple’ test would be best practice, with an option for 
adding PAPP-A measurements as the fourth marker.  Lastly, for those women who 
strongly favor a first trimester diagnosis over higher test performance, the first trimester 
combined test is appropriate.   
 
The next four sections rely on flow charts to show how each of these tests perform in 
indentifying trisomy 18 fetuses, among a general pregnancy population of 1,000,000 
singleton pregnancies.   The modeling shown here is sufficiently complete to allow for 
decision-making regarding protocol selection.  It is not, however, a comprehensive 
screening model.  For example, the model consists only of trisomy 18 and unaffected 
pregnancies; disregarding other pregnancy outcomes.  There are two important 
implications of this.  Some of the women who have positive results for trisomy 18 will 
also have positive results for Down syndrome.  Thus, these models provide the detection 
rate for trisomy 18, not the marginal increase in trisomy 18 detection.  As shown earlier, 
trisomy 18 test performance is extremely good, with high detection rates at very low false 
positive rates, usually below 0.3% (3 per 1000 false positives).  At such low rates, the 
model will not agree well with rates found in practice.  This is because other relatively 
rare outcomes (e.g., fetal death, anencephaly) that the trisomy 18 algorithms 
preferentially identify can result in a noticeable increase in the false positive rate (i.e., 
from 0.1% to 0.3%).  However, most of these additional ‘false positives’ are not 
unaffected pregnancies.  With these cautions in mind, the four testing protocols for 
trisomy 18 are presented below. 
 
Sequential testing  If NT measurements are available between 11 and 13 weeks’ 
gestation, the sequential test would be considered the optimal strategy.  The steps in 
sequential testing of 1,000,000 singleton pregnancies for trisomy 18 are shown in 
Figure 10-2.  Since the test starts in the first trimester, the prevalence of trisomy 18 is 
relatively high (9.61 per 10,000 versus 2.69 per 10,000 at term).  A reasonable first 
trimester cut-off is about 1:6 (equivalent to a term risk of 1:20).  Among the 
unaffected pregnancies, the false positive rate is less than 0.1% leading to about 500 
false positives.  Among the trisomy 18 pregnancies, the 70% detection rate translates 
into 673 screen positive cases.  Together, these 1,173 women could be offered first 
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trimester diagnostic testing, with an OAPR of about 1:1 (673:500).  All of the 
remaining 998,769 pregnancies would continue on for second trimester testing.  It 
would be preferable, if this group of women did not receive their first trimester risk 
result.  
 
In the second trimester, the triple markers would be added to the risk computation 
and using a second trimester risk cut-off of about 1:100 (term risk of 1:300), the 
detection rate for the remaining affected pregnancies would be about 67%.  The 
corresponding false positive rate would again be about 0.05%.  The OAPR would be 
1:2 and the OANR about 1:9,200.  Overall, the total detection rate is 90%, at a 0.1% 
false positive rate.  After accounting for fetal loss, there is the potential to reduce the 
birth prevalence from 2.69 to 0.27 per 10,000.  This performance is very nearly the 
same as would be found for full integrated testing. 
 
Serum integrated testing  Such testing is indicated if the gestational age is prior to 14 
weeks’ gestation, but reliable NT measurements are not available (Figure 10-3).  The 
second trimester prevalence is used, as that is the time when the risk will be 
reported.  Using a second trimester risk cut-off level of 1:105 (equivalent to 1:300 at 
term) the detection and false positive rates are 85% and 0.16%, respectively.   High 
risks will be assigned to 646 affected, and 1,599 unaffected pregnancies.  The OAPR 
will be about 1:3, while the OANR is about 1:8,100.  After accounting for fetal loss, 
there is the potential to reduce the birth prevalence from 2.69 to 0.43 per 10,000. 
 
Second trimester testing  Figure 10-4 shows the steps in second trimester testing.  
The prevalence of trisomy 18 at that time in pregnancy is less than the 961 found 
earlier for the first trimester, but the 769 is still considerably higher than the 269 
expected at term.  The most commonly used algorithm for trisomy 18 utilizes the 
existing ‘triple test’ markers (flowchart on the left of Figure 10-4).  Using a second 
trimester risk cut-off level of 1:35 (equivalent to 1:100 at term) the detection and false 
positive rates are 73% and 0.12%, respectively.  This leads to 561 trisomy 18 and 
1,119 unaffected pregnancies being assigned to the high risk category.  The OAPR is 
about 1:2 and the OANR is about 1:4,800.  After accounting for fetal loss, there is the 
potential to reduce the birth prevalence from 2.69 to 0.73 per 10,000. 
 
Figure 10-4 also shows an improved second trimester algorithm that requires an 
additional measurement of PAPP-A (flowchart on the right).  At the same risk cut-off 
level, the detection rate improves to 81% and the false positive rate is slightly 
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reduced to 0.1%.  This leads to 623 trisomy 18 pregnancies and 999 unaffected 
pregnancies assigned to the high risk category.  The OAPR is about 2:3; the OANR 
is about 1:6,800.  There is the potential to reduce the birth prevalence from 2.69 to 
0.52 / 10,000.  The performance would be similar, even if only a portion of the 
population were to have PAPP-A testing in a sequential protocol (i.e., only perform 
PAPP-A testing on women with very high risks as assigned by the triple test). 
 
First trimester testing  Figure 10-5 shows the steps in combined testing (NT, PAPP-A 
and free β hCG) in 1,000,000 singleton pregnancies.  Since testing begins in the first 
trimester, the prevalence of trisomy 18 in this population is again 961 (9.61 per 
10,000).  Using a first trimester risk cut-off level of 1:29 (equivalent to 1:100 at term), 
the combined test has a detection rate of 86% and false positive rate of 0.2%.  Thus, 
826 of the affected pregnancies, along with 1,998 of the unaffected pregnancies will 
be assigned a risk of 1:29 or higher.  In this group, the OAPR is about 1:2; the OANR 
is 1:6,800.  After accounting for fetal loss, there is the potential to reduce the birth 
prevalence from 2.69 to 0.52 per 10,000. 
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Figure 10-2.  Sequential testing for trisomy 18 in 1,000,000 singleton pregnancies 
in the general population.  The trimester-specific prevalence of trisomy 18, age 
associated risks and the test’s detection and false positive rates are taken from summary 
data presented in this chapter. 
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Figure 10-3.  Serum integrated testing for trisomy 18 in 1,000,000 singleton 
pregnancies in the general population.  The trimester-specific prevalence of trisomy 
18, age associated risks and the test’s detection and false positive rates are taken from 
summary data  presented in this chapter. 
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Figure 10-4.  Second trimester testing for trisomy 18 in 1,000,000 singleton pregnancies in the general population.  The left hand flow 
diagram shows performance of the ‘triple test’ composed of AFP, uE3 and hCG measurements.  The right hand flow diagram shows the 
changes in performance if a second trimester PAPP-A measurement were added to create the ‘quadruple test’.  The trimester-specific 
prevalence of trisomy 18, age associated risks and the test’s detection and false positive rates are taken from summary data presented in this 
chapter.
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Figure 10-5.  First trimester ‘combined’ testing for trisomy 18 in 1,000,000 
singleton pregnancies in the general population.  The trimester-specific prevalence 
of trisomy 18, age associated risks and the test’s detection and false positive rates are 
taken from summary data presented in this chapter. 
 
Since trisomy 18 testing is a re-interpretation of existing markers for Down syndrome, the 
timing and availability of marker results and type of testing offered (e.g., sequential, 
combined) will be determined by the Down syndrome screening test(s) offered.  The 
application of results in this thesis and considerations of the above suggested 
recommendations and best practices should make it possible to identify nearly all trisomy 18 
pregnancies for a very low false positive rate.
Pregnant women tested
1,000,000 
Unaffected pregnancy
999,039
Trisomy 18 pregnancy
961 (269 @ term)
Combined Test
DR  = 86%,  FPR = 0.2%
Cut ‐off of 1:29 (1:100 @ term)
Positive
1,998
Negative
997,041
Positive
826
Negative
135
OAPR
1:2 (826:1,998)
OANR
1:19,399 (146:998,324)
Birth prevalence reduced
From 2.69 to 0.52 / 10,000
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